All Congress attendees are invited to join us for the ASRM President's Gala benefiting the ASRM Research Institute.

Sunday, October 17, 2021
6:00 p.m.
Hilton, Baltimore - Inner Harbor

Ticket sales close on Friday, October 8.

For information on purchasing a ticket or to sponsor a table contact Brynne MacCann - 205-978-7702 or bmaccann@asm.org.

ASRM would like to extend a special thank you to the President's Gala Premier Sponsor, Ferring Pharmaceuticals for supporting this year's event and for their commitment to the advancement of science and increasing access to care.
OUR WEEKEND BEGINS with two exciting hands-on courses. The Embryo Transfer Simulation Course will be offered as a half-day course (morning and afternoon option available) and will focus on perfecting embryo transfer techniques using models ranging in levels of difficulty. The SRS Surgical hands-on course “The Art of Perfecting Myomectomies” will be offered as a full-day training course and will include tissue models to simulate removal of fibroids, tissue extraction and focus on suturing techniques.

In keeping with our ASRM 2021 Scientific Congress theme of “Reproduction Reimagined” we have an amazing line up of plenary speakers this year starting with Dr. Jennifer Doudna, who received the 2020 Nobel Prize in Chemistry for her pioneering work with CRISPR gene editing. The Scientific Congress Continuing Medical Education (CME) course offerings will include morning plenary and dual-afternoon lectures, symposia, and interactive sessions. You will hear innovative lectures that focus on personalized medicine, in vitro gametogenesis, artificial gametes from stem cells, the genetic basis of meiotic catastrophe, and applications of nuclear transplantation.

We will also celebrate the 40th anniversary of the 1st US IVF baby looking at the past, present and future of IVF. The symposia and interactive sessions will engage you in a variety of subjects from the use of social media in patient education, to strategies for developing a successful academic medicine career, from addressing inequalities in reproductive healthcare, to artificial intelligence in the IVF laboratory. Sessions related to diversity equity and inclusion, male reproduction, LGTBQ, and mental health are also in the lineup.

CME sessions will be complemented by non-CME activities including intimate roundtable luncheons covering the breadth and depth of reproductive medicine; and oral and poster-format scientific abstract presentations, representing cutting-edge research in reproductive medicine and biology.

Our Postgraduate courses selected by the Postgraduate Program Committee in collaboration with our affiliated societies, professional groups, special interest groups, and several International Societies and collaborating organizations will be ON-DEMAND again this year. These wide ranging multi-disciplinary courses, designed to emphasize innovation and discovery in the reproductive health and medicine arena, will be available for view until December 31st, 2021. We hope you will take advantage of these courses that allow you to view as your schedule permits through the end of the year.

We welcome our members, trainees, and colleagues from around the world to the ASRM 2021 Scientific Congress & Expo! We value your participation and engagement in all the educational and networking opportunities provided. I look forward to seeing you in the beautiful city of Baltimore, where together we will mark ASRM’s 77th Annual Congress. I also hope you will join us on Sunday night, October 17th, 2021 at the President’s Gala Celebration in support of the ASRM Research Institute and the outstanding research efforts of our Society members.

Sincerely,

Hugh Taylor, M.D.
ASRM President, 2020-2021
JOIN US FOR OUR

Opening Ceremony

Monday, October 18th, 7:45 am – 8:30 am

Plenary 1 will immediately follow in the same room.

A complimentary continental breakfast will be available
7:00 am – 7:45 am

Opening Ceremony continental breakfast is sponsored by Myovant Sciences, Inc.

Inside this Program

ASRM PRESIDENT’S GALA ................................................................. 2
ASRM WELCOME ................................................................. 3
OPENING CEREMONY ............................................................. 4
ASRM SCIENTIFIC CONGRESS PLANNING COMMITTEES .............. 6
ASRM OFFICERS AND BOARD OF DIRECTORS ....................... 6
ASRM 2021 AWARDS .............................................................. 7-19
SCHEDULE-AT-A-GLANCE .................................................. 20-24
SCIENTIFIC CONGRESS DAILY SCHEDULE ............. 25-33
ASRM SCIENTIFIC CONGRESS POLICIES AND DISCLAIMERS ... 36
REGISTRATION AND MEETING INFORMATION .................. 36
HOUSING INFORMATION ............................................................ 37
SPOTLIGHT EVENTS ............................................................... 39
NICHD-ASRM WORKSHOP .................................................. 40
TICKETED EVENTS ................................................................. 41
CONTINUING MEDICAL EDUCATION/CONTINUING EDUCATION . 44-45
Postgraduate PROGRAM ....................................................... 46-65
NEEDS ASSESSMENT AND LEARNING OBJECTIVES ............ 66
SCIENTIFIC CONGRESS DAILY SCHEDULE GRID ............. 67
SPECIALTY TRACKS .............................................................. 68-82
RESIDENT EDUCATION PROGRAM ........................................ 83-84
ROUNDTABLES ................................................................. 94-98
VIDEO ABSTRACT SESSIONS ............................................. 99-100
ORAL ABSTRACT SESSIONS ............................................... 103-117
POSTER PRESENTATION AND ABSTRACTS .................... 118-147
ASRM IS PAPERLESS ............................................................. 172
EXHIBITOR SECTION ............................................................. 176-199
BALTIMORE CONVENTION CENTER EXPO FLOOR ............. 178
INDUSTRY-SPONSORED SYMPOSIA ................................. 200-201
EXPO THEATER SCHEDULE ............................................. 202
FUTURE ASRM SCIENTIFIC CONGRESS & EXPO DATES .......... 203
Committees and Awards

- ASRM Scientific Congress Program  6
  Planning Committee
- ASRM Officers and Board of Directors  6
- ASRM Awards  7-19
- Schedule-at-a-Glance  20-24
- Daily Schedule  25-33
- ASRM Scientific Congress Policies and Disclaimers  36
ASRM 2021 Scientific Congress Program Planning Committees

Hugh S. Taylor, M.D., President
Paolo Rinaudo, M.D., Ph.D., Scientific Congress Program Chair
James H. Segars, M.D., Interactive Sessions Chair
Ruben Alvero, M.D., Roundtables Program Chair
Richard O. Burney, M.D., Postgraduate Program Chair
Erica B. Johnstone, M.D., M.Sc., Postgraduate Co-Chair
Samantha F. Butts, M.D., M.S.C.E., Postgraduate Coordinating Chair
Nancy Kaufman, L.C.S.W., Ad Hoc Committee Member
Valerie L. Baker, M.D., Society for Assisted Reproductive Technology Program Chair
Micah Hill, M.D., Society for Reproductive Endocrinology and Infertility Program Chair
Philip Li, M.D., Society for Male Reproduction and Urology Program Chair
Kathleen Hwang, M.D., Society for Reproductive Surgeons Program Chair
Liesl Nel-Themaat, Ph.D., Society for Reproductive Biologists and Technologists Program Chair
Kim Bergman, Ph.D., Mental Health Professional Group Program Chair
Lauren Nervi, N.P., Nurses’ Professional Group Program Chair
Nidhi Desai, J.D., Legal Professional Group Program Chair
Danielle Soltesz, M.B.A., M.P.H., Association of Reproductive Managers Program Chair
Rachel Donnell, M.Sc., Genetic Counseling Professional Group Program Chair

Vickie Gamble, M.P.P.M., Interim ASRM Chief Executive Officer
Chevis Shannon, Dr.P.H., M.B.A., M.P.H., M.E.R.C., ASRM Chief Education and Science Officer
Jody Thrash, M.B.A., ASRM Educational Programming and Special Projects Manager

ASRM VIDEO COMMITTEE
Michael I. Eisenberg, M.D., Video Program Chair
Balasubramanian Bhagavath, M.B.B.S.
Victor Beshay, M.D.
T. Arthur Chang, Ph.D., E.L.D., H.C.L.D.
James M. Hotaling, M.D., M.S.
Kathleen Hwang, M.D.
Anthony Imuda, M.D.
Edward D. Kim, M.D.
Steven R. Lindheim, M.D.
Philip S. Li, M.D.
Marius Meintjes, D.V.M., Ph.D.
Charles Miller, M.D.
Ceana H. Nezhat, M.D.

ASRM Officers and Board of Directors 2020 – 2021

ASRM OFFICERS
Hugh S. Taylor, M.D., President
Marcelle Cedars, M.D., President-Elect
Michael Thomas, M.D., Vice President
Catherine Racowsky, Ph.D., Immediate Past President
Peter N. Schlegel, M.D., Past President
James P. Toner, M.D., Ph.D., Secretary/Treasurer

ASRM BOARD OF DIRECTORS AT-LARGE MEMBERS
Peter Chan, M.D.
Amy Sparks, Ph.D.
Samantha Pfeifer, M.D.
Alan Penzias, M.D.
Lee Collins, J.D.
Lauri Pasch, Ph.D.

ASRM BOARD OF DIRECTORS AFFILIATED SOCIETY MEMBERS
Valerie L. Baker, M.D., (SART)
Stanton C. Honig, M.D., (SMRU)
Brad J. Milette, B.S., (SRBT)
Ruben J. Alvero, M.D., (SREI)
John C. Petrozza, M.D., (SRS)

ASRM CHIEF EXECUTIVE OFFICER
Vickie Gamble, M.P.P.M. (Interim)

ASRM CHIEF EDUCATION AND SCIENCE OFFICER
Chevis Shannon, Dr.P.H., M.B.A., M.P.H., M.E.R.C.

John Nichols, Jr, M.D.
John Petrozza, M.D.
Marc P. Portmann, M.T., M.H.A., E.L.D.
Salli Tazuke, M.D.
Mark Trolince, M.D.
Togas Tulandi, M.D.
DISTINGUISHED RESEARCHER AWARD
JAMES SEGARS, M.D.

The 2021 recipient of the ASRM Distinguished Researcher Award is James Segars, M.D. This award recognizes a member of the American Society for Reproductive Medicine who has made outstanding contributions to clinical or basic research in reproduction published during the previous 10 years. The recipient will have demonstrated sustained long-term commitment to advancing the frontiers of research in reproductive sciences and educating future scholars in the field.

Dr. Segars is the Howard and Georgeanna Seegar Jones Professor of Gynecology and Obstetrics, and Director Division of Women’s Health Research at Johns Hopkins. A major focus of his research for the past 20 years has explored the molecular mechanisms responsible for reproductive diseases, including endometriosis, uterine fibroids, PCOS, and infertility. He attended Duke University and Duke University School of Medicine with a National Health Service Corps Scholarship (NHSC). After an internship in surgery at the University of Virginia, he served for 2 years in the foothills of rural Georgia doing general practice before completing a residency in OB/GYN at Vanderbilt. Following a fellowship Reproductive Endocrinology and Infertility at Vanderbilt, a Reproductive Scientist Development Program (RSDP) award supported his 3-year post-doctoral training in the intramural program at the National Institute of Child Health and Human Development at NIH. Dr. Segars worked at NIH and Walter Reed Army Medical Center and Bethesda National Naval Medical Center for 20 years before moving to Johns Hopkins in 2015. During his time at NIH, Dr. Segars served as Fellowship Program Director of Reproductive Endocrinology and the Medical Director for the Walter Reed Program of Assisted Reproduction for 19 years. At Johns Hopkins, he leads a Division that performs clinical and translational research studies of fibroids, endometriosis and PCOS. He has been active in graduate medical education and served as member and Director of the Reproductive Endocrinology Division at the American Board of Obstetrics and Gynecology. Dr. Segars has served on boards of the American Society for Reproductive Medicine, the American Board of Obstetrics and Gynecology, the Society for Reproductive Investigation, and the American Gynecological and Obstetrical Society. Dr. Segars has published over 200 research papers and serves on several editorial boards.

LIFETIME ACHIEVEMENT AWARD
CHRISTOS COUTIFARIS, M.D., PH.D.

The 2021 recipient of ASRM’s Lifetime Achievement Award is Christos Coutifaris, M.D., Ph.D. This award honors a member of the American Society for Reproductive Medicine who has made exemplary contributions to the field of reproduction during his/her career. The recipient has demonstrated innovation, leadership, and other scholarly accomplishments that have a lasting impact on advancing clinical care, the frontiers of research in reproductive sciences, and the education of the scientific community.

Dr. Coutifaris is the Celso Ramon Garcia Professor of Obstetrics and Gynecology, Vice-Chair for Faculty Development and past Chief of the Division of Reproductive Endocrinology and Infertility at the Perelman School of Medicine at the University of Pennsylvania in the United States. After graduating with a Bachelor of Arts degree in Biophysics from Amherst College, he received his M.D. and Ph.D. degrees from the University of Pennsylvania and completed a residency in Obstetrics and Gynecology and a fellowship in Reproductive Endocrinology and Infertility both at the Hospital...
of the University of Pennsylvania. Dr. Coutifaris has directed both basic and clinical/translational research programs at Penn for more than 30 years under continuous NIH grant support. His current active research program involves understanding the cell biology of human trophoblast differentiation and how assisted reproductive technologies may lead to adverse perinatal outcomes through epigenetic alterations in the placenta. He was also the principal investigator of the Penn site of the NICHD-funded Reproductive Medicine Network of which Penn had been a member since the Network’s inception in 1990. He currently serves as Associate Director of the NICHD-funded Penn Center for the Study of Epigenetics in Reproduction. Dr. Coutifaris is a member of a number of professional and scientific organizations including the Endocrine Society, the Society for the Study of Reproduction, the American Gynecologic and Obstetrical Society (of which he is currently President-Elect), and the American College of Obstetricians and Gynecologists. He has been a member of ASRM since 1987 and has served the Society in multiple roles including as President of the Society for Reproductive Endocrinology and Infertility (2004-05) and program director of the NICHD-funded SREI T32 training grant for 15 years, Subsociety Representative to the Executive Board of the American College of Obstetricians and Gynecologists (2004-06), member of the ASRM Board of Directors (2011-2014) and member of the presidential chain (2015-2020) and President of the Society (2017-18). His presidential initiatives culminated in the establishment of the ASRM Research institute. He served the American Board of Obstetrics and Gynecology as a member of the Division of Reproductive Endocrinology and Infertility and as a specialty and sub-specialty board examiner. Dr. Coutifaris has been a member of several Federal Advisory Committees including the Reproductive Endocrinology Study Section and has participated in and chaired other special emphasis review panels of the NIH. He is currently Chair of the Oversight Committee for NIH’s Perinatology Research Branch/Program for Perinatal Research and Obstetrics. He has been a visiting professor and delivered endowed lectureships at multiple institutions including the University of Athens when, in 2007, he was awarded an honorary Doctorate Degree. In 2017, he was elected to the National Academy of Medicine.

IRA AND ESTER ROSENWAKS NEW INVESTIGATOR AWARD
supported by an endowment from Iev Rosenwaks, M.D.

AMANDA N. KALLEN, M.D.

Amanda N. Kallen, M.D., has been selected as the 2021 recipient of the Ira and Ester Rosenwaks New Investigator Award. This award recognizes a member of ASRM who has made outstanding contributions to clinical or basic research in reproductive sciences published within 10 years after completing research or clinical training and initiating an independent career as an investigator.

Dr. Amanda N. Kallen is an Associate Professor of Obstetrics and Gynecology at the Yale School of Medicine in the Division of Reproductive Endocrinology and Infertility, and a physician-scientist in the Yale Reproductive Sciences Division. Dr. Kallen’s current research program aims to improve our understanding of the regulatory mechanisms underlying reproductive aging in the mammalian ovary. During her REI fellowship, Dr. Kallen was awarded a position in the NICHD’s Reproductive Scientist Development Program (RSDP), a prestigious mentored career development program designed to develop academic reproductive physician-scientists equipped with the skills to address important problems in obstetrics and gynecology. She completed her RSDP training in the laboratory of her mentor, Dr. Yingqun Huang. Dr. Kallen is currently the PI of an NIH/NICHD-funded R01 which investigates non-coding RNA (ncRNA)-mediated regulation of ovarian follicular quantity and quality, a novel and understudied area of ovarian aging, which received an Impact Score of 10 (1st percentile). Dr. Kallen is also funded by the 2020 Global Consortium for Reproductive Longevity and Equality Junior Scholar Award for her work on ovarian aging. Her work was recognized by the Endocrine Society as one of the “Top Endocrine Discoveries of 2017”, and she received the 2019 American Society for Reproductive Medicine (ASRM) Research Grant as well as the 2020 Society for Reproductive Investigation (SRI) “Early Career Investigator” Award. Dr. Kallen has published in leading scientific journals, including a first-author publication in Molecular Cell cited nearly 600 times demonstrating that the ncRNA H19 is a molecular “sponge” for the micro RNA let-7. Dr. Kallen previously served on the American Congress of Obstetricians and Gynecologists Executive Board as the Junior Fellow Chair, and currently is the Associate Editor for Fertility & Sterility Reviews.
SUHEIL J. MUASHER, M.D., DISTINGUISHED SERVICE AWARD
supported by an endowment from Suheil J. Muasher, M.D.
ANDREA BRAVERMAN, PH.D.

The 2021 recipient of the Suheil J. Muasher, M.D., Distinguished Service Award is Andrea Braverman, Ph.D. Each year, ASRM honors individuals who have provided distinguished service to ASRM. Recipients are selected based on their scientific, leadership, organizational, political or societal service contributions to the ASRM, reproductive medicine and/or reproductive medicine patients.

Dr. Braverman is a Clinical Professor with a joint appointment in the Department of Obstetrics and Gynecology and Psychiatry and Behavioral Medicine at Thomas Jefferson University. Dr. Braverman is the Associate Director for the Educational Core for OB/Gyn and also serves as the Director of the College Learning Environment for the university. She is a health psychologist with a specialty in medical health management, infertility counseling, and third party reproduction issues. She received her M.A., M.S. and Ph.D. in psychology from the University of Pennsylvania. Dr. Braverman has lectured internationally on treatment issues and reproductive medicine before medical and patient audiences. Dr. Braverman has conducted research and published numerous articles in medical journals about the psychological aspects of infertility, attitudes of parents of children born with the use of ART, issues involved in the decision to end treatment, and psychological issues involved in using third-party donors. Dr. Braverman received the Timothy Jeffries Memorial award in 2011 for outstanding contributions as a health psychologist from the American Psychological Association and the Advocacy Award from the Family Equality Council and Path2Parenthood in 2018. She is the past president of the North American Society for Psychosocial Obstetrics and Gynecology and past chairperson of the Mental Health Professional Group of the American Society for Reproductive Medicine (ASRM).

KAVOUSSI FAMILY OUTSTANDING TEACHER AWARD
This Award is made possible through an educational endowment from K.M. Kavoussi, M.D., Homa Kavoussi, Shahryar Kavoussi, M.D., M.P.H., Mehryar Kavoussi, J.D., Parviz Kavoussi, M.D., and Austin Fertility & Reproductive Medicine/Westlake IVF.

DOLORES J. LAMB, PH.D.

Dolores J. Lamb, Ph.D. has been chosen to receive the 2021 Kavoussi Family Outstanding Teacher Award. This award honors an ASRM member who is recognized as an outstanding educator in undergraduate, graduate, postgraduate, professional or patient education in basic and/or clinical reproductive biology and medicine.

Dr. Lamb joined Weill Cornell Medicine on March 1, 2018 as Vice Chair for Research in the Department of Urology and Director of the Center for Reproductive Genomics. She will hold the Dow Professorship of Urology. She maintains an active presence in both the academic and research communities at Weill Cornell Medicine. Dr. Lamb is an investigator in the fields of urology, male infertility, steroid hormone action, prostate cancer and genitourinary birth defects. She was among the first researchers seeking to define the genetic basis of male infertility. She reported the first spermatogenesis gene defect identified in men with spermatogenic failure and was first to use whole exome sequencing to define a novel homozygous gene mutation in a consanguineous family with multiple males with non-obstructive azoospermia. She was the first to use array comparative genomic hybridization to reveal that disorders of sexual differentiation in many males are due to microdeletions and microduplications of syndromic dosage-sensitive genes which impact major developmental signaling pathways in ways never before considered, affecting not only genitourinary development, but other organs as well. Thus, “non-syndromic” males with genitourinary congenital defects may have unrecognized health problems and benefit from genomic diagnosis and early intervention. Her experience is unique as she has an extensive background in both the clinical diagnostic and the basic science arenas in men’s health, as well as having a remarkable record of achievement in the mentoring and development of clinician-scientists.
GLORIA RICHARD-DAVIS, M.D.

Gloria Richard-Davis, M.D. has been selected as the 2021 Arnold P. Gold Foundation Humanism in Medicine Award for Practicing Physicians. This award honors an ASRM member who as a practicing physician has best demonstrated the ideals of compassionate and respectful care for a patient’s physical and emotional well-being. The recipient of the award should demonstrate compassion, empathy, competence, respect, sensitivity, effective communication and trustworthiness.

Dr. Richard-Davis, Executive Director for UAMS Division of Diversity, Equity and Inclusion, is also a tenured Professor in Obstetrics and Gynecology and, Division Director for Reproductive Endocrinology and Infertility as well as Medical Director for the Physician Assistants program. She joined the UAMS faculty in January 2013. She is board certified in Reproductive Endocrinology and Infertility and Obstetrics and Gynecology. She previously served as Professor and Chair of the Obstetrics and Gynecology Department at Meharry Medical College and Executive Director for Center for Women Health Research (CWRH) from January 2007 – 2012. The CWHR was and remains the only center fully focused on conditions affecting women of color. Prior to her appointment, Dr. Richard-Davis served as the Section Head of Reproductive Health Services for Ochsner Clinic Foundation and the Medical Director of the Fertility Center at Ochsner from 2000-2007 in New Orleans. She was Assistant Dean in Student Affairs and Assistant Professor in the Department of Obstetrics and Gynecology at Tulane University School of Medicine from 1994 – 1998.

ASRM/NICHD/DUKE CLINICAL RESEARCH/REPRODUCTIVE SCIENTIST TRAINING (CREST) PROGRAM

This training program is offered by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Clinical Research Training Program (CRTLTP) at Duke University, the American Society for Reproductive Medicine (ASRM), and the University of Colorado School of Medicine. CREST meets an existing need for formalized academic training in the quantitative and methodological principles of clinical research in reproductive medicine. Designed specifically for physicians in private or academic clinical practice in reproductive medicine, this innovative 2-year program engages the practicing physician in clinical research while allowing the individual to maintain an active role in clinical practice. ASRM welcomes the class of 2021:

- Kelly S. Acharya, M.D.
- Jennifer K. Blakemore, M.D.
- Laura Bozzuto, M.D.
- Chelsea W. Fox, M.D.
- Luis R. Hoyos, M.D., F.A.C.O.G.
- Yetunde O. Ibrahim, M.D.
- Bruce D. Pier, M.D.

SCIENTIFIC CONGRESS PRIZE PAPERS

Candidates for two Scientific Congress Prizes are selected by the Research Committee from all abstracts submitted to the Congress regardless of designation of group for initial review. These oral presentations will be judged at the Congress and selection will be determined by the Research Committee. The presenters of the two Scientific Congress Prize papers will be awarded $1,000.00.

SCIENTIFIC CONGRESS PRIZE POSTERS

Posters must be put up on the appropriate boards on Sunday, October 17, between 1:00 p.m. and 5:00 p.m. or on Monday, October 18, between 9:00 a.m. and 12:00 p.m., and must remain in place for the entire Congress. Posters will be judged by the Prize Poster Committee beginning at 12:00 p.m. Monday. The awardees will receive:

- First Prize: $500
- Second Prize: $300
- Third Prize: $200

Formal recognition of these awards will take place during the ASRM Members’ Meeting and Awards ceremony on Wednesday, October 20, 2021, at 8:45 am.
ASRM CORPORATE MEMBER COUNCIL IN-TRAINING AWARDS

These awards are made possible through the generous support of the ASRM Board of Directors and the ASRM Corporate Member Council. Fifteen awards to trainee abstract presenters from the United States and five awards to trainee abstract presenters from countries outside the United. Recipients of this award are undergraduate, graduate, medical or allied health professions students, postdoctoral trainees, or clinical residents or fellows. Candidates are the first and presenting author of an abstract that has been selected for oral or poster presentation in the ASRM 2021 Scientific Congress. Selection is based on the scientific merit of the abstract and the qualifications of the author. The awardees receive:

- $1,000 (US presenters)
- $2,000 (Non-US presenters)

O-102, Tuesday, October 19, 2021, 12:00 PM
INVESTIGATING THE IMPACT OF mTOR INHIBITOR TREATMENT ON TRANSGENERATIONAL OFFSPRING HEALTH AND FERTILITY.

Lauren E Butler, MS1, Luhan Tracy Zhou, MS2, Kristine J. Moss, MS1, Camille L Mulcahy, BS1, Sarah R Wagner, BS1, Manuel Torres-Velez, MD1, Francesca E Duncan, PhD1 and Kara N. Goldman, MD3. 1Feinberg School of Medicine, Northwestern University, 2Feinberg School of Medicine, Northwestern University, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Chicago, IL

O-37, Monday, October 18, 2021, 10:45 AM
ICSI VS. CONVENTIONAL IVF USE IN NON-MALE FACTOR INFERTILITY.

Aya Iwamoto, MS, MD1, Karen M Summers, MPH CHES2, Amy E Sparks, PhD3, Abigail C Mancuso, MD4 and Bradley J Van Voorhis, MD4. 1University of Iowa Hospitals and Clinics, Iowa City, IA, 2University of Iowa, Iowa City, IA, 3University of Iowa Center for Advanced Reproductive Care, Iowa City, IA, 4University of Iowa Carver College of Medicine, Iowa City, IA, O-37, Monday, October 18, 2021, 10:45 AM

UPTAKE OF CANCER GENETIC TESTING IN THE INFERTILITY POPULATION MEETING NCCN CRITERIA.

Karrie A. B. Walker, D.O.1, Kiley Hunkler, M.D.2, Samad Jahandideh, Ph.D3, Jill Chisholm, MSN, WHNP, APNG4, Patrick Jr. James Chisholm, BS1, Kristie Hynnnman, AS4, Micah J Hill, DO1, Kate Devine, MD2, Alan H DeCherney, MD1 and Jeanne E O’Brien, MD, MSc3. 1Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Shady Grove Fertility Center, Rockville, MD, 4GeneScreen Counseling, Bernardsville, NJ

O-182, Tuesday, October 19, 2021, 11:00 AM
CONTROLLED OVARIAN STIMULATION LEADS TO GLANDULAR-STROMAL DYSSYNCHRONY AND DECREASED STROMAL PROLIFERATION IN GOOD RESPONDERS BUT NOT IN POOR RESPONDERS.

Anat Chemerinski, MD1, Qingshi Zhao, PhD1, Daniel Cho, BS2, Trystn Murphy, BS2, Aimee M Beaulieu, PhD2, Debra Heller, MD1, Sara S. Morelli, MD, PhD1 and Nataki C. Douglas, MD, PhD1. 1Rutgers New Jersey Medical School, Newark, NJ, 2Rutgers University, New Jersey Medical School, Newark, NJ

P-121, Tuesday, October 19, 2021: 6:30 AM - 7:45 AM
RELATIONSHIP BETWEEN LENGTH OF GONADOTROPIN STIMULATION FOR IN VITRO FERTILIZATION AND EMBRYONIC ANEUPLOIDY OF MATERNAL ORIGIN.

Robyn K. Power, MD1, Jocelyn Marie Wascher, MD1, Lydia Hughes, MD2, Christina E Boots, MD, MSCI2 and Dana B. McQueen, M.D., M.A.S.3. 1University of Chicago, Chicago, IL, 2Northwestern University, Chicago, IL

O-40, Monday, October 18, 2021, 11:30 AM
FACTORs ASSOCIATED WITH LARGE FOR GESTATIONAL AGE INFANTS BORN AFTER FROZEN EMBRYO TRANSFERS.

Anne Janece Roshong, MD1, Carol E DeSantis, MPH2, Kuo J Liao, PhD2, Ryan Heitmann, DO3, Anthony K Yartel, MPH4, Dmitry Kissin, MD, MPH4 and Bruce Pier, MD1. 1Division of Reproductive Endocrinology and Infertility, Tacoma, WA, 2Centers for Disease Control and Prevention, Chamblee, GA, 3West Virginia University Center for Reproductive Medicine, Morgantown, WV, 4Centers for Disease Control and Prevention (CDC), Atlanta, GA
P-475, Wednesday, October 20, 2021: 6:30 AM-7:45 AM

THE ROLE OF ENDOPLASMIC RETICULUM STRESS RESPONSE IN THE REGULATION OF ENDOMETRIAL INTERFERON BETAC PRODUCTION IN DECIDUALIZED VERSUS NON-DECIDUALIZED ENDOMETRIAL CELL.

Ramya Sethuram, MD1, Sana Salih, MD2, Gil Mor, MD PhD1, Pancharatnam Jeyasuria, PhD1 and Jennifer Condon. PhD1, 1Wayne State University School of Medicine, Detroit, MI, 2Wayne State University School of Medicine, Detroit

O-183, Tuesday, October 19, 2021, 11:15 AM

SINGLE CELL DNA SEQUENCING OF WHOLE HUMAN BLASTOCYSTS: NOVEL INSIGHTS INTO THE PHENOMÉNON OF EMBRYONIC MOSAICISM.

Jenna Friedenthal, M.D.1, Ethan Ellis, BS1, Joseph A. Lee, BA2, Christine Britton-Jones, PhD, HCLD1, Erkan Buyuk, MD1, Kristin Beaumont, PhD1, Robert P. Sebra, PhD1, Eric Schadt, PhD1 and Alan B Copperman, MD1, 1Icahn School of Medicine at Mount Sinai, New York, NY, 2Reproductive Medicine Associates of New York, New York, NY

O-86, Monday, October 18, 2021, 11:00 AM

INDICATIONS FOR SURROGACY FROM THE PERSPECTIVE OF THE GESTATIONAL CARRIER.

Amy Kaing, MD1, Brett Stark, MD1 and Lauri Pasch, Ph.D.2, 1University of California, San Francisco, Department of Obstetrics and Gynecology, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA

O-87, Monday, October 18, 2021, 11:15 AM

SPERM DONOR ATTITUDES AND EXPERIENCES ON DIRECT-TO-CONSUMER GENETIC TESTING.

Sascha Wodoslawsky, BA1, Joy Fatunbi, M.D.1, Rebecca Mercier, M.D., MPH2 and Andrea Mechanick Braverman. Ph.D.2, 1Sidney Kimmel Medical College, Thomas Jefferson University, Baltimore, MD, 2Thomas Jefferson University Hospital, Baltimore, MD

O-41, Monday, October 18, 2021, 11:45 AM

ENDOMETRIAL PREPARATION FOR FROZEN EMBRYO TRANSFER AND IMPACT ON BIRTH WEIGHT: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Kendal Frances Rosalik, Do1, Samantha Carson, MD2, Jacqueline Luizzi, MLIS, AHIP1, Justin Pilgrim, MD3, Gary Levy, MD2, Ryan Heitmann, DO4 and Bruce D Pier, MD5, 1Madigan Army Medical Center, 2Tripler Army Medical Center, 3Tripler Army Medical Center, Honolulu, HI, 4West Virginia University Medical Center, 5Division of Reproductive Endocrinology and Infertility, Tacoma, WA

O-73, Monday, October 18, 2021, 10:45 AM

CERVICAL LENGTH IN EARLY PREGNANCY AND PREGNANCY OUTCOMES.

Ali A Bazzi, MD. Wayne State University/Detroit Medical Center, MI, Zahra Alburkat, BS, Wayne State University School of Medicine, MI, Ramya Sethuram, MD, Wayne State University School of Medicine, Detroit, MI, Sana Salih, MD, Unknown and Awoniyi Olumide Awonuga, MD, Wayne State University, Southfield, MI

O-31, Monday, October 18, 2021, 10:45 AM

THE ROLE OF HOUSEHOLD INCOME AND INSURANCE COVERAGE ON LIVE BIRTH OUTCOMES IN INFERTILE PATIENTS RESIDING IN NEW YORK STATE.

Alice Chung, MD1, Phillip A Romanski, MD1, Pietro Bortoletto, MD2 and Steven D Spandorfer, MD1, 1The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, NY, 2The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, Boston, MA

O-205, Wednesday, October 20, 2021, 10:45 AM

EMBRYO VITRIFICATION WITH SLUSH NITROGEN YIELDS SIMILAR PREGNANCY OUTCOMES COMPARED TO LIQUID NITROGEN: A RANDOMIZED CONTROLLED TRIAL.

Amber M Klimczak, MD1, Nola S Herlihy, MD2, Brent M Hanson, MD1, Julia G Kim, MD, MPH1, Cheri K Margolis, MD1, Leah M Roberts, MD1, Emre Seli, MD2 and Richard T. Scott Jr., M.D.2, 1IVI-RMA New Jersey, Basking Ridge, NJ, 2IVI RMA New Jersey, Basking Ridge, NJ

O-175, Tuesday, October 19, 2021, 10:45 AM

DOSE-DEPENDENT EFFECT OF CONTEMPORARY MARIJUANA EXPOSURE ON FEMALE REPRODUCTIVE HEALTH IN A NON-HUMAN PRIMATE MODEL.

Kimberly S Ryan, MD1, Shruthi Mahalingaiah, MD, MS2, Victoria HJ Roberts, PhD3, Emily R Boniface, PhD3, Jason C Hedges, MD, PhD1, Carol B Hanna, Ph.D.3, Jon D Hennebold, PhD4 and Jamie O Lo, MD, MCR1, 1Oregon Health & Science University, Portland, OR, 2Fertility Center,
Massachusetts General Hospital, Boston, MA, Oregon National Primate Research Center, Beaverton, OR, Oregon National Primate Research Center, Division of Reproductive & Developmental Sciences, Beaverton, OR

O-13, Monday, October 18, 2021, 10:45 AM
LOW-PASS GENOME SEQUENCING IDENTIFIED MACROSCOPIC AND MICROSCOPIC CHROMOSOMAL MOSAICISMS TO EXPLAIN FIRST-TRIMESTER MISCARRIAGE.

Ying Li, Mphil, Ziru DONG, PhD, Kwong Wai Richard Choy, PhD and Pui Wah Jacqueline Chung, MD, The Chinese University of Hong Kong, Hong Kong, China

P-505, Wednesday, October 20, 2021, 6:30 AM - 7:45 AM
DOWNREGULATION OF SIRT3 CONTRIBUTES TO UTERINE FIBROID PHENOTYPE, WHICH IS INHIBITED BY NATURAL SIRT3 ACTIVATOR HONOKIOL.

Mohamed Ali, Ph.D1, Michal Ciebiera, MD, PhD2, Qiwei Yang, Ph.D.3, Jack L. Arbiser, MD, Ph.D4 and Ayman Al-Hendy, MD, PhD1, 1Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt, 2Center of Postgraduate Medical Education, Warsaw, Poland, 3Department of Obstetrics and Gynecology, University of Chicago, (4)Emory University, Atlanta, GA

P-136, Tuesday, October 19, 2021, 6:30 AM - 7:45 AM
IMPACT OF SUPEROVULATION AND IN VITRO FERTILIZATION ON LINE 1 COPY NUMBER AND TELOMERE LENGTH IN C57BL/6J MICE BLASTOCYSTS.

Thalita S Berteli, MSc1, Fang Wang, PhD2, Fabiana B Kohlrausch, PhD3, Caroline M Da Luz, MSc1, Fernanda V Oliveira, PhD1, David L Keefe, MD4 and Paula A Navarro, MD, PhD3, 1Faculty of Medicine of Ribeirão Preto - USP, Ribeirão Preto, Brazil, 2New York University, Langone Medical Center, New York, NY, 3Fluminense Federal University, Niterói, Brazil, (4)NYU Grossman School of Medicine, New York, NY

P-758, Wednesday, October 20, 2021, 6:30 AM – 7:45 AM
POLYMERIC AND COLLAGEN BIOMATERIALS ENHANCE IMPLANTATION OF MOUSE BLASTOCYSTS IN THREE-DIMENSIONAL CULTURE MODELS.

Yagmur Ergun, MSc1, Gizem Nur Sahin, MSc2, Kubra Sevgin, MSc1, Ahmet Kocabay, MSc3, Ali Cihan Taskin, PhD4, Deniz Basoz, MSc Student5, Deniz Yucel, PhD6, Mehmet Gonen, PhD7 and Sercin Karahuseyinoglu, MD8, 1MSc,Koc University, Graduate School of Health Sciences, Reproductive Biology, Istanbul, Turkey, 2PhD Candidate,Koc University, Graduate School of Health Sciences, Reproductive Medicine, Istanbul, Turkey, 3Veterinary Health Supervisor,Koc University, Research Center For Translational Medicine, Istanbul, Turkey, 4Animal Facility Research Coordinator,Koc University, Research Center for Translational Medicine, Istanbul, Turkey, 5MSc Student,Acibadem University, Graduate School of Health Sciences, Medical Biotechnology, Istanbul, Turkey, 6Asst. Prof.,Acibadem University, School of Medicine, Histology & Embryology, Istanbul, Turkey, 7Assoc. Prof.,Koc University College of Engineering, Istanbul, Turkey, 8Asst. Prof., Koc University School of Medicine, Histology & Embryology, Istanbul, Turkey

O-158, Tuesday, October 18, 2021, 11:00 AM
INHIBITION OF SHP2 DISRUPTS FSH-STIMULATED SYNTHESIS OF ESTROGEN IN GRANULOSA CELLS.

Sujuan Xi, Ph.D. student1, Zaiyi Li, Ph.D.1, Wenjing Lin, M.D.student1, Lin Chen, Ph.D.student1, Chengu Tia1, M.D.student1, Yanzhu Yang, M.D.3, Yao Guo, Ph.D.4, Zhihuang Zhao, Ph.D.2, Yun Chen, Ph.D.3 and Lin Ma, Ph.D.1, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China, 2University of Oklahoma Health Sciences Center, OK, 3The Seventh Affiliated Hospital of Sun Yat-sen University

RESIDENT IN-TRAINING AWARD

This award recognizes the presenter of an exceptional abstract who is currently a resident in training in the field of obstetrics and gynecology or urology. Recipients of these awards specified that they would like to be eligible for the “Resident In-Training Award” during the online abstract submission process. The awardee receives:

• $500
• One-year free ASRM membership
• Free registration to ASRM 2021 in Baltimore, MD

O-4, Monday, October 18, 2021, 11:30 AM
DISPARITIES IN SURGICAL MANAGEMENT OF TUBAL ECTOPIC PREGNANCY.

Alexandra G. Huttler, MD1, Christopher X. Hong, MD2 and Divya Kelath Shah, M.D., M.M.E.2, 1Pennsylvania Hospital, University of Pennsylvania Health System, Baltimore, MD, (2)University of Pennsylvania, Baltimore, MD
IN-TRAINING AWARDS FOR RESEARCH

Five In-Training Awards for Research are granted in recognition of outstanding research conducted by individuals who are in-training. Recipients of these awards specified that they would like to be eligible for the “In-Training Award for Research” during the online abstract submission process. He/she is the presenting author (first) and a medical student, resident, fellow or undergraduate, graduate or postdoctoral student. The awardees receive:

- $250
- One-year free ASRM membership
- Free registration to ASRM 2021 in Baltimore, MD

MITOQUINONE RESCUES STRESS INDUCED MITOPHAGY IN AGED OOCYTES.

Shahla A Khan, PhD, Heidi J Engelhorn, MS, Deirdre Logsdon, MS, Rebecca Kile, MS, Courtney Grimm, MS, Benjamin B Goheen, BS, Laura Reed, BS, William B Schoolcraft, MD, Ye Yuan, PhD and Rebecca L. Krisher, PhD, Colorado Center for Reproductive Medicine, Lone Tree, CO, *Genus PLC, DeForest, WI

DNA DOUBLE-STRAND BREAKS FREQUENTLY CAUSE CHROMOSOME LOSS IN HUMAN EMBRYOS.

Jenna M Turocy, M.D., Columbia University Fertility Center, New York, NY, Michael V Zuccaro, PhD, Division of Molecular Genetics, Department of Pediatrics and Naomi Berrie Diabetes Center, New York, NY, Diego Marin, PhD, Genomic Prediction, Jia Xu, PhD, Genomic Prediction, Inc., North Brunswick, NJ, Nathan R Treff, PhD, HCLD, Genomic Prediction, North Brunswick, NJ and Dieter Egli, PhD, 1150 St. Nicholas Avenue, New York, NY

DEFECTIVE DECIDUALIZATION AFTER SEVERE PREECLAMPSIA IS CONNECTED TO DYSREGULATION OF PROGESTERONE RECEPTOR B AND ESTROGEN RECEPTOR 1.

Tamara Garrido-Gómez*, PhD, Nerea Castillo-Marco*, PhD student, Irene Muñoz-Blat, PhD student, Teresa Cordero, MSc, Mónica Clemente-Ciscar, PhD, Rogelio Montfort, PhD, Alfredo Perales, PhD, MD and Carlos Simón, MD, PhD, Igenomix Foundation, INCLIVA, Valencia, Spain, 1Igenomix SL, Valencia, Spain, 2Hospital Universitario La Fe, Valencia, Spain, 3Hospital Universitario La Fe, Valencia, Spain, 4Institute of Biomedical Research of Valencia, Spain

SRS IN-TRAINING AWARDS FOR RESEARCH

Three (3) SRS In-Training Awards for research are granted. The purpose of these awards is to recognize outstanding research conducted by individuals in-training. Recipients of these awards specified that they would like to be eligible for the “SRS In-Training Award for Research” during the online abstract submission process and submitted their abstract to the “Reproductive Surgery” category. He/she is a presenting author (first), and a medical student, resident, fellow or undergraduate, graduate or postdoctoral student. The awardees receive:

- $250.00
- One-year free ASRM and SRS membership
- Free registration to ASRM 2021 in Baltimore, MD

IMMEDIATE START IVF STIMULATION FOLLOWING POLYPECTOMY DOES NOT IMPACT PREGNANCY OUTCOMES IN LARGE MULTICENTER COHORT OF OVER SIXTEEN HUNDRED EMBRYO TRANSFERS.

Steven Gay, MD, Ashley Ulker, MD, Samad Jahandideh, PhD, Micah J Hill, DO, Kate Devine, MD, Eric A Widra, M.D. and Alan H DeCherney, MD, Program in Reproductive Endocrinology and Gynecology, NICHD,
NIH, Bethesda, MD, 2 University of Miami Miller School of Medicine, Miami, FL, 3 Shady Grove Fertility, Washington D.C., DC, 4 NIH, Bethesda, MD, 5 SG Fertility, Washington, DC, 6 NIH-NICHD, Bethesda, MD

O-159, Tuesday, October 19, 2021, 11:15 AM

COMPARISON OF ORTHOTOPIC (OA) AND HETEROTOPIC (HA) AUTOLOGOUS CRYOPRESERVED OVARIAN TISSUE TRANSPLANTATION (ACOTT) OUTCOMES.

Kutluk H Oktay, M.D., Ph.D. and Loris Marin, M.D., Yale University School of Medicine, New Haven, CT

O-275, Wednesday, October 20, 2021, 11:45 AM

HYSTEROSCOPIC UTERINE SEPTUM REPAIR IMPROVES MISCARRIAGE AND LIVE BIRTH RATES IN WOMEN SEEKING FERTILITY TREATMENT REGARDLESS OF SEPTUM SIZE

Kassie Jean Bollig, MD1, Alexandra G. Huttler, MD1, Craig A. Bollig, MD2 and Monica Mainigi, MD3, (1) University of Pennsylvania, Philadelphia, PA, (2) Rutgers Robert Wood Johnson Medical School, (3) University of Pennsylvania, Philadelphia, PA

SOCIETY FOR MALE REPRODUCTION AND UROLOGY TRAVELING SCHOLARS PROGRAM

The annual Society for Male Reproduction and Urology Traveling Scholars Program allows a diverse group of young clinical physicians and basic science researchers the opportunity to explore a career in male reproductive medicine. The primary purpose of the program is to stimulate the scientific interests of residents and fellows in the study of male reproduction. Scholars are selected by the SMRU Research Committee based on the scores of their abstracts submitted for the Scientific Congress. The SMRU Traveling Scholars oral abstract session will take place on Monday, October 18, 2021. The following Traveling Scholars will present their research during the session: Daniel Pelzman, M.D., O-58 “DISTANCE FROM HOSPITAL DOES NOT REDUCE UTILIZATION OF FERTILITY PRESERVATION IN MEN”; Alvaro Santamaria, M.D., O-59 “EFFICACY OF CLOMIPHENE CITRATE IN SUBFERTILE MEN STRATIFIED BY PRE-TREATMENT SEX HORMONE LEVELS AND SPERM CONCENTRATION”;

Khodamoradi, Ph.D., O-60, “ANDROGEN RECEPTOR SIGNALING IN HUMAN CORPUS CAVERNOSUM IS NOT DEPENDENT UPON HALF-LIFE OF TESTOSTERONE THERAPY.”

CAPPY ROTHMAN, M.D., CHUCK SIMS, M.D., AND THE CALIFORNIA CRYOBANK TRAVELING SCHOLAR AWARD

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The recipient for 2021 is Kian Asanad, M.D., who will present abstract O-55, “GEOGRAPHICAL DIFFERENCES IN DEMOGRAPHICS AND FERTILITY HISTORIES OF MEN PRESENTING FOR INFERTILITY EVALUATION BETWEEN THE UNITED STATES AND CANADA: RESULTS FROM THE ANDROLOGY RESEARCH CONSORTIUM” in the SMRU Traveling Scholars oral abstract session on Monday, October 18, 2021.

SMRU LIPSHULTZ/LAMB TRAVELING SCHOLAR AWARD

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The recipient for 2021 is Raevti Bole, M.D., M.A., who will present abstract O-56, “TOTAL MOTILE SPERM COUNT IS ASSOCIATED WITH ICSI SUCCESS USING SPERM OBTAINED BY TESE” in the SMRU Traveling Scholars oral abstract session on Monday, October 18, 2021.

WEILL CORNELL MALE REPRODUCTIVE SURGERY AND UROLOGY TRAVELING FELLOW AWARD

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The recipient for 2021 is Jasper C Bash, M.D., who will present abstract O-57, “THE EFFECT OF CHRONIC DELTA-9-TETRAHYDROCANNABINOL USE ON MALE REPRODUCTIVE HEALTH IN RHESUS MACAQUES” in the SMRU Traveling Scholars oral abstract session on Monday, October 18, 2021.
AFFILIATED SOCIETY PRIZE PAPERS


SART PRIZE PAPER

O-241, Wednesday, October 20, 2021, 10:45 AM
A RANDOMIZED CONTROLLED TRIAL COMPARING LIVE BIRTH FROM SINGLE EUPLOID FROZEN BLASTOCYST TRANSFER USING STANDARDIZED TIMING VERSUS TIMING BY ENDOMETRIAL RECEPTIVITY ANALYSIS. Nicole Doyle, MD, PhD1, Samad Jahandideh, PhD1, Micah J Hill, DO2, Eric A Widra, M.D.1, Michael Levy, M.D.1 and Kate Devine, MD1, 1Shady Grove Fertility Center, Rockville, MD, 2NIH, Bethesda, MD

SRS PRIZE PAPER

O-194, Wednesday, October 20, 2021, 11:00 AM
POLYCYSTIC OVARY SYNDROME AND RISK OF ADVERSE PREGNANCY OUTCOMES: A REGISTRY LINKAGE STUDY FROM MASSACHUSETTS. Leslie V Farland, ScD1, Judy E Stern, PhD2, Chia-Ling Liu, RN, MPH, ScD3, Howard J Cabral, PhD, MPH, Charles C Coddington, MD5, Dmitriy Dukhovny, MD MPH6, Hafsataou Diop, MD, MPH3, Sunah S Hwang, MD MPH7 and Stacey A Missmer, Sc.D.8, 1Mel and Enid Zuckerman College of Public Health, Tucson, AZ, (2)Dartmouth-Hitchcock, Lebanon, NH, (3)MPDH, Boston, MA, (4)Boston University, Boston, MA, (5)Atrium Health Reproductive Medicine, Charlotte, NC, (6)Oregon Health & Science University, Portland, OR, (7)University of Colorado School of Medicine, Aurora, CO, (8)College of Human Medicine, Michigan State University, Grand Rapids, MI

SMBT BASIC SCIENCE AWARD

A prize of $500, made possible by a donation from LifeAire Systems, is awarded to a basic reproductive science abstract submitted in either a Reproductive Biology or Reproductive Technology category for the ASRM 2021 Scientific Congress. The abstract was selected for either oral or poster presentation. Abstracts were evaluated by the corresponding abstract grading committee based on originality, experimental design, quality, and significance.

O-183, Tuesday, October 19, 2021, 11:15 AM
SINGLE CELL DNA SEQUENCING OF WHOLE HUMAN BLASTOCYSTS: NOVEL INSIGHTS INTO THE PHENOMENON OF EMBRYONIC MOSAICISM. Jenna Friedenthal, M.D.1, Ethan Ellis, BS1, Joseph A. Lee, BA2, Christine Briton-Jones, PhD, HCLD1, Erkan Buyuk, MD1, Kristin Beaumont, PhD1, Robert P. Sebra, PhD1, Eric Schadt, PhD1 and Alan B Copperman, MD1, 1Icahn School of Medicine at Mount Sinai, New York, NY, 2Reproductive Medicine Associates of New York, New York, NY

SRBT CLINICAL SCIENCE AWARD

A prize of $500, made possible by a donation from Irvine Scientific, Inc., is awarded to a clinical reproductive science abstract submitted in either a Reproductive Biology or Reproductive Technology category for the ASRM 2021 Scientific Congress. The abstract was selected for either oral or poster presentation. Abstracts were evaluated by the corresponding abstract grading committee based on originality, experimental design, quality, and significance.

O-253, Wednesday, October 20, 2021, 10:45 AM
RECOMBINATION EVENTS THAT PREDISPOSE MATERNAL CHROMOSOMES TO INCREASED MISSEGREGATION ARE MORE THAN JUST A NUMBER. Blair R McCallie, PhD1, Mary E Haywood, PhD1, William B Schoolcraft, MD2 and Mandy G Katz-Jaffe, PhD1, 1CCRM Genetics, Lone Tree, CO, 2CCRM Colorado, Lone Tree, CO
PROFESSIONAL AND SPECIAL INTEREST GROUPS (SIG)

Several groups have selected prize papers for cash awards.

Association of Reproductive Managers Prize Paper
O-75, Monday, October 18, 2021, 11:15 AM

Early Pregnancy SIG Prize Papers
O-15, Monday, October 18, 2021, 11:15 AM
BEDSIDE TEST TO RULE OUT AN ECTOPIC PREGNANCY USING A MODIFIED FDA APPROVED KIT. Michelle Volovskiy, MBBS (Hons)1, Maria G Duarte, MD1, Hugh S. Taylor, MD2 and Amir Mor, MD PhD3, [1]Maimonides Medical Center, New York, NY, [2]Yale University, New Haven, CT, [3]Yale School of Medicine, New Haven, CT


Endometriosis SIG Prize Papers
O-119, Tuesday, October 19, 2021, 11:45 AM
MACROSCOPIC AND MICROSCOPIC FINDINGS OF THE PLACENTA IN WOMEN WITH ENDOMETRIOSIS AND ADENOMYOSIS. Simone Ferrero, MD PhD1, University of Genova, Genoa, Italy, Carolina Scala, MD, Istituto G. Gaslini, Genova, Italy, Umberto Leone Roberti Maggiore, MD, PhD, Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy, Stefano Bogliolo, MD, Lavagna Hospital, Lavagna, Italy, Fabio Barra, MD, DINOGMI, University of Genova, Genova, Italy and Valerio Gaetano Vellone, MD, PhD, Anatomic Pathology, Genova, Italy

Fertility Preservation SIG Prize Paper
O-110, Tuesday, October 19, 2021, 11:15 AM
A prize of $500 made possible by a donation from Ferring Pharmaceuticals, Inc., is awarded to an abstract submitted in the Fertility Preservation category.

CANCER TREATMENT IS ASSOCIATED WITH A MEASURABLE DECREASE IN LIVE BIRTHS IN A LARGE, POPULATION-BASED STUDY. Deepika Garg, MD1, Huong Dieu Meeks, PhD1, Erica Johnstone, MD1, Alexander W Pastuszak, MD, PhD2, Sarah L Berga, MD2, Ken R Smith, PhD1, James Hotaling, MD2 and Joseph M Letourneau, MD1, [1]University of Utah, Salt Lake City, UT, [2]University of Utah School of Medicine, Salt Lake City, UT
Fibroids SIG Prize Paper
This award is supported by the Fibroids Special Interest Group Leadership.

O-27, Monday, October 18, 2021, 11:15 AM
TRANSCRIPTOMICS ANALYSIS SHOWS PROFOUND ETHNIC DIFFERENCES IN AT RISK PRE-FIBROID MYOMETRIUM. Maria Victoria Bariani, Ph.D.1, Sandra L. Grimm, Ph.D.2, Mohamed Ali, Ph.D3, Cristian Coarfa, Ph.D.2, Qiwei Yang, Ph.D.1 and Ayman Al-Hendy, MD, PhD1, 1Department of Obstetrics and Gynecology, University of Chicago, 2Baylor College of Medicine, Houston, TX, 3Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

Health Disparities SIG Prize Paper
This award is supported by the Health Disparities Special Interest Group Chair.

O-32, Monday, October 18, 2021, 11:00 AM
INSURANCE COVERAGE DOES NOT MITIGATE RACIAL AND ETHNIC DISPARITIES SEEN IN FERTILITY TREATMENT UTILIZATION: A SURVEY OF US POSTPARTUM WOMEN. Jerrine R. Morris, MD, MPH,1 University of California, San Francisco School of Medicine, San Francisco, CA, Brent C. Monseur, MD, ScM, Stanford Hospitals and Clinics, Sunnyvale, CA, Tia Jackson-Bey, MD MPH, Reproductive Medicine Associates of New York, New York, NY and Heather S Hipp, MD, Emory University, Atlanta, GA

Nutrition SIG Prize Paper
A prize of $250 made possible by a donation from Theralogix, is awarded to an abstract submitted in the Nutrition category.

P-398, Tuesday, October 19, 2021, 6:30 AM - 7:45 AM
IMPACT OF VITAMIN D LEVEL ON EARLY PREGNANCY OUTCOMES IN OBESE PATIENTS FOLLOWING INTRAUTERINE INSEMINATION. Wes Urian, MD1, Elizabeth S Rubin, MD2, Pamela B. Parker, MD, MPH1, Mary O Solomon, MD3, Olivia Nolan, MD1, Bharti Garg, MBBS, MPH3, Diana Wu, MD1, Jamie Peregrine, MD, MS1, David Lee, MD4, Paula Arnato, MD1, Thomas O’Leary, PhD5 and Sacha A. Krieg, M.D., Ph.D., 1Oregon Health & Science University, Portland, OR, 2Oregon Health & Sciences University, OR, 3Oregon Health and Science University, Portland, OR, 4Oregon Health & Science University, 5Fertility Center of New Mexico, Albuquerque, NM

Reproductive Immunology SIG Prize Paper

O-265, Wednesday, October 20, 2021, 10:45 AM
IFN-B DISRUPTS INVASIVE EXTRAVILLOUS TROPHOBLASTS FUNCTION ON IMPLANTATION-ON-A-CHIP MODEL. Michael K. Simoni, MD1, Sneha Mani, PhD2, Ju Young Park, Ph.D.1, Dan Huh, PhD3, Kellie Jurado, Ph.D.1 and Monica Mainigi, MD2, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania

Final Program
77th ASRM Scientific Congress & Expo
Baltimore, Maryland
October 17-20, 2021

A final program for the 77th ASRM Scientific Congress & Expo is available, covering the event's dates and locations.
**VIDEO PRESENTATION AWARDS**

The Video Committee selects an overall first prize award video ($1,000), second place video ($500), and third prize video ($500). Individual category recognitions are identified by a certificate.

**First Prize Award Video**

V-1, Monday, October 18, 2021, 4:30 PM

3D SURFACE MAPPING FOR MORPHOLOGICAL EVALUATION OF HUMAN BLASTOCYSTS.

Guanqiao Shan, MASC1, Zhuoran Zhang, PhD1, Changsheng Dai, PhD1, Hang Liu, MASC1, Xian Wang, PhD2, Wenkun Dou, BS1, Khaled Abdalla, MASC3, Iryna Kuznyetsova, PhD3, Clifford Lawrence Librach, MD1 and Yu Sun, PhD1, 1University of Toronto, Toronto, ON, Canada, 2Hospital for Sick Children, Toronto, ON, Canada, 3CreAte Fertility Centre, Toronto, ON, Canada

**Second Place Video**

V-2, Monday, October 18, 2021, 4:42 PM

ROBOTIC-ASSISTED LIVING DONOR HYSTERECTOMY - TECHNIQUE AND OUTCOME (DALLAS UTERUS TRANSPLANT STUDY).

Liza Johannesson, MD, PhD, E Colin Koon, MD, PhD, Johanna Bayer, MD, Greg J McKenna, MD and Giuliano Testa, MD, Baylor University Medical Center, Dallas, TX

**Third Place Video**

V-3, Monday, October 18, 2021, 4:54 PM

OVARIAN TISSUE HARVESTING AND CRYOPRESERVATION FROM A TODDLER WITH CLASSIC GALACTOSEMIA: A MULTIDISCIPLINARY APPROACH.

Alla Vash-Margila, MD1, Katarzyna Szymanska, PhD1, Saurabh Saluja, MD2, Emily Christison-Lagay, MD1 and Kutluk H Oktyay, M.D., Ph.D.3, 1Yale University School of Medicine, New Haven, CT, 2Yale University, New Haven, CT, 3Yale University School of Medicine

**ASRM 2021 MILESTONE AWARDS**

The ASRM Service Milestone Award recognizes 10, 15, and 20-year milestones for service on boards and/or committees of ASRM or its affiliated societies, professional groups, or special interest groups.

**20-Year ASRM Service Milestone Award Recipient**

Elizabeth Ginsburg, M.D.

**15-Year ASRM Service Milestone Award Recipient**

Kevin Doody, M.D.

**10-Year ASRM Service Milestone Award Recipients**

Carli Chapman, B.S.
Anuja Dokras, M.D., Ph.D.
Micah Hill, D.O.
Stanton Honig, M.D.
James Hotaling, M.D.
Kathleen Hwang, M.D.
Ertug Kovanci, M.D.
Alex Polotsky, M.D.
Brooke Rossi, M.D.
Joanna Scheib, Ph.D.
**SCHEDULE-AT-A-GLANCE**  
**POSTGRADUATE COURSES ARE ON-DEMAND**  
**BEGINNING THURSDAY, OCTOBER 21, 2021 THROUGH DECEMBER 31, 2021.**

### HALF DAY COURSES

<table>
<thead>
<tr>
<th>Course ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG01</td>
<td>Lessons from COVID-19 and Access to Care</td>
</tr>
<tr>
<td>PG02</td>
<td>Difficult Conversations: Tools, Tips, and Training for Effective Communication</td>
</tr>
<tr>
<td>PG03</td>
<td>Primary Ovarian Insufficiency and Fertility: A Mind and Body Approach</td>
</tr>
<tr>
<td>PG04</td>
<td>Optimizing Fresh and Frozen Embryo Transfer: Newest Evidence on Measuring, Timing, and Replacing Progesterone</td>
</tr>
<tr>
<td>PG05</td>
<td>Unexplained Infertility: Have A Look And You’ll Find The Answers</td>
</tr>
</tbody>
</table>

### FULL DAY COURSES

<table>
<thead>
<tr>
<th>Course ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG06</td>
<td>Changing with the Times: Mitigating Risk for Your ART Practice While Improving Care for Your Patients</td>
</tr>
<tr>
<td>PG07</td>
<td>Controversies in Recurrent Implantation Failure</td>
</tr>
<tr>
<td>PG08</td>
<td>Endometriosis and Adenomyosis Diagnosis, and Assessment: Clinical and Pathophysiological Perspectives</td>
</tr>
<tr>
<td>PG09</td>
<td>Reproductive Aging: Meeting the Challenges in Clinical and Laboratory Practice</td>
</tr>
<tr>
<td>PG10</td>
<td>Comprehensive Review of Genetic Carrier Screening: Genetic Counseling, Legal, and Physician Perspectives</td>
</tr>
<tr>
<td>PG11</td>
<td>A Critical Assessment of Invasive and Non-Invasive PGT What’s the Impact on ART?</td>
</tr>
<tr>
<td>PG12</td>
<td>Addressing Controversies in the Work up and Treatment of Recurrent Pregnancy Loss</td>
</tr>
<tr>
<td>PG13</td>
<td>Tricks of the Trade: Small Things That Can Make a BIG Difference in the IVF Lab</td>
</tr>
<tr>
<td>PG14</td>
<td>Challenges in Freeze All Embryos</td>
</tr>
<tr>
<td>PG15</td>
<td>Male Infertility and ART: An Update on the Diagnosis, Treatment, and Optimization of ART Outcomes</td>
</tr>
<tr>
<td>PG16</td>
<td>A Review of Clinical and Laboratory Sperm Selection Technologies to Optimize ART Outcomes</td>
</tr>
<tr>
<td>PG17</td>
<td>Cross-Border Family Building: Big Dreams, Small World</td>
</tr>
<tr>
<td>PG18</td>
<td>Vaginal Microbiome and Reproductive Health: From Research to Clinical Practice</td>
</tr>
<tr>
<td>PG19</td>
<td>Riding the Wave of Change: Keys to Success</td>
</tr>
<tr>
<td>PG20</td>
<td>Strategies to Improve the Safety of Controlled Ovarian Stimulation Protocols: Paving the Way for Ohss-Free IVF?</td>
</tr>
</tbody>
</table>

---

**SCHEDULE-AT-A-GLANCE**  
**SUNDAY, OCTOBER 17, 2021**

### HANDS-ON COURSES

**1:00 pm - 5:00 pm** Embryo Transfer Skills Workshop Afternoon Session (Hands-on Simulation)

### SUNDAY EVENING

**6:00 pm** ASRM 2021 President’s Gala benefiting the ASRM Research Institute
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am - 7:45 am</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>7:45 am - 8:30 am</td>
<td>ASRM 2021 Opening Ceremony</td>
</tr>
<tr>
<td>8:30 am - 9:15 am</td>
<td>Plenary (CR) President’s Guest Lecture: CRISPR: Rewriting DNA and the Future of Humanity</td>
</tr>
<tr>
<td>9:00 am - 12:00 am</td>
<td>Poster Setup</td>
</tr>
<tr>
<td>9:15 am - 10:00 am</td>
<td>Plenary (CR) Big Data for Health and Pregnancy</td>
</tr>
<tr>
<td>10:00 am - 10:45 am</td>
<td>Break</td>
</tr>
<tr>
<td>10:45 am - 12:15 pm</td>
<td>Scientific Congress Prize Paper Session 1 Oral Abstract Sessions</td>
</tr>
<tr>
<td>11:00 am - 12:00 pm</td>
<td>MHPG Clinical Session Psychological and Medical Experiences of Compensated Gestational Carriers in the U.S.</td>
</tr>
<tr>
<td>12:15 pm - 1:30 pm</td>
<td>Break/Lunch</td>
</tr>
<tr>
<td>12:15 pm - 1:30 pm</td>
<td>Resident Learning Session RMC1 – RMC35</td>
</tr>
<tr>
<td>12:20 pm - 1:20 pm</td>
<td>Roundtable Discussions RMC1 – RMC35</td>
</tr>
<tr>
<td>12:20 pm - 1:20 pm</td>
<td>Symposium CMC Industry-Sponsored Lunch Symposium: Exploring Access, Education, and Advocacy: An Honest Conversation</td>
</tr>
<tr>
<td>1:30 pm - 2:45 pm</td>
<td>Symposia (CR) The ABOG Foundation - Kenneth J. Ryan Ethics Symposium: Reimagining Reproductive Counseling and Treatment in an Era of Uncertainty: Pandemic Impacts on Fertility Care</td>
</tr>
<tr>
<td></td>
<td>The Impact of Private Equity on the Fertility Industry</td>
</tr>
<tr>
<td></td>
<td>PGT Yesterday, Today, and Tomorrow</td>
</tr>
<tr>
<td></td>
<td>Multidisciplinary and Collaborative Approach to Endometriosis in Fertility</td>
</tr>
<tr>
<td></td>
<td>ON-DEMAND ONLY SESSION: With (Reproductive) Justice for All: Addressing Systemic Inequalities in Reproductive Healthcare</td>
</tr>
<tr>
<td></td>
<td>Symposium on Long-Term Storage of Germplasms at Room Temperature - the End of the Ice Age</td>
</tr>
<tr>
<td></td>
<td>Knowledge is Power: Educating the Modern Day REI Nurse</td>
</tr>
<tr>
<td></td>
<td>Reimagining the Future of Male Reproductive Medicine in the Age of Telemmedicine and Beyond</td>
</tr>
<tr>
<td></td>
<td>SART-CORS Registry: The State of the ART</td>
</tr>
<tr>
<td></td>
<td>ON-DEMAND ONLY SESSION: CFAS Symposium: Cutting-Edge Technologies in the Advancement of Our Understanding of Early Development</td>
</tr>
<tr>
<td>3:00 pm - 3:45 pm</td>
<td>Plenary (CR) The David and Rosemary Adamson Lecture on Excellence in Reproductive Medicine: A Supportive Physiologic Environment for the Extreme Premature Infant, Progress and Future Application</td>
</tr>
<tr>
<td>3:00 pm - 3:45 pm</td>
<td>Plenary (CR) American Urological Association (AUA) Bruce Stewart Memorial Lecture: Compelling Evidence that Collaboration with Qualified Male Reproductive Urologists Improves ART Outcomes</td>
</tr>
<tr>
<td>3:45 pm - 4:30 pm</td>
<td>Break</td>
</tr>
<tr>
<td>4:15 pm - 5:30 pm</td>
<td>Video Session 1</td>
</tr>
<tr>
<td>4:30 pm - 5:30 pm</td>
<td>NPG Clinical Session Preparation for the Nurse Certificate Course in REI and Beyond – Day 1</td>
</tr>
<tr>
<td>4:30 pm - 5:30 pm</td>
<td>Interactive Sessions G1 PGT-a for Pregnancy Loss Prevention. Who Is It Good for?</td>
</tr>
<tr>
<td></td>
<td>Evidence Based Selection of Ovarian Stimulation Protocols for Fertility Preservation</td>
</tr>
<tr>
<td></td>
<td>Integrating the Reproductive Urologist within the Modern ART Practice</td>
</tr>
<tr>
<td></td>
<td>Asherman’s Syndrome: Surgery vs. Gestational Carrier/Surrogacy</td>
</tr>
<tr>
<td></td>
<td>The Vagina Dialogues: How the Vaginal Microbiome Is Emerging As a Key Factor in Reproductive Health</td>
</tr>
<tr>
<td></td>
<td>How to Optimize Outcomes for the Infertility Patient with PCOS</td>
</tr>
<tr>
<td></td>
<td>Listen, Learn, Speak: Bridging the Gap to True Diversity, Equity &amp; Inclusion From Where We Are Today</td>
</tr>
<tr>
<td></td>
<td>Snap, Tweet, Talk! Reimagining Patient Education with the Use of Social Media</td>
</tr>
<tr>
<td></td>
<td>Open-Identity Gamete Donation: What Are the Children Saying?</td>
</tr>
<tr>
<td></td>
<td>Hormone Therapy for Primary Ovarian Insufficiency and Menopausal Symptoms: Case Presentations</td>
</tr>
<tr>
<td></td>
<td>Addressing Mental Health for Patients with Pregnancy Loss: Inside and Outside the Fertility Clinic</td>
</tr>
</tbody>
</table>
### SCHEDULE-AT-A-GLANCE  TUESDAY, OCTOBER 19, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am - 7:45 am</td>
<td>Poster Abstract Session and Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 am - 8:30 am</td>
<td>Plenary</td>
<td>Pre-Plenary Lecture: Uncovering the Molecular Determinants of Successful Implantation in the Human Blastocyst</td>
</tr>
<tr>
<td>8:30 am - 9:15 am</td>
<td>Plenary</td>
<td>Camran Nezhat, M.D. Lectureship in Innovations in Medicine: In Vitro Gametogenesis: Considerations for Reversing Infertility</td>
</tr>
<tr>
<td>9:15 am - 10:00 am</td>
<td>Plenary</td>
<td>Stem Cell-Derived Gametes — How They May Change Human Reproduction</td>
</tr>
<tr>
<td>10:00 am - 10:45 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 am - 12:15 pm</td>
<td>Scientific Congress Prize Paper Session 2 Oral Abstract Sessions</td>
<td></td>
</tr>
<tr>
<td>12:15 pm - 1:30 pm</td>
<td>Resident Learning Session</td>
<td></td>
</tr>
<tr>
<td>12:20 pm - 1:20 pm</td>
<td>Roundtable Discussions</td>
<td>RTT01 – RTT32</td>
</tr>
<tr>
<td>1:30 pm - 2:45 pm</td>
<td>Symposia</td>
<td>KY Cha Symposium in Stem Cell Technology and Reproductive Medicine: Regenerative Medicine As the New Frontier in ART</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Challenging IVF: Management of Patients with Serious Medical Problems</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endometriosis: Mechanism, Endometrial Receptivity and Infertility</td>
</tr>
<tr>
<td></td>
<td></td>
<td>From the Lab to the Clinic: nPGT-A for Embryo Prioritization</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Representation Matters: The Task to Increase Diversity in Subspecialty REI Training</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Artificial Intelligence (AI) in the IVF Laboratory</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“It’s All in Her Head.” or Not?! Demystifying Pelvic Pain in Adolescent Females</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Natural Killer Cell-Mediated Immune Pathology and Reproductive Failures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Ticking of the Clock: Managing the Age-Related DOR Patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placing Endometriosis on the Global Health Agenda: A Joint WHO-ASRM Symposium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The European Society of Human Reproduction and Embryology (ESHRE) Symposium: Reproduction has Defeated Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ON-DEMAND ONLY SESSION: Endometriosis: Mechanism, Endometrial Receptivity and Infertility</td>
</tr>
<tr>
<td>3:00 pm - 3:45 pm</td>
<td>Plenary</td>
<td>Contraception Keynote Lecture: New Frontiers in Contraception Research</td>
</tr>
<tr>
<td>3:00 pm - 3:45 pm</td>
<td>Plenary</td>
<td>The Society for the Study of Reproduction Keynote Lecture: Genetic Basis of Meiotic Catastrophe: From Mice to Men</td>
</tr>
<tr>
<td>3:45 pm - 4:30 pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4:15 pm - 5:30 pm</td>
<td>Video Session 2</td>
<td></td>
</tr>
<tr>
<td>4:30 pm - 5:30 pm</td>
<td>MHPG Clinical Session</td>
<td>Testing - A Therapeutic Assessment Model in the Psychological Screening of Gestational Carriers</td>
</tr>
<tr>
<td>4:30 pm - 5:30 pm</td>
<td>Interactive Sessions</td>
<td>Oncofertility and Sperm Cryopreservation during the Global COVID-19 Pandemic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chat with Journal Editors: Good Scientific Publication, Manuscript Review, an Editorial Process</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To ICSI ALL or NOT to ICSI ALL: That’s the Question!</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Where Are the Brown Eggs?: Increasing Access to and Utilization of Third Party Reproduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Baltimore IVF History: The Doctor, the Mother and the Baby, The 4th IVF Baby Born in the US</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PGT-a: Is Transferring Segmental (full or mosaic, large or small) Aneuploidy Embryos Safe</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reimagining Reproduction: 3D SIS or Hysteroscopy for Uterine Cavity Evaluation?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reimagining the Complex Needs of Ovarian Insufficiency and Creating the Ultimate Reproductive Team</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Let’s Talk Legal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Academic Medicine Boot Camp: Strategies for Developing a Successful Career</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Details</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>6:30 am - 7:45 am</td>
<td>Poster Abstract Session and Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 am - 8:45 am</td>
<td>Plenary 0000</td>
<td>Herbert H. Thomas Plenary Lecture: Applications of Nuclear Transplantation in Reproductive Medicine</td>
</tr>
<tr>
<td>8:45 am - 9:15 am</td>
<td>ASRM 2021 Members Business Meeting</td>
<td></td>
</tr>
<tr>
<td>9:15 am - 10:00 am</td>
<td>Plenary 0000</td>
<td>Past and Future of IVF</td>
</tr>
<tr>
<td>10:00 am - 10:45 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 am - 12:15 pm</td>
<td>Oral Abstract Sessions</td>
<td></td>
</tr>
<tr>
<td>11:00 am - 12:00 pm</td>
<td>NPG Clinical Session</td>
<td>Preparation for the Nurse Certificate Course in REI and Beyond – Day 3</td>
</tr>
<tr>
<td>11:00 am - 12:00 pm</td>
<td>MHPG Clinical Session</td>
<td>Ethics Course: Reproductive Healthcare Ethic and Challenges in Modern Times</td>
</tr>
<tr>
<td>12:15 pm - 1:30 pm</td>
<td>Break/Lunch</td>
<td></td>
</tr>
<tr>
<td>12:15 pm - 1:30 pm</td>
<td>Resident Learning Session</td>
<td></td>
</tr>
<tr>
<td>12:20 pm - 1:20 pm</td>
<td>Roundtable Discussions</td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 2:45 pm</td>
<td>Symposia 0000</td>
<td>Howard and Georgeanna Jones Symposium on Assisted Reproductive Technology: Epigenetic/Genomic Anomalies in Oocytes/Embryos: Current Insights and Clinical Implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adenomyosis and Infertility: Medical and Surgical Management Strategies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surrogacy and the Modern Family: Medical, Ethical and Emotional Challenges of Complex Gestational Surrogacy Cases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transgender Youth: Navigating Parents, Peers, and Society While Envisioning Future Family Planning</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Crises Management: What We Have Learned from Catastrophic Events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ON-DEMAND ONLY SESSION: The Environment: It Affects More Than the Ice Caps!</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-Cancer Female Fertility Preservation: Severe Endometriosis, Premature Ovarian Insufficiency, Sickle Cell Disease</td>
</tr>
<tr>
<td>3:00 pm - 3:45 pm</td>
<td>Plenary 0000</td>
<td>The Society of Reproductive Surgeons Lecture: A History of and Future For Endometriosis Surgery – What I Wish I Had Known in 1979</td>
</tr>
<tr>
<td>3:00 pm - 3:45 pm</td>
<td>Keynote 0000</td>
<td>Menopause Keynote Lecture: Menopausal HRT and Reduction of CVD and All-Cause Mortality: It’s About Time and Timing</td>
</tr>
<tr>
<td>3:45 pm - 4:45 pm</td>
<td>Interactive Sessions 0000</td>
<td>Varicocelectomy in the Management of Male Factor Infertility – an Interactive Discussion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Core Business Principles, Administrative Functions of IVF Practice and Best Marketing Strategies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Complex Family Planning Fellows Showcase</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ON-DEMAND ONLY: Say Her Name: Patient Perspectives and Advocacy for Black Women Facing Infertility</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endometrial Receptivity and ART Outcome: To Test or Not to Test?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Contemporary Management of Turner Syndrome: Case Presentations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dietary Patterns and Fertility</td>
</tr>
<tr>
<td></td>
<td></td>
<td>What Every ASRM Member Needs to Know about the New AUA/ASRM Male Infertility Guidelines</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ASRM Mullerian Anomaly Classification 2021</td>
</tr>
</tbody>
</table>

**SCHEDULE-AT-A-GLANCE  THURSDAY, OCTOBER 21, 2021**

ASRM Postgraduate Program (On-Demand) access opens today and runs to December 31, 2021
### SUNDAY, OCTOBER 17, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:15 pm - 6:00 pm</td>
<td>Preimplantation Genetic Testing Special Interest Group (PGTSIG)</td>
<td>Hilton Baltimore Inner Harbor - Poe</td>
</tr>
<tr>
<td></td>
<td>Menopause and Ovarian Insufficiency Special Interest Group (MOISIG)</td>
<td>Hilton Baltimore Inner Harbor - Calloway</td>
</tr>
</tbody>
</table>

### MONDAY, OCTOBER 18, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:45 pm - 6:30 pm</td>
<td>Social Media Group (SocMe)</td>
<td>Baltimore Convention Center - 327-328</td>
</tr>
<tr>
<td></td>
<td>Androgen Excess Special Interest Group (AESIG)</td>
<td>Baltimore Convention Center - 329</td>
</tr>
<tr>
<td>5:45 pm - 6:45 pm</td>
<td>Members’ Meeting: Genetic Counseling Professional Group (GCPG)</td>
<td>Baltimore Convention Center - 324-326</td>
</tr>
<tr>
<td>5:45 pm - 7:00 pm</td>
<td>Members’ Meeting: Nurses’ Professional Group (NPG) - Meeting &amp; Reception</td>
<td>Hilton Baltimore Inner Harbor - Calloway</td>
</tr>
<tr>
<td></td>
<td>Society for Assisted Reproductive Technology (SART)</td>
<td>Baltimore Convention Center - 321-323</td>
</tr>
<tr>
<td>6:00 pm - 7:00 pm</td>
<td>Fertility Preservation Special Interest Group (FPSiG) - Meeting &amp; Reception</td>
<td>Hilton Baltimore Inner Harbor - Poe</td>
</tr>
<tr>
<td></td>
<td>Legal Professional Group (LPG)</td>
<td>Hilton Baltimore Inner Harbor - Pickersgill</td>
</tr>
<tr>
<td>6:15 pm - 7:00 pm</td>
<td>Physician-Scientists’ Special Interest Group (PSSiG)</td>
<td>Baltimore Convention Center - 318-320</td>
</tr>
<tr>
<td>6:15 pm - 8:00 pm</td>
<td>Society of Reproductive Surgeons (SRS) - Meeting &amp; Fellows Reception</td>
<td>Hilton Baltimore Inner Harbor - Blake</td>
</tr>
</tbody>
</table>

### TUESDAY, OCTOBER 19, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:45 pm - 6:30 pm</td>
<td>Society for Reproductive Endocrinology &amp; Infertility (SREI)</td>
<td>Baltimore Convention Center - 324-326</td>
</tr>
<tr>
<td></td>
<td>LGBTQ Special Interest Group (LGBTQSIG)</td>
<td>Baltimore Convention Center - 329</td>
</tr>
<tr>
<td></td>
<td>Fibroids Special Interest Group (FSIG)</td>
<td>Baltimore Convention Center - 331-332</td>
</tr>
<tr>
<td></td>
<td>Endometriosis Special Interest Group (EndoSIG)</td>
<td>Baltimore Convention Center - 327-328</td>
</tr>
<tr>
<td>5:45 pm - 7:30 pm</td>
<td>Society of Reproductive Biologists &amp; Technologists (SRBT) - Meeting &amp; Reception</td>
<td>Hilton Baltimore Inner Harbor - Calloway B</td>
</tr>
<tr>
<td>6:15 pm - 7:00 pm</td>
<td>Turkish Special Interest Group (TSIG)</td>
<td>Baltimore Convention Center - 339-340</td>
</tr>
<tr>
<td>6:15 pm - 7:30 pm</td>
<td>Association of Reproductive Managers (ARM) - Meeting &amp; Reception</td>
<td>Hilton Baltimore Inner Harbor - Mencken</td>
</tr>
</tbody>
</table>
## Daily Schedule Key to Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>SART</td>
<td>Society for Assisted Reproductive Technology</td>
</tr>
<tr>
<td>SMRU</td>
<td>Society for Male Reproduction and Urology</td>
</tr>
<tr>
<td>SRBT</td>
<td>Society of Reproductive Biologists and Technologists</td>
</tr>
<tr>
<td>SREI</td>
<td>Society for Reproductive Endocrinology and Infertility</td>
</tr>
<tr>
<td>SRS</td>
<td>Society of Reproductive Surgeons</td>
</tr>
<tr>
<td>ARM</td>
<td>Association of Reproductive Managers</td>
</tr>
<tr>
<td>GCPG</td>
<td>Genetic Counseling Professional Group</td>
</tr>
<tr>
<td>LPG</td>
<td>Legal Professional Group</td>
</tr>
<tr>
<td>MHPG</td>
<td>Mental Health Professional Group</td>
</tr>
<tr>
<td>NPG</td>
<td>Nurses' Professional Group</td>
</tr>
<tr>
<td>ATCSIG</td>
<td>Access to Care Special Interest Group</td>
</tr>
<tr>
<td>AESIG</td>
<td>Androgen Excess Special Interest Group</td>
</tr>
<tr>
<td>CIMSIG</td>
<td>Complementary and Integrative Medicine Special Interest Group</td>
</tr>
<tr>
<td>CFPSIG</td>
<td>Complex Family Planning Special Interest Group</td>
</tr>
<tr>
<td>ChSIG</td>
<td>Chinese Special Interest Group</td>
</tr>
<tr>
<td>EndoSIG</td>
<td>Endometriosis Special Interest Group</td>
</tr>
<tr>
<td>EPSIG</td>
<td>Early Pregnancy Special Interest Group</td>
</tr>
<tr>
<td>ERSIG</td>
<td>Environment and Reproduction Special Interest Group</td>
</tr>
<tr>
<td>FPSIG</td>
<td>Fertility Preservation Special Interest Group</td>
</tr>
<tr>
<td>FSIG</td>
<td>Fibroids Special Interest Group</td>
</tr>
<tr>
<td>HDSIG</td>
<td>Health Disparities Special Interest Group</td>
</tr>
<tr>
<td>ISIG</td>
<td>Indian Special Interest Group</td>
</tr>
<tr>
<td>IRMSIG</td>
<td>Imaging in Reproductive Medicine Special Interest Group</td>
</tr>
<tr>
<td>LGBTQSIG</td>
<td>LGBTQ Special Interest Group</td>
</tr>
<tr>
<td>MOISIG</td>
<td>Menopause and Ovarian Insufficiency Special Interest Group</td>
</tr>
<tr>
<td>NutriSIG</td>
<td>Nutrition Special Interest Group</td>
</tr>
<tr>
<td>PAGSIG</td>
<td>Pediatric and Adolescent Gynecology Special Interest Group</td>
</tr>
<tr>
<td>PGTSIG</td>
<td>Preimplantation Genetic Testing Special Interest Group</td>
</tr>
<tr>
<td>PSSIG</td>
<td>Physician-Scientists' Special Interest Group</td>
</tr>
<tr>
<td>RISIG</td>
<td>Reproductive Immunology Special Interest Group</td>
</tr>
<tr>
<td>RMSCBSIG</td>
<td>Regenerative Medicine and Stem Cell Biology Special Interest Group</td>
</tr>
<tr>
<td>TSIG</td>
<td>Turkish Special Interest Group</td>
</tr>
<tr>
<td>UTSIG</td>
<td>Uterine Transplant Special Interest Group (Forming)</td>
</tr>
<tr>
<td>WC</td>
<td>Women’s Council</td>
</tr>
<tr>
<td>AE-PCOS Society</td>
<td>Androgen Excess and Polycystic Ovary Syndrome Society</td>
</tr>
<tr>
<td>ALMER</td>
<td>Latin American Association for Reproductive Medicine</td>
</tr>
<tr>
<td>AMMR</td>
<td>Mexican Association of Reproductive Medicine</td>
</tr>
<tr>
<td>ASPIRE</td>
<td>Asia Pacific Initiative in Reproduction</td>
</tr>
<tr>
<td>CFAS</td>
<td>Canadian Fertility and Andrology Society</td>
</tr>
<tr>
<td>CSRM</td>
<td>Chinese Society of Reproductive Medicine</td>
</tr>
<tr>
<td>ESHRE</td>
<td>European Society of Human Reproduction and Embryology</td>
</tr>
<tr>
<td>ISAR</td>
<td>Indian Society for Assisted Reproduction</td>
</tr>
<tr>
<td>JSAR</td>
<td>Japan Society of Assisted Reproduction</td>
</tr>
<tr>
<td>MEFS</td>
<td>Middle East Fertility Society</td>
</tr>
<tr>
<td>SSR</td>
<td>Society for the Study of Reproduction</td>
</tr>
</tbody>
</table>
**SUNDAY, OCTOBER 17, 2021**

1:00 PM – 5:00 PM
Embryo Transfer Skills Workshop
(Hands-on Simulation)
Afternoon session

6:00 PM
ASRM 2021 President’s Gala
Benefiting the ASRM Research Institute

**MONDAY, OCTOBER 18, 2021**

7:00 AM – 7:45 AM
Continental Breakfast
Opening Ceremony continental breakfast is sponsored by Myovant Sciences, Inc.

7:45 AM – 8:30 AM
ASRM2021 Opening Ceremony
Hugh S. Taylor, M.D.
Yale University School of Medicine

8:30 AM – 9:15 AM
Plenary
President’s Guest Plenary Lecture: CRISPR: Rewriting DNA and the Future of Humanity
Endowed by a 1987 grant from Ortho Women’s Health
Jennifer Doudna, Ph.D.
University of California, Berkeley

9:15 AM – 10:00 AM
Plenary
Plenary Lecture: Big Data for Health and Pregnancy
Endowed by a 1990 grant from TAP Pharmaceutical
Michael Snyder, Ph.D.
Stanford University

10:00 AM – 10:45 AM
Break

11:00 AM – 12:00 PM
Clinical Session
MPHG Clinical Session: Psychological and Medical Experiences of Compensated Gestational Carriers in the U.S.
Angela K. Lawson, Ph.D. (Chair)
Northwestern University
Guy E. Ringler, M.D.
California Fertility Partners
Janelle Watson, LMFT, PMH-C
California Fertility Partners

12:15 PM – 1:30 PM
Resident Learning Session
David Shin, M.D. (Chair)
Hackensack University Medical Center

12:20 PM – 1:20 PM
Roundtable Discussions
RTM01 – RTM35

12:20 AM – 1:20 PM
CME
Symposium
The ABOG Foundation - Kenneth J. Ryan Ethics Symposium: Reimagining Reproductive Counseling and Treatment in an Era of Uncertainty: Pandemic Impacts on Fertility Care Supported by a 2013 endowment from the American Board of Obstetrics and Gynecology
Louise Perkins King, M.D., J.D. (Chair)
Affiliation not provided
Enrique F Schisterman, Ph.D.
National Institute of Child Health and Human Development, Epidemiology Branch, DIPHR, NICHHD, NIH
Neil Silverman, M.D.
University of California, Los Angeles

1:30 PM – 2:45 PM
Symposium
Symposium on Long-Term Storage of Germplasms at Room Temperature - the End of the Ice Age
Pierre Comizzoli, D.V.M., Ph.D. (Chair)
Smithsonian Institution
Allison Hubel, Ph.D.
Smithsonian Institution
Pasqualino Loi, Ph.D.
Smithsonian Institution
Patrizio Pasquale, M.D., M.B.E., H.C.L.D.
University Hospitals Cleveland Medical Center/Case Western Reserve University

1:30 PM – 2:45 PM
Symposium
The Impact of Private Equity on the Fertility Industry
Brad Senstra, M.H.A. (Chair)
Seattle Reproductive Medicine
Derek Larkin, J.D., M.B.A.
Seattle Reproductive Medicine
Peter Klatsky, M.D.
In Vitro Sciences

1:30 PM – 2:45 PM
Symposium
PGT Yesterday, Today, and Tomorrow
Mark Hughes, Ph.D. (Chair)
CooperGenomics
James A. Grifo, M.D., Ph.D.
NYU Langone Prelude Fertility Center
Mike Large, Ph.D.
CooperSurgical
1:30 PM – 2:45 PM Symposium
Multidisciplinary and Collaborative Approach to Endometriosis in Fertility
Rebecca Flyckt, M.D. (Chair)
University Hospitals Cleveland Medical Center/Case Western Reserve University
Kathleen Hwang, M.D.
University Pittsburgh, Urology
Horace Roman, M.D., Ph.D.
Clinique Bouchard-Elsan

1:30 PM – 2:45 PM Symposium
SART-CORS Registry: The State of the ART
Amanda Nicole Kallen, M.D. (Chair)
Yale University
Jennifer F. Kawwass, M.D.
Emory University School of Medicine, Division of Reproductive Endocrinology and Infertility
Stacey A. Missmer, Sc.D.
Harvard T.H. Chan School of Public Health

1:30 PM – 2:45 PM Symposium
Knowledge Is Power: Educating the Modern Day REI Nurse
Jennifer M. Wood, R.N., B.S.N. (Chair)
Shady Grove Fertility
Jeanette Tomasino, Ph.D.
Northwell Health Fertility, Zucker School of Medicine at Hofstra/Northwell
Fady I. Sharara, M.D.
George Washington University
Allison B. Catherino, Ph.D.
EMD Serono, Inc.

1:30 PM – 2:45 PM Symposium
ON-DEMAND ONLY SESSION: CFA Symposium: Cutting-Edge Technologies in the Advancement of Our Understanding of Early Development
Simon Phillips, Ph.D. (Chair)
Ovo Clinic
Sophie Petropoulos, Ph.D.
Assistant Professor University of Montreal
Crystal Chan, M.D., M.Sc., F.R.C.S.C.
Lunenfeld-Tanenbaum Research Institute, Sinai Health System

3:00 PM – 3:45 PM Plenary
The David and Rosemary Adamson Lecture on Excellence in Reproductive Medicine: A Supportive Physiologic Environment for the Extreme Premature Infant, Progress and Future Application Endowed by Advanced Reproductive Care, Inc. and Rosemary and David Adamson, M.D.
Alan W. Flake, M.D., F.A.C.S., F.A.A.P.
CHOP Research Institute

3:00 PM – 3:45 PM Plenary
American Urological Association (AUA) Bruce Stewart Memorial Lecture: Compelling Evidence that Collaboration with Qualified Male Reproductive Urologists Improves ART Outcomes Supported by a grant from the American Urological Association
Marc Goldstein, M.D.
Weill Cornell Medicine, New York Presbyterian Hospital

4:30 PM – 5:30 PM Interactive Session
Snap, Tweet, Tok! Reimagining Patient Education with the Use of Social Media
Temeka Zore, M.D. (Chair)
Natalie M. Crawford, M.D., M.S.C.R.
Aspire Fertility Austin
Jasmine Johnson, M.D.
Aspire Fertility Austin

4:30 PM – 5:30 PM Interactive Session
NGC Clinical Session – Preparation for the Nurse Certificate Course in REI and Beyond – Day 1
Shalini Gunawardena, R.N., M.B.A. (Chair)
Kaiser Permanente Center for Reproductive Health
Kelly Lehl, B.S.N.
Kaiser Permanante Center for Reproductive Health
Meghan K. Pierce, M.S.N.
ARM
Dayna Browning, B.S.N.
IVI RMA New Jersey

4:30 PM – 5:30 PM Interactive Session
PGT-a for Pregnancy Loss Prevention. Who Is It Good for?
Paul Robert Brezina, M.D. (Chair)
Fertility Associates of Memphis
William G. Kearns, Ph.D.
Johns Hopkins University School of Medicine, Advagenix
Eric J. Forman, M.D.
Medical and Laboratory Director
Alleigh L.H. Boyd, M.S.
Stanford University
4:30 PM – 5:30 PM Interactive Session
Listen, Learn, Speak: Bridging the Gap to True Diversity, Equity & Inclusion From Where We Are Today
Tia Jackson-Bey, M.D., M.P.H. (Chair)
University of Illinois at Chicago, College of Medicine

4:30 PM – 5:30 PM Interactive Session
Open-Identity Gamete Donation: What Are the Children Saying?
Kriston Ward, M.S.N. (Chair)
Strong Fertility Center
Jennifer Gamper, B.S.N., M.S.W.
Strong Fertility Center
Greg Moga, B.A., J.D.
RMANJ
Wendy Kramer, B.A.
Donor Sibling Registry
Gina Davis, M.S., L.C.G.C.
Advocate Genetics

4:30 PM – 5:30 PM Interactive Session
Evidence Based Selection of Ovarian Stimulation Protocols for Fertility Preservation
Kutluk H. Oktay, M.D., Ph.D. (Chair)
Yale University School of Medicine
Clarisa Gracia, M.D., M.S.C.E.
University of Pennsylvania, Division of Reproductive Endocrinology and Infertility
Kenny A. Rodriguez-Wallberg, M.D., Ph.D.
Karolinska University Hospital

4:30 PM – 5:30 PM Interactive Session
Integrating the Reproductive Urologist within the Modern ART Practice
Cigdem Tanrikut, M.D. (Chair)
Shady Grove Fertility
Thomas L. Toth, M.D.
Boston IVF
S. Puneet Masson, M.D.
Penn Medicine

4:30 PM – 5:30 PM Interactive Session
Asherman’s Syndrome: Surgery vs. Gestational Carrier/Surrogacy
Samantha Pfeifer, M.D. (Chair)
Weill Medical College of Cornell University
Zaraq Khan, M.D.
Mayo Clinic
Carlos Simon, M.D., Ph.D.
University of Valencia; Igenomix Foundation-INCLIVA

4:30 PM – 5:30 PM Interactive Session
The Vagina Dialogues: How the Vaginal Microbiome Is Emerging As a Key Factor in Reproductive Health
Anne E. Burke, M.D., M.P.H. (Chair)
Johns Hopkins University School of Medicine
Michelle Shardell, Ph.D.
University of Maryland School of Medicine
Susan Tuddenham, M.D.
University of Maryland School of Medicine

4:30 PM – 5:30 PM Interactive Session
How to Optimize Outcomes for the Infertility Patient with PCOS
Heather G. Huddleston, M.D. (Chair)
University of California San Francisco
Anuja Dokras, M.D., Ph.D.
University of Pennsylvania Perelman School of Medicine
Richard S. Legro, M.D.
Penn State College of Medicine

4:30 PM – 5:30 PM Interactive Session
Addressing Mental Health for Patients with Pregnancy Loss: Inside and Outside the Fertility Clinic.
Lora K. Shahine, M.D. (Chair)
Pacific Northwest Fertility and IVF Specialists
Alice D. Domar, Ph.D.
Boston IVF

7:00 AM – 8:00 AM Women’s Council Breakfast

8:00 AM – 8:30 AM Plenary
Pre-Plenary Lecture: Uncovering the Molecular Determinants of Successful Implantation in the Human Blastocyst
Heidi Cook-Andersen, M.D., Ph.D.
University of California, San Diego

8:30 AM – 9:15 AM Plenary
Camran Nezhat, M.D. Lectureship in Innovations in Medicine: In Vitro Gametogenesis: Considerations for Reversing Infertility
Endowed by a 2011 Gift from Camran Nezhat, M.D. Dr. Camran Nezhat pioneered techniques of video-assisted endoscopic surgery, which revolutionized modern day surgery. He along with his brothers, Drs. Farr and Ceana Nezhat, performed some of the most advanced procedures with these techniques for the first time, thus opening the vistas for endoscopic surgeons all over the world. Amander T. Clark, Ph.D.
University of California, Los Angeles

9:15 AM – 10:00 AM Plenary
Plenary Lecture: Stem Cell-Derived Gametes — How They May Change Human Reproduction
Endowed by a 1990 grant from Astra-Zeneca
Henry T. Greely, J.D.
Stanford University

10:00 AM – 10:45 AM Break
10:45 AM – 12:15 PM
Video Surgical Tutorial
Repair of Cesarean Section Scar Defects: Hysteroscopic Vs. Laparoscopic Approach
Steven R. Lindheim, M.D., M.M.M. (Chair)
Wright State University
Balasubramanian Bhagavath, M.B.B.S.
University of Rochester Medical Center
Charles E. Miller, M.D.
The Advanced Gynecologic Surgery Institute/The Advanced IVF Institute,
Charles E. Miller, M.D. & Associates

11:00 AM – 12:00 PM
NPG Clinical Session
Preparation for the Nurse Certificate Course in REI and Beyond – Day 2
Erin Ann Yontz, B.A., M.S.N. (Chair)
AllianceRX Walgreen Prime
Lauri D. Black, M.S., C.G.C.
Pacific Reproductive Genetic Counseling

12:15 PM – 1:30 PM
Lunch / Break

12:15 PM – 1:30 PM
Resident Learning Session
Christopher Hemdon, M.D. (Chair)
Northwestern University

12:20 PM – 1:20 PM
Roundtable Discussions
RTO1 – RTO32

1:30 PM – 2:45 PM
Symposium
KY Cha Symposium in Stem Cell Technology and Reproductive Medicine: Regenerative Medicine As the New Frontier in ART
Supported by the Asia-Pacific Biomedical Research Foundation
T. Arthur Chang, Ph.D., H.C.L.D., E.L.D. (Chair)
University of Texas Health Science Center
Shoukhart Mitalipov, Ph.D.
Oregon Health & Science University
Monica M Laronda, Ph.D.
Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago

1:30 PM – 2:45 PM
Symposium
The Ticking of the Clock: Managing the Age-Related DOR Patient
Hayley Eichlin, D.N.P., A.P.R.N., W.H.N.P.-BC. (Chair)
Sheri Hovdestad, M.A., L.P.C., N.C.C.
IVI-RMA Global

1:30 PM – 2:45 PM
Symposium
ON-DEMAND ONLY SESSION: Endometriosis: Mechanism, Endometrial Receptivity and Infertility
Qing Xue, M.D., Ph.D. (Chair)
Peking University First Hospital
Jae-Wook Jeong, Ph.D.
Michigan State University
Meirong Du, Ph.D.
Fudan University Shanghai Medical College

1:30 PM – 2:45 PM
Symposium
Representation Matters: The Task to Increase Diversity in Subspecialty REI Training
Mia Mallory, M.D., M.Ed. (Chair)
John Hopkins Medicine
Gloria Richard-Davis, M.D.
University of Arkansas Medical Sciences
Sherita Hill Golden, M.D., M.H.S.
John Hopkins Medicine

1:30 PM – 2:45 PM
Symposium
Placing Endometriosis on the Global Health Agenda: A Joint WHO-ASRM Symposium
G. David Adamson, M.D. (Co-chair)
Stanford University
Valerie Flores, M.D. (Co-chair)
Yale School of Medicine
James N. Kiarie, M.D.
World Health Organization
Stacey Misser, Sc.D.
Michigan State University
Sylvia Mechsner, M.D.
Charite University
Kelechi Nnoaham, M.D., Ph.D.
Public Health Foundation of Nigeria
Hugh S. Taylor, M.D.
Yale School of Medicine

1:30 PM – 2:45 PM
Symposium
"It's All in Her Head." or Not?! Demystifying Pelvic Pain in Adolescent Females
Alla Vash-Margita, M.D. (Chair)
Yale University School of Medicine
Lauren Fussner, Ph.D.
Yale University School of Medicine
Leonel Rodriguez, M.D., M.S.
Yale University School of Medicine

1:30 PM – 2:45 PM
Symposium
Natural Killer Cell-Mediated Immune Pathology and Reproductive Failures
Joanne Kwak-Kim, M.D., M.P.H. (Chair)
Reproductive Medicine and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science
Atsushi Fukui, M.D., Ph.D.
Hyogo College of Medicine
Warren J Huber III, M.D., Ph.D.
W.H.N.P-BC.
Warren Alpert Medical School of Brown University; Women & Infants Hospital

1:30 PM – 2:45 PM
Symposium
From the Lab to the Clinic: niPGT-A for Embryo Prioritization
Alyssa Snider, M.S., Ph.D., C.G.C. (Chair)
igenomix
Erin Barone, M.S., G.C.
igenomix
Nina Resettova, M.D., M.B.A.
Beth Israel Deaconness Medical Center/Harvard Medical School

1:30 PM – 2:45 PM
Symposium
"The Ticking of the Clock: Managing the Age-Related DOR Patient"
Hayley Eichlin, D.N.P., A.P.R.N., W.H.N.P.-BC. (Chair)
Sheri Hovdestad, M.A., L.P.C., N.C.C.
IVI-RMA Global
1:30 PM – 2:45 PM Symposium
Challenging IVF: Management of Patients with Serious Medical Problems
Aylin P. Cili, M.D. (Chair)
American Hospital
Samir Babayev, M.D.
Yale University School of Medicine
Carl A. Laskin, M.D., FRCPC
University of Toronto

1:30 PM – 2:45 PM Symposium
The European Society of Human Reproduction and Embryology (ESHRE) Symposium: Reproduction has Defeated Cancer
Frederic Amant, M.D., Ph.D. (Chair)
National Cancer Institute,
Amsterdam, The Netherlands
Pedro Alessandro Peccatori, M.D., Ph.D.
National Cancer Institute,
Amsterdam, The Netherlands
Umberto Leone Roberto Maggiore, M.D., Ph.D.
European Institute of Oncology

3:00 PM – 3:45 PM Plenary
The Society for the Study of Reproduction (SSR) Keynote Lecture: Genetic Basis of Meiotic Catastrophe: From Mice to Men
P. Jeremy Wang, M.D., Ph.D.
University of Pennsylvania

3:00 PM – 3:45 PM Plenary
Contraception Keynote Lecture: New Frontiers in Contraception Research
Regine Sitruk-Ware, M.D.
Eastern Virginia Medical School

3:45 PM – 4:30 PM Break

4:30 PM – 5:30 PM Interactive Session
Let’s Talk Legal
Susan Crockin, J.D. (Chair)
Georgetown University
Michael J. Tucker, P.D.
Shady Grove Fertility

4:30 PM – 5:30 PM Clinical Session
The Completeness and Safety of Aneuploidy Embryos Safe
Kangpu Xu, Ph.D. (Chair)
Weill Cornell Medical College of Cornell University

4:30 PM – 5:30 PM Interactive Session
Reimagining the Complex Needs of Ovarian Insufficiency and Creating the Ultimate Reproductive Team
Kelly Lee Whiteside, L.Ac., MSOM, F.A.B.O.R.M. (Chair)
Fertility Centers of Illinois

4:30 PM – 5:30 PM Interactive Session
Baltimore IVF History: The Doctor, the Mother and the Baby. The 4th IVF Baby Born in the US
William D. Petok, Ph.D. (Chair)
Thomas Jefferson University
Jairo Garcia, M.D.
Thomas Jefferson University
Kristen Flanagan
Thomas Jefferson University

4:30 PM – 5:30 PM Interactive Session
Chat with Journal Editors: Good Scientific Publication, Manuscript Review, and Editorial Process
T. Arthur Chang, Ph.D., H.C.L.D., E.L.D. (Chair)
University of Texas Health Science Center
David F Albertini, Ph.D., M.S. (Chair)
Center for Human Reproduction
Alexander M. Quaas, M.D., Ph.D.
University of California San Diego
Richard J. Paulson, M.D., M.S.
Keck School of Medicine of the University of Southern California
Denny Sakkas, Ph.D.
Boston IVF

4:30 PM – 5:30 PM Interactive Session
To ICSI ALL or NOT to ICSI ALL: That’s the Question!
Liesl Nel-Themaat, Ph.D., H.C.L.D. (Chair)
University of Colorado Anschutz Medical Campus
Mitchel C. Schiewe, Ph.D., H.C.L.D.
Ovation Fertility
David H. McCulloh, Ph.D.
NYU Grossman School of Medicine
Caroline McCaffrey, Ph.D.
NYU Langone Fertility Center
William Venier, M.Sc., E.L.D. (ABB)
San Diego Fertility Center
4:30 PM – 5:30 PM  
**Interactive Session**  
*Where Are the Brown Eggs?: Increasing Access to and Utilization of Third Party Reproduction*  
Jerrine R. Morris, M.D., M.P.H. (Chair)  
University of California, San Francisco, Department of Obstetrics and Gynecology  
Heather G. Huddleston, M.D.  
University of California San Francisco  
Jerisa Berry, M.D.  
University of California San Francisco  

**Wednesday, October 20, 2021**

8:00 AM – 8:45 AM  
**Plenary Session**  
Herbert H. Thomas Plenary Lecture: Applications of Nuclear Transplantation in Reproductive Medicine  
Endowed by a 1992 grant from EMD Serono, Inc.  
Shoukhrat Mitalipov, Ph.D.  
Oregon Health & Science University  

8:45 AM – 9:15 AM  
**Plenary: Past and Future of IVF**  
Supported by an Endowment by a 1992 grant from Wyeth with a 2021 Special Guest Lecture supported by the Jones Foundation  
Eli Y. Adashi, M.D.  
The Warren Alpert Medical School  
Elizabeth Carr  

10:00 AM – 10:45 AM  
**Break**  

11:00 AM – 12:00 PM  
**Clinical Session**  
NPG Clinical Session – Preparation for the Nurse Certificate Course in REI and Beyond – Day 3  
Lisa A. Rinehart, R.N., J.D. (Chair)  
Legal Care Consulting  
Shannon M. Lighton, B.S.N., M.S.N.  
Legal Care Consulting, Inc.  
Jamie Walsh, R.N., B.S.N.  
Legal Care Consulting, Inc.  

11:00 AM – 12:00 PM  
**Clinical Session**  
MHPG Clinical Session: Ethics Course: Reproductive Healthcare Ethic and Challenges in Modern Times  
Alice D. Domar, Ph.D. (Chair)  
Boston IVF  
Elizabeth Anne Grill, Psy.D.  
Weill Cornell Medical College  
Kim Bergman, Ph.D.  
Growing Generations  

12:15 PM – 1:30 PM  
**Lunch / Break**  

2:30 PM – 3:45 PM  
**Symposium**  
Non-Cancer Female Fertility Preservation: Severe Endometriosis, Premature Ovarian Insufficiency, Sickle Cell Disease  
Mindy S. Christianson, M.D. (Chair)  
Johns Hopkins Medical Institutions  
David Cohen, M.D.  
Infertility IHR  
Jacqueline Yano Maher, M.D., M.A.  
Johns Hopkins University, School of Medicine  

2:30 PM – 3:45 PM  
**Symposium**  
Surrogacy and the Modern Family: Medical, Ethical and Emotional Challenges of Complex Gestational Surrogacy Cases  
Mark Schiff, M.A. (Chair)  
Reproductive Medicine Associates of Connecticut  
Mark Leondires, M.D.  
Reproductive Medicine Associates of Connecticut  
Lisa Schuman, M.S.W.  
Reproductive Medicine Associates of Connecticut  

2:30 PM – 3:45 PM  
**Symposium**  
ON-DEMAND ONLY SESSION: The Environment: It Affects More Than the Ice Caps!  
Linda C. Giudice, M.D., Ph.D. (Chair)  
Washington State University  
Patricia Hunt, Ph.D.  
Washington State University  
Dean E. Morbeck, Ph.D., M.B.A.  
Fertility Associates, Auckland
1:30 PM – 2:45 PM
Symposium
Transgender Youth: Navigating Parents, Peers, and Society While Envisioning Future Family Planning
Jamie M. Joseph, Ph.D. (Chair)
Private Practice
Molly B. Moravek, M.D., M.P.H.
University of Michigan
Marjorie E. Dixon, M.D.
Anova Fertility and Reproductive Health

1:30 PM – 2:45 PM
Symposium
Adenomyosis and Infertility: Medical and Surgical Management Strategies
Linnea R. Goodman, M.D. (Chair)
University of North Carolina
Paul C. Lin, M.D.
Seattle Reproductive Medicine
Hisao Osada, M.D., Ph.D.
The World Egg Bank

1:30 PM – 2:45 PM
Symposium
Crisis Management: What We Have Learned from Catastrophic Events
Sangita K. Jindal, Ph.D. (Chair)
Montefiore Institute for Reproductive Medicine and Health
Roman Pyrzak, Ph.D.
Albert Einstein College of Medicine/Montefiore Medical Center
Kimball O. Pomeroy, Ph.D.
The World Egg Bank

1:30 PM – 2:45 PM
Symposium
Howard and Georgeanna Jones Symposium on Assisted Reproductive Technology: Epigenetic/Genomic Anomalies in Oocytes/Embryos: Current Insights and Clinical Implications
Endowed by a 2010 educational grant from EMD Serono, Inc.
Manuel Vioitti, Ph.D. (Chair)
Zouves Foundation for Reproductive Medicine
Fuchou Tang, Ph.D.
Peking University
McCoy Rajiv, Ph.D.
Peking University

3:00 PM – 3:45 PM
Plenary
Endowed by a 1990 grant from Ethicon Endo-Surgery, Inc.
Dan Martin, M.D.
University of Tennessee

3:00 PM – 3:45 PM
Plenary
Menopause Keynote Lecture: Menopausal HRT and Reduction of CVD and All-Cause Mortality: It’s About Time and Timing
Howard N. Hodis, M.D.
Keck School of Medicine of University of Southern California

3:45 PM – 4:45 PM
Interactive Session
Varicocelectomy in the Management of Male Factor Infertility – an Interactive Discussion
Joseph P. Alukal, M.D. (Chair)
Columbia University
Larry I. Lipshultz, M.D.
Baylor College of Medicine
Armand Zini, M.D., F.R.C.S.C.
University of Iowa
Karl R. Hansen, M.D., Ph.D.
University of Oklahoma Health Sciences Center

3:45 PM – 4:45 PM
Interactive Session
Core Business Principles, Administrative Functions of IVF Practice and Best Marketing Strategies
Munire Erman, M.D., M.Sc., M.B.A. (Chair)
Akdeniz University School of Medicine
Griffin Jones, B.A.
ASRM and ARM Member
Francisco Arredondo, M.D.
Positif Fertility

3:45 PM – 4:45 PM
Interactive Session
Dietary Patterns and Fertility
Malgorzata E. Skaznik-Wiikiel, M.D. (Chair)
University of Colorado - Anschutz Medical Campus
Sunni L. Mumford, Ph.D.
Epidemiology Branch, DIPHR, NICHD, NIH
Jorge E Chavarro, M.D., Sc.D.
Harvard School of Public Health

3:45 PM – 4:45 PM
Interactive Session
What Every ASRM Member Needs to Know About the New AUA/ASRM Male Infertility Guidelines
Stan Honig, M.D. (Chair)
Yale University
Peter N. Schlegel, M.D.
Weill Cornell Medicine, New York Presbyterian Hospital
Mark Sigman, M.D.
Brown University
Barbara Lynn Collura, M.A.
RESOLVE: The National Infertility Association
3:45 PM – 4:45 PM  
Interactive Session  
Complex Family Planning Fellows Showcase  
Elizabeth Micks, M.D. M.P.H. (Chair)  
Oregon Health & Science University

3:45 PM – 4:45 PM  
Interactive Session  
Endometrial Receptivity and ART Outcome: To Test or Not to Test?  
Ilan Tur-Kaspa, M.D. (Chair)  
Jones Institute  
Carlos Simon, M.D., Ph.D.  
University of Valencia; Igenomix Foundation-INCLIVA  
Zev Williams, M.D., PhD.  
Columbia University Medical Center

3:45 PM – 4:45 PM  
Interactive Session  
ASRM Mullerian Anomaly Classification 2021  
Samantha M. Pfeifer, M.D. (Chair)  
Weill Medical College of Cornell University  
Steven R. Lindheim, M.D., M.M.M.  
Wright State University, OB/GYN  
Beth W. Rackow, M.D.  
Columbia University Medical Center  
Sarah D. Ramaiah, M.S.Ed.  
American Society for Reproductive Medicine
Your company is invited to become a member of the ASRM Corporate Member Council

The Mission of the ASRM Corporate Member Council reflects a partnership between the ASRM Officers and Directors and the Corporate Members and is designed to facilitate open and ongoing dialogue between the two; to identify and maximize common interests related to reproductive medicine; and to develop collaborative educational initiatives which serve to enhance the practice of reproductive medicine.

Why become a Corporate Member?

• Participation in Collaborative Initiatives
• Visibility
• Networking
• Website Link on ASRM Website
• Interaction/Collaboration with ASRM Board of Directors
• Special Recognition
• Preferred Support Opportunities
• Two (full) ASRM Memberships (CMC Representatives)

Making a Difference One Initiative at a Time

• Patient Education Fact Sheets
• Patient Education Videos
• www.ReproductiveFacts.org
• In-Training Awards
• Question-based Learning Program
• Webinar Training
• Industry-Specific Sessions

For more information please contact Keith Ray at kray@asrm.org or call 205-978-5001
The Premier Supporters of the ASRM 2021 Scientific Congress & Expo:

**RUBY LEVEL**
EMD Serono
Ferring Pharmaceuticals, Inc.

**PLATINUM LEVEL**
Cooper Surgical
Myovant Sciences, Inc.

**SILVER LEVEL**
Vitrolife, Inc.

**BRONZE LEVEL**
California Cryobank
Cook Medical Incorporated
Esco Technologies, Inc.
Fairfax Cryobank
Freedom Fertility Pharmacy
FUJIFILM Irvine Scientific
Igenomix
Kitazato
Natera, Inc.
NextGen LifeLabs
Organon LLC
Ovation Fertility
Oxford Nanopore Technologies
Progenesis
TMRW Life Sciences, Inc.
Thermo Fisher Scientific
ASRM Scientific Congress Policies and Disclaimers

CANCELLATION POLICY
The American Society for Reproductive Medicine reserves the right to cancel this activity due to unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to the registrant.

REFUND/NON-ATTENDANCE POLICY
Cancellations received on or before September 11th, will receive a full refund minus a $150 processing fee. Cancellation requests must be submitted in writing. Cancellations received after September 11th will not be eligible for a refund. On-Demand Congress Registration Fees are non-refundable.

ADA STATEMENT
The American Society for Reproductive Medicine fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Please notify the American Society for Reproductive Medicine, 1209 Montgomery Highway, Birmingham, Alabama, USA, 35216, telephone 1-205-978-5000, a minimum of 10 working days in advance of the event if a reasonable accommodation for a disability is needed.

EQUAL OPPORTUNITY STATEMENT
The American Society for Reproductive Medicine values and promotes diversity among its members, officers, and staff. The Society prohibits discrimination toward any member or employee due to race, color, religion, age, gender, sexual orientation, national origin, citizenship, disability, military status, or other basis prohibited by law. ASRM strives to achieve gender, racial, and ethnic balance in hiring and governance. ASRM maintains policies, procedures, and personnel actions that conform to the letter and spirit of all laws and regulations pertaining to equal opportunity and nondiscrimination in employment, appointments, and elections to office.

DISCLAIMER STATEMENT
The content and views presented in this educational activity are those of the faculty/authors and do not necessarily reflect those of the American Society for Reproductive Medicine. This material is prepared based on a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity to make clinical decisions about individual patients.

Registration and Information
Choices may be limited on-site. Pre-registration is recommended.

ON-SITE REGISTRATION DESK:
BALTIMORE CONVENTION CENTER
Saturday, October 16 .......... 2:00 pm – 6:00 pm
Sunday, October 17 .......... 7:00 am – 5:00 pm
Monday, October 18 .......... 6:30 am – 5:00 pm
Tuesday, October 19 .......... 7:00 am – 5:00 pm
Wednesday, October 20 ...... 7:00 am – 2:00 pm

BE SURE TO VISIT THE EXPO HALL
Monday, October 18 .......... 9:00 am – 5:00 pm
Tuesday, October 19 .......... 9:00 am – 5:00 pm
Wednesday, October 20 .... 9:00 am – 2:00 pm

Children under 16 are allowed on the Expo Floor only when accompanied/supervised by an adult. No strollers allowed.
The headquarter hotel is Hilton Baltimore.

1. **Hilton Baltimore Inner Harbor HQ**
   410 W Pratt Street
   Attached to BCC

2. **Hyatt Regency Baltimore**
   300 Light Street
   Attached to BCC

3. **Sheraton Inner Harbor**
   300 S Charles Street
   Attached to BCC

4. **Baltimore Marriott Inner Harbor at Camden Yards**
   110 South Eutaw Street
   1 block

5. **Days Inn Inner Harbor**
   100 Hopkins Place
   1 block

6. **Kimpton Hotel Monaco Baltimore**
   2 North Charles
   2 blocks

7. **Renaissance Baltimore Harborplace**
   202 East Pratt Street
   2 blocks

8. **Holiday Inn Inner Harbor**
   101 West Fayette Street
   3 blocks

9. **Hampton Inn Baltimore-Downtown/Convention Center**
   550 Washington Blvd
   3 blocks

10. **Lord Baltimore Hotel**
    20 West Baltimore Street
    3 blocks

11. **Royal Sonesta Harbor Court**
    550 Light Street
    3 blocks

12. **Baltimore Marriott Waterfront Hotel**
    700 Aliceanna Street
    8 blocks
Discounted ASRM Membership for Reproductive Care Specialists in Low and Lower-Middle Income Countries

The editorial team at Fertility and Sterility is pleased to announce a special Journal Club Global live from The ASRM 2021 Scientific Congress & Expo to discuss a recently published article. This exciting event will be streamed live. Please join us live in Baltimore or register to watch online.

To join at a discounted rate:

1. Go to www.asrm.org and log in to your ASRM account.
2. Click on the “My Account” tab and click the red “Join” button.
3. Choose the appropriate membership that includes the online journal.
4. Complete information and pay. (The discounted price will show at checkout.)
spotlight on asrm2021

What you should know about the
ASRM 2021 Scientific Congress & Expo

1. **Schedule changes!** Take a good look at the daily schedule for Monday, Tuesday, & Wednesday. You’ll see that Symposia have moved from the afternoon and are now from 1:30 pm to 2:45 pm!

2. **Additional schedule changes!** The Postgraduate Program, consisting of 20 diverse courses, will be fully on-demand once again this year. Separate registration is required for these, but you have access to the content from October 21st to December 31st! The only courses happening on-site will be limited capacity hands-on courses on Sunday, October 17th.

3. **Lunch** is a designated time, 12:15 pm - 1:15 pm, for either a ticketed lunchtime activity or for you to grab lunch and network with colleagues. Baltimore offers lots of local spots to enjoy close to the convention center!

4. Check out our **Roundtable discussions** – Monday, Tuesday, and Wednesday!

5. Our fully interactive and very useful **meeting app** is a must-have for all Congress attendees. Complete your in-app profile and network with other attendees, locate your next in-person session easily with directions from where you are to where you need to be, and play the **Expo Passport Game** in the app while on-site at the Congress.

6. **Virtual Poster Wall** - to keep all in-person attendees and presenters safe, the poster sessions will be smaller this year. However, all posters will be available online on our virtual Poster Wall including audio for each poster and a place to ask questions of the poster authors!

7. **The President’s Gala** will be in-person on Sunday, October 17th. Tickets are $500 per person up to six individuals with all proceeds benefiting the ASRM Research Institute. Purchase your ticket at www.asrmcongress.org when you register for the Congress. For larger groups or table sales, contact Brynne MacCann at bmaccann@asrm.org.
Use of Artificial Intelligence/Machine Learning to Develop Personalized Approaches to Improve Reproductive Health Outcomes

2021 NICHD-ASRM WORKSHOP

The Eunice Kennedy Shriver National Institute of Child Health and Human Development and The American Society for Reproductive Medicine

Needs Assessment and Description
Despite significant advances in live birth success rates using various forms of ART over the past few decades, further improvements may require the integration and mining of large datasets acquired through omics technologies to generate predictive algorithms. The purpose of this meeting is to present the current state of knowledge relative to the application of artificial intelligence (AI)/machine learning (ML) and precision medicine approaches to the practice of medicine with the goal of informing attendees on how to use AI/ML to develop personalized approaches to improve outcomes of infertile couples. While there is some activity which demonstrates the potential usefulness of AI/ML approaches to improve IVF success, greater emphasis is needed to apply and integrate AI and precision medicine to develop more effective strategies for improving outcomes of all patients seeking fertility treatments. The meeting sessions will focus on the use of AI/ML in other medical fields, AI/ML approaches to improve IVF outcomes, and 3) AI/ML, precision medicine and the future of reproductive medical practice. The sessions will be complemented by Keynote and Special Lectures.

Learning Objectives
At the end of this session, the audience members should be able to:
1. Discuss the current state of knowledge relative to artificial intelligence (AI), machine learning (ML), and precision medicine.
2. Recognize how AI and ML complement precision medicine when developing approaches to infertility and assessing IVF outcomes.
3. Consider how AI/ML and precision medicine can impact the future of reproductive medical practice.

The NICHD-ASRM Joint Meeting will be online instead of in-person. The NICHD will host this event on their platform. It will not be part of the ASRM On-Demand Congress. NICHD will send to each registrant a link and instructions to get into the event. NICHD-ASRM Joint Meeting registration is $50.

SCHEDULE
Thursday, October 21, 2021
10:00 am Welcome
Dr. Louis DePaolo, Eunice Kennedy Shriver NICHD, NIH
Dr. Alan DeCherney, Eunice Kennedy Shriver NICHD, NIH
Dr. Chevis Shannon, ASRM

10:10 am Keynote Address
Emotions, Social Robots, and a New Human-Robot Relationship
Cynthia Breazeal, Massachusetts Institute of Technology

Session I – Use of AI/ML in Other Fields
11:00 am Moderator – Alison Cernich, Eunice Kennedy Shriver NICHD, NIH

11:10 am Deep Neural Networks for Population Genetics and Evolutionary Biology
Sara Mathieson, Haverford College

11:50 am Artificial Intelligence in Interventional and Diagnostic Radiology: Opportunities and Pitfalls from the Frontline
Ferdinand Hui, University of Hawaii

12:10 pm Panel Discussion

12:30 pm Break

Session II – AI/ML and Precision Medicine: The Future of Medical Practice
1:00 pm (Title TBD)

1:10 pm (Title TBD)
Stephanie Seminara, Massachusetts General Hospital

1:40 pm Improving Fertility Treatment Access and Outcomes Using AI/ML Prognostics at Point-of-Care and in R&D
Mylene Yao, UNIVFY

2:10 pm Ethical and Legal Considerations and Dilemmas Raised by AI in Health Care and Reproductive Health
Sarah Gerke, Penn State Dickinson College

2:40 pm Panel Discussion

3:00 pm Break

Session III – AI/ML to Improve ART Outcomes
3:20 pm Moderator – David Albertini, Bedford Research Foundation

3:30 pm The Promise and Future Opportunity of AI/ML for Gamete Selection
Catherine Racowsky, Foch Hospital, Suresnes, France

4:00 pm AI: An Automated Tool for Non-Invasive Embryo Selection
Marcos Meseguer, IVF/IVM Valencia, Spain

4:30 pm Three Ways of Knowing: The Integration of Clinical Expertise, Evidence-Based Medicine, and Artificial Intelligence in Assisted Reproductive Technologies
Gerard Letterie, Seattle Reproductive Medicine

5:00 pm Panel Discussion

5:20 pm Adjourn
TICKETED EVENTS

Ticketed events listed in the daily schedule are marked with a 🛋️ icon.

SUNDAY, OCTOBER 17, 2021

Half-day Embryo Transfer Course
(Limited in-person access only)

DAILY

Resident Learning Sessions
12:15 pm - 1:30 pm
Monday, Tuesday, and Wednesday
(Lunch provided • registration required)

TUESDAY, OCTOBER 19, 2021

7:00 am - 8:45 am
Women’s Council Breakfast
$50 Fee

6:00 pm
ASRM 2021 President’s Gala

Roundtable Luncheons
Monday, Tuesday, and Wednesday
12:20 pm - 1:20 pm
$60 Fee/day
See pages 94-98 for a list of roundtable titles and speakers

Tickets are $50 per person up to six individuals with all proceeds benefiting the ASRM Research Institute. Purchase your ticket at www.asmcongress.org when you register for the Congress. For larger groups or table sales, contact Brynne MacCann at bmaccann@asrm.org.
Embryo Transfer Skills Workshop
Hands-on Course

Limited Capacity/Pre-registration Required

(Hands-on Simulation)

This half-day hands-on course titled “Embryo Transfer Skills Workshop” will include both lecture and hands-on simulation using the ASRM Embryo Transfer Simulator. The course will focus on perfecting embryo transfer techniques using models ranging in levels of difficulty.

Sunday, October 17, 2021
1:00 pm – 5:00 pm

$295

Do you know a resident attending the Scientific Congress?

Participants in the ASRM Resident Education Program will attend a flipped-classroom, interactive learning session, led by experts in reproductive medicine and medical education (boxed lunch provided), and a related symposium.

This ASRM-sponsored program (no additional cost to participants) is open to the first 64 residents who opt in at the time they register for the Scientific Program using a dialogue box that will open during the registration process.

Questions? Email Sarah Ramaiah at sramaiah@asrm.org.
Continuing Education/ CME Sessions

- Continuing Medical Education/ Continued Education 44-45
- Postgraduate Courses 46-65
- Scientific Congress Needs Assessment and Learning Objectives 66
- ASRM 2021 Congress Grid 67
- Specialty Tracks 68-82
- Resident Educational Program 83-84
- Speaker Index 85-88
- Speaker Disclosures 89-92
ASRM Continuing Education Programs
The goal of ASRM is to sponsor educational activities that provide learners with the tools needed to conduct research, practice the best medicine, and provide the best, most current care to patients.

ASRM adheres to the Essentials and Policies of the Accreditation Council for Continuing Medical Education (ACCME). CME activities must address specific, documented, clinically important gaps in physician knowledge, competence, or performance; be documented to be effective at increasing physician knowledge, competence, performance, or outcomes; and conform to the ACCME Standards for Commercial Support.

All planners and presenters disclose commercial and financial relationships pertaining to reproductive medicine. These disclosures were reviewed by the Subcommittee for Standards for Commercial Support of the ASRM CME Committee and the Executive Program Committee, which resolved perceived potential conflicts of interest.

How to Claim Continuing Medical Education/Continuing Education Credits
For Postgraduate (PG) Courses:
• Register for the on-demand Postgraduate Courses
• Register for the On-Demand Postgraduate course
• Complete the course(s)
• Login using the link that was emailed to you for access to On Demand course.
• Assessment must be completed to obtain credits.
• Download and print Certificates
For the Scientific Congress (SC):
• Attend sessions of your choice in person or view on demand.
• Login using the link that was emailed to you for access to On Demand Congress website.
• Assessment will be available 1 hour after attending/viewing session and must be completed to obtain credits.
• Download and print Certificates

Final date to claim credit is December 31, 2021.
Email questions to education@asrm.org.

The following may receive honoraria and/or discounted or free registration: Plenary, Symposia, and Interactive Session speakers, and Postgraduate faculty. Honoraria are not provided for Roundtable presenters, Oral and Poster Abstract presenters, and Video presenters.

Disclosures of faculty and presenters for the Postgraduate and Scientific Congress may be in a presentation slide, printed material, and will be printed in the ASRM Final Program. Abstract authors’ disclosures will be printed in the 2021 Program. Roundtable and Expert Encounter presenters should provide a copy of their disclosure to participants at their table.
How to Claim Continuing Medical Education/Continuing Education Credits

The Accreditation Council for Continuing Medical Education (ACCME)
The American Society for Reproductive Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASRM 2021 Scientific Congress Designation Statement
The American Society for Reproductive Medicine designates this activity for a maximum of 77.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASRM 2021 Post Graduate Course Program Designation Statement
The American Society for Reproductive Medicine designates Post Graduate Courses 06-20 for a maximum range of 5.25 to 9.0 AMA PRA Category 1 Credits™ per course. Post Graduate Courses 01-05 are approved for a maximum range of 3.0 to 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Obstetricians and Gynecologists (ACOG)
The American College of Obstetricians and Gynecologists has assigned up to 77.25 cognate credits to the Scientific Congress; 6.75 Cognates to Post Graduate course 8; 6 Cognates to course 12; 5.50 to course 7; 3.5 Cognates courses 1 and 3; 3.25 Cognates to course 5.

American Board of Bioanalysis (ABB)
The American Society for Reproductive Medicine has been approved to provide Professional Enrichment Education Renewal (PEER) credit through the American Board of Bioanalysis for this event. Up to 0.70 PEER CEU (7.0 hours) will be recognized for Post Graduate course 6. Post Graduate course 15 will be recognized for 0.625 CEUs (6.25 hours); 0.65 CEUs (6.5 hours each) will be recognized for courses 13 and 19; 0.55 CEUs (5.5 hours each) for courses 7,10,11 and 16. Scientific Congress has been approved for 31.50 hours or 3.150 CEUs. (This includes interactives, plenaries, lectures, and symposia). In person meeting will also include select abstracts for CEUs.

Nursing Credits: National Association of Nurse Practitioners in Women’s Health
Post Graduate Course 18: “Vaginal Microbiome and Reproductive Health: From Research to Clinical Practice” has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health. NPWH Activity no. 21-18. Maximum credit for 2021 is 21.25 contact hours.

American Psychological Association (APA)
The Mental Health Professional Group (MHPG) of the American Society for Reproductive Medicine is approved by the American Psychological Association to sponsor continuing education for psychologists. MHPG maintains responsibility for this program and its content. CE credits will be available for Post Graduate Courses 2,3,17 and 19; MHPG Clinical Sessions CSM01, CST02, CSW01 and other selected sessions.

National Association of Social Workers (NASW)
Application will be made to the National Association of Social Workers (NASW) for select sessions of the Scientific Congress and selected Post Graduate Courses 02, 03, 17 and 19.

National Society of Genetic Counselors (NSGC)
Application will be made to the National Society of Genetic Counselors for Category 1 contact hours for Post Graduate Courses 10, 11 and selected sessions in the Scientific Congress. Participants requesting NSGC CEUs will have a service fee of $30 added to their meeting registration to cover payment to the National Society of Genetic Counselors for the filing and awarding of CEU certificates.

Final date to claim credit is December 31, 2021.
Questions? email education@asrm.org
HALF DAY COURSES

PG01  Lessons from COVID-19 and Access to Care  CME
Developed in cooperation with the Society for Reproductive Endocrinology and Infertility (SREI), and the Access to Care Special Interest Group

Faculty
Eve C. Feinberg, M.D., (Chair)
Kenan Omurtag, M.D.
Tarun Jain, M.D.

Target Audience
Professionals in the field of reproductive medicine, MDs, nurses, psychologists, urologists and other advocates for access to care.

Needs Assessment
The challenge of the COVID-19 pandemic exacerbated an already large challenge of access to infertility care. Unique solutions to both emerged during the COVID-19 pandemic that enhanced access to care and enabled individuals and couples to seek fertility care in more creative ways. Telemedicine emerged as the new way to see patients safely and various platforms have been utilized. This course will address the different telehealth platforms and billing codes to optimize reimbursement. Additional challenges of education for trainees were encountered and novel teaching strategies enhanced education and broadened thinking about how to best educate our trainees. Society recommendations sparked debate about what "essential" care is and this can be applied to broadening insurance mandates for infertility. This course will also address the idea of state mandated care and how "essential" services like infertility should be included in insurance mandates.

Description
The course will cover the novel use of mechanisms to increase access to care and educational opportunity. Home semen analysis, ovarian reserve testing will be discussed. Telehealth platforms, billing strategies will be explained. Use of electronic platforms for debates, journal clubs, fellowship interview days will be demonstrated and the decision of what "essential" care is and how that interplays with state insurance mandates will be discussed.

ACGME Competency
Communication, Roles/Responsibilities, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Systems-based Practice

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Discuss the definition of "essential" and understand why insurance coverage should be broadened to include infertility
2. Implement the use of electronic platforms to enhance educational opportunity
3. Describe different platforms for telehealth and different types of consultations that can be done via telehealth
Difficult Conversations: Tools, Tips, and Training for Effective Communication

Developed in cooperation with the Society for Reproductive Endocrinology and Infertility (SREI), Association of Reproductive Managers (ARM), Mental Health Professional Group (MHPG), and the Nurses’ Professional Group (NPG)

Faculty
Tamara Tobias, A.R.N.P. (Chair)
Lindsay Nicholas, R.N.
LaTasha B. Craig, M.D.
Elizabeth Anne Grill, Psy.D.

Target Audience
This interprofessional course is intended for all reproductive medicine physicians, nurses, advanced practice providers, mental health professionals, genetic counselors, and any allied health providers involved in direct patient care.

Needs Assessment
Engaging in difficult conversations is hallmark for anyone involved with caring for those struggling with infertility. Without the proper tools, these challenging conversations can lead to both patient and staff burnout. This course will offer needed education, training, and concrete tools for effective communication for health care professionals. These skills may enable all staff to provide competent, effective, and consistent patient care. Providing consistent, quality patient care enhances the overall patient experience, improves patient satisfaction, and hopes to reduce patient complaints. The faculty from this course have a goal to turn this session into an Air-learning module available to all ASRM members so they can share with their clinical teams.

Description
This interdisciplinary course will provide evidence-based tools that can be utilized to improve communication skills. Topics in this course include setting patient expectations, coping strategies for loss, how to deliver bad news, motivational interviewing, and empathy training. Specific methods for difficult patient encounters will be explored. Additionally, this class will include a session for how to address unique issues in treating LGBTQ patients. Training on how to effectively manage difficult conversations may help decrease stress and burnout for staff and may provide coping skills for patients to enhance their overall health and REI experience.

ACGME Competency
Communication, Teams and Teamwork, Values/Ethics, Interpersonal and Communication Skills, Professionalism

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Engage in an interactive practice session to improve communication skills.
2. Use empathy training to help set patient expectations and provide strategies for coping with loss.
3. Apply motivational interviewing skills for behavior change.
4. Use tools and tips for delivering bad news and managing difficult patient encounters.
PG03 **Primary Ovarian Insufficiency and Fertility: A Mind and Body Approach**

Developed in cooperation with the Mental Health Professional Group (MHPG), Menopause and Ovarian Insufficiency Special Interest Group, and the Pediatric and Adolescent Gynecology Special Interest Group

**Faculty**
Mindy S. Christianson, M.D. *(Chair)*
Krista Childress, M.D.
Danielle Kaplan, Ph.D.

**Target Audience**
This course will target reproductive endocrinologists, menopause specialists, clinical fellows and advanced practice providers.

**Needs Assessment**
Primary ovarian insufficiency (POI) impacts 1% of women prior to age 40 and many may desire future pregnancy but not be ready to immediately attempt to conceive. This course will update participants on the current, most up-to-date, diagnosis and treatment of POI. In addition, the course will address treatment for POI for all age groups, including adolescents and those of reproductive age. According to the 2019 ASRM Gap Analysis and Educational Needs Assessment, management of fertility for patients with POI was an identified gap. Additionally, the psychiatric needs of reproductive endocrinology and infertility patients was identified as a gap. In addition to addressing fertility needs for patients with POI, this course will also address the emotional and psychological needs of women with POI, which is often a shocking diagnosis that brings with it life-changing implications. By collaborating with the Mental Health Professionals Group, this course will also provide information for clinicians on how to address the psychological needs of patients diagnosed with primary ovarian insufficiency. The need to counsel and provide treatment options as well as psychosocial support for this group spans the goals of three different special interest groups (MOISIG, PAGSIG and MHPG) in terms of clinical education.

**Description**
This course will address the clinical management and recommended psychosocial support for women diagnosed with primary ovarian insufficiency. Proposed course content includes the following topics: 1) Diagnosis and evaluation of patients with primary ovarian insufficiency, 2) Treatment and long-term follow up for patients with POI, 3) Psychosocial support for patients with POI at time of diagnosis, 4) Fertility options for patients with POI, 5) Impact of receiving a diagnosis of POI across the reproductive lifespan. 4) Psychological support for patients with POI with respect to family building choices.

**ACGME Competency**
Communication, Roles/Responsibilities, Teams and Teamwork, Interpersonal and Communication Skills, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

**Learning Objectives**
At the conclusion of this course, participants should be able to:
1. Describe the natural history, epidemiology, clinical evaluation and diagnosis for primary ovarian insufficiency (POI).
2. Counsel patients with POI regarding treatment, including options for future fertility.
3. Recommend psychosocial support options for patients diagnosed with POI as well as those considering fertility options.
4. Describe impact of receiving a diagnosis of POI across the reproductive lifespan and identify times when patients may most benefit from consultation with a mental health professional.
Optimizing Fresh and Frozen Embryo Transfer: Newest Evidence on Measuring, Timing, and Replacing Progesterone

Developed in cooperation with the Society for Assisted Reproductive Technology (SART), Society for Reproductive Endocrinology and Infertility (SREI), and the Early Pregnancy Special Interest Group

Faculty
Kate Devine, M.D. (Chair)
Christos Venetis, M.D., M.Sc, Ph.D.
Frauke Versen-Höynck, M.D., M.Sc.

Target Audience
This interprofessional course is designed for physicians, embryologists, advanced practice providers, nurses, and researchers.

Needs Assessment
According to the CDC ART National Summary, frozen embryo transfer represents 33% of all US ART cycles, with a prevalence surpassing fresh embryo transfer. While vitrification has resulted in increased embryo survival and warmed embryo implantation, the optimal endometrial preparation is unclear. Recent evidence suggests that a natural cycle FET may have reduced obstetrics risks and suggests a role for the corpus luteum in ART treatments. Progesterone is vital for endometrial preparation, implantation, and pregnancy development. The timing of progesterone rise, the effect of premature progesterone elevation, exogenous versus endogenous sources, and route of administration are all progesterone dependent factors in successful implantation and optimal obstetric outcomes. Recent randomized controlled evidence has demonstrated that progesterone in oil is superior to vaginal progesterone for frozen embryo transfers. Premature progesterone elevation occurs in up to 38% of all ART cycles and diminishes fresh embryo transfer success, affecting tens of thousands of treatment cycles annually. This course addresses the Gap/Need to educate on the role of progesterone to guide fresh or frozen embryo transfer, to educate on the usefulness of natural cycle frozen embryo transfer, and provide an evidence based session to improve patient ART outcomes.

Description
This course addresses the practice knowledge gap to understand how serum progesterone measurements can determine fresh or frozen embryo transfer, education on the usefulness of natural cycle frozen embryo transfer, and optimizing patient ART outcomes. Education will be given on the progesterone assay, how reproductive physiology influences the interpretation of serum progesterone values, using progesterone to determine fresh or frozen transfer, optimal timing of progesterone initiation in frozen transfers, route of progesterone administration, and the role of the corpus luteum on natural cycle frozen transfer outcomes.

ACGME Competency
Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Differentiate the physiologic considerations to interpret a single serum progesterone value: assay issues, timing of measurement, interpretation in the context of gonadotropins, and contribution of the adrenals
2. Counsel patients on serum progesterone levels and optimal fresh or frozen embryo transfer decisions.
3. Apply best evidence for route and timing of progesterone administration in frozen embryo transfer.
4. Review the most recent evidence on natural cycle frozen embryo transfer pregnancy and obstetric outcomes.
PG05 Unexplained Infertility: Have A Look And You’ll Find The Answers  
Developed in cooperation with the European Society of Human Reproduction and Embryology (ESHRE)

Faculty
Stephan Gordts, M.D. (Chair)  
Leuven Instituut voor Fertiliteit en Embryologie, Belgium  
Maribel Acién, M.D., Ph.D.  
San Juan University Hospital, Spain  
Antoine Watrelot, M.D.  
Lyon Natecia Hospital, France

Target Audience
This interprofessional course is designed for clinicians, surgeons and practice managers.

Needs Assessment
Unexplained infertility diagnosis strongly depends on the roll out path that couples follow. With the advances of endoscopy, and the need of re-imaging reproduction, the truth is that having a look may help finding the explanation and following a “see and treat” protocol. With some research papers showing contradictory results, clinicians still need to elaborate the path on how to diagnose and treat mild hydrosalpinges, endometriosis, adenomyosis or Müllerian anomalies to improve IVF outcomes, how to prioritize and the pros/cons of ART or diagnostic and surgical treatments. Optimizing patient outcomes in ART is mandatory but the long-term reproductive performance needs also to be considered.

Description
This course addresses the educational needs that health-care professionals in reproductive medicine face on their daily practice; outline best strategies for ruling out the unexplained infertility and improve their knowledge on how surgery can find the answers and improve the reproductive performance not only prior to ART but also for the reproductive future of the patient. In terms of practice management the course will address the interest of the endoscopic techniques in the management of unexplained infertility, including mild hydrosalpinges, minimal endometriosis and those pathologies distorting the uterine cavity. Emphasis will be given on establishing a route for health care.

ACGME Competency
Medical Knowledge, Patient Care and Procedural Skills

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Appraise the paper of endoscopic surgery on the unexplained infertility
2. Select which patients would benefit from minimal endometriosis surgical treatment prior to ART
3. Debate the alternatives in case of mild hydrosalpinx
4. Review the paper of hysteroscopy on the evaluation of pathologies affecting the uterine cavity
**FULL DAY COURSES**

**PG06 Changing with the Times: Mitigating Risk for Your ART Practice While Improving Care for Your Patients**

Developed in cooperation with the Society for Assisted Reproductive Technology (SART), Society of Reproductive Biologists and Technologists (SRBT), and the Legal Professional Group (LPG)

**Faculty**
Amy E. Sparks, Ph.D. (Chair)
Jennifer F. Kawwass, M.D.
Nidhi Desai, J.D.

**Target Audience**
This interprofessional course is designed for physicians, embryologists, advanced practice providers, nurses, practice managers, and attorneys.

**Needs Assessment**
ART practices navigate an increasingly complex array of challenges that are unique to the practice of in vitro fertilization. These challenges must be handled thoughtfully to optimize outcomes for patients and to mitigate risk for the practice. Prior ASRM gap analysis has identified several key topics where discussion and recommendations for best practice are needed. These topics include requests for transfer of embryos outside of established guidelines, transfer of embryos with abnormal results for pre-implantation genetic testing, elements of informed consent, disposition of abandoned embryos, and disaster management planning. In addition, embryologists have stated that they have a need for more information about how to minimize the risk of cryopreservation tank failures, incubator failures, human error in the IVF laboratory and liabilities brought about by inadequate staffing and/or reliance on traveling staff for the laboratory.

**Description**
This course will include frank discussions regarding what to do when confronting risk and areas of uncertainty. We will discuss developing policy for transferring embryos with pre-implantation genetic test results suggesting mosaicism or aneuploidy, including recommendations, logistics, review of ethical concerns, and legal risk. We will discuss criteria to consider in accepting gametes and embryos from outside laboratories, policies surrounding abandoned embryos, and best practices for mitigating risk of cryopreservation tank failure, incubator failure and human error in the IVF laboratory, as well as laboratory staffing needs. Finally, this course will present ideas for confronting future risk and disaster management.

**ACGME Competency**
Communication, Roles/Responsibilities, Teams and Teamwork, Values/Ethics, Interpersonal and Communication Skills, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Professionalism, Systems-based Practice

**Learning Objectives**
At the conclusion of this course, participants should be able to:
1. Formulate a disaster management plan including laboratory safety, monitoring and alarm systems, contingency plans, and public relations management
2. Develop a plan for accepting frozen gametes and embryos from outside practices
3. Discuss the staffing needs of the embryology laboratory and precautions needed for clinics as well as embryologists in an embryology consulting agreement, such as insurance and competency of hired consultants
4. List strategies to minimize the risk of cryopreservation tank failures, incubator failures and human error in the IVF laboratory
5. Describe issues to consider in the disposition of abandoned embryos
6. Develop practice policy for transferring embryos with pre-implantation testing results suggesting mosaicism or aneuploidy
PG07 **Controversies in Recurrent Implantation Failure**

Developed in cooperation with the Society for Assisted Reproductive Technology (SART), Society for Reproductive Endocrinology and Infertility (SREI), Endometriosis Special Interest Group, Physician-Scientists' Special Interest Group, and the Early Pregnancy Special Interest Group

**Faculty**
Steven L. Young, M.D., Ph.D. (Chair)
Jason M. Franasiak, M.D.
Zev Williams, M.D., Ph.D.
Caroline McCaffrey, Ph.D.

**Target Audience**
This interprofessional course is designed for physicians, embryologists, advanced practice providers, nurses, and researchers.

**Needs Assessment**
Recurrent implantation failure (RIF) is a challenging clinical scenario for providers and patients. RIF is relatively common with an estimated prevalence of 5-15%. There remains no consensus diagnostic criteria for RIF and no standard algorithm for evaluation and treatment. This results in wide variation in clinical practice patterns and controversy over diagnostic and management options. Advances in diagnostic testing have opened up new avenues for evaluation of the endometrium and embryo. Novel treatments may offer new therapeutic options, but rigorous evaluation of the supportive evidence is imperative. ASRM has identified four gaps in knowledge related to recurrent implantation failure: uterine factors important for fertility, endometrial testing after failed euploid frozen embryo transfer, emerging technology in embryo implantation and uterine receptivity, and optimizing ART outcomes. This course will provide educational material that covers these knowledge gaps and educational needs, while documenting the closing panel discussion on reaching ideal consensus for defining RIF and areas of research need to close existing knowledge gaps.

**Description**
This course will address educational needs regarding oocyte, spermatozoa, embryo, and endometrial causes of recurrent implantation failure. The course will explore the controversies in how recurrent implantation failure is defined and the evidence behind testing and treatment strategies. Experimental diagnostics and treatments will be critically examined from an evidence-based approach. Participants will gain knowledge in diagnosis and management tools for this challenging clinical scenario. The course will end with a panel discussion on defining recurrent implantation failure and identifying research gaps, to help define and guide novel areas of research.

**ACGME Competency**
Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

**Learning Objectives**
At the conclusion of this course, participants should be able to:
1. Appraise emerging literature and strength of evidence for novel therapies.
2. Examine the evidence regarding potential therapeutic strategies to improve implantation.
3. Differentiate embryo and endometrial contributions to implantation.
4. Examine the evidence for embryo and endometrial diagnostic testing strategies.
5. Summarize the evidence on methods to improve ART outcomes in the setting of recurrent implantation failure.
6. Apply evidence presented at final panel discussion to generate diagnostic criteria and research needs analysis.
PG08  **Endometriosis and Adenomyosis Diagnosis, and Assessment: Clinical and Pathophysiological Perspectives**  
Developed in cooperation with the Endometriosis Special Interest Group, and the Imaging in Reproductive Medicine Special Interest Group

**Faculty**
Laurel Stadtmauer, M.D., PhD (Chair)  
Steven L. Young, M.D., Ph.D.  
Laura Detti, M.D.  
Caterina Exacoustos, M.D., Ph.D.

**Target Audience**
The target audience includes all healthcare providers that engage in reproductive imaging and care in clinical practice of patients with endometriosis. This includes nurses, gynecologists, reproductive endocrinologists, and ultrasound technologists.

**Needs Assessment**
The incidence of endometriosis is as high as 10% in the general population, and at least 40% in the infertility population, making the disease highly relevant for reproductive medicine professionals. Over the last few years, there have been improvements in the diagnosis of endometriosis by 3-D ultrasound imaging. ASRM has reported a significant knowledge gap and educational need in the new medical and surgical management for endometriosis and adenomyosis for both pain and fertility and the place of surgical treatment in patients considering IVF. The current knowledge gap is compounded by a lack of experience with newly emerging biomarkers and their role in affecting implantation and new medical therapies. The Gap analysis from 2019 relevant to this course in endometriosis, adenomyosis, reproductive imaging and surgery include: management options for endometriosis beyond standard therapy, newer medical therapies and surgical treatments for endometriosis, overview of adenomyosis and its relationship to the biology of reproduction with a focus on current techniques for treatment, and how to manage congenital uterine anomalies.

**Description**
This course will help close these knowledge and practice gaps and improve skills in the areas of imaging in reproductive medicine, endometriosis and adenomyosis, with presentations from experts. It will cover new approaches of diagnosis and treatment from a mechanistic and clinical perspective to optimize outcomes in infertile patients with endometriosis. Controversial areas covered include the role of surgical removal of endometriomas before IVF as well as when to correct uterine anomalies associated with endometriosis. The diagnosis of endometriosis will focus on new techniques in ultrasound and MRI imaging and novel endometriosis biomarkers.

**ACGME Competency**
Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

**Learning Objectives**
At the conclusion of this course, participants should be able to:
1. Summarize endometriosis biomarkers that are useful for diagnosis and treatment of endometriosis.
2. Review imaging diagnosis of endometriosis and adenomyosis including deep infiltrating endometriosis.
3. Assess innovative imaging and treatment techniques for endometriosis.
Reproductive Aging: Meeting the Challenges in Clinical and Laboratory Practice

Developed in cooperation with the Turkish Special Interest Group

Faculty
Kutluk H. Oktay, M.D., Ph.D. (Chair)
Nanette F. Santoro, M.D.
Aleksandar Rajkovic, M.D.
Murat Sonmez, M.D. professor

Target Audience
This course is designed to educate REI fellows, REI subspecialists, nurses, embryologists, clinical and laboratory researchers in reproductive medicine.

Needs Assessment
Reproductive aging affects both genders and is one of the key reasons why patients seek help from reproductive endocrinologists. As gathered from the 2019-2020 Gap Analysis document, there are numerous topics relating to reproductive aging that need to be addressed. These include biology of reproductive aging, addressing genetic basis of primary ovarian insufficiency/early ovarian aging, maximizing IVF outcomes in the face of advance age, fertility preservation for non-medical indications/against reproductive aging, genetic screening methods in the face of reproductive aging. We have successfully conducted this course in 2019 which received high remarks from the participants. We have been repeatedly asked to have the course repeated both by those who were able to attend and who could not. We anticipate that this PG course will have even bigger success this year and will again receive excellent evaluations.

Description
Reproductive aging and its consequences affect a large segment of the population in both genders. Despite the significance consequences such as infertility, pregnancy losses, and chromosomal abnormalities, the knowledge on the mechanisms and potential treatments for reproductive aging is limited. The goals of this activity are to update practitioners on available laboratory and clinical remedies in addressing reproductive aging while providing insights into the areas of development. The lectures and discussions by the expert faculty will enhance the skills of the practitioners in dealing with clinical and laboratory challenges related to reproductive aging.

ACGME Competency
Medical Knowledge, Patient Care and Procedural Skills

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Review the mechanisms of gonadal aging.
2. Summarize available laboratory and clinical remedies in addressing reproductive aging.
3. Examine areas of development and research in reproductive aging.
**Comprehensive Review of Genetic Carrier Screening: Genetic Counseling, Legal, and Physician Perspectives**

Developed in cooperation with the Legal Professional Group (LPG), and the Genetic Counseling Professional Group (GCPG)

**Faculty**
Amy C. Vance, M.S., L.C.G.C. (Chair)
Susan Crockin, J.D.
Lauren Isley, M.S., C.G.C.

**Target Audience**
This interprofessional course is designed for physicians, advanced practice providers, nurses, practice managers, allied health providers, genetic counselors, mental health professionals, geneticists, attorneys.

**Needs Assessment**
Use of expanded carrier screening continues to provide challenges in the ART clinic including balancing the benefits and costs of testing, education regarding different genetic screening tests, risks and benefits with different panel sizes, need for improved understanding of platforms and the genes on the chosen panel, patient education and follow up. Although carrier screening is used routinely in ART practice, there continue to be ongoing struggles due to the complexity of genetic information and relative lack of education about genetics for most clinical staff. This need is supported by the below (pending publication in Fert Steril) abstract: GENETIC TESTING AND GENETIC COUNSELING FOR ANONYMOUS EGG DONORS: RESULTS FROM A SURVEY OF 21 CLINICS IN THE US SHOW CONTINUED NEED FOR GENETICS EDUCATION FOR PROVIDERS. Amy Vance, M.S., L.C.G.C., Bay Area Genetic Counseling, San Anselmo, CA and Tamara Tobias, ARNP, Seattle Reproductive Medicine, Bellevue, WA

**Description**
This course will provide a review of expanded carrier screening (clinical utility, size of panel, variant curation and need to re-contact, when is updated testing indicated), the difference between genetic carrier screening and direct to consumer testing, issues to consider when carrier testing identifies increased risk for disease, special issues to consider with gamete donors, RE perspectives on carrier testing, legal implications of carrier screening, case presentations, and an open forum-invitation to bring cases for discussion. At the end of the course, participants will be able to evaluate their own screening protocol and make adjustments as necessary.

**ACGME Competency**
Communication, Roles/Responsibilities, Teams and Teamwork, Values/Ethics, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Systems-based Practice

**Learning Objectives**
At the conclusion of this course, participants should be able to:
1. Describe the use of expanded carrier screening.
2. Review ACOG/ASRM guidelines for carrier screening.
3. Differentiate the differences between clinical carrier screening and direct to consumer testing.
4. Identify special issues with carrier screening for gamete donors.
5. Distinguish examples of genes on carrier screening panels in which carriers can have symptoms and how to best handle these cases.
6. Detect informed consent issues that can arise related to carrier screening.
7. Summarize legal aspects of carrier screening.
8. Assess standard of care and guidelines in ART regarding carrier screening and how this affects carrier screening choices.
9. Discuss different roles that the IVF physician can play in the delivery/ management of genetic carrier screening results.
10. Develop tools to evaluate your screening protocol and make adjustments as necessary.
11. Describe the value of the Genetic Counselor in carrier screening consultations.
12. Review cases to deepen understanding of relevant carrier screening topics.
A Critical Assessment of Invasive and Non-Invasive PGT: What's the Impact on ART?

Developed in cooperation with the Preimplantation Genetic Testing Special Interest Group

Faculty
Kangpu Xu, Ph.D. (Chair)
Svetlana Rechitsky, Ph.D.
Carmen Rubio, Ph.D.
Manuel Viotti, Ph.D.

Target Audience
This inter-professional course is designed for physicians, embryologists, geneticists, and genetic counselors.

Needs Assessment
The ultimate challenge in embryology is to select a single genetically "normal" embryo with highest implantation potential for transfer in a fresh or FET cycle, which leads to the birth of a healthy baby from fertile couples with genetic predisposition, and subfertile or infertile couples who need assisted reproductive technology (ART). Preimplantation genetic testing (PGT) for aneuploidy (PGT-A), monogenic disorders (PGT-M) and structural rearrangements (PGT-SR) have been an effective modality through invasive procedures, polar body, cleavage or late preimplantation stage biopsy, in the last three decades. Latest development in minimum or non-invasive PGT (mi/niPGT) opens a new avenue to test the embryos with much less labor and at lower cost. Many questions remain for the embryology laboratories as well as for the genetic testing laboratories. When is the time to change their practice, coexisting or gradually replacing? What are the impact of the new approaches on various PGT indications? This course will focus and discuss these critical questions.

Description
This course will describe the lastest methodologies and detailed data to give the participants a comprehensive reviews, and thus an understanding of the current development in the field of embryo selection by PGT. Specific details and the pros and cons of invasive and/or non-invasive PGT will be presented. The limitations and future potential will also be discussed so that participants will learn and bring home the ideas regarding if and how to change their practice.

ACGME Competency
Medical Knowledge, Patient Care and Procedural Skills

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Describe the general concept for embryo viability selection.
2. Explain the use of PGT in ART practices.
3. Summarize the latest available methods for invasive and mi/niPGT.
4. Discuss main reasons for PGT-A's false negatives and false positives.
5. Assess the pros of invasive and mi/niPGT.
6. Analyze the cons of invasive and mi/niPGT.
8. Analyze how monogenic and polygenic diseases can be avoided by niPGT.
9. Summarize the clinical implications of introducing PGT for common late-onset disorders.
10. Define the benefits of PGT.
11. Review challenges for embryo selection within the context of ART.
Addressing Controversies in the Work up and Treatment of Recurrent Pregnancy Loss
Developed in cooperation with the Early Pregnancy Special Interest Group

Faculty
Kristin A. Bendikson, M.D. (Chair)
Paul Robert Brezina, M.D.
Winifred Mak, M.D., Ph.D.
Lia A. Bernardi, M.D.

Target Audience
This interprofessional course is designed for physicians, advanced practice providers, and nurses.

Needs Assessment
Recurrent Pregnancy Loss affects 1-5% of couples attempting pregnancy. The smaller number of patients impacted makes the analysis of appropriate diagnostic evaluations and treatments more challenging. While there are guidelines published by ESHRE and a best practices opinion published by ASRM, these published documents do not align in all recommendations. Both publications acknowledge the controversies that exist in both the work up and treatment of these types of patients. The difference in opinion in approach leads to varied practice patterns and patients receiving widely different clinical care dependent on whom they receive care from. There are six areas that have been identified where the largest controversies exist: testing of products of conception, testing for chronic endometritis, testing for other markers related to implantation and early pregnancy loss, genetic testing of embryos for aneuploidy, immunologic testing and treatment, and impact of patient health/nutrition/supplements on losses. This course addresses the following gaps in knowledge: health of the oocyte in recurrent pregnancy loss, lifestyle modifications and its potential impact on recurrent pregnancy loss, Genetic testing in couples with recurrent pregnancy loss and Lack of knowledge of alternative remedies to treat recurrent implantation failure.

Description
This course will address what the controversies in the diagnostic work up and treatment of patients with recurrent pregnancy loss are, exploring both sides to each topic. There will be an educational presentation on each topic. We will also be soliciting participation from the audience as we work through two case presentations and break the audience into groups to work together to come up with both diagnostic and treatment plans for the patient based on the lecture material, engaging the groups to compare their proposed plans and having audience members move around ‘caucus’ style to see the prevailing approaches.

ACGME Competency
Roles/Responsibilities, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Identify and understand the controversies in the diagnostic work up of patients with recurrent pregnancy loss.
2. Identify and understand the controversies in the treatment of patients with recurrent pregnancy loss.
3. Prepare a diagnostic and treatment plan for a patient with recurrent pregnancy loss.
Tricks of the Trade: Small Things That Can Make a BIG Difference in the IVF Lab
Developed in cooperation with the Society of Reproductive Biologists and Technologists (SRBT)

Faculty
Liesl Nel-Themaat, Ph.D., HCLD (Chair)
Jacques Cohen, PhD, HCLD
Joe Conaghan, PhD
Debbie Venier, MS

Target Audience
This course is designed for all reproductive lab staff (directors, embryologists and andrologists), as well as physicians, fellows, nurses and administrative staff who would like to learn more about lab procedures.

Needs Assessment
Reproductive lab specialists are faced with a multitude of choices regarding the best way to perform procedures to optimize success rates. In addition to formal research and training, their global knowledge, including specific technical tips and tricks as well as lesser known ancillary procedures come from mainly two sources: (1) Historically inherited knowledge formed over years of experience in the minds of the pioneers as they figured things out during infancy of our field, and (2) New trainees coming into the workforce bringing new ideas and improving things anecdotally. Although many such tricks and tips could be shared in person, they are not necessarily published in the literature, so few people benefit from them and such tricks may be lost over time.

Description
The course will teach participants about the lab environment, what makes a difference and what doesn’t, getting the most out of sperm specimens, maximizing success with conventional insemination, maximizing ICSI success using ancillary procedures, how to choosing a culture system, factors affecting FET success rates and when PGT makes sense. These topics will help lab professionals broaden their knowledge in these fundamental issues we address on a daily basis and help improve overall success rates.

ACGME Competency
Roles/Responsibilities

Learning Objectives
At the conclusion of this seminar, participants should be able to:
1. Identify areas to easily improve lab setup by making small changes.
2. Assess knowledge about procedures for maximizing sperm yield from various sources.
3. Analyze success rates following ICSI, including what to do after failed fertilization.
4. Summarize the differences in various culture systems and the pros and cons of each, and make informed choices.
5. Develop informed decisions about what factors could improve frozen embryo transfer success rates.
6. Review when PGT is truly necessary and actually improves outcomes.
PG14 Challenges in Freeze All Embryos
Developed in cooperation with the Indian Special Interest Group, the Indian Society of Assisted Reproduction (ISAR), and the Indian Fertility Society (IFS)

Faculty
Narendra Malhotra, M.B.B.S., M.D. (Chair)
Jaideep Malhotra, M.B.B.S., M.D.
Neena Malhotra, M.D., D.N.B., F.R.C.O.G. (UK)
Manish Bankar, M.D.

Target Audience
Gynecologist interested / practicing in IVF and Assisted Reproduction

Needs Assessment
Freezing all Embryos after a fresh cycle of Controlled Ovarian Stimulation (COS), followed by Embryo transfer in a thaw cycle, has become the norm for managing ART cycles in many Centers globally. It is known to offer better success rates compared to fresh cycles, especially if the cycles are over stimulated. By converting an IVF cycle into 2 segments, it increases the time spent by the couple in completing a cycle, plus the cost of the fresh and the thaw cycle. The fresh cycle includes the cost of ovarian stimulation, ovum pick up and freezing the prepared embryos. The thaw cycle includes preparing the endometrium, thawing the embryos, monitoring the endometrium under ultrasound control, all of which increases the overall cost of one attempt at Embryo transfer. It is valid to carry out the procedure in women who are hyper stimulated, in order to prevent harm to them, if they conceive. It also overcomes the endometrial embryo asynchrony which occurs in COS cycles. But is this concept necessary to follow in all fresh cycles of ART? The safety and effectiveness of this protocol has been studied and long term follow up of children born from frozen embryos is being evaluated.

Description
This Course will discuss the advantages and disadvantages of freezing embryos, when and why to freeze, safety measures to follow during Vitrification and storage, and discuss the current research associated with ‘the freeze all’ concept. The Course will discuss the latest data on frozen embryos, their success rates versus fresh embryos, the perinatal issues and long term complications in children after frozen versus fresh transfer. Safety issues related to freezing, thawing and other technologies such as embryo biopsy for PGT-A , assisted hatching etc. will also be discussed.

ACGME Competency
Practice-based Learning and Improvement

Learning Objectives
At the conclusion of this course, participants should be able to:
1. To discuss whether Freeze all cycle should be offered to all ART patients
2. To discuss the safety aspects of freezing, thawing, manipulating embryos
3. To review the possible long term complication in children born after frozen embryo transfer

Do you know a resident attending the Scientific Congress?
Participants in the ASRM Resident Education Program will attend a flipped-classroom, interactive learning session, led by experts in reproductive medicine and medical education (boxed lunch provided), and a related symposium.
This ASRM-sponsored program (no additional cost to participants) is open to the first 64 residents who opt in at the time they register for the Scientific Program using a dialogue box that will open during the registration process.
Questions? Email Sarah Ramaiah at sramaiah@asrm.org.
**Male Infertility and ART: An Update on the Diagnosis, Treatment, and Optimization of ART Outcomes**

Developed in cooperation with the Society for Male Reproduction and Urology (SMRU), and the Society of Reproductive Surgeons (SRS)

**Faculty**

R. Matt Coward, M.D. (Chair)
Ryan P. Smith, M.D.
Ranjith Ramasamy, M.D.
Akanksha Mehta, M.D.

**Target Audience**

Reproductive endocrinologists and infertility specialists, andrologists, embryologists, urologists, fellows and residents, advanced practice providers, and nurses who seek an in-depth understanding of the evaluation and treatment of the infertile male in optimizing outcomes within the modern ART practice, while focusing on case management and discussion, and serving as a comprehensive review in addressing the male fertility patient.

**ACGME Competency**

Communication, Roles/Responsibilities, Teams and Teamwork, Values/Ethics, Interpersonal and Communication Skills, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Professionalism, Systems-based Practice

**Needs Assessment**

Approximately half of all infertile couples have a contributing or sole male factor etiology. While the utilization of assisted reproductive technology (ART) has steadily increased in recent years, only 20% of male partners in an infertile couple receive an evaluation. This concerning reality is most alarming given numerous recent studies linking male fertility with overall male health, including cardiovascular outcomes and the development of cancer. The role of the reproductive urologist in the modern ART practice is to diagnose serious or life-threatening conditions, identify and treat reversible causes of infertility, define untreated causes of testis failure, and to perform sperm procurement procedures to enable IVF-ICSI. The careful evaluation and successful treatment of male factor infertility overall leads to optimization of ART outcomes.

**Learning Objectives**

At the conclusion of this course, participants should be able to:
1. Describe the evaluation of male factor infertility and understand the potential associated health risks with its diagnosis.
2. Summarize the latest medical and surgical treatments for the most common etiologies of male factor infertility.
3. Review how optimization of male factor infertility leads to improved ART outcomes.
4. Determine how to implement the integration of the male factor evaluation and treatment on-site within a modern ART practice.

**Description**

This course will present the latest clinical developments in male infertility. Attendees will learn the latest advancements in the medical management of the infertile male, including the controversies in idiopathic male infertility treatment. We will review methods for optimizing sperm prior to ART, discuss the management of varicocele in the era of ART, and present the methods sperm retrieval techniques. The course will highlight the role of the reproductive urologist in...
A Review of Clinical and Laboratory Sperm Selection Technologies to Optimize ART Outcomes

Developed in cooperation with the Society for Male Reproduction and Urology (SMRU), and the Society of Reproductive Biologists and Technologists (SRBT)

Faculty
James Hotaling, M.D. (Chair)
Gianpiero D. Palermo, M.D., Ph.D.
Michael L. Eisenberg, M.D.
Jingtao Guo, Ph.D.

Target Audience
This interprofessional course is designed for physicians, embryologists, and andrologists.

Needs Assessment
50% of couple infertility is male factor with 10% of these with azoospermia and up to 25% with moderate or severe oligozoospermia. Although the advent of ICSI made paternity possible for these men there are still significant knowledge gaps in the field. Men with severe male factor infertility represent a difficult patient population to treat. Currently, most techniques available for sperm selection rely on visual identification of optimal sperm to use for the assisted reproductive technologies with IVF/ICSI. While some of these techniques rely on sperm motility, there are no technologies available to determine the ultimate reproductive potential of a sperm without destroying it. Currently, there are several options available for urologists and embryologists for sperm selection with multiple other technologies becoming widely available in the next several years. ASRM has identified gaps in knowledge related to options currently available for sperm selection in men with severe male factor as well as knowledge of what technologies will likely become available in the future. This course will review all of the current technologies available for sperm sorting, their indication, go over practical solutions for the embryologist and urologist and highlight new technologies that will shape the future of male infertility.

Description
This course will offer a summary of available sperm selection techniques and tools as well as the evidence supporting their indications. It will bring together world class experts to showcase, demonstrate and explain the rationale and data for a variety of techniques to process ejaculated and surgical sperm with the goal of optimizing sperm for ART. We will also review current technologies such as microfluidics, TESE to minimize the impact of DNA fragmentation, sperm processing techniques to maximize surgical sperm yield and a discussion of other technologies such as spermatogonial stem cell culture which have potential to transform the field.

ACGME Competency
Communication, Roles/Responsibilities, Teams and Teamwork, Values/Ethics, Interpersonal and Communication Skills, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement, Professionalism, Systems-based Practice

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Examine the limitations of current sperm selection techniques.
2. Describe the role of DNA fragmentation in workup of infertile men and role of TESE.
3. Counsel patients about different microfluidic sperm sorting options.
4. Summarize what the future of sperm selection might hold.
PG17  Cross-Border Family Building: Big Dreams, Small World  
Developed in cooperation with the Society for Reproductive Endocrinology and Infertility (SREI), Legal Professional Group (LPG), Mental Health Professional Group (MHPG), and the Nurses’ Professional Group (NPG)

Faculty
Kim Bergman, Ph.D. (Chair)
Will Halm, J.D.
Said Daneshmand, M.D.
Barbara Tanaka, N.P.

Target Audience
This course will address issues of concern for psychologists, nurses, reproductive endocrinologists, attorneys, practice managers and third-party agencies.

Needs Assessment
Since the United States has some of the most advanced fertility care in the world, many intended parents from outside the US will seek their care here. Intended parents who need third party assisted reproductive care often face legal, medical, financial, logistical and psychological risks and challenges. 2020 demonstrated how risky cross border family building can be and presented us a unique set of challenges. For example, in 2020 many Chinese intended parents have been unable to travel to the US to care for their babies born through US surrogacy and emergency sources of care have been required. The legal climate and in many countries makes family building arduous and complicated and third party assisted reproduction parenting via surrogacy, egg donation and sperm donation is unavailable and even illegal in many countries. And yet the wish for parenthood is universal and does not stop at borders. COVID-19 and Zika have presented unique medical and logistical challenges requiring practices to be nimble, innovative, and prepared. This multidisciplinary course will address and update the medical, psychosocial, ethical, practical and legal issues in treating incoming international patients and will offer direction to providers for how to establish best practices.

Description
Objectives: 1. Review the paths to parenthood for incoming international patients. 2. Identify challenges and ethical issues. 3. Develop best practices for incoming cross-border patient care. 4. Explain the legal climate for international parents seeking care in the US and legal path to parenthood. 5. Determine pitfalls and develop contingencies in cross-border care. 6. Identify components of teamwork necessary for this care. This course will address the multiple, unique treatment issues for international fertility patients that might expose them to increased psychological, legal and emotional risks.

ACGME Competency
Teams and Teamwork, Interpersonal and Communication Skills, Patient Care and Procedural Skills, Systems-based Practice

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Review the paths to parenthood for international patients seeking fertility and/or third party care in the US.
2. Identify challenges and ethical issues that need to be considered in incoming cross-border care.
4. Explain the legal climate for international patients seeking care in the US and the legal path to parenthood.
5. Determine pitfalls and develop contingencies in incoming cross-border care.
6. Identify the components of teamwork necessary for incoming cross-border reproductive care.
PG18 Vaginal Microbiome and Reproductive Health: From Research to Clinical Practice
Developed in cooperation with the Society for the Study of Reproduction (SSR)

Faculty
Charu Kaushic, Ph.D. (Chair)
Gregor Reid, Ph.D.
Douglas Kwon, M.D., Ph.D.
Kjersti M Aagaard, M.D., Ph.D.

Target Audience
Clinicians, basic scientists, trainees, health care professionals, geneticists, toxicologists, epidemiologists.

Needs Assessment
There is increasing evidence that dysbiosis of the vaginal microbiota and the related condition associated with clinical symptoms, bacterial vaginosis (BV), leads to adverse pregnancy outcomes and increased susceptibility to sexually transmitted infections, including HIV-1. BV is a difficult condition to treat, with over 50% of women having recurrence in less than 12 months, despite antibiotic treatment. New research showing that common lab-based methods to measure dysbiosis are not very accurate, that dysbiosis of vaginal microbiota leads to inflammatory environment in the genital tract leading to poor reproductive and sexual health outcomes. Clinicians and health care providers need to understand these and other new developments in the field of probiotics and their application in treatment for BV. This will enable application of evidence to clinical practice. This topic falls under the gap areas of optimal reproductive health in women, lifestyle modifications and their impact on recurrent spontaneous pregnancy loss and well as alternative remedies to treat recurrent implantation failure.

Description
The course is designed for clinicians and researchers in reproductive medicine, to enhance understanding on vaginal microbiome and its affects reproductive health. Participants will be provided the latest information regarding the characteristics of vaginal microbiome, how colonization with specific types of bacteria has been associated with either positive outcomes of pregnancy or bacterial vaginosis, poor reproductive outcomes and increased incidence of sexually transmitted infections, including HIV-1. The speakers are international leaders in these topics and will review both basic information, clinical applications, and latest research, which the participants can apply in their own clinical practice and research.

ACGME Competency
Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Describe the latest information on the characteristics of vaginal microbiota, the community state types (CST), the bacteria associated with different CSTs, temporal dynamics, effect of hormonal status and ethnicity on the microbiome.
2. Analyse and contrast vaginal dysbiosis, clinical symptoms associated with BV, issues with current diagnostic methods, molecular techniques that allow distinction of BV from dysbiosis and the association of both with underlying inflammatory condition.
3. Describe the effects of alterations in vaginal microbiota and different CSTs on pregnancy outcomes such as pre-term birth and sexually transmitted infections, including HIV-1.
4. Critically assess the latest information on probiotics, their benefits versus risk to treat BV, improve outcomes of pregnancy and decrease risk of sexually transmitted infections.
Riding the Wave of Change: Keys to Success

Developed in cooperation with the Association of Reproductive Managers (ARM), Legal Professional Group (LPG), and the Mental Health Professional Group (MHPG)

Faculty
Danielle Soltesz, M.B.A., M.P.H. (Chair)
Mahshid Albrecht, M.B.A.
Deborah Guston, J.D.
Amelia Swanson, Ph.D.

Target Audience
This interprofessional course is designed for practice managers, nurses managers, physicians, legal professionals and mental health professionals.

Needs Assessment
In a world of constant change, organizational change management has become a critical component of every business plan and strategy. 2020 was a pivotal year for our industry with key issues faced including the COVID-19 Pandemic, Black Lives Matter movement and rapid industry consolidation. The global COVID-19 pandemic has challenged our industry to manage their enterprises in newfound ways. In the short term, they’re facing enormous scope changes to their business plans; in the long term, they must adapt and continue to make progress on their original goals. This interprofessional group will aim to give industry leaders a toolbox for managing change.

Description
This Postgraduate course aims to prepare leaders on change management. Specific topics include:
1. Managing Organizational Change
2. Metrics for Measuring Success in Change Management
3. I’m a Pandemic Survivor
4. Preparing for a Crisis
5. Telehealth Transition for Patients- How do you keep them connected to you remotely
6. Remote Working & Employee Engagement
7. Legal Aspects of Telehealth & Telework Environments
8. Tips to tackle workplace stress and encourage and motivate your employees.

ACGME Competency
Communication, Roles/Responsibilities, Teams and Teamwork

Learning Objectives
At the conclusion of this course, participants should be able to:
1. Review and outline key components of Change Management.
2. Summarize critical components for patient engagement following a telehealth visit.
3. Recommend to attendees tools for leaders to address a crisis.
4. Identify key ways to engage your workforce in a remote work environment.
5. Describe legal areas of concern for telehealth and telework environments.
6. Identify ways to address workplace stress for your employees.
Strategies to Improve the Safety of Controlled Ovarian Stimulation Protocols: Paving the Way for OHSS-Free IVF?

Developed in cooperation with the Middle East Fertility Society (MEFS)

PG20

Faculty
Johnny Awwad, M.D., H.C.L.D. (Chair)
Mohamed A Aboulghar, M.D.
Peter Humaidan, M.D., Ph.D.
Juan A Garcia-Velasco, M.D., Ph.D.

Target Audience
This intermediate to advanced level interprofessional course is designed for physicians, advanced practice providers, nurses, ART allied health professionals, practice managers, embryologists, and scientists.

Needs Assessment
The use of GnRH agonists to trigger final oocyte maturation has gained momentum over the use of hCG in women at risk for OHSS. Because of the shorter agonist-induced LH surge, earlier demise of the corpus luteum yielded a reduction in OHSS at the peril of poor embryo implantation. Dissociating ovarian and endometrial events was therefore proposed to restore reproductive success without compromising safety. The success of cycle segmentation however is highly dependent on the performance of the cryopreservation program in place. For fresh embryo transfers, alternative strategies to improve the profoundly deficient luteal phase were suggested. The use of intensive hormonal supplementation has been inadequately investigated. Whether standardized or individualized protocols are more suitable in this context remain inconclusive. The administration of low dose hCG to prevent corpus luteum demise was met with improved success. These protocols are very heterogenous and differ in the dose and timing of hCG administration. Their safety when used in high responders has not been fully confirmed. Incidents of partial or complete failure of oocyte collection have also been reported after agonist triggering. Risk factors have been poorly explored, while preventive and corrective measures remain largely erratic.

Description
This course appraises the scientific evidence which evaluates the benefits and limitations of the use of GnRHa triggering strategies to improve the safety of controlled ovarian stimulation protocols. This course sheds the light on the physiologic effects of GnRHa triggering on luteal events. Emphasis will be on developing best practice models for an OHSS-free IVF clinic, while identifying knowledge gaps in GnRHa triggering research which require immediate attention through the proper design of high-quality basic and translational research. This course is designed using an interactive learning format which involves didactic lectures, case discussions and problem-solving of clinical vignettes.

ACGME Competency
Communication, Teams and Teamwork, Medical Knowledge, Patient Care and Procedural Skills, Practice-based Learning and Improvement

Learning Objectives
At the conclusion of this course, participants should be able to:

1. Design safer ovarian stimulation protocols tailored to patients’ individual characteristics; and counsel women undergoing controlled ovarian stimulation for IVF about the number of oocytes needed to optimize success without compromising safety.
2. Describe the physiological effects of GnRH agonist on LH surge characteristics, oocyte maturation, and follicular luteinization.
3. Design an intensive luteal support protocol to improve implantation of fresh embryos in GnRHa triggered IVF cycles; and demonstrate safety and efficacy in relation to patients’ endocrine profile and ovarian response.
4. Estimate the benefits and perils of LH luteal support for fresh embryo transfer after GnRHa triggering.
5. Identify risk factors associated with a compromised LH surge after GnRHa triggering, interpret markers that predict poor oocyte yield and maturation rates, and implement preventive and corrective measures.
6. Appraise OHSS risk associated with GnRHa triggering according to the
The theme of the 2021 Scientific Congress of the American Society for Reproductive Medicine is "Reproduction Reimagined." The scope of reproductive medicine is broad ranging from puberty to menopause, including males and females, while having a focus that is both molecular and macroscopic. The program is balanced between science at the cellular level and application of reimagining reproduction in using cutting edge information in the clinical care of patients to promote positive outcomes for families. This live program is designed for physicians, nurses, andrology and embryology laboratory personnel, genetic counselors, social workers, practice and laboratory managers, as well as specialists in mental health, law, and ethics to advance exemplary medical care and disseminate cutting-edge research. These goals will be addressed by a wide array of educational activities.

The CME/CE portion of the Scientific Congress will include plenary, lectures, symposia, and interactive sessions interweaving the theme of the annual Congress. Plenary lectures will feature exceptional speakers covering a wide range of themes in reproductive medicine including: a supportive physiologic environment for the extreme premature infant, compelling evidence that collaboration with qualified male reproductive urologists improves ART outcomes, new frontiers in contraception research, genetic basis of meiotic catastrophe, applications of nuclear transplantation in reproductive medicine, past and future IVF, and a history of and future for endometriosis surgery. Congress symposia will provide more in-depth coverage of basic and clinical subjects. Topics range from a wide variety of interests including: reimagining the future of male reproductive medicine in the age of telemedicine and beyond, SART-CORS registry, educating the modern day REI nurse, addressing systemic inequities in reproductive healthcare, reimagining reproductive counseling and treatment in an era of uncertainty; pandemic impacts on fertility care, long-term storage of gamete at room temperature, multidisciplinary and collaborative approach to endometriosis, PGT yesterday, today, and tomorrow, neonatal programming and lessons from the lactocline hypothesis, the impact of private equity on the fertility industry, managing the age related DOR patient, endometriosis: mechanism, endometrial receptivity and infertility, demystifying pelvic pain in adolescent females, regenerative medicine as the new frontier in ART, natural killer cell-mediated immune pathology and reproductive failures, nPGT-A for embryo prioritization, management of patients with serious medical problems, the task to increase diversity in subspecialty REI training, artificial intelligence (AI) in the IVF laboratory, transgender youth: navigating parents, peers, and society while envisioning future family planning, what we have learned from catastrophic events, the environment affects more than the ice caps, epigenetic/genomic anomalies in oocytes/embryos: current insights and clinical implications, fertility preservation for women and girls with POI, and medical and surgical management of adenomyosis and infertility.

The interactive sessions cover a wide range of stimulating topics and are meant to be a forum for discussion and interaction, including topics such as, open identity gamete donation, evidenced based selection of ovarian stimulation protocols for fertility preservation, integrating the reproductive urologist within an ART practice, PGT-A for pregnancy loss prevention, case presentations on hormone therapy for POI and menopause, reimagining patient education with the use of social media, Asherman’s syndrome, diversity, equity and inclusion task force, vaginal microbiome is emerging as a key factor in reproductive health, optimize outcomes for the infertility patient with PCOS, video surgical tutorial on repair of c-section scar defects, strategies for a successful career, reimagining complex needs of ovarian insufficiency and creating the ultimate reproductive team, oncology and sperm cryopreservation during the COVID-19 pandemic, chat with journal editors, let’s talk legal, 3D SIS or hysteroscopy for uterine cavity evaluation, transferring segmental aneuploidy embryos safe, Baltimore IVF history, increasing access to third party reproduction, to ICSI all or not, varicocelectomy in the management of male factor infertility, core business principles, endometrial receptivity and ART outcomes, addressing mental health for patients with pregnancy loss, contemporary management of Turner syndrome, patient perspectives and advocacy for black women facing infertility, complex family planning, dietary patterns, new AUA/ASRM infertility guidelines, and ASRM Mullerian anomaly classification. Supplemeting the CME/CE program will be non-CME/CE events including roundtable luncheons and Expert Encounters that will provide opportunities for in-depth discussion with experts in small-group settings as well as oral and poster scientific abstract presentations that enable investigators to present cutting-edge scientific research in reproductive medicine and biology. Included in the diverse program are “tracks” for specialty and interest areas to enable participants to focus on specific topics and identify areas to expand their knowledge. The 2021 Scientific Congress should provide ample opportunity for learning, improvement of clinical competence, and reimagining reproduction for the future of family fertility care.

Learning Objectives

At the conclusion of the Scientific Congress, participants should be able to:
1. Propose appropriate treatments for reproductive dysfunctions in females and males at different ages throughout life—childhood, adolescence, adulthood, and reproductive senescence.
2. Summarize how the extensive range of reproductive technologies from the cellular level to clinical application using collaborative teams impact infertility and fertility preservation.
3. Discuss current knowledge of endometriosis, fibroids, adenomyosis, contraception, and polycystic ovary syndrome.
4. Explain the relevance of genetics and genomics to reproductive care.
5. Describe the ethical, legal, and psychosocial ramifications of third-party reproduction.
6. Review the latest scientific advances in embryo biology and assessment to the optimization of embryo transfer.
7. Apply strategies that simplify technology, reduce costs, and broaden accessibility.

ACGME Competencies

Interpersonal and communication skills
Medical knowledge
Patient care
Practice-based learning and improvement
Professionalism
Systems-based practice

Interprofessional Competencies

Values/ethics for interprofessional practice
Roles/responsibilities
Interprofessional communication
Teams and teamwork
<table>
<thead>
<tr>
<th>Date</th>
<th>Sunday 17-Oct</th>
<th>Monday 18-Oct</th>
<th>Tuesday 19-Oct</th>
<th>Wednesday 20-Oct</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0630</td>
<td></td>
<td>0630</td>
<td>Poster Abstract Sessions</td>
<td>Poster Abstract Sessions</td>
</tr>
<tr>
<td>0700</td>
<td>0700</td>
<td>0700</td>
<td>0700</td>
<td></td>
</tr>
<tr>
<td>0715</td>
<td>0715</td>
<td>0715</td>
<td>0715</td>
<td></td>
</tr>
<tr>
<td>0730</td>
<td></td>
<td>0730</td>
<td>0730</td>
<td></td>
</tr>
<tr>
<td>0745</td>
<td>0745</td>
<td>0745</td>
<td>0745</td>
<td></td>
</tr>
<tr>
<td>0800</td>
<td>0800</td>
<td>0800</td>
<td>Pre-Plenary Special Session</td>
<td>Plenary 5: Herbert Thomas Lecture</td>
</tr>
<tr>
<td>0815</td>
<td>0815</td>
<td>0815</td>
<td>0815</td>
<td></td>
</tr>
<tr>
<td>0830</td>
<td>0830</td>
<td>0830</td>
<td>Plenary 3: Nezhat Lectureship</td>
<td>Plenary 6</td>
</tr>
<tr>
<td>0845</td>
<td>0845</td>
<td>0845</td>
<td>0845</td>
<td></td>
</tr>
<tr>
<td>0900</td>
<td>0900</td>
<td>0900</td>
<td>0900</td>
<td></td>
</tr>
<tr>
<td>0915</td>
<td>0915</td>
<td>0915</td>
<td>0915</td>
<td></td>
</tr>
<tr>
<td>0930</td>
<td>0930</td>
<td>0930</td>
<td>0930</td>
<td></td>
</tr>
<tr>
<td>0945</td>
<td></td>
<td>0945</td>
<td>0945</td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
<td></td>
</tr>
<tr>
<td>1015</td>
<td>1015</td>
<td>1015</td>
<td>1015</td>
<td></td>
</tr>
<tr>
<td>1030</td>
<td>1030</td>
<td>1030</td>
<td>1030</td>
<td></td>
</tr>
<tr>
<td>1045</td>
<td>1045</td>
<td>1045</td>
<td>1045</td>
<td></td>
</tr>
<tr>
<td>1100</td>
<td></td>
<td>1100</td>
<td>1100</td>
<td></td>
</tr>
<tr>
<td>1115</td>
<td>1115</td>
<td>1115</td>
<td>1115</td>
<td></td>
</tr>
<tr>
<td>1130</td>
<td>1130</td>
<td>1130</td>
<td>1130</td>
<td></td>
</tr>
<tr>
<td>1145</td>
<td>1145</td>
<td>1145</td>
<td>1145</td>
<td></td>
</tr>
<tr>
<td>1200</td>
<td></td>
<td>1200</td>
<td>1200</td>
<td></td>
</tr>
<tr>
<td>1215</td>
<td>1215</td>
<td>1215</td>
<td>1215</td>
<td></td>
</tr>
<tr>
<td>1230</td>
<td>1230</td>
<td>1230</td>
<td>1230</td>
<td></td>
</tr>
<tr>
<td>1245</td>
<td>1245</td>
<td>1245</td>
<td>1245</td>
<td></td>
</tr>
<tr>
<td>1300</td>
<td>1300</td>
<td>1300</td>
<td>1300</td>
<td></td>
</tr>
<tr>
<td>1315</td>
<td>1315</td>
<td>1315</td>
<td>1315</td>
<td></td>
</tr>
<tr>
<td>1330</td>
<td>1330</td>
<td>1330</td>
<td>1330</td>
<td></td>
</tr>
<tr>
<td>1345</td>
<td>1345</td>
<td>1345</td>
<td>1345</td>
<td></td>
</tr>
<tr>
<td>1400</td>
<td>1400</td>
<td>1400</td>
<td>1400</td>
<td></td>
</tr>
<tr>
<td>1415</td>
<td>1415</td>
<td>1415</td>
<td>1415</td>
<td></td>
</tr>
<tr>
<td>1430</td>
<td>1430</td>
<td>1430</td>
<td>1430</td>
<td></td>
</tr>
<tr>
<td>1445</td>
<td>1445</td>
<td>1445</td>
<td>1445</td>
<td></td>
</tr>
<tr>
<td>1500</td>
<td>1500</td>
<td>1500</td>
<td>1500</td>
<td></td>
</tr>
<tr>
<td>1515</td>
<td>1515</td>
<td>1515</td>
<td>1515</td>
<td></td>
</tr>
<tr>
<td>1530</td>
<td>1530</td>
<td>1530</td>
<td>1530</td>
<td></td>
</tr>
<tr>
<td>1545</td>
<td>1545</td>
<td>1545</td>
<td>1545</td>
<td></td>
</tr>
<tr>
<td>1600</td>
<td>1600</td>
<td>1600</td>
<td>1600</td>
<td></td>
</tr>
<tr>
<td>1615</td>
<td>1615</td>
<td>1615</td>
<td>1615</td>
<td></td>
</tr>
<tr>
<td>1630</td>
<td>1630</td>
<td>1630</td>
<td>1630</td>
<td></td>
</tr>
<tr>
<td>1645</td>
<td>1645</td>
<td>1645</td>
<td>1645</td>
<td></td>
</tr>
<tr>
<td>1700</td>
<td>1700</td>
<td>1700</td>
<td>1700</td>
<td></td>
</tr>
<tr>
<td>1715</td>
<td>1715</td>
<td>1715</td>
<td>1715</td>
<td></td>
</tr>
<tr>
<td>1730</td>
<td>1730</td>
<td>1730</td>
<td>1730</td>
<td></td>
</tr>
<tr>
<td>1745</td>
<td>1745</td>
<td>1745</td>
<td>1745</td>
<td></td>
</tr>
<tr>
<td>1800</td>
<td>1800</td>
<td>1800</td>
<td>1800</td>
<td></td>
</tr>
<tr>
<td>1815</td>
<td>1815</td>
<td>1815</td>
<td>1815</td>
<td></td>
</tr>
<tr>
<td>Members' Meetings</td>
<td>5:15 pm - 6:00 pm</td>
<td>Members' Meetings</td>
<td>Members' Meetings</td>
<td>Members' Meetings</td>
</tr>
<tr>
<td>ASRM President's Gala</td>
<td>6:00 PM</td>
<td>5:45 pm - 8:00 pm</td>
<td>5:45 pm - 7:00 pm</td>
<td></td>
</tr>
</tbody>
</table>
Specialty Tracks

These at-a-glance content track pages are built around attendee special interests, so that groupings of course offerings according to content can easily be identified. Most of the content of the Scientific Congress addresses the interests of our REI and ART-focused attendees. Therefore, REI and ART content courses are not shown as separate tracks. Access all sessions by track via our online schedule here: https://asrm.confex.com/asrm/2021/meetingapp.cgi/Index/CB_Track

Access to Care Track

Monday, October 18

1:30 PM - 2:45 PM Symposium CME
With (Reproductive) Justice for All: Addressing Systemic Inequities in Reproductive Healthcare
Rachael Bailey, J.D.
International Reproductive Law Group
Angela Bethea-Walsh, Ph.D.
Private Practice, Atlanta, GA
Danielle Kaplan, Ph.D.
NYU Langone

Tuesday, October 19

1:30 PM - 2:45 PM Symposium CME
Representation Matters: The Task to Increase Diversity in Subspecialty REI Training
Gloria Richard-Davis, M.D.
UAMS, Little Rock, AR
Sherita Hill Golden, M.D., M.H.S.,
John Hopkins Medicine
Mia Mallory, M.D., M.Ed.
University of Cincinnati College of Medicine/Cincinnati Children’s Hospital Medical Center

4:30 PM - 5:30 PM Interactive Session CME
Where Are the Brown Eggs?: Increasing Access to and Utilization of Third Party Reproduction
Heather Gibson Huddleston, M.D.
University of California San Francisco, San Francisco, CA
Jerisa Berry, M.D.
Secure Your Fertility
Jerrine R. Morris, M.D., M.P.H.
University of California, San Francisco, Department of Obstetrics and Gynecology, San Francisco, CA

Wednesday, October 20

1:30 PM - 2:45 PM Symposium CME
Transgender Youth: Navigating Parents, Peers, and Society While Envisioning Future Family Planning
Molly B. Moravek, M.D., M.P.H.
University of Michigan
Marjorie E. Dixon, M.D.
Anova Fertility and Reproductive Health, Toronto, ON, Canada
Jamie M. Joseph, Ph.D.,
Private Practice

3:45 PM - 4:45 PM Interactive Session CME
Say Her Name: Patient Perspectives and Advocacy for Black Women Facing Infertility
Regina Townsend
The Broken Brown Egg
Shantana Hazel
Sister Girl Foundation
Stacey Edwards-Dunn, D.Min., M.P.H.
Fertility for Colored Girls
Camille Hammond, M.D.
The Cade Foundation
Assisted Reproductive Technology Lab Track

Monday, October 18

1:30 PM - 2:45 PM Symposia
PGT Yesterday, Today, and Tomorrow
James A Grifo, MD, PhD, New York University
Mike Large, Ph.D.
CooperSurgical
Mark Hughes, Ph.D.
COOPERGENOMICS

CME

Symposium on Long-Term Storage of Germplasms at Room Temperature - the End of the Ice Age.
Allison Hubel, Ph.D.
University of Wisconsin
Pasqualino Loi, Ph.D.
University of Teramo, Italy
Pasquale Patrizio, M.D., M.B.E., H.C.L.D.
Yale Fertility Center
Pierre Comizzoli, D.V.M., Ph.D.
Smithsonian Institution

SART-CORS Registry: The State of the ART
Jennifer F Kawwass, M.D., Emory University School of Medicine, Division of Reproductive Endocrinology and Infertility
Stacey A Mismer, Sc.D.
College of Human Medicine, Michigan State University
Amanda Nicole Kallen, M.D.
Yale School of Medicine

CME

Tuesday, October 19

1:30 PM - 2:45 PM Symposium
Artificial Intelligence (AI) in the IVF Laboratory
Alan B. Copperman, M.D.
Sema4
Reproductive Medicine Associates of New York
Danielle Soltesz, M.B.A., M.P.H.
RMA of New York

CME

4:30 PM - 5:30 PM Interactive Session
Let’s Talk Legal
Michael J Tucker, Ph.D.
Shady Grove Fertility
Susan Crockin, J.D.
Georgetown University

CME

To ICSI ALL or NOT to ICSI ALL: That’s the Question!
Mitchel C. Schiewe, M.S., Ph.D., H.C.L.D.(ABB)
Ovation Fertility
David H. McCulloh, Ph.D.
NYU Grossman School of Medicine
Caroline McCaffrey, Ph.D.
NYU Langone School of Medicine
William Venier, M.Sc., E.L.D. (ABB)
San Diego Fertility Center
Liesl Nel-Themaat, Ph.D., H.C.L.D.
University of Colorado

CME

Wednesday, October 20

1:30 PM - 2:45 PM Symposia
Howard and Georgeanna Jones Symposium on Assisted Reproductive Technology: Epigenetic/Genomic Anomalies in Oocytes/Embryos: Current Insights and Clinical Implications
Fuchou Tang, Ph.D.
Peking University, Beijing, CA, China
McCoy Rajiv, Ph.D.
Johns Hopkins University
Manuel Vioiti, Ph.D.
Zouves Foundation for Reproductive Medicine

CME

Crisis Management: What We Have Learned from Catastrophic Events
Roman Pyrzak, Ph.D.
The Fertility Institute of New Orleans
Kimball O. Pomeroy, Ph.D.
The World Egg Bank
Sangita K. Jindal, Ph.D.
Albert Einstein College of Medicine / Montefiore Medical Center

The Environment: It Affects More Than the Ice Caps!
Patricia Hunt, Ph.D.
Washington State University
Dean E Morbeck, Ph.D., M.B.A.
Sunfert International Fertility Centre, Malaysia
Linda C Giudice, M.D., Ph.D.
Washington State University
Contraception Track

Monday, October 18

4:30 PM - 5:30 PM Interactive Session
The Vagina Dialogues: How the Vaginal Microbiome Is Emerging As a Key Factor in Reproductive Health
Michelle Shardell, Ph.D.
University of Maryland School of Medicine
Susan Tuddenham, M.D.
Johns Hopkins University School of Medicine
Anne E. Burke, M.D., M.P.H.
Johns Hopkins School of Medicine

Tuesday, October 19

3:00 PM - 3:45 PM Keynote Lecture
Contraception Keynote Lecture: New Frontiers in Contraception Research
Regine Sitruk-Ware, M.D.
Population Council

Wednesday, October 20

3:45 PM - 4:45 PM Interactive Session
Complex Family Planning Fellows Showcase
Elizabeth Micks, M.D. M.P.H.
Oregon Health & Science University
Ethics & Legal Track

Monday, October 18

1:30 PM - 2:45 PM Symposium  
**The ABOG Foundation - Kenneth J. Ryan Ethics**  
Symposium: Reimagining Reproductive Counseling and Treatment in an Era of Uncertainty: Pandemic Impacts on Fertility Care  
Enrique F. Schisterman, Ph.D.  
National Institute of Child Health and Human Development, Epidemiology Branch, DIghPR, NICHD, NIH  
Neil Silverman, M.D.  
Center for Fetal Medicine and Women’s Ultrasound  
Louise Perkins King, M.D., J.D.

1:30 PM - 2:45 PM Symposium  
**With (Reproductive) Justice for All: Addressing Systemic Inequities in Reproductive Healthcare**  
Rachael Bailey, J.D.  
International Reproductive Law Group  
Angela Bethea-Walsh, Ph.D.  
Private Practice  
Danielle Kaplan, Ph.D.  
NYU Langone

Tuesday, October 19

9:15 AM - 10:00 AM Plenary  
Plenary Lecture: Ethics/Artificial Gametes From Stem Cells and on Widespread IVF Utilization in the Fertile Population to Allow Genetic Testing  
Henry T. Greely, J.D.  
Stanford University

4:30 PM - 5:30 PM Interactive Session  
**Let’s Talk Legal**  
Michael J Tucker, Ph.D.  
Shady Grove Fertility  
Susan Crockin, J.D.  
Georgetown University

Wednesday, October 20

11:00 AM - 12:00 PM Clinical Session  
**MHPG Clinical Session: Ethics Course: Reproductive Healthcare Ethic and Challenges in Modern Times**  
Alice D. Domar, Ph.D.  
Boston IVF  
Elizabeth Anne Grill, Psy.D.  
Weill Cornell Medical College  
Kim Bergman, Ph.D.  
Growing Generations

1:30 PM - 2:45 PM Symposium  
**Surrogacy and the Modern Family: Medical, Ethical and Emotional Challenges of Complex Gestational Surrogacy Cases**  
Mark Leondires, M.D.  
Reproductive Medicine Associates of Connecticut  
Lisa Schuman, M.S.W.  
Reproductive Medicine Associates of Connecticut  
Mark Schiff, M.A.  
Growing Generations

1:30 PM - 2:45 PM Symposium  
**Crisis Management: What We Have Learned from Catastrophic Events**  
Roman Pyrzak, Ph.D.  
The Fertility Institute of New Orleans  
Kimball O. Pomeroy, Ph.D.  
The World Egg Bank  
Sangita K. Jindal, Ph.D.  
Albert Einstein College of Medicine / Montefiore Medical Center
Fertility Preservation Track

Monday, October 18

1:30 PM - 2:45 PM Symposia
Symposium on Long-Term Storage of Germplasms at Room Temperature - the End of the Ice Age.
Allison Hubel, Ph.D.
University of Wisconsin
Pasqualino Loi, Ph.D.
University of Teramo, Italy
Pasquale Patrizio, M.D., MBE, HCLD
Yale Fertility Center
Pierre Comizzoli, D.V.M., Ph.D.
Smithsonian Institution

Stacey A. Missmer, Sc.D.
College of Human Medicine, Michigan State University
Amanda Nicole Kallen, M.D.
Yale School of Medicine

4:30 PM - 5:30 PM Interactive Session
Evidence Based Selection of Ovarian Stimulation Protocols for Fertility Preservation
Clarisa Gracia, M.D., M.S.C.E.
Hospital of the University of Pennsylvania
Kenny A. Rodriguez-Wallberg, M.D., Ph.D.
University of Karolinska, Sweden
Kutluk H. Oktay, M.D., Ph.D.
Yale University School of Medicine

Tuesday, October 19

4:30 PM - 5:30 PM Interactive Session
Oncofertility and Sperm Cryopreservation during the Global COVID-19 Pandemic
Joshua A. Halpern, M.D., M.S.
Northwestern University, Feinberg School of Medicine
Dolores J. Lamb, Ph.D.
Male Infertility
Robert E. Brannigan, M.D.
Northwestern University Feinberg School of Medicine

Wednesday, October 20

1:30 PM - 2:45 PM Symposia
Fertility Preservation for Women and Girls with Primary Ovarian Insufficiency: Current Strategies
Kutluk H. Oktay, M.D., Ph.D.
Yale University School of Medicine
David Cohen, M.D.
Infertility IHR
Mindyl S. Christianson, M.D.
Johns Hopkins Fertility Center

Crisis Management: What We Have Learned from Catastrophic Events
Roman Pyrzak, Ph.D.
The Fertility Institute of New Orleans
Kimball O. Pomeroy, Ph.D.
The World Egg Bank
Sangita K. Jindal, Ph.D.
Albert Einstein College of Medicine / Montefiore Medical Center

3:45 PM - 4:45 PM Interactive Session
What Every ASRM Member Needs to Know about the New AUA/ASRM Male Infertility Guidelines
Peter N. Schlegel, M.D.
Weill Cornell Medicine, New York Presbyterian Hospital
Mark Sigman, M.D.
Brown University
Barbara Lynn Collura, M.A.
RESOLVE: The National Infertility Association
Stan Honig, M.D.
Yale University
Genetic Counseling Track

Monday, October 18

4:30 PM - 5:30 PM Interactive Sessions
PGT-a for Pregnancy Loss Prevention. Who Is It Good for? CME
William G. Kearns, PhD
AdvaGenix, Johns Hopkins University School of Medicine
Eric J. Forman, M.D.
Medical and Laboratory Director
Alleigh L.H. Boyd, MS
Stanford University
Paul Robert Brezina, M.D.
Fertility Associates of Memphis

Open-Identity Gamete Donation: What Are the Children Saying? CME
Jennifer Gamper, B.S.N., M.S.W.
RMANJ
Greg Moga, B.A., J.D.
Seattle Sperm Bank
Wendy Kramer, B.A.
Donor Sibling Registry
Gina Davis, M.S., L.C.G.C.
Advocate Genetics
Kriston Ward, M.S.N.
Strong Fertility Center

Tuesday, October 19

1:30 PM - 2:45 PM Symposium
From the Lab to the Clinic: nPGT-A for Embryo Prioritization CME
Erin Barone, M.S., G.C.
New Hope Fertility Center
Nina Resetkova, M.D., M.B.A.
Boston IVF
Alyssa Snider, M.S., Ph.D., C.G.C.
Igenomix

4:30 PM - 5:30 PM Interactive Session
PGT-a: Is Transferring Segmental (full or mosaic, large or small) Aneuploidy Embryos Safe CME
Mousa Shamonki, M.D.
Fertility and Surgical Associates of California
Ann Carlson, M.S., C.G.C.
Weill Cornell Medical College of Cornell University
Kangpu Xu, Ph.D.
Weill Cornell Medical College of Cornell University
Valerie L Baker, M.D.
Johns Hopkins Fertility Center

Wednesday, October 20

1:30 PM - 2:45 PM Symposium
Howard and Georgeanna Jones Symposium on Assisted Reproductive Technology: Epigenetic/Genomic Anomalies in Oocytes/Embryos: Current Insights and Clinical Implications CME
Fuchou Tang, Ph.D.
Peking University, Beijing, CA, China
McCoy Rajiv, Ph.D.
Johns Hopkins University
Manuel Viotti, Ph.D.
Zouves Foundation for Reproductive Medicine

3:45 PM - 4:45 PM Interactive Session
Contemporary Management of Turner Syndrome: Case Presentations CME
Katherine Hayes, M.D.
University of Utah
Noor Ebbiary, M.B.B.Ch., M.D.
University of Sheffield
Jamie Dokson, M.S., L.C.G.C.
Navigate Genetic Counseling
Staci E. Pollack, M.D., M.S.
Albert Einstein College of Medicine
Genetics Track

Monday, October 18

8:30 AM - 9:15 AM Plenary
President’s Guest Plenary Lecture: CRISPER and Gene Editing
Jennifer Doudna, Ph.D.
University of California, Berkeley

1:30 PM - 2:45 PM Symposium
PGT Yesterday, Today, and Tomorrow
James A. Grifo, M.D., Ph.D.
New York University
Mike Large, Ph.D.
CooperSurgical
Mark Hughes, Ph.D.
COOPERGENOMICS

4:30 PM - 5:30 PM Interactive Sessions
Open-Identity Gamete Donation: What Are the Children Saying?
Jennifer Gamper, B.S.N., M.S.W.
RMANJ
Greg Moga, B.A., J.D.
Seattle Sperm Bank
Wendy Kramer, B.A.
Donor Sibling Registry
Gina Davis, M.S., L.C.G.C.
Advocate Genetics
Kriston Ward, M.S.N.
Strong Fertility Center

PGT-a for Pregnancy Loss Prevention. Who Is It Good for?
William G. Kearns, Ph.D.
AdvaGenix, Johns Hopkins University School of Medicine
Eric J. Forman, M.D.
Medical and Laboratory Director
Alleigh L.H. Boyd, M.S.
Stanford University
Paul Robert Brezina, M.D.
Fertility Associates of Memphis

Tuesday, October 19

8:00 AM - 8:30 AM Lecture
Pre-Plenary Lecture: Uncovering the Molecular Determinants of Successful Implantation in the Human Blastocyst
Heidi Cook-Andersen, M.D., Ph.D.
University of California, San Diego

9:15 AM - 10:00 AM Plenary
Plenary Lecture: Ethics/Artificial Gametes From Stem Cells and on Widespread IVF Utilization in the Fertile Population to Allow Genetic Testing
Henry T. Greely, J.D.
Stanford University

1:30 PM - 2:45 PM Symposium
KY Cha Symposium in Stem Cell Technology and Reproductive Medicine: Regenerative Medicine As the New Frontier in ART
Shoukhrat Mitalipov, Ph.D.
Oregon Health & Science University
Monica M. Laronda, Ph.D.
Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital of Chicago
T. Arthur Chang, Ph.D., H.C.L.D., E.L.D.
University of Texas Health Science Center

3:00 PM - 3:45 PM Keynote Lecture
The Society for the Study of Reproduction Keynote Lecture: Genetic Basis of Meiotic Catastrophe: From Mice to Men
P. Jeremy Wang, M.D., Ph.D.
University of Pennsylvania
Genetics Track

Tuesday, October 19

4:30 PM - 5:30 PM Interactive Session
PGT-a: Is Transferring Segmental (full or mosaic, large or small) Aneuploidy Embryos Safe
Mousa Shamonki, M.D.
Fertility and Surgical Associates of California
Ann Carlson, M.S., C.G.C.
Weill Cornell Medical College of Cornell University
Kangpu Xu, Ph.D.
Weill Cornell Medical College of Cornell University
Valerie L. Baker, M.D.
Johns Hopkins Fertility Center

Wednesday, October 20

8:00 AM - 8:45 AM Plenary
Herbert H. Thomas Plenary Lecture: Applications of Nuclear Transplantation in Reproductive Medicine
Shoukhrat Mitalipov, Ph.D.
Oregon Health & Science University

1:30 PM - 2:45 PM Symposium
Howard and Georgeanna Jones Symposium on Assisted Reproductive Technology: Epigenetic/Genomic Anomalies in Oocytes/Embryos: Current Insights and Clinical Implications
Fuchou Tang, Ph.D.
Peking University, Beijing, CA, China
McCoy Rajiv, Ph.D.
Johns Hopkins University
Manuel Viotti, Ph.D.
Zouves Foundation for Reproductive Medicine
### Male Reproduction Track

#### Monday, October 18

**1:30 PM - 2:45 PM Symposium**
Reimagining the Future of Male Reproductive Medicine in the Age of Telemedicine and Beyond
- James M. Dupree IV, M.D., M.P.H.
  - University of Michigan
- Tolu Bakare, M.D.
  - University of Texas Southwestern Medical Center
- James Smith, M.D.
  - University of California, San Francisco

**4:30 PM - 5:30 PM Interactive Session**
Integrating the Reproductive Urologist within the Modern ART Practice
- Thomas L. Toth, M.D.
  - Boston IVF
- Puneet Masson, MD
  - Penn Medicine
- Cigdem Tanrikut, MD
  - Shady Grove Fertility

#### Tuesday, October 19

**3:00 PM - 3:45 PM Keynote Lectures**
- Contraception Keynote Lecture: New Frontiers in Contraception Research
  - Regine Sitruk-Ware, M.D.
    - Population Council
- The Society for the Study of Reproduction Keynote Lecture: Genetic Basis of Meiotic Catastrophe: From Mice to Men
  - P. Jeremy Wang, M.D., Ph.D.
    - University of Pennsylvania

**4:30 PM - 5:30 PM Interactive Session**
Oncofertility and Sperm Cryopreservation during the Global COVID-19 Pandemic
- Joshua A. Halpem, M.D., M.S.
  - Northwestern University, Feinberg School of Medicine
- Dolores J. Lamb, Ph.D.
  - Male Infertility
- Robert E. Brannigan, M.D.
  - Northwestern University Feinberg School of Medicine

#### Wednesday, October 20

**3:45 PM - 4:45 PM Interactive Session**
Varicocelectomy in the Management of Male Factor Infertility – an Interactive Discussion
- Larry I. Lipshultz, M.D.
  - Baylor College of Medicine
- Armand Zini, M.D., F.R.C.S.C.
  - McGill University, Montréal, QC, Canada
- Karl R. Hansen, M.D., Ph.D.
  - University of Oklahoma College of Medicine
- Joseph P. Alukal, M.D.
  - Columbia University Fertility Center

**3:45 PM - 4:45 PM Interactive Session**
What Every ASRM Member Needs to Know About the New AUA/ASRM Male Infertility Guidelines
- Peter N. Schlegel, M.D.
  - Weill Cornell Medicine, New York Presbyterian Hospital
- Mark Sigman, M.D.
  - Brown University
- Barbara Lynn Collura, M.A.
  - RESOLVE: The National Infertility Association
- Stan Honig, M.D.
  - Yale University
Menopause and Primary Ovarian Insufficiency (POI) Track

Monday, October 18

4:30 PM - 5:30 PM Interactive Session
The Vagina Dialogues: How the Vaginal Microbiome Is Emerging As a Key Factor in Reproductive Health
Michelle Shardell, Ph.D.
University of Maryland School of Medicine
Susan Tuddenham, M.D.
Johns Hopkins University School of Medicine
Anne E. Burke, M.D., M.P.H.
Johns Hopkins School of Medicine

4:30 PM - 5:30 PM Interactive Session
Hormone Therapy for Primary Ovarian Insufficiency and Menopausal Symptoms: Case Presentations
Satu Kuokkanen, M.D., Ph.D.
NYU Langone
Lubna Pal, M.B.B.S.
Yale University
Jessica B. Spencer, M.D., M.Sc.
Emory University School of Medicine, Division of Reproductive Endocrinology and Infertility

Wednesday, October 20

1:30 PM - 2:45 PM Symposium
Fertility Preservation for Women and Girls with Primary Ovarian Insufficiency: Current Strategies
Kutluk H. Oktay, M.D., Ph.D.
Yale University School of Medicine
David Cohen, M.D.
Infertility IHR
Mindy S. Christianson, M.D.
Johns Hopkins Fertility Center

3:45 PM - 4:45 PM Interactive Session
Contemporary Management of Turner Syndrome: Case Presentations
Katherine Hayes, M.D.
University of Utah
Noor Ebbiary, M.B.B.Ch., M.D.
University of Sheffield
Jamie Dokson, M.S., L.C.G.C.
Navigate Genetic Counseling
Staci E. Pollack, M.D., M.S.
Albert Einstein College of Medicine

3:00 PM - 3:45 PM Keynote Lecture
Menopause Keynote Lecture: Menopausal HRT and Reduction of CVD and All-Cause Mortality: It’s About Time and Timing
Howard N. Hodis, M.D.
Keck School of Medicine of USC
Mental Health Track

Monday, October 18

11:00 AM - 12:00 PM Clinical Session
MHPG Clinical Session: Psychological and Medical Experiences of Compensated Gestational Carriers in the U.S.
Angela K. Lawson, Ph.D.
Northwestern University Feinberg School of Medicine, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility
Guy E Ringler, M.D.
California Fertility Partners
Janelle Watson, L.M.F.T., P.M.H-C.
Growing Generations

1:30 PM - 2:45 PM Symposium
The ABOG Foundation - Kenneth J. Ryan Ethics Symposium: Reimagining Reproductive Counseling and Treatment in an Era of Uncertainty: Pandemic Impacts on Fertility Care
Enrique F Schisterman, Ph.D.
National Institute of Child Health and Human Development, Epidemiology Branch, DIPHR, NICHD, NIH
Neil Silverman, M.D.
Donor Sibling Registry
Louise Perkins King, M.D., J.D.
Affiliation not provided

1:30 PM - 2:45 PM Symposium
With (Reproductive) Justice for All: Addressing Systemic Inequities in Reproductive Healthcare
Rachael Bailey, J.D.
International Reproductive Law Group
Angela Bethea-Walsh, Ph.D.
Private Practice
Danielle Kaplan, Ph.D.
NYU Langone

4:30 PM - 5:30 PM Interactive Session
Open-Identity Gamete Donation: What Are the Children Saying?
Jennifer Gamper, B.S.N., M.S.W.
RMANJ
Greg Moga, B.A., J.D.
Seattle Sperm Bank
Wendy Kramer, B.A.
Donor Sibling Registry
Gina Davis, M.S., L.C.G.C.
Advocate Genetics
Kriston Ward, M.S.N.
Strong Fertility Center

Tuesday, October 19

1:30 PM - 2:45 PM Symposium
The Ticking of the Clock: Managing the Age-Related DOR Patient
Sheri Hovdestad, M.A., L.P.C., N.C.C.
SBH Counseling Services LLC
Hayley Eichlin, D.N.P., A.P.R.N., W.H.N.P-BC.
RMANJ

4:30 PM - 5:30 PM Interactive Session
Baltimore IVF History: The Doctor, the Mother and the Baby. The 4th IVF Baby Born in the US
William D Petok, Ph.D.
Thomas Jefferson University
Jairo Garcia, M.D.
Johns Hopkins Medical Center
Kristen Flanagan

1:30 PM - 2:45 PM Clinical Session
MHPG Clinical Session: Testing - A Therapeutic Assessment Model in the Psychological Screening of Gestational Carriers
Mary P. Riddle, Ph.D.
Penn State University
Miranda Montrone, M.A.
Health Psychologist/Counseling Place Australia, Glebe, NSW, Australia
Mental Health Track

11:00 AM - 12:00 PM Clinical Session
MHPG Clinical Session: Ethics Course: Reproductive Healthcare Ethic and Challenges in Modern Times
Alice D. Domar, Ph.D.
Boston IVF
Elizabeth Anne Grill, Psy.D.
Weill Cornell Medical College
Kim Bergman, Ph.D.
Growing Generations

1:30 PM - 2:45 PM Symposia
Surrogacy and the Modern Family: Medical, Ethical and Emotional Challenges of Complex Gestational Surrogacy Cases
Mark Leondires, M.D.
Reproductive Medicine Associates of Connecticut
Lisa Schuman, M.S.W.
Reproductive Medicine Associates of Connecticut
Mark Schiff, M.A.
Growing Generations

Transgender Youth: Navigating Parents, Peers, and Society While Envisioning Future Family Planning
Molly B. Moravek, M.D., M.P.H.
University of Michigan
Marjorie E. Dixon, M.D.
Anova Fertility and Reproductive Health, Toronto, ON, Canada
Jamie M. Joseph, Ph.D.
Private Practice

3:45 PM - 4:45 PM Interactive Sessions
Say Her Name: Patient Perspectives and Advocacy for Black Women Facing Infertility
Regina Townsend
The Broken Brown Egg
Shantana Hazel
Sister Girl Foundation
Stacey Edwards-Dunn, D.Min., M.P.H.
Fertility for Colored Girls
Camille Hammond, M.D.
The Cade Foundation

Addressing Mental Health for Patients with Pregnancy Loss: Inside and Outside the Fertility Clinic.
Alice D. Domar, Ph.D.
Boston IVF
Lora K Shahine, M.D.
Pacific Northwest Fertility
Nursing Track

Monday, October 18

1:30 PM - 2:45 PM  Symposium
The ABOG Foundation - Kenneth J. Ryan Ethics CME
Symposium: Reimagining Reproductive Counseling and Treatment in an Era of Uncertainty: Pandemic Impacts on Fertility Care
Enrique F. Schisterman, Ph.D.
National Institute of Child Health and Human Development, Epidemiology Branch, DfPHR, NICHD, NIH
Neil Silverman, M.D.
Center for Fetal Medicine and Women’s Ultrasound
Louise Perkins King, M.D., J.D.
Affiliation not provided

Beyond Barker: Neonatal Programming & Lessons from the Lactocrine Hypothesis CME
Carol A. Bagnell, Ph.D.
Professor
Katie Hinde, Ph.D.
Associate Professor
Frank (Skip) F. Bartol, M.S., Ph.D.
Alumni Professor & Associate Dean for Research and Graduate Studies

Knowledge Is Power: Educating the Modern Day REI Nurse CME
Jeanette Tomasino, Ph.D.
Northwell Health Fertility, Zucker School of Medicine at Hofstra/Northwell
Fady I. Sharara, M.D.
Virginia Center for Reproductive Medicine
Allison B. Catherino, Ph.D.

EMD Serono, Inc. (a business of Merck KGaA, Darmstadt, Germany)
Jennifer M. Wood, R.N., B.S.N.
Shady Grove Fertility

4:30 PM - 5:30 PM  Clinical Session
NPG Clinical Session –Preparation for the Nurse Certificate Course in REI and Beyond – Day 1 CME
Shalini Gunawardena, R.N., M.B.A.
Kaiser Permanante Center for Reproductive Health
Kelly Lehl, B.S.N.
CCRM Management Company
Meghan K Pierce, M.S.N.
IVI RMA
Dayna Browning, B.S.N.
IVI RMA

4:30 PM - 5:30 PM  Interactive Session
Open-Identity Gamete Donation: What Are the Children Saying? CME
Jennifer Gamper, B.S.N., M.S.W.
RMANJ
Greg Moga, B.A., J.D.
Seattle Sperm Bank
Wendy Kramer, B.A.
Donor Sibling Registry
Gina Davis, M.S., L.C.G.C.
Advocate Genetics
Kriston Ward, M.S.N.
Strong Fertility Center

Tuesday, October 19

11:00 AM - 12:00 PM  Clinical Session
NPG Clinical Session –Preparation for the Nurse Certificate Course in REI and Beyond – Day 2 CME
Erin Ann Yontz, B.A., M.S.N.
University of Cincinnati Center for Reproductive Health
Lauri D. Black, M.S., C.G.C.
Pacific Reproductive Genetic Counseling

1:30 PM - 2:45 PM  Symposium
The Ticking of the Clock: Managing the Age-Related DOR Patient CME
Sheri Hovdestad, M.A., L.P.C., N.C.C.
SBH Counseling Services LLC
Hayley Eichlin, D.N.P., A.P.R.N., W.H.N.P-BC.
RMANJ

Wednesday, October 20

11:00 AM - 12:00 PM  Clinical Session
NPG Clinical Session –Preparation for the Nurse Certificate Course in REI and Beyond – Day 3 CME
Lisa A Rinehart, R.N., J.D.
Legal Care Consulting, Inc.
Shannon M Lighton, BSN, MSN
RMA NJ
Jamie Walsh, RN, BSN
CCRM
Reproductive Surgery Track

Monday, October 18

1:30 PM - 2:45 PM
Multidisciplinary and Collaborative Approach to Endometriosis in Fertility
Kathleen Hwang, M.D.
University Pittsburgh, Urology
Horace Roman, M.D., Ph.D.
Clinique Tivoli-Ducos, Bordeaux, France
Rebecca Flyckt, M.D.
University Hospitals Cleveland Medical Center/Case Western Reserve University

4:30 PM - 5:30 PM
Asherman’s Syndrome: Surgery vs. Gestational Carrier/Surrogacy
Zaraq Khan, M.D.
Mayo Clinic
Carlos Simón, M.D., Ph.D.
Igenomix Foundation, INCLIVA, Department of Obstetrics and Gynecology, Valencia University, Valencia, Spain; Department of Obstetrics and Gynecology, BIDMC, Harvard University
Samantha Pfeifer, M.D.
Weill Medical College of Cornell University

Tuesday, October 19

8:30 AM - 9:15 AM Plenary
Camran Nezhat, M.D. Lectureship in Innovations in Medicine: In Vitro Gametogenesis

10:45 AM - 12:15 PM Surgery Session
Repair of Cesarean Section Scar Defects: Hysteroscopic Vs. Laparoscopic Approach
Balasubramanian Bhagavath, M.B.B.S.
University of Rochester Medical Center
Charles E. Miller, M.D.
Advocate Lutheran General Hospital
Steven R. Lindheim, M.D., M.M.M.
Wright State University, Boonshoft School of Medicine

Wednesday, October 20

1:30 PM - 2:45 PM Symposium
Adenomyosis and Infertility: Medical and Surgical Management Strategies
Paul C. Lin, M.D.
Seattle Reproductive Medicine
Hisao Osada, M.D., Ph.D.
Shinjuku ART Clinic
Linnea R. Goodman, M.D.
University of North Carolina

3:45 PM - 4:45 PM Interactive Session
Varicocelectomy in the Management of Male Factor Infertility – an Interactive Discussion
Larry I. Lipshultz, M.D.
Baylor College of Medicine
Armand Zini, M.D., F.R.C.S.C.
McGill University, Montréal, QC, Canada
Karl R. Hansen, M.D., Ph.D.
University of Oklahoma College of Medicine
Joseph P. Alukal, M.D.
Columbia University Fertility Center

3:00 PM - 3:45 PM Lecture
Dan Martin, M.D.,
University of Tennessee
Reproductive Managers Track

Monday, October 18

1:30 PM - 2:45 PM Symposia
The Impact of Private Equity on the Fertility Industry
Derek Larkin, JD, MBA
In Vitro Sciences
Peter Klatasky, MD
Spring Fertility
Brad Senstra, M.H.A.
Seattle Reproductive Medicine

Reimagining the Future of Male Reproductive Medicine in the Age of Telemedicine and Beyond
James M. Dupree IV, M.D., M.P.H.
University of Michigan
Tolu Bakare, M.D.
University of Texas Southwestern Medical Center
James Smith, M.D.
University of California, San Francisco

Tuesday, October 19

1:30 PM - 2:45 PM Symposium
Artificial Intelligence (AI) in the IVF Laboratory
Alan B. Copperman, M.D.
Sema4
Reproductive Medicine Associates of New York
Danielle Soltesz, M.B.A., M.P.H.
RMA of New York

4:30 PM - 5:30 PM Interactive Session
Let’s Talk Legal
Michael J. Tucker, Ph.D.
Shady Grove Fertility
Susan Crockin, J.D.
Georgetown University

Wednesday, October 20

3:45 PM - 4:45 PM Interactive Session
Core Business Principles, Administrative Functions of IVF Practice and Best Marketing Strategies
Griffin Jones, B.A.
ASRM and ARM Member
Francisco Arredondo, M.D.
RMA of Texas
Munire Erman, M.D., M.Sc., M.B.A.
Island Health, Campbell River, BC, Canada
Resident Education Program

Purpose

ASRM is committed to facilitating and promoting education of reproductive health professionals at all levels. As part of this mission, the Society develops and coordinates educational activities for resident physicians in training in reproductive medicine. The program emphasizes the understanding of complex topics, the interaction with other disciplines, and the psychosocial sequelae and ethical concerns in human reproduction. Residents will also be exposed to a variety of interactive educational methods and have an opportunity to network/interaction with faculty with expertise in the specific topic for the day.

Description

ASRM has organized an education program consisting of two parts:

1. Medical Education: A series of educational sessions coupled with corresponding scientific symposium or plenary. On two days of the Scientific Congress, there will be interactive educational presentations corresponding to a symposium or plenary on each of those days. The activities will be evidence-based, free from bias, and independent of commercial influence. The discussions, which will utilize different learning pedagogies, will require advance independent study of articles, videos, or handouts relevant to the topic of ~20 minutes. Fifteen minutes are reserved at the end of these sessions for interaction with fellows who are also attending the sessions.

2. Networking/Interaction with Fellows: Fellows will attend the educational sessions as peer faculty. Learners are encouraged to ask questions about the fellowship interview process and the panelists’ experiences.

Proposed Plenary and Symposium

1. Stem Cell-Derived Gametes — How They May Change Human Reproduction
   a. Speaker: Henry T. Greely, JD, Stanford University
   b. Tuesday 9:15 - 10:00 am

2. Surrogacy and the Modern Family: Medical, Ethical and Emotional Challenges of Complex Gestational Surrogacy Cases
   a. Speakers: Mark Leondires, M.D., Reproductive Medicine Associates of Connecticut, Norwalk, CT, Lisa Schuman, MSW, Reproductive Medicine Associates of Connecticut, Norwalk, NY and Mark Schiff, MA, Growing Generations
   b. Wednesday 1:30 – 2:45 pm

Procedure

1. Residents will register online for the program during their regular registration process by checking YES on the invitation that will appear for all registrants who designate “resident” as their practice code. There is no charge for participation.

2. Registrants will receive an email 2 weeks in advance of the Scientific Congress with a link to materials to prepare for the learning sessions and symposia/plenary.

3. A boxed lunch is provided for learners Monday through Wednesday at the lunchtime learning sessions.

4. On Monday and Tuesday of the Scientific Congress, registrants will gather for an interactive learning session with a prominent medical educator and content expert(s) from the day’s corresponding plenary or symposium. Each day will employ an interactive learning modality that will require a small amount of advance preparation. Those sessions will include an opportunity to interact with current fellows throughout the session. Registrants are encouraged to attend the plenary or symposium corresponding to the day’s learning session.

5. On Wednesday, the session will be a panel discussion with current fellows and fellowship directors.

6. Registrants will receive a pre and post survey.
### Resident Education Program

**Monday, October 18 | 12:15 pm – 1:30 pm**

<table>
<thead>
<tr>
<th>Program</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and Introduction</td>
<td>Dr. Carol Wheeler, M.D.</td>
</tr>
<tr>
<td>Educational Moment</td>
<td>Dr. Jacqueline Lee, M.D.</td>
</tr>
<tr>
<td>Didactics with Team Based Learning</td>
<td>Dr. David Shin, M.D. &lt;br&gt;Dr. Pietro Bortolatto, M.D. &lt;br&gt;Dr. Holly, M.D. M.Ed. (will not attend in-person)</td>
</tr>
<tr>
<td>Content experts</td>
<td>Dr. Raymond Anchan, M.D., Ph.D. &lt;br&gt;Dr. Elizabeth Ginsburg, M.D.</td>
</tr>
</tbody>
</table>

**Tuesday, October 19 | 12:15 pm – 1:30 pm**

<table>
<thead>
<tr>
<th>Program</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and Introduction</td>
<td>Dr. Carol Wheeler, M.D.</td>
</tr>
<tr>
<td>Educational Moment</td>
<td>Dr. Quinton Katler, M.D., M.S.</td>
</tr>
<tr>
<td>Didactics with Team Based Learning</td>
<td>Dr. Christopher Herndon, M.D. &lt;br&gt;Dr. Heather Hipp, M.D.</td>
</tr>
<tr>
<td>Content experts</td>
<td>Dr. Steve Lindheim, M.D. &lt;br&gt;Dr. Andrea Braverman, Ph.D.</td>
</tr>
</tbody>
</table>

**Wednesday, October 20 | 12:15 pm – 1:15 pm**

<table>
<thead>
<tr>
<th>Program</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and Introduction</td>
<td>Dr. Carol Wheeler, M.D.</td>
</tr>
<tr>
<td>Fellowship Directors</td>
<td>Dr. Alan Penzias, M.D. &lt;br&gt;Dr. Nicole Noyes &lt;br&gt;Dr. Jeffrey Goldberg</td>
</tr>
<tr>
<td>Fellows</td>
<td>Dr. Kassie J. Bollig, M.D. &lt;br&gt;Dr. Philip Romanski, M.D. &lt;br&gt;Dr. Lisa Shandley, M.D., M.Sc. &lt;br&gt;Dr. Meghan Ozcan, M.D.</td>
</tr>
</tbody>
</table>

Brought to you by the ASRM Education Committee, Professor Carol Wheeler, M.D., Chair – **BOXED LUNCH provided**
<table>
<thead>
<tr>
<th>Name</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grifo, James</td>
<td>SYM04</td>
</tr>
<tr>
<td>Grill, Elizabeth</td>
<td>PG02, CSW01, INT08</td>
</tr>
<tr>
<td>Grobel, Maya</td>
<td>RTW07</td>
</tr>
<tr>
<td>Gunawardena, Shalini</td>
<td>CSM02</td>
</tr>
<tr>
<td>Gunnala, Vinay</td>
<td>RTW09</td>
</tr>
<tr>
<td>Guo, Jingtao</td>
<td>PG16</td>
</tr>
<tr>
<td>Guston, Debra</td>
<td>PG19</td>
</tr>
<tr>
<td>Halm, Will</td>
<td>PG17</td>
</tr>
<tr>
<td>Halpern, Joshua</td>
<td>INT01</td>
</tr>
<tr>
<td>Hammond, Camille</td>
<td>INW04</td>
</tr>
<tr>
<td>Hansen, Karl</td>
<td>INW01</td>
</tr>
<tr>
<td>Harton, Gary</td>
<td>RTT14</td>
</tr>
<tr>
<td>Hayes, Katherine</td>
<td>INW07</td>
</tr>
<tr>
<td>Hazel, Shantaana</td>
<td>INW04</td>
</tr>
<tr>
<td>Henkel, Andrea</td>
<td>INW03</td>
</tr>
<tr>
<td>Herati, Amin</td>
<td>RTW17</td>
</tr>
<tr>
<td>Herndon, Christopher</td>
<td>RLS-02</td>
</tr>
<tr>
<td>Hershberger, Patricia</td>
<td>RTM13</td>
</tr>
<tr>
<td>Hill, Micah</td>
<td>RTW13</td>
</tr>
<tr>
<td>Hinde, Katie</td>
<td>SYM02</td>
</tr>
<tr>
<td>Hodis, Howard</td>
<td>LCT07</td>
</tr>
<tr>
<td>Hokianto, Haryanto</td>
<td>RTM02</td>
</tr>
<tr>
<td>Honig, Stan</td>
<td>INW09, RTT22</td>
</tr>
<tr>
<td>Hotaling, James</td>
<td>PG16</td>
</tr>
<tr>
<td>Hovdestad, Sheri</td>
<td>SYT10</td>
</tr>
<tr>
<td>Hubel, Allison</td>
<td>SYM07</td>
</tr>
<tr>
<td>Huber, Warren</td>
<td>SYT09</td>
</tr>
<tr>
<td>Huddleston, Heather</td>
<td>INM06, INT04</td>
</tr>
<tr>
<td>Hughes, Mark</td>
<td>SYM04</td>
</tr>
<tr>
<td>Humaidan, Peter</td>
<td>PG20</td>
</tr>
<tr>
<td>Hunt, Patricia</td>
<td>SYW07</td>
</tr>
<tr>
<td>Hwang, Kathleen</td>
<td>SYM05</td>
</tr>
<tr>
<td>Isaacson, Keith</td>
<td>INT07</td>
</tr>
<tr>
<td>Isley, Lauren</td>
<td>PG10</td>
</tr>
<tr>
<td>Jackson-Bey, Tia</td>
<td>INM07, RTT09</td>
</tr>
<tr>
<td>Jain, Tarun</td>
<td>PG01</td>
</tr>
<tr>
<td>James-Todd, Tamarra</td>
<td>RTT07</td>
</tr>
<tr>
<td>Jee, Jae-Wook</td>
<td>SYT04</td>
</tr>
<tr>
<td>Jindi, Sangita</td>
<td>RTW22, SYW06</td>
</tr>
<tr>
<td>Johnson, Jasmine</td>
<td>INM08</td>
</tr>
<tr>
<td>Jones, Griffin</td>
<td>INW02, RTM01</td>
</tr>
<tr>
<td>Jordan, Philip</td>
<td>RTM20</td>
</tr>
<tr>
<td>Kallen, Amanda</td>
<td>SYM10</td>
</tr>
<tr>
<td>Kaplan, Danielle</td>
<td>PG03, SYM06</td>
</tr>
<tr>
<td>Kaushic, Charu</td>
<td>PG18</td>
</tr>
<tr>
<td>Kavanagh, Dori</td>
<td>RTW06</td>
</tr>
<tr>
<td>Kawwass, Jennifer</td>
<td>PG06, RTM23, SYM10</td>
</tr>
<tr>
<td>Ke, Raymond</td>
<td>RTT26</td>
</tr>
<tr>
<td>Kearnis, William</td>
<td>INM01</td>
</tr>
<tr>
<td>Kelley, Erica</td>
<td>RTT11</td>
</tr>
<tr>
<td>Kiare, James</td>
<td>SYT11</td>
</tr>
<tr>
<td>King, Louise</td>
<td>SYM01</td>
</tr>
<tr>
<td>Klatsky, Peter</td>
<td>SYM03</td>
</tr>
<tr>
<td>Kramer, Wendy</td>
<td>INM09</td>
</tr>
<tr>
<td>Kudessa, Rashmi</td>
<td>RTM16</td>
</tr>
<tr>
<td>Kuokkanen, Sato</td>
<td>INM10</td>
</tr>
<tr>
<td>Kwak-Kim, Joanne</td>
<td>SYT09</td>
</tr>
<tr>
<td>Kwon, Douglas</td>
<td>PG18</td>
</tr>
<tr>
<td>Lamb, Dolores</td>
<td>INT01, RTT21</td>
</tr>
<tr>
<td>Large, Mike</td>
<td>SYM04</td>
</tr>
<tr>
<td>Larkin, Derek</td>
<td>SYM03</td>
</tr>
<tr>
<td>Laronda, Monica</td>
<td>SYT01</td>
</tr>
<tr>
<td>Lawson, Angela</td>
<td>CSM01</td>
</tr>
<tr>
<td>Legro, Richard</td>
<td>INM06</td>
</tr>
<tr>
<td>Leonides, Mark</td>
<td>SYW04</td>
</tr>
<tr>
<td>Lessey, Bruce</td>
<td>PG08</td>
</tr>
<tr>
<td>Lewis, Leigh</td>
<td>RTM03</td>
</tr>
<tr>
<td>Li, Philip</td>
<td>RTM28</td>
</tr>
<tr>
<td>Lin, Paul</td>
<td>SYW02</td>
</tr>
<tr>
<td>Lindheim, Steven</td>
<td>INW10, VRS01</td>
</tr>
<tr>
<td>Lipshultz, Larry</td>
<td>INW01</td>
</tr>
<tr>
<td>Loi, Pasqualino</td>
<td>SYM07</td>
</tr>
<tr>
<td>Madjunkova, Svetlana</td>
<td>RTM19</td>
</tr>
<tr>
<td>Maggiore, Umberto</td>
<td>SYT02</td>
</tr>
<tr>
<td>Maher, Jacqueline</td>
<td>SYW03</td>
</tr>
<tr>
<td>Mak, Winifred</td>
<td>PG12, RTT04</td>
</tr>
<tr>
<td>Malhotra, Jaideep</td>
<td>PG14</td>
</tr>
<tr>
<td>Malhotra, Narendra</td>
<td>PG14</td>
</tr>
<tr>
<td>Malhotra, Neena</td>
<td>PG14</td>
</tr>
<tr>
<td>Mallory, Mia</td>
<td>SYT06</td>
</tr>
<tr>
<td>Marsh, Erica</td>
<td>HOC02</td>
</tr>
<tr>
<td>Martin, Dan</td>
<td>LCT06</td>
</tr>
<tr>
<td>Masaba, Erin</td>
<td>RTM04</td>
</tr>
<tr>
<td>Masson, Puneet</td>
<td>INM03</td>
</tr>
<tr>
<td>McBain, Lindsey</td>
<td>RTT01</td>
</tr>
<tr>
<td>McCaffrey, Caroline</td>
<td>PG07, INT03</td>
</tr>
<tr>
<td>McCulloh, David</td>
<td>INT03</td>
</tr>
<tr>
<td>Mechsner, Sylvia</td>
<td>SYT11</td>
</tr>
<tr>
<td>Mehta, Akanksha</td>
<td>PG15</td>
</tr>
<tr>
<td>Melnick, Alexis</td>
<td>RTT03</td>
</tr>
<tr>
<td>Mendola, Pauline</td>
<td>RTM07</td>
</tr>
<tr>
<td>Micks, Elizabeth</td>
<td>INW03</td>
</tr>
<tr>
<td>Miller, Charles</td>
<td>VRS01</td>
</tr>
<tr>
<td>Miller, Jenna</td>
<td>INM01</td>
</tr>
<tr>
<td>Mills, Jesse</td>
<td>INW01</td>
</tr>
<tr>
<td>Missmer, Stacey</td>
<td>SYM10, SYT11</td>
</tr>
<tr>
<td>Mitalipov, Shoukhrat</td>
<td>PLE05, SYT01</td>
</tr>
<tr>
<td>Moga, Greg</td>
<td>INM09</td>
</tr>
<tr>
<td>Montrone, Miranda</td>
<td>CST02</td>
</tr>
<tr>
<td>Mooney, Sara</td>
<td>RTT20</td>
</tr>
<tr>
<td>Moravek, Molly</td>
<td>SYW05</td>
</tr>
<tr>
<td>Morbeck, Dean</td>
<td>RTW21, SYW07</td>
</tr>
<tr>
<td>Morelli, Sara</td>
<td>HOC01, HOC03, INT10</td>
</tr>
<tr>
<td>Morris, Jemine</td>
<td>INT04</td>
</tr>
<tr>
<td>Mumford, Sunni</td>
<td>INW08</td>
</tr>
<tr>
<td>Nel-Themaat, Liesl</td>
<td>PG13, INT03, RTM32</td>
</tr>
</tbody>
</table>
Nicholas, Lindsay ........................................ PG02
Niederberger, Craig ................................. RTT24
Nitibhun, Vanessa ................................ RTW03
Nnaaham, Kelechi ................................ SYT11
O'Brien, Jeanne ......................................... PG10, RTT25
Oktay, Kutlu ............................................ PG09, INW02, RTT31
Omurlag, Kenan ........................................ PG01
Osada, Hisao ........................................... SYW02
Osteen, Kevin .......................................... RTM06
Ouyang, David .......................................... SYM01
Owen, Carter ........................................... RTT18
Pal, Lubna ............................................. INM10
Palermo, Gianpiero .................................... PG16
Pang, Samuel ........................................ RTW05
Parry, John Preston ................................ RTT30
Patrizio, Pasquale ................................ SYM07
Paulson, Richard ................................ INT02
Pearlman Shapiro, Marit .......................... INW03
Peccatori, Fedro .................................. SYT02, INT05
Petok, William ......................................... INT05
Petropoulos, Sophie ............................... SYM11
Petrozza, John ........................................ HOC02, RTM05
Pfeiffer, Samantha ................................ INM04, INW10, RTM34
Phillips, Simon ....................................... SYM11
Pierce, Meghan ....................................... CSM02
Pirtea, Paul ............................................. RTM29
Plowden, Torie ........................................ RTM09
Pollack, Staci ......................................... INW07
Pomeroy, Kimball .................................... RTT29, SYW06
Pyraz, Roman .......................................... SYW06
Quaas, Alexander .................................. INT02
Quinn, Gwendolyn ................................ SYW05
Rackow, Beth .......................................... INW10
Rajiv, McCoy .......................................... SYW01
Rajkovic, Aleksandar ............................. PG09
Ramaiah, Sarah ...................................... INW10
Ramasamy, Ranjith ................................. PG15, RTM26
Rapp, Hayley .......................................... SYT10
Reagan, Mirin ......................................... SYW04
Rechitsky, Svetlana ................................ PG11
Reid, Gregor ............................................ PG18
Reindollar, Richard .............................. HOC01, HOC03
Resetkova, Nina .................................. SYT05
Revelli, Alberto .................................. INT07, RTW04
Richard-Davis, Gloria ............................ SYT06
Riddle, Mary .......................................... CST02
Rinehart, Lisa ......................................... CSM02
Ringler, Guy ............................................ CSM01
Rodriguez, Leonel ................................ SYT08
Rodriguez-Wallberg, Kenny .................. INM02
Ross, Heather .......................................... SYW04
Rubio, Carmen ....................................... PG11
Rutter, April .......................................... RTW01
Sakkas, Denny ....................................... INT02
Santamaria, Xavier ................................. INM04
Santoro, Nanette .................................. PG09
Schiewe, Mitchel .................................. INT03, RTT28
Schiff, Mark ......................................... RTM10
Schisterman, Enrique ............................. SYM01
Schlegel, Peter ....................................... INW09, RTW15
Schuman, Lisa ....................................... SYW04
Seli, Emre ............................................. RTM24
Senstra, Brad .......................................... SYM03
Shah, Divya ............................................ RTM33
Shah, Duru ............................................. PG14
Shahine, Lora ......................................... INM11
Shamongki, Mousa ................................. INT06
Sharara, Fady ......................................... SYM08
Shardell, Michelle ................................ INM05
Shaykh, Marwan ................................ RTW20
Shin, David ............................................ RLS-01
Sigman, Mark .......................................... INW09
Simon, Carlos .......................................... INW06
Sitruk-Ware, Regine ............................... LCT04
Skaznik-Wikiel, Malgorzata .................. INW08
Silkin, Richard ........................................ SYT07
Smith, James .......................................... SYM09, SYW05
Smith, Ryan ............................................. PG15
Snider, Alyssa ......................................... SYT05
Snyder, Michael ..................................... PLE02
Soltész, Danielle ...................................... PG19, SYT07
Sonmez, Murat ....................................... PG09, RTW24
Sparks, Amy .......................................... PG06
Spencer, Jessica ..................................... INM10
Stadtmauer, Laurel ................................ PG08
Stewart, Joshua ....................................... RTW02
Sun, Tammy ........................................... LIV09
Swanson, Amelia .................................. PG19
Syrtash, Andrea ...................................... LIV09
Tanaka, Barbara ..................................... PG17
Tang, Fuchou .......................................... SYW01
Tanrikut, Cigdem .................................. INM03
Taylor, Hugh .......................................... LIV03, SYT11
Tobias, Tamara ...................................... PG02, CSM02
Tomaso, Jeanette ................................ SYM08
Toth, Thomas .......................................... INM03
Townsend, Regina .................................. INW04, LIV09
Trachman, Ellen ..................................... RTM25
Tucker, Michael ...................................... INT09
Tuddenham, Susan ................................. INM05
Tur-Kaspa, Ilan ....................................... INW06, RTT10
Vance, Amy ............................................. PG10
Vash-Margita, Alla ................................ SYT08
Venetis, Christos .................................. PG04
Venier, Bill .......................................... INT03, SYT05
Venier, Debbie ....................................... PG13
Viotti, Manuel .......................... PG11, SYW01
von Versen-Höynck, Frauke .............. PG04
Walsh, Jamie .............................. CSW02
Wang, P. Jeremy ............................. LCT05
Wang, Wei-Hua .............................. RTW10
Ward, Kriston ................................. INM09
Watrelot, Antoine .............................. PG05
Watson, Janelle ............................... CSM01, RTM12
Weinerman, Rachel ............................ RTW19
Wells, Dagan ................................. RTM17
Wheeler, Carol .............................. RLS-03
Whiteside, Kelly Lee ....................... INTO8
Williams, Zev .............................. PG07, INW06
Wood, Jennifer .............................. RTM14, SYM08
Xu, Jing .......................... RTT02
Xu, Kangpu ................................. PG11, INTO6
Xue, Qing ............................... SYT04
Yontz, Erin ............................... CST01
Young, Steven ............................. PG07
Zore, Temeka ................................. INM08
## DISCLOSURES INDEX

All speakers at the 2021 ASRM Scientific Congress were required to complete a disclosure form. Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

<table>
<thead>
<tr>
<th>Company Officer</th>
<th>Direct Stockholder</th>
<th>Full-Time Company Employee</th>
<th>Grant Recipient</th>
<th>Honoraria</th>
<th>Immediate Family Member</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adamson, G.</td>
<td>Abbott; Advanced Reproductive Care; LabCorp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Al-Hendy, A.</td>
<td>Abbvie; Bayer; Myovant; Novartis; OBSEVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anderson, A. R.</td>
<td>Invo Biosciences</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arredondo, F.</td>
<td>INVOBioscience</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Awwad, J.</td>
<td>Rovi pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baker, V. L.</td>
<td>IBSA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Banker, M.</td>
<td>Abbott India Limited; Merck Specialties Pvt Ltd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beltzos, A.</td>
<td>EMD Serono; Ferring; Future Fertility(Offered stock- not sure of start date); Merck; MRS; TMRW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendikson, K. A.</td>
<td>Theralogix (medical advisory board)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bhagavath, B.</td>
<td>Hologic, Inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black, L. D.</td>
<td>NextGen Genetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burke, A. E.</td>
<td>Merck (Research support); Scope/Chemo (Research support)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Callum, P.</td>
<td>Generate Life Sciences; Tandem Genetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carlsson, I.</td>
<td>INVO Bioscience</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catherino, A. B.</td>
<td>EMD Serono</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catherino, W.</td>
<td>American Board of Obstetrics and Gynecology (Board Member for REI Division); American Society for Reproductive Medicine; EMD Serono</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cebert-Gaitors, M.</td>
<td>Modern Fertility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, S. H.</td>
<td>Cooper Genomics; FertilityAnswers; Genomic Prediction (Medical Advisory Board)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohen, J.</td>
<td>Althea Science; DADI; IVF 2.0; KindBody; TMRW</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conaghan, J.</td>
<td>Irvine Scientific</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copperman, A. B.</td>
<td>Progyny (Medical Director); Sema4 (CMO)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coward, R. M.</td>
<td>Maximus (Advisory Board)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crawford, N. M.</td>
<td>Plan B One Step</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crockin, S.</td>
<td>Adagene; Aegenus; Apexigen; Asher Bio; Astraeneca; Aveo (Advisory Board); BMS (Advisory Board); Calithera (Advisory Board); Celsion (Advisory Board); Exelixis (Advisory Board); Genentech-Roche; Idera; Iovance (Advisory Board); Merck (Advisory Board); Neoleuken; Novartis (Advisory Board); PACT (Advisory Board); Pfizer (Advisory Board); Pneuma8b (Advisory Board); Pyxis Oncology (Advisory Board, Stock Options); Sano (Advisory Board, Stock Options); XPharma (Advisory Board)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Disclosures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Davis, G.</td>
<td>Advocate Genetics(^1a); EMPOWER DONATION LLC(^1a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dokras, A.</td>
<td>Ablacare(^6a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domar, A. D.</td>
<td>Best Shot(^6); EMD Serono(^7); Ferring(^6)(^8) (paid to create stress management materials); FertiCalm LLC(^12); Merck(^7); Nestle(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doody, K. J.</td>
<td>Ferring Pharmaceutical(^8); INVO Bioscience(^12)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duke, C. M.</td>
<td>CONFIRMED by Buddy Cheque(^6)(^7) (Scientific Advisor); Pregnantish(^7); Proov by MFB(^8) (Medical Advisor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dupree, J. M.</td>
<td>Lipocine(^2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eisenberg, M. L.</td>
<td>Hannah(^2); Ro(^2); Sandstone(^2); Underdog(^2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feinberg, E. C.</td>
<td>Ferring(^5)(^8) (one time consultant role for Ferring (above)); Fertility and Sterility(^8) (Associate Editor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flake, A. W.</td>
<td>Children's Hospital of Philadelphia(^8)(I hold patents related to the technology); Vitara Biomedical(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flores, V. A.</td>
<td>Abbvie(^7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fransasiak, J. M.</td>
<td>Ferring Pharmaceuticals(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garcia-Velasco, J.</td>
<td>Ferring(^4); Gedeon Richter(^4); Merck(^4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gargiulo, A. R.</td>
<td>Lumenis(^5); medtronic(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giudice, L. C.</td>
<td>ForEndo(^6); MERC(^2); Myovant(^4); PIZER(^2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldstein, M.</td>
<td>Theralogix(^5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodman, L. R.</td>
<td>LiNA Medical(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gordts, S.</td>
<td>Karl Storz, Germany(^5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grifo, J. A.</td>
<td>Inception Fertility(^2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grill, E. A.</td>
<td>Donor Egg Meeting(^5); FertiCalm, FertiStrong, Aliz LLC(^1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hammond, C.</td>
<td>AireSupport(^1); Arthrex(^5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hansen, K. R.</td>
<td>Ablacare(^6)(^7) (consultant); Ferring4c; NICHD4a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harton, G.</td>
<td>Cryos International(^7); PerkinElmer(^2); The World Egg Bank(^7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herti, A. S.</td>
<td>Dadi8a(Advisor); Teleflex(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hershberger, P.</td>
<td>Midwest Nursing Research Society Foundation Board (^8) (Trustee)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hill, M. J.</td>
<td>A Life(^6); Thread Robotics(^5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honig, S.</td>
<td>Clarus67a; coloplast(^6); endo(^7); posterity health(^2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotaling, J.</td>
<td>advanced conceptions(^2); andro360(^2); Boston Scientific(^5); streamdx(^3); turtle health(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hubel, A.</td>
<td>BlueCube Bio(^1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huddleston, H. G.</td>
<td>Abbvie(^4); Exactech(^4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hughes, M.</td>
<td>Cooper Surgical(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humaidan, P.</td>
<td>Gedeon Richter(^4); Merck(^4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isaacson, K.</td>
<td>Karl Storz Endoscopy(^4); medtronic(^6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isley, L.</td>
<td>Generate Life Sciences(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ke, R. W.</td>
<td>Ferring Pharma(^4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Klatsky, P.</td>
<td>Spring Fertility(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Lamb, D. J. American Board of Bioanalysts\textsuperscript{[a]}(Secretary Treasurer of the Board); Fellow\textsuperscript{[a]}(Stock Options not executed)

Large, M. CooperSurgical\textsuperscript{[2a]}

Larkin, D. First Fertility\textsuperscript{[1a]}

Laronda, M. M. Dimension Inx\textsuperscript{[8a]}(Advisor, options)

Legro, R. S. Guerbet\textsuperscript{[4a]}; Insudd\textsuperscript{6}

Lessey, B. A. CiceroDx\textsuperscript{[8a]}(intellectual property licensing and royalties)

Lipshultz, L. I. Abbvie\textsuperscript{[6a]}; American Medical Systems\textsuperscript{[8a]}(Speaker); Augmenta LLC\textsuperscript{2a}; Aytu BioScience\textsuperscript{[6a]}; Clarus Therapeutics\textsuperscript{[4a]}; Endo Pharmaceuticals\textsuperscript{[6a]}; Inherent Biosciences\textsuperscript{[8a]}(Advisor); Lipocine\textsuperscript{[6a]}; Vault Health, Inc.\textsuperscript{[8a]}(Advisor)

McCoy, R. C. Johns Hopkins University\textsuperscript{[8a]}(I am a co-inventor on a provisional patent application by Johns Hopkins University, where I am an employee: https://www.biorxiv.org/content/10.1101/2021.05.18.444721v1)

McCullough, D. H. Biogenetics Corporation\textsuperscript{[1a]}; Buffalo Infertility and IVF Associates\textsuperscript{[8a]}; Ferring Pharmaceuticals\textsuperscript{[5a]}; GranataBio\textsuperscript{[8a]}(Member Advisory Board); NYU Langone Fertility Center\textsuperscript{[2a]}; ReproART: Georgian American Center for Reproductive Medicine\textsuperscript{[1a]}; Sperm and Embryo Bank of New York\textsuperscript{[1a]}

Miller, C. E. AbbVie\textsuperscript{[27a]}(Research Study); Allergan\textsuperscript{[8a]}(Research Study); Blue Seas Med Spa\textsuperscript{[8a]}(Investor); Boston Scientific\textsuperscript{[6a]}; Espiner Medical\textsuperscript{[8a]}(Research Study); Eximis Surgical, Inc.\textsuperscript{[6a]}; Gynesonics\textsuperscript{[24a]}; Halt Medical\textsuperscript{[2a]}; Hologic\textsuperscript{[6a]}; Karl Storz\textsuperscript{4a}; Medtronic\textsuperscript{[6a]}; Seikagaku Corporation\textsuperscript{[6a]}; Temple Therapeutics B.V.\textsuperscript{[28a]}(Advisory Board Member)

Miller, J. O. CooperSurgical\textsuperscript{[8a]}

Mills, J. Boston Scientific\textsuperscript{[6c]}; Endo\textsuperscript{[4c]}

Missmer, S. A. AbbVie\textsuperscript{[6a]}; Frontiers in Reproductive Health\textsuperscript{[6a]}(Field Chief Editor for Journal)

Moga, G. M. Seattle Sperm Bank\textsuperscript{[12a]}

Moravec, M. B. NUVO\textsuperscript{[8b]}(Investor)

Morbeck, D. E. CooperSurgical\textsuperscript{[6a]}; Dadi, Inc\textsuperscript{[8a]}(Advisor)

Niederberger, C. American Board of Urology\textsuperscript{[8a]}(Examiner); American Society for Reproductive Medicine\textsuperscript{[8a]}(Journal editor); American Urological Association\textsuperscript{[8a]}(Journal section editor); COMMIT\textsuperscript{[8a]}(Advisor); Ferring\textsuperscript{[8a]}(Scientific study); Letters and Sciences LLC\textsuperscript{[57a]}; Posterity Health\textsuperscript{[28a]}(Advisory board)

Ouyang, D. UpToDate\textsuperscript{[5a]}

Patrizio, P. FertileSafe Ltd\textsuperscript{[8a]}(Co-Founder)

Peccatori, F. A. Ipsen\textsuperscript{[6a]}; merck\textsuperscript{[4a]}

Petrozza, J. C. Hologic\textsuperscript{[6a]}

Pfeifer, S. M. RESOLVE\textsuperscript{[8a]}(Medical Advisory Board); RESOLVE\textsuperscript{[8a]}(Medical Advisory Board); Roman Health\textsuperscript{[4b]}; Theralogix\textsuperscript{[5b]}

Pomeroy, K. O. Fuji Irvine\textsuperscript{[7a]}; The World Egg Bank\textsuperscript{[3a]}

Rackow, B. W. Allara Health\textsuperscript{[8a]}(Medical Advisor)

Ramasamy, R. Acerus Pharmaceuticals\textsuperscript{[4]}

Rechitsky, S. RGI\textsuperscript{[12a]}

Reid, G. KKG Science\textsuperscript{[6]}; Seed\textsuperscript{[1a]}

Resetkova, N. ReScripted\textsuperscript{[8a]}(seed investor); WIN Fertility\textsuperscript{[8a]}(Medical Advisory Board)
<table>
<thead>
<tr>
<th>Name</th>
<th>Organization/Institution</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodriguez, L.</td>
<td>IHS</td>
<td>8a (Consultant)</td>
</tr>
<tr>
<td>Ross, H. E.</td>
<td>Accelerated Diagnostics</td>
<td>2a; BHVN 2a</td>
</tr>
<tr>
<td>Rubio, C.</td>
<td>Igenomix</td>
<td>8a (employment with Igenomix)</td>
</tr>
<tr>
<td>Sakkas, D.</td>
<td>EMD Serono</td>
<td>7a; Igenomix 8a (Scientific Advisory Board); Legacy 8a (Consultant)</td>
</tr>
<tr>
<td>Santamarina, X.</td>
<td>Igenomix</td>
<td>5a</td>
</tr>
<tr>
<td>Santoro, N. F.</td>
<td>Ansh Labs, Inc</td>
<td>6a; Astellas 6a; Menogenix, Inc 4a</td>
</tr>
<tr>
<td>Schisterman, E. F.</td>
<td>American Journal of Epidemiology 8a (Editor-In-Chief)</td>
<td></td>
</tr>
<tr>
<td>Schlegel, P. N.</td>
<td>Ferring Pharmaceuticals</td>
<td>8a (Paid for talk 8/2020); Posternity Health 2a; Roman Health 2a; Theralogix 5a</td>
</tr>
<tr>
<td>Seli, E.</td>
<td>Foundation for Embryonic Competence</td>
<td>44a</td>
</tr>
<tr>
<td>Shah, D. S.</td>
<td>Metropolis Healthcare Ltd</td>
<td>2b; Pfizer Ltd., India 5a</td>
</tr>
<tr>
<td>Sharara, F. I.</td>
<td>Ferring Pharmaceuticals</td>
<td>7a</td>
</tr>
<tr>
<td>Shin, D.</td>
<td>Fellow Health</td>
<td>2a</td>
</tr>
<tr>
<td>Simon, C.</td>
<td>Igenomix SL</td>
<td>25a</td>
</tr>
<tr>
<td>Sitruk-Ware, R.</td>
<td>NICHD4a; Population Council- a not for profit research organization 6a (part-time employee of the Council who is IND holder and developer of estorone vaginal and transdermal delivery systems.)</td>
<td></td>
</tr>
<tr>
<td>Smith, J.</td>
<td>Fellow Health</td>
<td>8a (Stock Options); Posternity Health 2a</td>
</tr>
<tr>
<td>Snider, A.</td>
<td>Igenomix</td>
<td>3a</td>
</tr>
<tr>
<td>Snyder, M.</td>
<td>January AI</td>
<td>2; Mirvie 2; Personalis 26a; Qbio 2; SensOomics 2a</td>
</tr>
<tr>
<td>Sparks, A. E.</td>
<td>Ferring Pharmaceuticals</td>
<td>5a</td>
</tr>
<tr>
<td>Tanrikut, C.</td>
<td>New England Cryogenic Center 8a (Medical Director); Swimmers 8a (Advisory Board)</td>
<td></td>
</tr>
<tr>
<td>Townsend, R. M.</td>
<td>Ferring Pharmaceuticals</td>
<td>6a</td>
</tr>
<tr>
<td>Tuddenham, S.</td>
<td>Luca Biologics</td>
<td>8a; Medscape 5a; UPTODATE 8a (author, receive honoraria)</td>
</tr>
<tr>
<td>Venetis, C.</td>
<td>Ferring 45a; Merck 45a; Merck, Sharp &amp; Dohme; Virtus Health 20</td>
<td></td>
</tr>
<tr>
<td>Venier, B.</td>
<td>NextGen Genetics</td>
<td>2a; TMRW 2a</td>
</tr>
<tr>
<td>von Versen-Höynck, F.</td>
<td>MSD Sharp &amp; Dohme GmbH</td>
<td>5a</td>
</tr>
<tr>
<td>Watrelot, A. a.</td>
<td>laboratoire guerbet</td>
<td>5a</td>
</tr>
<tr>
<td>Williams, Z.</td>
<td>Sorrento Therapeutics</td>
<td>6</td>
</tr>
<tr>
<td>Young, S. L.</td>
<td>CiceroDx</td>
<td>8a (patent license)</td>
</tr>
<tr>
<td>Zore, T.</td>
<td>Modern Fertility</td>
<td>8a (on their medical advisory board); Progyny 8a (on their medical advisory board)</td>
</tr>
</tbody>
</table>
Non-CME Educational Sessions

- Roundtable Discussions 94-98
- Video Abstract Sessions 99-100
- Abstract Review Committees 101-102
- Oral Abstract Sessions 103-117
- Poster Presentations and Abstracts 118-147
- Abstract Topic Index 148-157
- Disclosures 158-171
Roundtable Discussions

MONDAY, OCTOBER 18, 2021

Association of Reproductive Managers

RTM01
You've Got New Patients in the Door, but How Do You Convert Them to IVF?
Griffin Jones, B.A.
ASRM and ARM Member

RTM02
Practice Management during Mergers & Acquisitions—What Should be Top of Mind?
Haryanto Hokianto, B.S.

Early Pregnancy Special Interest Group

RTM04
Treatment of Chronic Endometritis: Wading through the Different Antibiotic Regimens
Erin Masaba, M.D.
University of Rochester

Endometriosis Special Interest Group

RTM05
Improving the Endometriosis Classification: Benefits and Hurdles
John Petrozza, M.D.
Massachusetts General Hospital Fertility Center

RTM06
Organ-on-Chips for the Study of Endometriosis
Kevin Osteen, Ph.D.
Vanderbilt University

Nutrition Special Interest Group

RTM07
Air Pollution and Reproductive Health
Pauline Mendola, Ph.D.

Genetic Counseling Special Interest Group

RTM08
Polygenic Risk Scores and Embryo Selection: Should We?
Speaker TBD

Health Disparities Special Interest Group

RTM09
Identifying and Managing Implicit Bias As a Physician
Torie Plowden M.D., M.P.H.
Womack Army Medical Center

LGBTQ Special Interest Group

RTM10
Interviewing for Strengths: Identifying the Traits and Characteristics That Will Help a Gestational Carrier Candidate Go on to Have a Successful Journey
Mark Schiff, M.A.
Growing Generations

Nurses' Professional Group

RTM13
The Good, the Bad and the Ugly: Taking a Closer Look at Children’s Books That Aid Gamete and Embryo Recipient Parents’ Disclosure
Patricia Hershberger, Ph.D., A.P.R.N., F.N.P-BC., F.A.A.N.
University of Illinois at Chicago

Pediatric and Adolescent Gynecology Special Interest Group

RTM16
Hypothalamic Amenorrhea & PCOS in the Adolescent: Clinical Pearls for Diagnosis, Counseling and Management
Rashmi Kudesia, M.D.
CCRM Fertility Houston

Preimplantation Genetic Testing Special Interest Group

RTM17
The Future of PGT
Dagan Wells, Ph.D.
JUNO GENETICS

RTM18
Alternative Embryo Transfer Strategy for Patients Utilize Preimplantation Genetic Testing for Aneuploidy
Pak Chung, M.D.
The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine

RTM19
Embryological Aspects of Collecting Culture Medium for Nipgt to Ensure the Sensitivity and Accuracy

Regenerative Medicine and Stem Cell Biology Special Interest Group

RTM20
Meiotic Errors, Aneuploidy, and Infertility
Philip Jordan, Ph.D.
Johns Hopkins University Bloomberg School of Public Health
Roundtable Discussions

Reproductive Immunology Special Interest Group
RTM21 Endometrial Evaluation for Reproductive Failures
Kenneth Beaman, Ph.D.
Clinical Immunology Lab, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science

Society for Reproductive Endocrinology and Infertility
RTM30 What Tests Are Indicated after the First Euploid Miscarriage?
Paul Brezina, M.D.
Fertility Associates of Memphis
RTM31 Advocacy As an Rx for Physician Burnout – Small Things You Can Do That Will Make a Big Difference for You and Your Patients
Serena Chen, M.D.
Division of Reproductive Medicine, IRMS at St Barnabas

Society for Assisted Reproductive Technology
RTM22 What the IVF Doctor Needs to Know about the IVF Laboratory
Eric Forman, M.D.
Columbia University Fertility Center
RTM23 Evidence Based Embryo Transfer
Jennifer Kawwass, M.D.
Emory University School of Medicine, Division of Reproductive Endocrinology and Infertility

Society for Male Reproduction and Urology
RTM35 The ART of Personalizing IVF Treatments
Samir Babayev, M.D.
Mayo Clinic

Early Pregnancy Special Interest Group
RTT03 COVID19- Early Pregnancy Impact – a Review
Alexis Melnick, M.D.
The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine

Endometriosis Special Interest Group
RTT05 Using Progesterone Receptor Status for Personalized Endometriosis Treatment
Valerie Flores, M.D.
Yale School of Medicine
RTT06 Disease Modeling the Endometriotic Phenotype Using Organoids
Juan Gnecco, Ph.D.

Environment and Reproduction Special Interest Group
RTT07 Environmental Racism and Reproductive Health
Tamarra James-Todd, Ph.D.
Roundtable Discussions

Genetic Counseling Special Interest Group

RTT08
Carrier Screening Panels-How to Tell the Difference and Assess What Is Most Important
Pamela Callum, M.S., C.G.C.
Tandem Genetics

Health Disparities Special Interest Group

RTT09
When America Gets the Cold, Minorities Get the Flu: How Disparities in COVID-19 Outcomes Impact Reproductive and Infertility Care
Tia Jackson-Bey, M.D. M.P.H.
Reproductive Medicine Associates of New York

Imaging in Reproductive Medicine Special Interest Group

RTT10
Uterine Cavity and Tubal Patency Assessment Tests Should be Pain Free
Ilan Tur-Kaspa, M.D.
Institute for Human Reproduction

Mental Health Professional Group - Scientific Congress

RTT11
Addressing Sexual Dysfunction in Individuals and Couples Diagnosed with Infertility
Erika Kelley, Ph.D.

RTT12
Breaking Bad News to Infertility Patients: Strategies for Patient Support
Alice Domar, Ph.D.
Boston IVF

Nurses’ Professional Group

RTT13
Effective Strategies for Counseling Egg Donors
Kirby Adlam, C.N.M.

Preimplantation Genetic Testing Special Interest Group

RTT14
A Simple but Effective Approach to Perform PGT-M and PGT-a
Gary Harton, Ph.D.
PERKIN ELMER

RTT15
How to Interpret Embryo Mosaicism and to Counsel PGT Patients for Transferring Mosaic Embryos
Andria Besser, MS, CGC
NYU Langone Fertility Center

Society for Assisted Reproductive Technology

RTT18
Sperm DNA Fragmentation: Clinical Applications for the REI
Carter Owen, M.D.

RTT19
Answering Questions about Mosaic Embryos: Legal Perspective
Lisa Rinehart, R.N., J.D.
Legal Care Consulting, Inc.

RTT20
How Practice Managers Can Best Utilize SART
Sara Mooney, B.A.
ARM

Society for Male Reproduction and Urology

RTT21
What’s New in the Genetic Evaluation for Couples with Male Factor Infertility
Dolores Lamb, Ph.D.
Weill Cornell Medical College

RTT22
Home Sperm Testing: Before, during, and after the Pandemic
Stan Honig, M.D.
Yale University

Society of Reproductive Surgeons

RTT24
Artificial Intelligence in Male Reproductive Urology
Craig Niederberger, M.D.

RTT25
Polygenic Risk Scores and Embryo Selection: Can We, Should We?
Jeanne O’Brien, M.D., M.Sc.
Shady Grove Fertility Center

RTT26
Fertility Preservation in the Adolescent Cancer Patient
Raymond Ke, M.D.

Society of Reproductive Biologists and Technologists

RTT27
Emerging Bioengineering Technologies in the ART Labs
T. Arthur Chang, PhD, HCLD, ELD
University of Texas Health Science Center

RTT28
“Be a Scientist, Not a Robot”. Is That a Lost ART?”
Mitchel Schiewe, M.S., Ph.D.
Ovation Fertility

RTT29
The Ideal Cryopreservation Storage System - Characteristics and Equipment
Kimball Pomeroy, Ph.D.
The World Egg Bank
Roundtable Discussions

Society of Reproductive Surgeons
RTT30
Controversies in Managing the Septate Uterus and Why It Is so Hard to Get a Clear Answer
Preston Parry, MD
Parryscope Fertility

Turkish Special Interest Group
RTT31
Ovarian Tissue Freezing for Non-Medical (Elective) Indications: Is It Ready for Prime Time?
Kutluk Oktay, M.D., Ph.D.
Yale University School of Medicine

WEDNESDAY, OCTOBER 20, 2021

Early Pregnancy Special Interest Group
RTW02
Beyond the Initial Workup of Rsab: What's Next When They Keep Miscarrying
Joshua Stewart, M.D.
The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine

LGBTQ Special Interest Group
RTW05
Unique Considerations in Family Building for Gay Men
Samuel Pang, M.D.
Boston IVF

Preimplantation Genetic Testing Special Interest Group
RTW09
How Multiple Freeze Thaw Cycles Will Impact Pregnancy Outcomes?
Vinay Gunnala, M.D.
Southwest Fertility Center

RTW10
Tricks, Tips and All Issues Related Embryo Biopsy for PGT
Wei-Hua Wang, Ph.D.

Regenerative Medicine and Stem Cell Biology Special Interest Group
RTW11
Stem Cell Based Treatment of Female Infertility
Ayman Al-Hendy, M.D., Ph.D.
Department of Obstetrics and Gynecology, University of Chicago

Society for Assisted Reproductive Technology
RTW12
Evidence-Based Endometrial Preparation for Frozen Embryo Transfer (FET)
Kate Devine, MD
Shady Grove Fertility Center

RTW13
Premature Progesterone Rise and IVF Outcomes
Micah Hill, DO
Walter Reed National Military Medical Center

RTW14
Patient Consultation after Failure of IVF Treatment
Kevin Doody, M.D.
CARE Fertility

Peter Schlegel, M.D.
Weill Cornell Medicine, Cornell University, New York Presbyterian Hospital

RTW16
Health Insurance Reform and Infertility Care: From Advocacy to Action
James Dupree, M.D., M.P.H.
University of Michigan
Roundtable Discussions

Society for Reproductive Endocrinology and Infertility

RTW18
The ABCs of E&m and CPT: Coding Updates
Silvina Bocca, M.D., Ph.D. H.C.L.D.
Jones Institute

RTW19
Navigating IVF and Patients’ Religious Needs: What Should You Know
Rachel Weinerman, M.D.
UH Fertility Center/Case Western University

RTW20
Transvaginal Ultrasound Guided Embryo Transfer
Marwan Shaykh, M.D.

RTW21
Looking Past the Hype: Realistic Expectations for AI-Based Embryo Selection
Dean Morbeck, Ph.D., M.B.A.
Fertility Associates

RTW22
Lab Disaster Management: Prepare Today be Ready Tomorrow
Sangita Jindal, Ph.D.
Albert Einstein College of Medicine/Montefiore Medical Center

RTW23
New Lab Equipment: Better Outcomes?
EmbryoDirector.com

Turkish Special Interest Group

RTW24
Random Start Ovarian Stimulation in Fertility Preservation
Murat Sonmezer, M.D. professor
Ankara University
VIDEO ABSTRACT SESSION 1

4:15 PM  Welcome/Awarding of Certificates.

4:30 PM  Video 1  3D SURFACE MAPPING FOR MORPHOLOGICAL EVALUATION OF HUMAN BLASTOCYSTS. Guanqiao Shan, MASc1, Zhuoran Zhang, PhD1, Changsheng Dai, PhD1, Hang Liu, MASc1, Xian Wang, PhD2, Wenkun Dou, BS1, Khaled Abdalla, MASc3, Iryna Kuznyetsova, PhD3, Clifford Lawrence Librach, MD3 and Yu Sun, PhD1. 1University of Toronto, Toronto, ON, Canada, 2Hospital for Sick Children, Toronto, ON, Canada, 3CREAte Fertility Centre, Toronto, ON, Canada

4:37 PM  Discussion Break.

4:42 PM  Video 2  ROBOTIC-ASSISTED LIVING DONOR HYSTERECTOMY - TECHNIQUE AND OUTCOME (DALLAS UTERUS TRANSPLANT STUDY). Liza Johannesson, MD, PhD, E Colin Koon, MD, PhD, Johanna Bayer, MD, Greg J McKenna, MD and Giuliano Testa, MD, Baylor University Medical Center, Dallas, TX

4:49 PM  Discussion Break.

4:54 PM  Video 3  OVARIAN TISSUE HARVESTING AND CRYOPRESERVATION FROM A TODDLER WITH CLASSIC GALACTOSEMIA: A MULTIDISCIPLINARY APPROACH. Alla Vash-Margita, MD1, Katarzyna Szymanska, PhD1, Saurabh Saluja, MD2, Emily Christison-Lagay, MD1 and Kutlu H Oktay, M.D., Ph.D.3. 1Yale University School of Medicine, New Haven, CT, 2Yale University, New Haven, CT, 3Yale University School of Medicine

5:01 PM  Discussion Break.

5:06 PM  Video 4  AQUEOUS VAGINAL CONTRAST AND SCHEDULED HEMATOCOLPOS WITH MAGNETIC RESONANCE IMAGING TO DELINEATE COMPLEX MÜLLERIAN ANOMALIES. Phillip A Romanski, MD1, Ashley Aluko, MD1, Pietro Bortoletto, MD2, Robert N Troiano, MD1 and Samantha M Pfeifer, M.D., 1The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, NY, 2The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, Boston, MA

5:13 PM  Discussion Break.

5:18 PM  Video 5  MALE HAPLOID CELLS THROUGH DIRECT SPHERIFICATION. Sherina Lawrence, B.S.1, Philip Xie, B.S.1, Mounia Haddad, M.D.2, Zev Rosenwaks, M.D.1 and Gianpiero D. Palermo, M.D., Ph.D.1. 1The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, NY, 2American University of Beirut, Beirut, Lebanon

5:25 PM  Discussion Break.
4:15 PM  V-6  ROBOTIC-ASSISTED EXCISION OF A FUSED NON-COMMUNICATING FUNCTIONAL UTERINE HORN IN A HIGH-BMI PATIENT. Natalia C Llarena, MD and Elliott G Richards, MD, Cleveland Clinic, Cleveland, OH

4:23 PM  V-7  IN-DEPTH INSIGHT INTO THE PERFORMANCE OF PREDICTIVE MODELS BASED ON ARTIFICIAL NEURAL NETWORKS: DEMONSTRATION OF THE CLINICAL UTILITY OF ARTIFICIAL INTELLIGENCE IN THE IVF LABORATORY. Lorena Bori, Ph.D. Student1, Elena Paya, Ph.D. Student2, Maria de los Ángeles Valera, PhD Student1, Jose Maria De los Santos, PhD3, Jose Remohi, MD PhD4 and Marcos Meseguer, Ph.D.1. 1IVIRMA Global; IVI Foundation, Valencia, Spain, 2Universitat Politècnica de Valencia, Valencia, Spain, 3IVIRMA Global, Valencia, Spain, 4IVIRMA Valencia, Valencia, Spain

4:31 PM  V-8  THE LAPAROSCOPIC REMOVAL OF AN EMBEDDED COPPER IUD FRAGMENT. Christine Hur, MD and Jeffrey M Goldberg, M.D., Cleveland Clinic, Cleveland, OH

4:38 PM  Discussion Break.

4:48 PM  V-9  CROSSED VASOEPIDIDYMOSTOMY: A STEP-BY-STEP GUIDE. Rohit Reddy, B.S.1, Thiago Fernandes Negris Lima, MD1, Jesse Ory, MD1 and Ranjith Ramasamy, M.D.2, 1University of Miami, Miami, FL, 2University of Miami Miller School of Medicine, Miami, FL

4:56 PM  V-10  ISTHMOCELE ENDOMETRIOSIS - THE RELATIONSHIP BETWEEN CESAREAN SECTION AND ENDOMETRIOSIS. Liron Bar-El, MD1, Karli Provost Goldstein, DO1, Serin I Seckin, MD2, Sarah Werner, MD1, Sabina Hajiyeva, MD1 and Tamer A Seckin, MD1, 1Lenox Hill Hospital/Northwell Health, New York, NY, 2SUNY Downstate Medical Center, Brooklyn, NY

5:02 PM  V-11  A COMPLEX CASE OF LAPAROSCOPIC ABDOMINAL CERCLAGE PLACEMENT WITH STAGE IV ENDOMETRIOSIS. Shabnam Gupta, MD, Golnaz Namazi, MD, Louise Perkins King, MD, JD, Mobolaji Ajao, MD MPH and Jon Ivar Einarsrud, MD PhD MPH, Brigham & Women’s Hospital, Boston, MA

5:08 PM  Discussion Break.

5:10 PM  V-12  ON THE SHOULDERS OF GIANTS: THE HISTORY OF MINIMALLY INVASIVE REPRODUCTIVE SURGERY. Kathryn D Coyne, MD1, Rebecca K Chung, MD2, Rebecca Flyckt, MD3, John C Petrozza, M.D.4 and Steven R. Lindheim, M.D., MMM5, 1University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 2Cleveland, OH, 3UH Fertility Center, REI Division, 4Massachusetts General Hospital Fertility Center, Boston, MA, 5Wright State University, Boonshoft School of Medicine, Dayton, OH
ASRM appreciates those who volunteered to review the 2021 abstract submissions. Thank you for your time and participation.

Galal Abdo
Glen Adaniya
Lusine Aghajanova
Asima Ahmad
Ali Ahmady
Ayman Al-Hendy
Christine Allen
Joseph Alukal
Ruben Alvero
Paula Amato
Linda Anderson
Marlene Angle
David Archer
Kenneth Aston
Valerie Baker
G. David Ball
Kurt Barnhart
Kenneth Beaman
Barry Behr
Kristen Bendikson
Dara Berger
Lia Bernardi
Andria Besser
Zeki Beyhan
Bala Bhagavath
Andrea Bird
Cecily Bishop
Silvina Bocca
Charles Bormann
Pietro Bortoletto
Robert Brannigan
Kathleen Brennan
Paul Brezina
Christine Briton-Jones
Alicia Broussard
Heather Burks
Teresa Cacchione
Pamela Callum
Katherine Cameron
William Catherino
Marcelle Cedars
Gerard Celia
Grace Centola
Anthony Chan
Jessica Chan
T. Arthur Chang
Jorge Chavarro
Mindy Christianson
Gregory Christman
Sandy Chuan
Scott Chudnoff
Melanie Clemmer
Charles Coddington
Stephen Collins
Joe Conaghan
Laura Cooney
Brian Cooper
Laura Covington
Robert Coward
Natalie Crawford
Ali Dabaja
Michael Dahan
Danny Dasig
Darlene Davies
Joseph Davis
Lynn Davis
Christina Davis-Kankanamge
Candice Dersch
Nina Desai
Laura Detti
Kate Devine
Anuja Dokras
Alice Domar
Andrew Dorfmann
Erma Drobnis
Jamie Dubaut
Anil Dubey
Antoni Duleba
Eyup Duran
Abey Eapen
Jennifer Eaton
Michael Eisenberg
Ahmed El-Damen
Rony Elias
Lawrence Engmann
Ashley Eskew
Max Ezzati
Tommaso Falcone
Ruth Farrell
Simone Ferrero
Rebecca Flyckt
Eric Forman
Nastaran Foyouzi
Melanie Freeman
Aisaku Fukuda
Atsushi Fukui
Amber Gamma
Audrey Gaskins
Ghina Ghazeeri
Luca Gianaroli
Daniella Gilboa
Elizabeth Ginsburg
Kathryn Go
Kara Goldman
Bruce Goldstein
Linnea Goodman
Emily Goulet
Ellen Greenblatt
Daniel Grow
Lisa Halvorson
Karen Hammond
Alan Handyside
Karl Hansen
Gary Harton
Michael Heard
Christopher Herndon
Patricia Hershberger
Timothy Hickman
Micah Hill
Heather Hipp
Jennifer Hirshfeld-Cytron
Devyn Hodge
Kathleen Hoeger
Sarah Holley
Rebecca Holmes
Peter Holach
Stan Honig
James Hotaling
Luis Hoyos
Kathleen Hwang
Anthony Imudia
Mohamad Irani
Lauren Isley
Kristen Ivani
Tarun Jain
Grace Janik
Jeffrey Jensen
Sangita Jindal
Beth Johnson
Julia Johnson
Amy Jones
Amy Jones
Philip Jordan
Emily Jungheim
Semra Kahraman
Amanda Kallen
Joshua Kapothamer
Mandy Katz-Jaffe
Jennifer Kawwass
Jeffrey Keenan
Dawn Kelk
Maureen Kelly
Levent Keskinpe
Zaraq Khan
Edward Kim
Violet Klenov
Sigal Klipstein
Jennifer Knudtson
Peter Koletts
Alexander Kotlyar
Jessica Kresowik
Rebecca Krisher
Abbey Kruper
Rashmi Kudesia
Anver Kuliev
Saru Kuokkanen
Vitaly Kushnir
William Kutteh
Antoine La
Dolores Lamb
Michael Lanham
Shannon Laughlin-Tommaso
Angela Lawson
Michael Lee
Chelsey Leisinger
Mark Leonidires
Eric Levens
Gary Levy
Philip S. Li
Yu Liang
Juergen Liebermann
Paul Lin
Steven R. Lindheim
Larry Lipshultz
Kirk Lo
Erica Louden
Marla Lujan
Kelly Lynch
Cristina Magli
Winifred Mak
Abigail Mancuso
Diego Marin
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>O-1</td>
<td>LAPAROSCOPICALLY-CONFIRMED ENDOMETRIOSIS AND RISK OF INCIDENT STROKE: A PROSPECTIVE COHORT STUDY.</td>
<td>L. V. Farland</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>O-2</td>
<td>MITOQUINONE RESCUES STRESS INDUCED MITOPHAGY IN AGED OOCYTES.</td>
<td>S. A. Khan</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>O-3</td>
<td>DNA DOUBLE-STRAND BREAKS FREQUENTLY CAUSE CHROMOSOME LOSS IN HUMAN EMBRYOS.</td>
<td>J. M. Turocy</td>
</tr>
<tr>
<td>10:45 AM</td>
<td>O-4</td>
<td>DISPARITIES IN SURGICAL MANAGEMENT OF TUBAL ECTOPIC PREGNANCY.</td>
<td>A. G. Huttler</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>O-5</td>
<td>LIBERTY RANDOMIZED WITHDRAWAL STUDY: 2-YEAR EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS.</td>
<td>A. Al-Hendy</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>O-6</td>
<td>OVARIAN TISSUE OOCYTES IN VITRO MATURATION AS A METHOD OF FERTILITY PRESERVATION IN PATIENTS WITH GYNECOLOGICAL CANCER: A PILOT STUDY.</td>
<td>A. Kirillova</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OSM-02 Art Lab</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>O-7</td>
<td>CLINICAL BENEFITS OF CULTURING INTRACYTOPLASMIC SPERM INJECTION- DERIVED NONPRONUCLEATED (0PN) AND MONOPRONUCLEATED (1PN) ZYGOTES, AND THE IMPORTANCE OF VERIFYING BIPARENTAL CHROMOSOME INHERITANCE IN 1PN-DERIVED BLASTOCYSTS.</td>
<td>K. Wozniak</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>O-8</td>
<td>THE PRESENCE OF CELL EXTRUSION OR EXCLUSION DURING EMBRYONIC COMPACTION IS ASSOCIATED WITH LOWER RATES OF BLASTOCYST FORMATION AND POORER MORPHOLOGIC GRADE.</td>
<td>K. Wozniak</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>O-9</td>
<td>A RANDOMISED CONTROLLED BLINDED TRIAL ASSESSING THE EFFECTIVENESS OF EMBRYOGLUE AS AN EMBRYO TRANSFER MEDIUM IN IVF CYCLES.</td>
<td>T. J. Child</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>O-10</td>
<td>LIVE BIRTH RATES ARE SIGNIFICANTLY DECREASED FOLLOWING TRANSFER OF A EUPLOID BLASTOCYST WITH DIRECT UNEQUAL CLEAVAGE.</td>
<td>C. N. Fortin</td>
</tr>
<tr>
<td>11:45 AM</td>
<td>O-11</td>
<td>MAKING ICSI MORE NATURAL: SELECTING SPERM BOUND TO THE ZONA PELLUCIDA (ZP).</td>
<td>H. Abu Elmagd</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>O-12</td>
<td>SINGLE-STEP VS SEQUENTIAL MEDIA: UNBIASED COMPARISON OF CLINICAL OUTCOME BETWEEN TWO INDIVIDUAL EMBRYO CULTURE STRATEGIES IN A TIME-LAPSE INCUBATOR.</td>
<td>M. Valera</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>OSM-03 Early Pregnancy</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>O-13</td>
<td>LOW-PASS GENOME SEQUENCING IDENTIFIED MACROSCOPIC AND MICROSCOPIC CHROMOSOMAL MOSAICISMS TO EXPLAIN FIRST-TRIMESTER MISCARRIAGE.</td>
<td>Y. Li</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>O-14</td>
<td>MESENCHYMAL STEM CELLS INDUCE BONE MARROW MEMORY TO REDUCE INFLAMMATION AND ENDOMETRIOSIS.</td>
<td>R. Mamillapalli</td>
</tr>
</tbody>
</table>
11:15 AM O-15 BEDSIDE TEST TO RULE OUT AN ECTOPIC PREGNANCY USING A MODIFIED FDA APPROVED KIT. M. Volovsky

11:30 AM O-16 LUTEAL PHASE PROGESTERONE SUPPORT IN IVF CYCLES IS RENDERED REDUNDANT UNLESS IT IS HYDROXYLATED TO 17-Α-HYDROXYPROGESTERONE (17-Α-OHP): A MOLECULE THAT ROBUSTLY STIPULATES ENDOMETRIAL RECEPIVITY AND PREDICTS PREGNANCY OUTCOMES. B. N. Chimote

11:45 AM O-17 ANXIETY DURING THE COVID-19 PANDEMIC: PRELIMINARY FINDINGS FROM THE UCSF ASPIRE STUDY. J. R. Morris

12:00 PM O-18 TREATMENT OUTCOMES AFTER HIGHLY-PURIFIED HUMAN MENOPAUSAL GONADOTROPIN (HP-HMG) OVARIAN STIMULATION AND LUTEAL SUPPORT WITH A NOVEL PROGESTERONE VAGINAL SYSTEM (PVS): SARA TRIAL ANALYSIS. V. L. Schnell

OSM-05 FIBROADS

10:45 AM O-25 ASSESSMENT OF COMMON ADVERSE EVENTS OF RELUGOLIX COMBINATION THERAPY IN PREMENOPAUSAL WOMEN TREATED FOR SYMPTOMATIC ESTROGEN-DRIVEN CONDITIONS: LIBERTY AND SPIRIT STUDIES. A. Al-Hendy

11:00 AM O-26 INHIBITION OF BRD PROTEINS SUPPRESSES THE PHENOTYPE OF UTERINE FIBROIDS VIA REGULATION OF N6-METHYLADEMOSINE REGULATORS. Q. Yang

11:15 AM O-27 TRANSCRIPTOMICS ANALYSIS SHOWS PROFOUND ETHNIC DIFFERENCES IN AT RISK PRE-FIBROID MYOMETRIUM. M. V. Bariani

OSM-04 FERTILITY PRESERVATION

10:45 AM O-19 OPTIMAL NUMBER OF EUPLOID EMBRYOS NEEDED TO ACHIEVE A DESIRED FAMILY SIZE: A PERSONALIZED PREDICTIVE MODEL. D. Aharon

11:00 AM O-20 DOES HARVESTING OVARIAN TISSUE TO DELAY REPRODUCTIVE AGING HAVE A NEGATIVE IMPACT ON THE NATURAL AGE OF MENOPAUSE IN HEALTHY WOMEN? B. Petrikovsky

11:15 AM O-21 THE IMPACT OF DURATION OF OOCYTE CRYOPRESERVATION ON LIVE BIRTH OUTCOMES IN IVF CYCLES USING AUTOLOGOUS THAWED OOCYTES. G. E. Whiteley

11:30 AM O-22 CYCLE CHARACTERISTICS AND TREATMENT OUTCOMES AMONG BRCA MUTATION CARRIERS UNDERGOING IN VITRO FERTILIZATION. L. A. Ghidei

11:45 AM O-23 RIPE FOR THE TAKING – LEVERAGING BIG DATA TO ESTIMATE OVARIAN RESERVE. B. Zhou

12:00 PM O-24 EFFECT OF MALIGNANT DISEASE ON SEMEN PARAMETERS. G. Shrem

OSM-06 HEALTH DISPARITIES

10:45 AM O-31 THE ROLE OF HOUSEHOLD INCOME AND INSURANCE COVERAGE ON LIVE BIRTH OUTCOMES IN INFERTILE PATIENTS RESIDING IN NEW YORK STATE. A. Chung

11:00 AM O-32 INSURANCE COVERAGE DOES NOT MITIGATE RACIAL AND ETHNIC DISPARITIES SEEN IN FERTILITY TREATMENT UTILIZATION: A SURVEY OF US POSTPARTUM WOMEN. J. R. Morris

11:15 AM O-33 SOCIOECONOMIC DISPARITIES EXIST IN FERTILITY TREATMENTS AND ARE ASSOCIATED WITH LIKELIHOOD OF LIVE-BIRTH FOLLOWING IN VITRO FERTILIZATION. E. Manvelyan

11:30 AM O-34 INFERTILITY AND RISK OF CARDIO-VASCULAR DISEASE AMONG POSTMENOPAUSAL PARTICIPANTS IN THE WOMEN’S HEALTH INITIATIVE. G. Murugappan
ORAL ABSTRACTS

11:45 AM O-35 BLACK AND HISPANIC WOMEN TAKE LONGER TO ENTER FERTILITY TREATMENT THAN WHITE WOMEN, BUT ONCE IN TREATMENT, SHOW SIMILAR TIME TO PREGNANCY. T. Jackson-Bey

12:00 PM O-36 EFFECT OF RACE ON EUPLOIDY STATUS AND LIVE BIRTH RATES IN ART TREATMENTS. T. Alkon

OSM-07 IVF OUTCOME PREDICTORS 1

10:45 AM O-37 ICSI VS. CONVENTIONAL IVF USE IN NON-MALE FACTOR INFERTILITY A. Iwamoto

11:00 AM O-38 RANDOMIZED CONTROLLED DOUBLE BLINDED TRIAL OF GNRHA AT TIME OF EMBRYO TRANSFER: INTERIM ANALYSIS OF THE GRAET (Gnrh Agonist At Time Of Embryo Transfer) Study N. M. Marchetto

11:15 AM O-39 REVISITING OLD HABITS: THERE IS NO BENEFIT IN PRESCRIBING METHYLPPREDNISOLONE ADMINISTRATION DURING EUPLOID EMBRYO TRANSFERS IN THE GENERAL INFERTILE POPULATION. C. Hernandez-Nieto

11:30 AM O-40 FACTORS ASSOCIATED WITH LARGE FOR GESTATIONAL AGE INFANTS BORN AFTER FROZEN EMBRYO TRANSFERS. A. J. Roshong

11:45 AM O-41 ENDOMETRIAL PREPARATION FOR FROZEN EMBRYO TRANSFER AND IMPACT ON BIRTH WEIGHT: A SYSTEMATIC REVIEW AND META-ANALYSIS. K. F. Rosalik

12:00 PM O-42 IVF OUTCOMES IN BRCA CARRIERS WITH AND WITHOUT ADDITION OF LETROZOLE TO STIMULATION. C. M. Canon

OSM-09 GENETICS (NON-PGT)

10:45 AM O-49 IN MICE WITH GENETICALLY-INDUCED MITOCHONDRIAL DYSFUNCTION AND INFERTILITY, INTRAOVARIAN PLATELET RICH Plasma (PRP) INJECTION DOES NOT IMPROVE REPRODUCTIVE PARAMETERS. M. Cozzolino

11:00 AM O-50 PREIMPLANTATION AND PRENATAL GENETIC TESTING UPTAKE IN MOTHERS FOLLOWING ASSISTED REPRODUCTIVE TECHNOLOGY. M. T. Markwei

11:30 AM O-52 REPRODUCTIVE OUTCOMES OF TURNER SYNDROME WOMEN. DOES THE KARYOTYPE MATTER? G. Rivera-Cruz

11:45 AM O-53 FERTILITY CENTERS AND CELL-FREE FETAL DNA SCREENING (CFFDNA): A REVIEW OF MATERNIT® 21 PLUS PERFORMANCE IN THE REPRODUCTIVE HEALTH SETTING. V. Nitibhon

12:00 PM O-54 SIGNIFICANCE OF Ser680Asn POLYMORPHISM OF FSHR (FOLLICLE STIMULATING HORMONE RECEPTOR) GENE IN MALE INFERTILITY - A STUDY ON INDIAN POPULATION. A. Udumudi
OSM-10 MALE REPRODUCTION AND UROLOGY: TRAVELING SCHOLARS

10:45 AM O-55 GEOGRAPHICAL DIFFERENCES IN DEMOGRAPHICS AND FERTILITY HISTORIES OF MEN PRESENTING FOR INFERTILITY EVALUATION BETWEEN THE UNITED STATES AND CANADA: RESULTS FROM THE ANDROLOGY RESEARCH CONSORTIUM. K. Asanad

11:00 AM O-56 TOTAL MOTILE SPERM COUNT IS ASSOCIATED WITH ICSI SUCCESS USING SPERM OBTAINED BY TESA. R. Bole

11:15 AM O-57 THE EFFECT OF CHRONIC DELTA-9- TETRAHYDROCANNABINOL USE ON MALE REPRODUCTIVE HEALTH IN Rhesus Macaques. J. C. Bash

11:30 AM O-58 DISTANCE FROM HOSPITAL DOES NOT REDUCE UTILIZATION OF FERTILITY PRESERVATION IN MEN. D. Pelzman

11:45 AM O-59 EFFICACY OF CLOMIPHENE CITRATE IN SUBFERTILE MEN STRATIFIED BY PRE-TREATMENT SEX HORMONE LEVELS AND SPERM CONCENTRATION. A. Santamaria

12:00 PM O-60 ANDROGEN RECEPTOR SIGNALING IN HUMAN CORPUS Cavernosum IS NOT DEPENDENT UPON HALF-LIFE OF TESTOSTERONE THERAPY. K. Khodamoradi

OSM-11 OVARIAN STIMULATION

10:45 AM O-61 EVALUATION OF POSSIBLE FACTORS CONTRIBUTING TO EARLY PREGNANCY LOSS IN PREDICTED HIGH-RESPONDERS: MENOPUR IN GNRH (GONADOTROPIN RELEASING HORMONE) ANTAGONIST SINGLE EMBRYO TRANSFER - HIGH RESPONDER (MEGASET-HR) TRIAL ANALYSIS. C. C. Slater

11:00 AM O-62 ARE THERE OVARIAN Responsive INDEXES THAT PREDICT CUMULATIVE LIVE BIRTH RATES IN WOMEN OVER 39 YEARS? S. Cesarano

11:15 AM O-63 ASSOCIATION BETWEEN DURATION OF CONTROLLED OVARIAN STIMULATION AND REPRODUCTIVE OUTCOMES: AN ANALYSIS OF > 50,000 FRESH, AUTOLOGOUS IVF TREATMENT CYCLES FROM SARTCORS DATABASE. A. Eapen

11:30 AM O-64 SERUM GONADOTROPIN (GN) LEVELS PREDICT RESPONSE TO GONADOTROPIN-RELEASING HORMONE (GnRH) TRIGGER IN ANTAGONIST CONTROLLED OVARIAN HYPERSTIMULATION (COH) CYCLES. A. M. Wiltshire

11:45 AM O-65 OVARIAN STIMULATION-INTRAUTERINE INSEMINATION CYCLES: HOW MANY IS TOO MANY? M. B. Evans

12:00 PM O-66 IVF OUTCOMES IN 510 WOMEN WITH POOR OVARIAN RESPONSE (POR) TREATED WITH INTRAOVARIAN INJECTION OF AUTOLOGOUS PLATELET RICH PLASMA (PRP). Y. Cakiroglu

OSM-12 PATIENT EDUCATION AND SUPPORT

10:45 AM O-67 UNDERSTANDING THE PATIENT EXPERIENCE IN THE DIGITAL AGE: VIRTUAL MEDICINE AND PATIENT PROGRESSION TO FERTILITY TREATMENT. D. Soltesz

11:00 AM O-68 TAKING THE PLUNGE: ASSESSMENT OF THE DESIRE FOR GREATER PARTNER INVOLVEMENT IN THE INTRA-UTERINE INSEMINATION PROCEDURE. A. Starostanko


11:30 AM O-70 CREATING AFFILIATIONS, LEARNING, AND MINDFULNESS FOR IN VITRO FERTILIZATION PATIENTS (CALM IVF). R. M. Whynott

11:45 AM O-71 AN EXAMINATION OF FERTILITY KNOWLEDGE BEFORE AND AFTER RECEIVING AT-HOME ANTI-MÜLLERIAN HORMONE TEST RESULTS. S. Briggs

12:00 PM O-72 INNOVATIONS IN FERTILITY NURSING: THE IMPACT OF COVID-19 ON THE DELIVERY OF PATIENT CARE. F. M. Steyn

OSM-13 PRACTICE MANAGEMENT

10:45 AM O-73 CERVICAL LENGTH IN EARLY PREGNANCY AND PREGNANCY OUTCOMES. A. A. Bazzi

11:00 AM O-74 NATIONAL TRENDS IN THE USE OF INTRACYTOPLASMIC SPERM INJECTION
ORAL ABSTRACTS

11:15 AM O-75 A DECISION MODEL PREDICTING THE SUCCESS AND COST OF IVF USING FROZEN BANKED VERSUS FRESH DIRECTED DONOR OOCYTES. I. Beshar

11:30 AM O-76 CHANGING GENDER DISPARITY GAP OVER TIME WITH REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY PHYSICIANS: AN SREI REPORT. L. Stadtmauer

11:45 AM O-77 TELEHEALTH PROVIDER EXPERIENCE IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY CLINICS DURING THE COVID-19 PANDEMIC AND BEYOND. E. A. Dilday

12:00 PM O-78 PATIENT SATISFACTION WITH TELEMEDICINE VISITS FOR REPRODUCTIVE ENDOCRINOLOGY PATIENTS IN THE ERA OF COVID-19. K. L. Anderson

OSM-15 THIRD PARTY REPRODUCTION

10:45 AM O-85 THE ROLE OF ELAGOLIX IN THE SUPPRESSION OF OVULATION IN DONOR OOCYTE CYCLES. C. Boniface

11:00 AM O-86 INDICATIONS FOR SURROGACY FROM THE PERSPECTIVE OF THE GESTATIONAL CARRIER. A. Kaing

11:15 AM O-87 SPERM DONOR ATTITUDES AND EXPERIENCES ON DIRECT-TO-CONSUMER GENETIC TESTING. S. Wodoslawsky

11:30 AM O-88 THE USE OF OVULATION PREDICTOR KITS FOR DONOR SPERM INSEMINATION CYCLES: THE DATA IS CLEAR. K. D. Schoyer

11:45 AM O-89 ATTITUDES AMONG OOCYTE DONORS REGARDING POTENTIAL OPTION FOR CONCURRENT FERTILITY PRESERVATION. D. Tober

12:00 PM O-90 WHAT RECIPIENT FACTORS AFFECT SUCCESS IN WOMEN UTILIZING FRESH DONOR EGGS? A SART DATABASE ANALYSIS R. Chattopadhyay

OSM-14 PREIMPLANTATION GENETIC TESTING 1

10:45 AM O-79 TRANSFER OF MOSAIC EMBRYOS RESULT IN ONGOING PREGNANCY AND LIVE BIRTH OF HEALTHY BABIES. M. Madjunkov

11:00 AM O-80 PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY USING NEXT GENERATION SEQUENCING IS SUPERIOR TO CONVENTIONAL IVF IN 35 YEARS OR OLDER PATIENTS. P. Sarkar

11:15 AM O-81 IN VITRO FERTILIZATION VS INTRACYTOPLASMIC SPERM INJECTION FOR NON-MALE FACTOR PREIMPLANTATION GENETIC TESTING-ANEUPOIDY CYCLES: ARE THERE DIFFERENCES IN EMBRYOS SUITABLE FOR TRANSFER & PREGNANCY OUTCOMES? A SART CORS ANALYSIS J. N. Tozour

11:30 AM O-82 TRENDS IN PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M). A. G. Besser

11:45 AM O-83 DO ULTRASOUND CHARACTERISTICS PREDICT MISCARRIAGE IN PGT-A TESTED EUPLOID EMBRYOS? M. G. Brolinson

12:00 PM O-84 MOSAICISM AND ANEUPLOIDY LEAD TO GRADUAL LOSS OF BIOCHEMICAL IDENTITY AND INDUCE APOPTOSIS IN HUMAN BLASTOCYSTS. A. Martin

OSV-01 2021 ON-DEMAND PRIZE PAPER SESSION

10:45 AM O-91 THE ADMINISTRATION OF LUTEAL PHASE LOW MOLECULAR WEIGHT HEPARIN TO IMPROVE LIVE BIRTHS AFTER RECURRENT IMPLANTATION FAILURE: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL. J. Awwad

10:55 AM O-92 DEFECTIVE DECIDUALIZATION AFTER SEVERE PREECLAMPSIA IS CONNECTED TO DYSREGULATION OF PROGESTERONE RECEPTOR B AND ESTROGEN RECEPTOR 1. N. Castillo-Marco*

11:05 AM O-93 RESTORING OVARIAN ANTIOXIDANT BALANCE TO COMBAT FEMALE REPRODUCTIVE AGING. S. L. Lane

11:15 AM O-94 THE 2020 BEIRUT BLAST: EFFECTS ON IVF/ICSI TREATMENT OUTCOMES. F. Choucair

11:25 AM O-95 AMH IS STRONGLY ASSOCIATED WITH CUMULATIVE LIVE BIRTH RATE INDEPENDENT OF AGE: AN ANALYSIS OF 132,466 CYCLES FROM THE SART-CORS DATABASE FOR 2014-2016. R. Tal

11:35 AM O-96 PRODUCTS OF CONCEPTION (POC) TESTING OF OOCYTE DONOR- DERIVED PREGNANCIES: ACTIONABLE FINDINGS THAT MAY IMPACT MEDICAL MANAGEMENT AND RECURRENT RISK. K. L. Howard
Tuesday, October 19, 2021

ORAL ABSTRACTS

SCIENTIFIC CONGRESS PRIZE PAPER SESSION 2

The first six papers are candidates for the ASRM Scientific Congress Prize Paper Awards. Six additional candidates will be presented during the Prize Paper Candidates' session on Tuesday.

Moderator: TBD

10:45 AM O-97 OUTCOMES OF OOCYTES ICSI'D WITH SPERM PROCESSED WITH EITHER DENSITY GRADIENT PREPARATION OR THE ZYMOT PREPARATION DEVICE; A PROSPECTIVE RANDOMIZED STUDY UTILIZING SIBLING OOCYTES. T. H. Taylor

11:00 AM O-98 CONCURRENT ULTRASTRUCTURAL ANALYSIS AND GENOMIC ASSESSMENT OF SPERMATOZOA TO ACCURATELY DIAGNOSE RARE AND SEVERE FORMS OF MALE INFERTILITY. P. Xie

11:15 AM O-99 EFFECTS OF INTRAOVARIAN INJECTION OF PLATELET RICH PLASMA (PRP) ON A PRIMARY OVARIAN INSUFFICIENCY (POI) MOUSE MODEL. M. Cozzolino

11:30 AM O-100 EFFECT OF PREMATURELY ELEVATED LATE FOLLICULAR PROGESTERONE ON PREGNANCY OUTCOMES FOLLOWING OVARIAN STIMULATION-INTRAUTERINE INSEMINATION FOR UNEXPLAINED INFERTILITY. S. Z. Gavrizi

11:45 AM O-101 HISTORY OF INFERTILITY AND RISK OF BREAST CANCER: A PROSPECTIVE COHORT STUDY. L. V. Farland

12:00 PM O-102 INVESTIGATING THE IMPACT OF mTOR INHIBITOR TREATMENT ON TRANSGENERATIONAL OFFSPRING HEALTH AND FERTILITY. L. E. Butler

Tuesday, October 19, 2021

ORAL ABSTRACT SESSION 2

OST-02 ACCESS TO CARE

10:45 AM O-103 ONCOFERTILITY RESEARCH PITFALL? RECALL BIAS AMONG YOUNG ADULT CANCER SURVIVORS E. H. Chung

11:00 AM O-104 TESTICULAR TISSUE CRYOPRESERVATION IN A COORDINATED NETWORK OF ACADEMIC CENTERS. K. Tran

11:15 AM O-105 THE NEW NORMAL: PATIENT PROGRESSION TO FERTILITY TREATMENT IN A COVID-19 WORLD. E. Hsyeh

11:30 AM O-106 SEXUAL ASSAULT AND LIFETIME INFERTILITY DIAGNOSIS IN MALE AND FEMALE U.S. MILITARY VETERANS G. L. Ryan

11:45 AM O-107 RACIAL DISPARITIES IN ACCESS TO INFERTILITY CARE IN A STATE WITH MANDATED INFERTILITY COVERAGE. A. Korkidakis

12:00 PM O-108 ACCESS TO ONCOFERTILITY SERVICES IN THE UNITED STATES: A GEOSPATIAL ANALYSIS. N. R. Potapragada

OST-03 CONTRACEPTION AND COMPLEX FAMILY PLANNING

10:45 AM O-109 A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF STRONG CYP3A INDUCTION ON THE PHARMACOKINETICS OF SEGESTERONE ACETATE AND ETHINYL ESTRADIOL IN A CONTRACEPTIVE VAGINAL SYSTEM. L. Haddad

11:00 AM O-110 A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF STRONG CYP3A INHIBITION ON THE PHARMACOKINETICS OF SEGESTERONE ACETATE AND ETHINYL ESTRADIOL IN A CONTRACEPTIVE VAGINAL SYSTEM. L. Haddad

11:15 AM O-111 THE PHASE 2 DATA OF A NOVEL LEVONORGESTREL 52 MG INTRAUTERINE SYSTEM WITH A NIITNOL FRAME: 3-YEAR OUTCOMES. M. A. Thomas
11:30 AM O-112 AGE- AND CONTRACEPTIVE-SPECIFIC ANTI-MÜLLERIAN HORMONE REFERENCE VALUES FROM OVER 25,000 REPRODUCTIVE-AGE WOMEN. S. Briggs

11:45 AM O-113 EVALUATION OF THE HANG-UP TECHNIQUE FOR TRANS-CESEAREAN COPPER INTRAUTERINE DEVICE INSERTION: A RANDOMIZED CONTROLLED TRIAL. A. M. Abbas

12:00 PM O-114 EXPECTATIONS FOR FAMILY BUILDING, ASSISTED REPRODUCTION, AND ADOPTION AMONG LESBIANS IN THE NATIONAL SURVEY OF FAMILY GROWTH, 2017-2019. C. Violette

11:00 AM O-115 A NOVEL MOUSE MODEL OF RETROGRADE MENSTRUATION FOR THE STUDY OF ENDOMETRIOSIS. E. Pelosi

11:15 AM O-116 INTEGRATED LONG-TERM BONE MINERAL DENSITY (BMD) OUTCOMES IN WOMEN RECEIVING RELUGOLIX COMBINATION THERAPY IN LIBERTY AND SPIRIT STUDIES VS NON-TREATED WOMEN. R. B. Wagman

11:30 AM O-117 ARID1a INVOLVEMENT IN ENDOMETRIOSIS DISEASE PROGRESSION. V. A. Flores

11:45 AM O-118 RELUGOLIX COMBINATION THERAPY IMPROVES MULTIPLE DIMENSIONS OF QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM THE SPIRIT PROGRAM. S. As-Sanie

12:00 PM O-119 MACROSCOPIC AND MICROSCOPIC FINDINGS OF THE PLACENTA IN WOMEN WITH ENDOMETRIOSIS AND ADENOMYOSIS. S. Ferrero

12:00 PM O-120 RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BOTULINUM TOXIN FOR ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN. P. Stratton

11:00 AM O-122 THE IMPACT OF OBESITY ON ANTI-MÜLLERIAN HORMONE (AMH) AND AMH TRAJECTORIES: A LONGITUDINAL STUDY AMONG REPRODUCTIVE AGED AFRICAN AMERICAN WOMEN. S. B. Schon

11:15 AM O-123 THE EFFECT OF OBESITY ON PREGNANCY COMPLICATION RISKS IN WOMEN WITH POLYCYSTIC Ovary SYNDROME. M. H. Dahan

11:30 AM O-124 DO OBESE WOMEN WHO PRESENT FOR INFERTILITY CARE GET ADVICE ON WEIGHT LOSS MANAGEMENT PRIOR TO REFERRAL? M. O’Neill

11:45 AM O-125 HIGH-FAT DIET INDUCED OBESITY ALTERS Dnmt1 AND Dnmt3a LEVELS AND GLOBAL DNA METHYLATION IN MOUSE OVARY AND TESTES. F. Uysal

12:00 PM O-126 EFFECTS OF LEPTIN ON LEYDIG STEM CELL DIFFERENTIATION AND TESTOSTERONE PRODUCTION ARE SPECIFIC TO PATIENTS BMI. H. Arora

OST-06 GENETIC COUNSELING

10:45 AM O-127 UPTAKE OF CANCER GENETIC TESTING IN THE INFERTILITY POPULATION MEETING NCCN CRITERIA. K. A. Walker

11:00 AM O-128 THE IMPORTANCE OF TRIPLOIDY IN PREGNANCY LOSS: A DEEP DIVE INTO A LABORATORY’S 10-YEAR EXPERIENCE. M. K. Maisenbacher

11:15 AM O-129 PREIMPLANTATION TESTING OF EMBRYOS FOR POLYGENIC RELATED CONDITIONS: THE ETHICAL CONCERNS SURROUNDING IT AND THE POSITION OF GENETIC COUNSELORS. S. T. Terek

11:30 AM O-130 IDENTIFICATION OF A PATIENT WITH A CRYPTIC TRANSLOCATION VIA PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY: A CASE REPORT. T. A. Cacchione

11:45 AM O-131 UTILIZATION OF PREIMPLANTATION GENETIC TESTING FOR MONOGENIC GENE MUTATIONS ASSOCIATED WITH INCREASED CANCER RISK. K. A. Walker

12:00 PM O-132 FERTILITY PRESERVATION MANAGEMENT AND OVARIAN TISSUE CRYOPRESERVATION IN AN INFANT GIRL WITH CLASSIC GALACTOSEMIA. K. Szymanska
ORAL ABSTRACTS

OST-07 IMAGING IN REPRODUCTIVE MEDICINE

10:45 AM O-133 ETHIOIDIZED POPPYSEED OIL-BASED CONTRAST MEDIUM IS SUPERIOR TO WATER-BASED CONTRAST MEDIUM DURING HYSSTEROSALPINGOGRAPHY REGARDING IMAGE QUALITY IMPROVEMENT AND FERTILITY ENHANCEMENT: A MULTICENTRIC RANDOMIZED CONTROLLED TRIAL. J. Zhang

11:00 AM O-134 WOMEN WITH COMBINED ADENOMYOSIS AND ENDOMETRIOSIS HAVE WORSE IVF/ICSI OUTCOMES COMPARED TO ADENOMYOSIS AND ENDOMETRIOSIS ALONE: A MATCHED RETROSPECTIVE COHORT STUDY. C. O. Rees

11:15 AM O-135 CERVICAL HARDNESS RATIO: CORRELATION WITH RECURRENT PREGNANCY LOSS? M. A. Rasouli

11:30 AM O-136 OIL-BASED OR SALINE-BASED CONTRAST FOR SONO-HSG IN INFERTILE WOMEN: A PILOT RANDOMIZED CONTROLLED TRIAL. R. S. Legro

11:45 AM O-137 THE INCIDENCE AND IMPORTANCE OF THE PSEUDOGESTATIONAL SAC REVISITED. I. T. Lee

12:00 PM O-138 OBSTETRICAL OUTCOMES OF LATE PRESENTING INTRAUTERINE PREGNANCIES. O. Dawodu

OST-08 IVF OUTCOME PREDICTORS 2

10:45 AM O-139 FOLLICULAR PHASE LENGTH (FPL) AND PREGNANCY OUTCOME IN WOMEN WITH UNEXPLAINED INFERTILITY UNDERGOING OVARIAN STIMULATION WITH INTRAUTERINE INSEMINATION (OS-IUI) CYCLES IN A MULTICENTER TRIAL. P. Hosseinizadeh

11:00 AM O-140 LIVE BIRTH OUTCOMES AMONG INFERTILE WOMEN WITH AN UNDETECTABLE AMH LEVEL: PERSISTENCE PAYS OFF. P. A. Romanski

11:15 AM O-141 IVF/ICSI OUTCOMES DURING THE COVID-19 PANDEMIC. I. J. Chamani

11:30 AM O-142 SHOULD TREATMENT BE DIFFERENT WHEN SPERM IS PURCHASED?: A DECISION ANALYSIS COMPARING IUI TO IVF COSTS WHEN DONOR SPERM IS UTILIZED. D. Smith

11:45 AM O-143 LOW AND SLOW, SMOOTH AS SILK: EMBRYO PLACEMENT, TRANSFER VELOCITY AND AVOIDING CERVICAL TRAUMA PREDICT EMBRYO TRANSFER SUCCESS. D. B. McQueen

OST-09 LGBTQ

10:45 AM O-145 ACCESS TO FERTILITY PRESERVATION FOR TRANSGENDER PATIENTS: A MYSTERY CALLER STUDY. K. E. Kolbe

11:00 AM O-146 FERTILITY PRESERVATION OUTCOMES IN TRANSGENDER MEN ON TESTOSTERONE THERAPY. C. R. Douglas

11:15 AM O-147 DOES SEXUAL ORIENTATION AFFECT SPERM PARAMETERS? I. Feferkorn

11:30 AM O-148 FERTILITY PRESERVATION IN TRANSGENDER MEN AND THE NEED FOR UNIFORM TEMPLATES FOR COMPREHENSIVE COUNSELING: A REVIEW. S. U. Park

11:45 AM O-149 ASSESSMENT OF LESBIAN, GAY, BISEXUAL, TRANSGENDER, AND QUESTIONING AWARENESS WITHIN A LARGE SOUTHEAST TRAINING PROGRAM. Z. Walker

12:00 PM O-150 TRANSGENDER CONTENT ON REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY CLINIC WEBSITES: IS THERE AN AREA FOR IMPROVEMENT AND INCLUSIVITY? L. Abern

OST-07 IMAGING IN REPRODUCTIVE MEDICINE

10:45 AM O-133 ETHIOIDIZED POPPYSEED OIL-BASED CONTRAST MEDIUM IS SUPERIOR TO WATER-BASED CONTRAST MEDIUM DURING HYSSTEROSALPINGOGRAPHY REGARDING IMAGE QUALITY IMPROVEMENT AND FERTILITY ENHANCEMENT: A MULTICENTRIC RANDOMIZED CONTROLLED TRIAL. J. Zhang

11:00 AM O-134 WOMEN WITH COMBINED ADENOMYOSIS AND ENDOMETRIOSIS HAVE WORSE IVF/ICSI OUTCOMES COMPARED TO ADENOMYOSIS AND ENDOMETRIOSIS ALONE: A MATCHED RETROSPECTIVE COHORT STUDY. C. O. Rees

11:15 AM O-135 CERVICAL HARDNESS RATIO: CORRELATION WITH RECURRENT PREGNANCY LOSS? M. A. Rasouli

11:30 AM O-136 OIL-BASED OR SALINE-BASED CONTRAST FOR SONO-HSG IN INFERTILE WOMEN: A PILOT RANDOMIZED CONTROLLED TRIAL. R. S. Legro

11:45 AM O-137 THE INCIDENCE AND IMPORTANCE OF THE PSEUDOGESTATIONAL SAC REVISITED. I. T. Lee

12:00 PM O-138 OBSTETRICAL OUTCOMES OF LATE PRESENTING INTRAUTERINE PREGNANCIES. O. Dawodu

OST-08 IVF OUTCOME PREDICTORS 2

10:45 AM O-139 FOLLICULAR PHASE LENGTH (FPL) AND PREGNANCY OUTCOME IN WOMEN WITH UNEXPLAINED INFERTILITY UNDERGOING OVARIAN STIMULATION WITH INTRAUTERINE INSEMINATION (OS-IUI) CYCLES IN A MULTICENTER TRIAL. P. Hosseinizadeh

11:00 AM O-140 LIVE BIRTH OUTCOMES AMONG INFERTILE WOMEN WITH AN UNDETECTABLE AMH LEVEL: PERSISTENCE PAYS OFF. P. A. Romanski

11:15 AM O-141 IVF/ICSI OUTCOMES DURING THE COVID-19 PANDEMIC. I. J. Chamani

11:30 AM O-142 SHOULD TREATMENT BE DIFFERENT WHEN SPERM IS PURCHASED?: A DECISION ANALYSIS COMPARING IUI TO IVF COSTS WHEN DONOR SPERM IS UTILIZED. D. Smith

11:45 AM O-143 LOW AND SLOW, SMOOTH AS SILK: EMBRYO PLACEMENT, TRANSFER VELOCITY AND AVOIDING CERVICAL TRAUMA PREDICT EMBRYO TRANSFER SUCCESS. D. B. McQueen

OST-09 LGBTQ

10:45 AM O-145 ACCESS TO FERTILITY PRESERVATION FOR TRANSGENDER PATIENTS: A MYSTERY CALLER STUDY. K. E. Kolbe

11:00 AM O-146 FERTILITY PRESERVATION OUTCOMES IN TRANSGENDER MEN ON TESTOSTERONE THERAPY. C. R. Douglas

11:15 AM O-147 DOES SEXUAL ORIENTATION AFFECT SPERM PARAMETERS? I. Feferkorn

11:30 AM O-148 FERTILITY PRESERVATION IN TRANSGENDER MEN AND THE NEED FOR UNIFORM TEMPLATES FOR COMPREHENSIVE COUNSELING: A REVIEW. S. U. Park

11:45 AM O-149 ASSESSMENT OF LESBIAN, GAY, BISEXUAL, TRANSGENDER, AND QUESTIONING AWARENESS WITHIN A LARGE SOUTHEAST TRAINING PROGRAM. Z. Walker

12:00 PM O-150 TRANSGENDER CONTENT ON REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY CLINIC WEBSITES: IS THERE AN AREA FOR IMPROVEMENT AND INCLUSIVITY? L. Abern

OST-07 IMAGING IN REPRODUCTIVE MEDICINE

10:45 AM O-133 ETHIOIDIZED POPPYSEED OIL-BASED CONTRAST MEDIUM IS SUPERIOR TO WATER-BASED CONTRAST MEDIUM DURING HYSSTEROSALPINGOGRAPHY REGARDING IMAGE QUALITY IMPROVEMENT AND FERTILITY ENHANCEMENT: A MULTICENTRIC RANDOMIZED CONTROLLED TRIAL. J. Zhang

11:00 AM O-134 WOMEN WITH COMBINED ADENOMYOSIS AND ENDOMETRIOSIS HAVE WORSE IVF/ICSI OUTCOMES COMPARED TO ADENOMYOSIS AND ENDOMETRIOSIS ALONE: A MATCHED RETROSPECTIVE COHORT STUDY. C. O. Rees

11:15 AM O-135 CERVICAL HARDNESS RATIO: CORRELATION WITH RECURRENT PREGNANCY LOSS? M. A. Rasouli

11:30 AM O-136 OIL-BASED OR SALINE-BASED CONTRAST FOR SONO-HSG IN INFERTILE WOMEN: A PILOT RANDOMIZED CONTROLLED TRIAL. R. S. Legro

11:45 AM O-137 THE INCIDENCE AND IMPORTANCE OF THE PSEUDOGESTATIONAL SAC REVISITED. I. T. Lee

12:00 PM O-138 OBSTETRICAL OUTCOMES OF LATE PRESENTING INTRAUTERINE PREGNANCIES. O. Dawodu
ORAL ABSTRACTS

11:15 AM  O-153  CLINICAL CONSEQUENCES OF MICRODISSECTION TESTICULAR EXTRACTION AND INTRACYTOPLASMIC SPER INJECTION (ICSI) IN COUPLES WITH KLINEFELTER SYNDROME (KS). T. Ishikawa

11:30 AM  O-154  ANDROLOGY IN THE ERA OF COVID. L. L. Penrose

11:45 AM  O-155  ADVANCING PATERNAL AGE NEGATIVELY IMPACTS ODDS OF LIVE BIRTH IN FRESH EMBRYO TRANSFER CYCLES. N. Punjani

12:00 PM  O-156  UTILIZING SPERMATOZOA WITH THE HIGHEST GENOMIC INTEGRITY ENHANCES ICSI OUTCOME. D. Keating

OST-11 MENOPAUSE AND PRIMARY OVARIAN INSUFFICIENCY

10:45 AM  O-157  SHOULD ROUTINE GYNECOLOGIC CARE INCLUDE SCREENING TO IDENTIFY UNDETECTABLE ANTI-MÜLLERIAN HORMONE LEVELS? ANALYSIS OF RESULTS FROM OVER 18,000 REPRODUCTIVE-AGE WOMEN. T. Shirazi

11:00 AM  O-158  INHIBITION OF SHP2 DISRUPTS FSH-STIMULATED SYNTHESIS OF ESTROGEN IN GRANULOSA CELLS. S. Xi

11:15 AM  O-159  COMPARISON OF ORTHOTOPIC (OA) AND HETEROTOPIC (HA) AUTOLOGOUS CRYOPRESERVED OVARIAN TISSUE TRANSPLANTATION (ACOTT) OUTCOMES. L. Marin

11:30 AM  O-160  INCIDENTAL FINDINGS ON CORONARY COMPUTED TOMOGRAPHY IN WOMEN WITH REPRODUCTIVE DISORDERS. C. v. Zwol-Janssens

11:45 AM  O-161  REPRODUCTIVE POTENTIAL AMONG WOMEN WITH POI IS DIMINISHED, BUT NOT ABSENT, COMPARED TO AGE MATCHED CONTROLS. L. E. Verrilli

12:00 PM  O-162  ASSOCIATION OF MENOPAUSAL SYMPTOMS AND HISTORY OF INFERTILITY. V. W. Fitz

OST-12 MENTAL HEALTH

10:45 AM  O-163  A BALANCING ACT: SEX SELECTION AFTER PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) FOR FIRST VERSUS SECOND BABY. M. Bayefsky

11:00 AM  O-164  ARE FERTILITY TREATMENT RETENTION RATES Affected By PATIENT PSYCHIATRIC HISTORY? S. R. Brownridge

11:15 AM  O-165  THE IMPACT OF COVID-19 DIAGNOSIS ON FERTILITY-RELATED STRESS AND FERTILITY OUTCOMES IN AN IVF POPULATION. S. M. Salaris

11:30 AM  O-166  THE RELATIONSHIP BETWEEN PERCEIVED STRESS DURING THE COVID-19 PANDEMIC AND MENSTRUAL CYCLES AND SYMPTOMS. S. M. Malloy

11:45 AM  O-167  IMPACT OF EMPATHIC PHYSICIAN CONTACT ON PATIENT ANXIETY AND DISTRESS DURING THE WAITING PERIOD AFTER EMBRYO TRANSFER (ET): A RANDOMIZED CONTROLLED STUDY. J. S. Shah

12:00 PM  O-168  PSYCHOLOGICAL EFFECT OF COVID-19 PANDEMIC AMONG WOMEN UNDERGOING INFERTILITY CARE, A FRENCH COHORT – PSYCOVART. O. Lablanche

OST-13 PROFESSIONAL DEVELOPMENT

10:45 AM  O-169  GENDER AND RACIAL DIVERSITY IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY TRAINEES IN THE UNITED STATES: A CROSS-SECTIONAL 3-YEAR ANALYSIS OF OB/GYN FELLOWSHIP PROGRAMS. A. Peyser

11:00 AM  O-170  TRENDS OVER TIME IN GENDER DIVERSITY AMONG REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY PROGRAM DIRECTORS AND FELLOWSHIP TRAINEES. A. Peyser

11:15 AM  O-171  GENDER DISPARITIES IN CITATIONS IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY LITERATURE: ARE THE SCALES TIPPING? M. G. Brolinson

11:30 AM  O-172  PERCEPTION OF GENDER DISPARITY IN ACADEMIC REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY. J. Selter

11:45 AM  O-173  THE TIME IS NOW: ASSESSING FERTILITY KNOWLEDGE, REPRODUCTIVE CONCERNS, AND DESIRE FOR FERTILITY EDUCATION IN UNDERGRADUATES. R. A. Okine
12:00 PM  O-174  THE INFLUENCE OF VIRTUAL INTERVIEWS ON THE FELLOWSHIP MATCH IN OBSTETRICS AND GYNECOLOGY (OBGYN). A. Armstrong

OST-14 PUBLIC HEALTH AND REPRODUCTION

10:45 AM  O-175  DOSE-DEPENDENT EFFECT OF CONTEMPORARY MARIJUANA EXPOSURE ON FEMALE REPRODUCTIVE HEALTH IN A NON-HUMAN PRIMATE MODEL. K. S. Ryan

11:00 AM  O-176  MATERNAL AND NEONATAL HOSPITALIZATION COSTS ARE HIGHER IN PATIENTS UTILIZING ASSISTED REPRODUCTIVE TECHNOLOGY (ART). W. Urian

11:15 AM  O-177  mRNA COVID-19 VACCINES DO NOT COMPROMISE IMPLANTATION OF EUPLOID EMBRYOS. D. Aharon

11:30 AM  O-178  COST-EFFECTIVENESS ANALYSIS OF THE ACTIVE TREATMENT OR NO TREATMENT (ACT OR NOT) RANDOMIZED CONTROLLED TRIAL OF THE OPTIMAL MANAGEMENT OF PERSISTENT PREGNANCIES OF UNKNOWN LOCATION. J. R. Walter

11:45 AM  O-179  METABOLIC DYSFUNCTION AS A PREDICTOR OF FIBROID RECURRENCE. A. A. Allen

12:00 PM  O-180  CLINICAL TRIAL OUTCOMES IN REI AND OTHER GYNECOLOGY SUBSPECIALTIES: AN ANALYSIS OF EARLY DISCONTINUATION, RESULTS REPORTING AND PUBLICATION BETWEEN 2007-2020. J. R. Steinberg

OST-15 REPRODUCTIVE BIOLOGY: HUMAN STUDIES

10:45 AM  O-181  GONADOTROPIN STIMULATION ALTERS HUMAN MATERNAL UTERINE IMMUNE CELL NUMBER AND FUNCTION DURING THE WINDOW OF IMPLANTATION. J. R. Kanter

11:00 AM  O-182  CONTROLLED OVARIAN STIMULATION LEADS TO GLANDULAR-STROMAL DYSSYNCHRONY AND DECREASED STROMAL PROLIFERATION IN GOOD RESPONDERS BUT NOT IN POOR RESPONDERS. A. Chemerinski

11:15 AM  O-183  SINGLE CELL DNA SEQUENCING OF WHOLE HUMAN BLASTOCYSTS: NOVEL INSIGHTS INTO THE PHENOMENON OF EMBRYONIC MOSAICISM. J. Friedenthal

11:30 AM  O-184  SODIUM TUNGSTATE INDUCES ENDOMETRIAL GENE EXPRESSION CHANGES DURING THE WINDOW OF IMPLANTATION IN HEALTHY WOMEN OF CHILDBEARING AGE. I. Canals

11:45 AM  O-185  THE BIOLOGICAL CLOCK IS TICKING- ON OOCYTES AGING AND EPIGENETICS. P. Wasserzug Pash

12:00 PM  O-186  FOLLICULAR FLUID HYALURONIC ACID POLYDISPERSY IS ASSOCIATED WITH AGE AND IN VITRO FERTILIZATION CYCLE OUTCOME: A PILOT STUDY. E. Babayev
OSW-01 LATE-BREAKING ABSTRACT SESSION

10:45 AM O-187 MT-2990, A NOVEL IL-33 INHIBITOR, REDUCES ENDOMETRIOSIS-RELATED PELVIC PAIN: RESULTS FROM A PHASE 2 STUDY. Y. Komatsu

11:00 AM O-188 LEVONORGESTREL 52 MG INTRA-UTERINE SYSTEM EFFICACY AND SAFETY THROUGH 8 YEARS OF USE. M. D. Creinin

11:15 AM O-189 EDUCATING BY EXPERIENCE – DO FELLOW PERFORMED EMBRYO TRANSFERS AFFECT LIVE BIRTH RATES? S. H. Bjorkman

11:30 AM O-190 EXPOSURE OF OVARIIES TO COVID-19 VACCINATION DOES NOT IMPAIR FERTILITY. R. S. Morris

11:45 AM O-191 EFFECT OF ALKYLATING AGENT CHEMOTHERAPY ON THE UTERUS OF YOUNG ADULT CANCER SURVIVORS. D. Garg

12:00 PM O-192 A NOVEL NON-INVASIVE OOCYTE SCORING SYSTEM USING AI APPLIED TO 2-DIMENSIONAL IMAGES. D. Nayot

OSW-02 ANDROGEN EXCESS AND POLYCYSTIC OVARY SYNDROME

10:45 AM O-193 FEMALE 21-OH CONGENITAL ADRENAL HYPERPLASIA CARRIER STATUS IS NOT ASSOCIATED WITH SUBOPTIMAL IMPLANTATION RATES AFTER A SINGLE EUPOI D EMBRYO TRANSFER. C. Hernandez-Nieto

11:00 AM O-194 POLYCYSTIC OVARY SYNDROME AND RISK OF ADVERSE PREGNANCY OUTCOMES: A REGISTRY LINKAGE STUDY FROM MASSACHUSETTS. L. V. Farland

11:15 AM O-195 ADIPOSE CLC-3 DEFICIENCY PROTECTS AGAINST DIET-INDUCED OBESITY AND INSULIN RESISTANCE BY REGULATING GLUT4 THROUGH THE PI3K/AKT PATHWAY. X. Zhao

11:30 AM O-196 NORMOANDROGENIC VERSUS HYPERANDROGENIC WOMEN WITH POLYCYSTIC OVARY SYNDROME AND THEIR METABOLIC AND CARDIOVASCULAR PROFILE LATER IN LIFE. K. V. Ham

OSW-04 CRYOPRESERVATION

10:45 AM O-205 EMBRYO VITRIFICATION WITH SLUSH NITROGEN YIELDS SIMILAR PREGNANCY OUTCOMES COMPARED TO LIQUID NITROGEN: A RANDOMIZED CONTROLLED TRIAL. A. M. Klimczak

11:00 AM O-206 FROZEN IN TIME: INTERVAL OF CRYOPRESERVATION DOES NOT AFFECT REPRODUCTIVE POTENTIAL OF VITRIFIED BLASTOCYSTS. N. S. Herlihy
11:15 AM O-207 SHORT INTERPREGNANCY INTERVAL (IPI) DOES NOT DECREASE LIVE BIRTH RATES AMONG PATIENTS UNDERGOING SUBSEQUENT FROZEN EMBRYO TRANSFER (FET). M. Palmor

11:30 AM O-208 FATE OF M1 CONVERTED M2 OOCYTE AND ITS DEVELOPMENT POTENTIAL. N. J. Brahmbhatt

11:45 AM O-209 CRYOPRESERVED SINGLE EMBRYO TRANSFERS RESULT IN IMPROVED NEONATAL OUTCOMES OVER FRESH SINGLE EMBRYO TRANSFERS AND HAVE SIMILAR OUTCOMES TO NATURALLY-CONCEIVED NEWBORNS: A STUDY OF 8,671 SINGLETON BIRTHS. A. Reig

12:00 PM O-210 VACUUM LOSS OF LIQUID NITROGEN TANKS CAN BE RAPIDLY DETECTED BY MEASURING OUTSIDE SURFACE TEMPERATURE. C. S. Hansen

OSW-05 ENVIRONMENT AND REPRODUCTION

10:45 AM O-211 WILDFIRE SMOKE EXPOSURE IS ASSOCIATED WITH DECREASED TOTAL MOTILE SPERM COUNT. E. S. Rubin

11:00 AM O-212 ON THE MOVE: THE IMPACT OF THE COVID-19 PANDEMIC ON MOVEMENT OF CRYOPRESERVED OOCYTES AND EMBRYOS. A. G. Kelly


11:30 AM O-214 REPRODUCTIVE CONCERN AMONG FEMALE AND MALE UNITED STATES VETERANS EXPOSED TO ENVIRONMENTAL, CHEMICAL, AND HAZARDOUS MATERIALS. A. C. Mancuso

11:45 AM O-215 SEMEN ANALYSIS PARAMETERS DO NOT CHANGE DURING ACTIVE COVID INFECTION IN KNOWN SPERM DONORS. C. Antonelli

12:00 PM O-216 HIGH GROUNDWATER ARSENIC CONTAMINATION IS ASSOCIATED WITH STILLBIRTH, RECURRENT PREGNANCY LOSS, AND INFERTILITY: A POPULATION-BASED STUDY IN INDIA OF 643,944 REPRODUCTIVE AGED WOMEN. B. C. Monseur

OSW-06 INFERTILITY AND CANCER

10:45 AM O-217 ANTI-MÜLLERIAN HORMONE PROTECTS OVARIAN RESERVE FROM CYCLOPHOSPHAMIDE WHEN ADMINISTERED AS RECOMBINANT PROTEIN OR MODIFIED RNA. L. Man

11:00 AM O-218 THE THERAPEUTIC POTENTIAL OF IMMATURE OOCYTES FROM FERTILITY PRESERVATION PROCEDURES AND THEIR IN-VITRO MATURATION AT DIFFERENT AGES:. P. Wasserzug Pash

11:15 AM O-219 OOCYTE CRYOPRESERVATION: ONCOLOGIC Versus NON-ONCOLOGIC CYCLE CHARACTERISTICS. L. M. Shandley

11:30 AM O-220 COMBINED SUPPRESSION OF FOLLICLE ACTIVATION VIA INTRINSIC AND EXTRINSIC PATHWAYS COMPLETELY PROTECTS AGAINST CYCLOPHOSPHAMIDE-INDUCED OVARIAN RESERVE LOSS IN MICE. O. Kashi

11:45 AM O-221 OOCYTE VITRIFICATION FOR FERTILITY PRESERVATION DOES NOT DELAY THE INITIATION OF NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER. M. Grynberg

12:00 PM O-222 CHOOSING NOT TO USE: EXAMINING THE REASONS BEHIND DISCARDING VITRIFIED EGGS. A. Namath

OSW-07 MALE REPRODUCTION AND UROLOGY 2

10:45 AM O-223 SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) USE IS NOT ASSOCIATED WITH IMPAIRED SEMEN PARAMETERS. M. N. Pham

11:00 AM O-224 SECONDARY POLYCYTHEMIA IN MEN RECEIVING TESTOSTERONE THERAPY INCREASES RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND VENOUS THROMBOEMBOLISM: INSIGHTS FROM A GLOBAL HEALTH RESEARCH NETWORK. J. Ory

11:15 AM O-225 ALGORITHMS FOR PREDICTING THE PROBABILITY OF AZOOSPERMIA FROM FOLLICLE STIMULATING HORMONE: DESIGN AND MULTI-INSTITUTIONAL EXTERNAL VALIDATION. M. B. Tradewell
11:30 AM O-226 MEASURING ERGONOMIC RISK BY USING WEARABLE TECHNOLOGY: A COMPARISON OF A 4K-3D EXOSCOPE TO THE OPERATING MICROSCOPE IN MALE FERTILITY MICROSURGERY. D. Gonzalez

11:45 AM O-227 HOPE FOR MALE FECUNDITY – CLINICALLY INSIGNIFICANT CHANGES IN SEMEN PARAMETERS OVER 10 YEARS AT A SINGLE CLINIC WHILE ASSESSING AN INFERTILITY POPULATION. I. Feferkorn

12:00 PM O-228 SARS-COV-2 ENDOTHELIAL DYSFUNCTION CAN CAUSE ERECTILE DYSFUNCTION: HISTOPATHOLOGICAL, IMMUNOHISTOCHEMICAL AND ULTRASTRUCTURAL STUDY OF THE HUMAN PENIS. E. Kresch

OSW-08 PEDIATRIC OR ADOLESCENT

10:45 AM O-229 PLASMA PROTEOMIC PROFILES ASSOCIATED WITH POST-SURGICAL PERSISTENT PELVIC PAIN IN ADOLESCENTS AND YOUNG ADULTS WITH ENDOMETRIOSIS. N. Sasamoto

11:00 AM O-230 ASSESSMENT OF A TRAINING MODULE ON REPRODUCTIVE HEALTH COMMUNICATION FOR SEXUAL AND GENDER MINORITY (SGM) ADOLESCENTS AND YOUNG ADULTS (AYAs) WITH CANCER. J. Pecoriello

11:15 AM O-231 LONGITUDINAL ASSESSMENT OF PELVIC PAIN SYMPTOMS AMONG ADOLESCENTS AND ADULT WOMEN WITH AND WITHOUT ENDOMETRIOSIS. A. L. Shafrir

11:30 AM O-232 GERM CELLS ARE MORE COMMONLY OBSERVED IN ADOLESCENT KLINEFELTER SYNDROME PATIENTS. C. Kang

11:45 AM O-233 CHARACTERIZING PRIMARY AMENORREA IN A LARGE DIVERSE COHORT. M. F. Sumida

12:00 PM O-234 A MULTI-INSTITUTION EVALUATION OF ADOLESCENTS WITH KLINEFELTER SYNDROME AND ASSESSING THE UTILITY OF EVALUATING SEMEN SAMPLES FOR CRYOPRESERVATION. K. Y. Chu

OSW-09 PREIMPLANTATION GENETIC TESTING 2

10:45 AM O-235 OBSERVED OUTCOMES OF FMR1 PGT-M ANALYSIS WITH INCORPORATION OF CGG REPEAT EXPANSION CAN LEAD TO EXTRA EMBRYOS SUITABLE FOR TRANSFER. M. Discenza

11:00 AM O-236 EMBRYONIC PREDICTOR FACTORS FOR A SUCCESSFUL BLASTOCYST BIOPSY PGT-A (PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY) CYCLE. M. Florensa

11:15 AM O-237 COMPARISON OF IVF OUTCOMES FROM CONCURRENT USE OF 3 DIFFERENT PGT-A LABORATORIES. K. Wiemer

11:30 AM O-238 DOES EMBRYO BIOPSY INCREASE THE RISK OF ECTOPIC PREGNANCY? A. Domney

11:45 AM O-239 MALE FACTORS AFFECTING PREIMPLANTATION GENETIC TESTING RESULTS IN JAPANESE DONOR EGG IN VITRO FERTILIZATION CYCLES. R. Ghatnekar

12:00 PM O-240 EUPLOIDY AND PREGNANCY RATES IN FRESHLY BIOPSIED VERSUS THAWED AND BIOPSIED BLASTOCYSTS. V. Purusothaman

OSW-10 ART TECHNIQUES

10:45 AM O-241 A RANDOMIZED CONTROLLED TRIAL COMPARING LIVE BIRTH FROM SINGLE EUPLOID FROZEN BLASTOCYST TRANSFER USING STANDARDIZED TIMING VERSUS TIMING BY ENDOMETRIAL RECEPTIVITY ANALYSIS. N. Doyle

11:00 AM O-242 A MACHINE LEARNING APPROACH FOR FORECASTING FOLLICLE GROWTH AND PREDICTING THE OPTIMAL DAY OF TRIGGER DURING OVARIAN STIMULATION. K. E. Loewke

11:15 AM O-243 NON-INVASIVE METHOD FOR Blastocyst PLOIDY PREDICTION BASED ON ARTIFICIAL INTELLIGENCE, TIME-LAPSE IMAGES AND PATIENT PARAMETERS. A. R. Lorenzon

11:30 AM O-244 THE USE OF PROPENSITY SCORE MATCHING TO EVALUATE THE ENDOMETRIAL RECEPTIVITY ANALYSIS (ERA) IN EUPLOID FROZEN EMBRYO TRANSFER CYCLES. K. Bergin
11:45 AM O-245 EFFECTS OF SUBENDOMETRIAL AUTOLOGOUS PLATELET RICH PLASMA INJECTION ON ENDOMETRIUM AND PREGNANCY RATES IN PATIENTS WITH UNRESPONSIVE THIN ENDOMETRIUM UNDERGOING FROZEN-THAWED EMBRYO TRANSFER. Y. Cakiroglu

12:00 PM O-246 ENDOMETRIAL FLUID ASSOCIATED PATHOLOGIES IN FROZEN EMBRYO TRANSFER (FET) CYCLES. L. Lapensée

OSW-11 REGENERATIVE MEDICINE AND STEM CELL BIOLOGY

10:45 AM O-247 THE COMPARISON OF DIFFERENT DELIVER WAYS FOR BMSCs ON THE REGENERATIVE EFFECTS ON THIN ENDOMETRIUM. Y. Chang

11:00 AM O-248 HUMAN PLATELET-DERIVED EXOSOMES INDUCE CELL PROLIFERATION AND WOUND HEALING IN HUMAN ENDOMETRIAL ADENOCARCINOMA CELLS IN VITRO. C. Miller

11:15 AM O-249 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR ENHANCE HAPLOID PARthenogenetic PSEUDO-BLASTOMERE REPROGRAMMING POTENTIAL. P. Xie

11:30 AM O-250 LEPTIN SECRETED FROM TESTICULAR MICROENVIRONMENT BINDS TO LEPTIN RECEPTOR ON LEYDIG CELLS AND MODULATES THEIR ENDOGENOUS FUNCTION. H. Arora

11:45 AM O-251 IDEAL CULTURE CONDITIONS FOR ENHANCING FULL PREIMPLANTATION DEVELOPMENT OF EMBRYOS GENERATED THROUGH SOMATIC CELL HAPLOIDIZATION. A. Trout

OSW-13 REPRODUCTIVE ENDOCRINOLOGY

10:45 AM O-259 THE RATIO AMH/ANTRAL FOLLICLE COUNT VARIES ACCORDING TO THE ETIOLOGIES OF DIMINISHED OVARIAN RESERVE SUGGESTING DIFFERENCES IN FOLLICULAR HEALTH. M. Grynberg

11:00 AM O-260 OOCYTE SECRETED FACTORS REGULATE THE EXPRESSION OF INDUCERS OF THE OVULATORY CASCADE IN CUMULUS CELLS. J. Buratini

11:15 AM O-261 DOES ADJUVANT LETROZOLE DURING OVARIAN STIMULATION FOR IVF REDUCE THE NEED FOR LUTEAL SUPPORT? A RANDOMIZED CONTROLLED TRIAL M. D. Holt

11:30 AM O-262 CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-OH DEFICIENCY CARRIER STATUS IS NOT ASSOCIATED WITH IMPAIRED OOCYTE OR EMBRYONIC QUALITY. C. Hernandez-Nieto

OSW-12 REPRODUCTIVE BIOLOGY: ANIMAL AND EXPERIMENTAL STUDIES

10:45 AM O-253 RECOMBINATION EVENTS THAT PREDISPOSE MATERNAL CHROMOSOMES TO INCREASED MISSEGREGATION ARE MORE THAN JUST A NUMBER. B. R. McCallie

11:15 AM O-261 DOES ADJUVANT LETROZOLE DURING OVARIAN STIMULATION FOR IVF REDUCE THE NEED FOR LUTEAL SUPPORT? A RANDOMIZED CONTROLLED TRIAL M. D. Holt

11:30 AM O-262 CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-OH DEFICIENCY CARRIER STATUS IS NOT ASSOCIATED WITH IMPAIRED OOCYTE OR EMBRYONIC QUALITY. C. Hernandez-Nieto

11:45 AM O-263 THE IMPACT OF AT-HOME ANTI-MÜLLERIAN HORMONE TEST RESULTS ON EMOTIONS AND PROACTIVE FERTILITY BEHAVIORS. S. Briggs
12:00 PM O-264 CHARACTERIZATION OF DEPRESSION PHENOTYPES IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. O. M. Dayo

OSW-15 REPRODUCTIVE SURGERY AND PROCEDURES
10:45 AM O-271 IMMEDIATE START IVF STIMULATION FOLLOWING POLYPECTOMY DOES NOT IMPACT PREGNANCY OUTCOMES IN LARGE MULTICENTER COHORT OF OVER SIXTEEN HUNDRED EMBRYO TRANSFERS. S. Gay
11:00 AM O-272 NEONATAL OUTCOMES AFTER UTERUS TRANSPLANTATION: DALLAS UTERUS TRANSPLANT STUDY. L. Johannesson
11:15 AM O-273 UPDATED CLINICAL PREGNANCY RATES AFTER UTERUS TRANSPLANTATION AND IN VITRO FERTILIZATION: DALLAS UTERUS TRANSPLANT STUDY. J. Putman
11:30 AM O-274 INNOVATIVE ULTRA-RAPID VITRIFICATION METHOD FOR FIVE OR FEWER TESTICULAR SPERMATOZOA FROM NON-OBSTRUCTIVE AZOOSPERMIC MEN AFTER MICROSURGICAL TESTICULAR SPERM EXTRACTION (MICRO-TESE). A. Tanaka
11:45 AM O-275 HYSTEROSCOPIC UTERINE SEPTUM REPAIR IMPROVES MISCARRIAGE AND LIVE BIRTH RATES IN WOMEN SEEKING FERTILITY TREATMENT REGARDLESS OF SEPTUM SIZE. K. J. Bollig
12:00 PM O-276 LIVE BIRTH RATE IN INFERTILE PATIENTS WITH RECTOSIGMOID ENDOOMETRIOSIS TREATED BY SURGERY OR IVF/ICSI. S. Ferrero

OSW-14 REPRODUCTIVE IMMUNOLOGY
10:45 AM O-265 IFN-B DISRUPTS INVASIVE EXTRAVILLOUS TROPHOBLASTS FUNCTION ON IMPLANTATION-ON-A-CHIP MODEL. M. K. Simoni
11:00 AM O-266 RELATIONSHIP BETWEEN SENESCENT CELLS AND IMMUNE CELLS IN HUMAN ENDOMETRIUM. D. Parvanov
11:15 AM O-267 THE SEX OF PRIOR PREGNANCIES AFFECTS THE RISK OF PRIMARY OVARIAN INSUFFICIENCY. A. Benor
11:30 AM O-268 CHARACTERIZING REPRODUCTIVE TRACT MICROBIOME THROUGH SHOTGUN METAGENOMIC SEQUENCING AT TIME OF IVF, A PILOT STUDY. J. D. Bardos
11:45 AM O-269 IMMUNE CELLS IN THE ENDOMETRIUM DURING MID-LUTEAL PHASE. R. Ganeva
12:00 PM O-270 THE EFFECTS OF SEXUAL FREQUENCY AND IMMUNE BOOSTING MINERAL INTAKE ON IMMUNE STATUS IN COVID-19 SUSCEPTIBLE INDIVIDUALS. M. A. Ramadhan
### POSTER SESSION 1

#### PST-01 POSTER SESSION: ACCESS TO CARE

<table>
<thead>
<tr>
<th>P-1</th>
<th>IMPACT OF STATE IVF INSURANCE MANDATES ON IVF UTILIZATION AND OUTCOMES IN THE UNITED STATES.</th>
<th>B. J. Peipert</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-2</td>
<td>MORE COVERAGE, MORE CARE: INCREASED FERTILITY PRESERVATION VOLUME BEFORE AND AFTER STATEWIDE INSURANCE MANDATES.</td>
<td>E. Trawick</td>
</tr>
<tr>
<td>P-3</td>
<td>CROWDFUNDING TO SUPPORT INFERTILITY CARE: IS THIS THE NEW NORM?</td>
<td>R. A. Frankel</td>
</tr>
<tr>
<td>P-4</td>
<td>FERTILITY OUTCOMES IN A RESOURCE-LIMITED CLINIC FOR AN UNDERSERVED POPULATION.</td>
<td>J. Karten</td>
</tr>
<tr>
<td>P-5</td>
<td>THE RELATIONSHIP BETWEEN IVF CLINIC VOLUME AND SUCCESS RATES IN SART REPORTING CLINICS.</td>
<td>E. A. Wilkinson</td>
</tr>
<tr>
<td>P-6</td>
<td>INFERTILITY TREATMENTS IN THE USA: IS THE INSURANCE MANDATES THE ANSWER FOR FERTILITY RATE DECLINE?</td>
<td>S. M. Nelson</td>
</tr>
</tbody>
</table>

#### PST-02 POSTER SESSION: ANDROGEN EXCESS AND PCOS

| P-7 | POLYCYSTIC OVARY SYNDROME: IMPACT ON OBSTETRIC AND NEONATAL OUTCOMES. | S. L. Robinson |
| P-9 | THE EFFECT OF BARIATRIC SURGERY ON OBESITY IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) PATIENTS' OBSTETRICAL AND NEONATAL OUTCOMES: A POPULATION BASED STUDY. | M. S. Bazarah |
| P-10 | EFFECTS OF IN-VITRO FERTILIZATION ON PREGNANCY RISK FACTORS ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME. | G. Mills |
| P-11 | INFERTILITY TREATMENT USING HUMAN MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLE IN LETROZOLE INDUCED PCOS MOUSE MODEL. | H. Park |
| P-12 | ANTI-MULLERIAN HORMONE (AMH) LEVELS IS EFFECTIVE IN DETECTION AND DIAGNOSIS OF VARIOUS POLYCYSTIC OVARIAN SYNDROME (PCOS) PHENOTYPES. | C. N. Cortes |
| P-13 | ELEVATED SERUM TESTOSTERONE (T) TO ANDROSTENEDIONE (A4) RATIO AS A BIOMARKER OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) ACTIVITY ACOMPANIES IMPROVED METABOLIC FUNCTION IN NORMAL-WEIGHT POLYCYSTIC OVARY SYNDROME (PCOS) WOMEN. | A. Tulberg |
| P-14 | THE DEGREE OF MENSTRUAL DISTURBANCE IS ASSOCIATED WITH THE SEVERITY OF INSULIN RESISTANCE IN PCOS. | X. Zhao |
| P-15 | EXCESSIVE PREGNANCY WEIGHT GAIN: PCOS IS NOT THE PROBLEM. | L. Rafferty |
| P-16 | IS IT TIME TO UPDATE THE SCREENING RECOMMENDATIONS FOR PATIENTS WITH POLYCYSTIC OVARY SYNDROME? | S. B. Kaiser |
| P-17 | OBSTRUCTIVE SLEEP APNEA RISK IS ASSOCIATED WITH LOWER HEALTH-RELATED QUALITY OF LIFE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. | X. P. Zhou |
| P-18 | THE ROLE OF ETHNICITY AND POLYCYSTIC OVARY SYNDROME ON PREGNANCY COMPLICATIONS. AN ANALYSIS OF A POPULATION DATABASE. | A. Badeghiesh |
| P-19 | DOES BODY MASS INDEX REALLY IMPACT THE OVARIAN RESPONSE IN FRESH ANTAGONIST CYCLES? | A. M. Abdelmagied |
| P-20 | NEWBORNS OF WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) HAVE HIGHER ANTI-MULLERIAN HORMONE (AMH) LEVELS: A SYSTEMATIC REVIEW AND META-ANALYSIS. | S. Zhou |
| P-21 | UTILITY OF THE INSULIN CURVE IN ADDITION TO OGTT IN DETECTING HYPERINSULINEMIA IN PATIENTS WITH PCOS. | E. Kravitz |
| P-22 | NECK CIRCUMFERENCE IS A GOOD PREDICTOR FOR METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. | C. Liu |
| P-23 | IMPACT OF POLYCYSTIC OVARY SYNDROME ON EARLY PREGNANCY LOSS RATES AMONG WOMEN UNDERGOING INTRARTERINE INSEMINATION. | P. B. Parker |
| P-24 | NECK CIRCUMFERENCE IS A GOOD PREDICTOR FOR HYPERURICEMIA IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. | L. Mu |
| P-25 | REDUCED OVARIAN RESPONSE TO FOLLICLE STIMULATING HORMONE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) COMPARED TO OVULATORY CONTROLS. | T. H. Harrison |
| P-26 | VALIDATION OF DIAGNOSTIC CRITERIA AND ANDROGEN SUPPLEMENTATION AS TREATMENT IN WOMEN WITH THE HYPOANDROGENIC PCOS-LIKE PHENOTYPE (H-PCOS). | N. Gleicher |
P-27 DOES OVARIAN MORPHOLOGY AFFECT THE REPRODUCTIVE OUTCOMES OF IN-VITRO MATURATION CYCLES IN POLYCYSTIC OVARY SYNDROME? S. Tannus

P-28 PCOS PATIENTS ARE TWICE AS LIKELY TO HAVE A PRE-RECEPTIVE ENDOMETRIAL RECEPTIVITY ASSAY COMPARED TO OTHER DIAGNOSES. A. Bader

PST-03 POSTER SESSION: ART LAB: EMBRYO CULTURE

P-29 PROSPECTIVE COMPARISON BETWEEN TWO COMMERCIAL SINGLE CULTURE MEDIA USING SIBLING DONOR OOCYTES COLLECTED FROM RANDOMIZED OVARIIES. C. Miret

P-30 EFFECT OF MICROINJECTION OF MESSENGER RNA OF PLCZ INTO ZYGOTE IN MOUSE EMBRYO DEVELOPMENT IN VITRO. S. Yoon

P-31 THE ADDITION OF ANTIOXIDANTS EVERY 12 HOURS TO THE CULTURE MEDIUM SIGNIFICANTLY INCREASES THE RATES OF TOTAL USEABLE AND EXPANDED BLASTOCYSTS IN RECIPIENT PATIENTS: A PROSPECTIVE RANDOMIZED CONTROL STUDY OF 553 SIBLING DONOR OOCYTES. I. Maldonado Rosas

P-32 COMPARISON OF GLOBAL, G-TL, AND NXC MEDIA FOR CONTINUOUS EMBRYO CULTURE IN A TIME-LAPSE INCUBATOR. V. Nanavaty

P-33 EFFECTS OF RECOMBINANT HUMAN ALBUMIN AS A PROTEIN SOURCE ON MOUSE EMBRYO DEVELOPMENT AND HUMAN BLASTOCYST EXTENDED CULTURE. H. J. Engelhorn

P-34 THE INTRODUCTION OF A GROUP CULTURE PROTOCOL IN DONOR OOCYTE-RECIPIENT CYCLES DID NOT INCREASE THE TOTAL USEABLE BLASTOCYST RATES: A RETROSPECTIVE STUDY. M. Gallardo

P-35 CONCO2 RANDOMIZED CONTROLLED TRIAL INTERIM UPDATE: EMBRYO CULTURE IN A CONTINUOUS CARBON DIOXIDE SETTING DOES NOT NEGATIVELY IMPACT BLASTOCYST FORMATION RATES. J. G. Kim

P-36 IMPROVED QUANTITATION OF LOW PEROXIDE VALUE IN HIGHLY REFINED OIL INTENDED FOR USE DURING EMBRYO CULTURE USING A COMMERCIALLY AVAILABLE METHOD. E. M. White

P-37 THE EXPRESSION OF PREGNANCY-ASSOCIATED PLASMA PROTEIN-A (PAPP-A) IN HUMAN BLASTOCOEEL FLUID-CONDITIONED MEDIA. S. K. Kavoussi

P-38 THE TIMING FROM OOCYTE PICK-UP TO DENUDATION MAKES THE DIFFERENCE IN EMBRYO CULTURE OUTCOME. M. Marti-Vilanova

P-39 A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL (RCT) COMPARING DAY 3 - FRESH EMBRYO TRANSFER CYCLES WITH FREEZE ALL CYCLES IN IVF-ICSI. R. Singh

P-40 THE EXPRESSION OF ALPHA-FETOPROTEIN IN BLASTOCOEEL FLUID-CONDITIONED MEDIA IN VITRO: A PROOF OF CONCEPT STUDY. S. K. Kavoussi

P-41 THE IMPACT OF USING GPS DISHES FOR OOCYTE PICK UP ON THE IN-VITRO EMBRYOLOGICAL PARAMETERS AND THE PGT-A RESULTS, A RANDOMIZED CONTROLLED TRIAL. A. Elshimy

P-42 A NOVEL ZONA PELLUCIDA (ZP)-FREE CULTURE SYSTEM FOR SEVERE CYTOPLASMIC FRAGMENTATION CASES: A PILOT STUDY USING 3PN EMBRYOS AND TIME-LAPSE CINEMATOGRAPHY. M. Sugishima

P-43 DOES CULTURE MEDIA PH VARY IN A DEFINED CARBON DIOXIDE SETTING WITHIN DIFFERENT BENCHTOP INCUBATOR MODELS. R. Ashraf

P-44 MOST EFFECTIVE INCUBATOR TO IMPROVE BLASTOCYST FORMATION RATE AND IMPLANTATION RATE TIMELAPSE BENCHTOP OR STANDARD BENCHTOP: A CASE REFERENT STUDY. N. J. Brahmmbhatt

PST-04 POSTER SESSION: ART LAB: OUTCOMES

P-45 ANALYSIS OF THE IVF LABORATORY KEY PERFORMANCE INDICATORS (KPIs) IN IVF PATIENTS WITH DIFFERENT OVULATION TRIGGER REGIMENS. S. C. Lee

P-46 CUMULATIVE CLINICAL PREGNANCY RATES PER OOCYTE RETRIEVAL AFTER IN VITRO FERTILIZATION. T. Tao

P-47 OUTCOMES OF SINGLE EUPLOID TRANSFERS BASED ON DIFFERENT “CUT-OFF” VALUES FOR PERCENTAGE OF EUPLOID CELLS IN THE BIOPSY SAMPLE, RESULTS FROM A SINGLE CENTER. J. L. Patrick

P-48 VITRIFICATION DOES NOT INCREASE ANEUPLOIDY OR CHROMOSOME BREAKAGE IN DONOR OOCYTE CYCLES. T. Schlenker

P-49 RESCUE-IVM AND THE TRANSFER OF A EUPLOID BLASTOCYST PROVIDED IMPROVED ODDS FOR PATIENTS WITH POOR PROGNOSIS TO CONCEIVE. Y. Yuan

P-50 SECONDARY SEX RATIO IN ASSISTED REPRODUCTIVE TECHNOLOGY PROGRAMS. M. Shishimorova

P-51 TIME-LAPSE VARIABILITY OF HUMAN EMBRYOS IS ASSOCIATED WITH IVF OUTCOME. D. Cvetkov

P-52 CLEAVAGE STAGE MORPHOLOGY IS NOT ASSOCIATED WITH THE IMPLANTATION
<table>
<thead>
<tr>
<th>Abstract ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-53</td>
<td>A SPERM SELECTION TECHNIQUE TO IMPROVE EMBRYO PLOIDY.</td>
<td>D. Keating</td>
</tr>
<tr>
<td>P-54</td>
<td>A FALSE START: CAN SINGLE PRONUCLEAR ZYGOTES GET BACK ON TRACK?</td>
<td>J. Shaw</td>
</tr>
<tr>
<td>P-55</td>
<td>DAY 6 BLASTOCYST TRANSFER FOR ALL WHEN ICSI IS PLANNED ON TUESDAY: IS IT A SAFE APPROACH?</td>
<td>S. Mnallah</td>
</tr>
<tr>
<td>P-56</td>
<td>LASER-ASSISTED HATCHING ON DAY 1 DEMONSTRATES EQUIVALENT EMBRYO YIELD, TIMING OF BLASTOCYST DEVELOPMENT AND EMBRYO EUPLOIDY RATES COMPARED WITH STANDARD DAY 3 ASSISTED HATCHING.</td>
<td>E. A. Dilday</td>
</tr>
<tr>
<td>P-57</td>
<td>CLINICAL OUTCOMES OF HUMAN OOCYTE IN VITRO MATURATION (IVM) FOLLOWING DIFFERENT IVM PROTOCOLS.</td>
<td>R. Kile</td>
</tr>
<tr>
<td>P-58</td>
<td>ARTIFICIAL OOCYTE ACTIVATION WITH CALCIUM IONOPHORE; IS IT SAFE?</td>
<td>I. Chabchoub</td>
</tr>
<tr>
<td>P-59</td>
<td>CORRELATION ANALYSIS OF THE EUPLIOD BLASTOCYST FORMATION FREQUENCY AND THE NUMBER OF FRESH DONATED MATURE OOCYTES RETRIEVED PER CYCLE OF ICSI-PGT-A TREATMENT USING CRYOPRESERVED EJACULATED SPERM.</td>
<td>Y. Han</td>
</tr>
<tr>
<td>P-60</td>
<td>DOES DURATION OF VITRIFICATION STORAGE AFFECT PREGNANCY OUTCOMES OF FROZEN THAWED EMBRYO TRANSFERS?</td>
<td>E. kadour-Peero</td>
</tr>
<tr>
<td>P-61</td>
<td>MEDIUM REFRESH USING SINGLE-STEP CULTURE MEDIUM: COMPARING DAY 3 OR DAY 4.</td>
<td>R. Holmes</td>
</tr>
<tr>
<td>P-62</td>
<td>PREDICTIVE CUMULATIVE LIVE-BIRTH RATE BASED ON FACTOR OF SURVIVAL RATE FOR SUBSEQUENT CYCLE IN UNDISTURBED EMBRYO CULTURE IN TIME-LAPSE INCUBATOR, DOES POOLING EFFECT THE LIVE BIRTH RATE IN TIME-LAPSE INCUBATOR?</td>
<td>A. Garg</td>
</tr>
<tr>
<td>P-63</td>
<td>ZONA PELLUCIDA DYSMORPHOLOGY IS ASSOCIATED WITH LOWER FERTILIZATION RATES IN ICSI.</td>
<td>W. Miyamoto</td>
</tr>
<tr>
<td>P-64</td>
<td>STUDY ON THE RELATIONSHIP BETWEEN THE ANGLE OF MII SPINDLE AND THE DIFFERENCE IN THE SIZE OF 2PN IN HUMAN ZYGOTE USING TIME-LAPSE SYSTEM.</td>
<td>S. Kim</td>
</tr>
<tr>
<td>P-65</td>
<td>DOES MICROFLUIDIC SPERM SORTING IMPROVE EMBRYO DEVELOPMENT AND EUPLOIDY RATES IN PATIENTS UNDERGOING ICSI?</td>
<td>A. Robles</td>
</tr>
<tr>
<td>P-66</td>
<td>FROM OOCYTE DENUDATION TO ICSI: HOW LONG CAN WE WAIT?</td>
<td>J. Jaldo-Garcia</td>
</tr>
<tr>
<td>P-67</td>
<td>PRE-VITRIFICATION BLASTOCYST MORPHOMETRY IS A WEAK PREDICTOR OF POST-TAW MORPHOMETRY AND IMPLANTATION POTENTIAL.</td>
<td>C. E. Bedient</td>
</tr>
<tr>
<td>P-68</td>
<td>BLASTOCYST FORMATION IS NOT AFFECTED BY FEMALE OBESITY: A MORPHOKINETIC STUDY.</td>
<td>P. Brandão</td>
</tr>
<tr>
<td>P-69</td>
<td>NON-INVASIVE QUALITY OF BLASTOCYSTS EVALUATED BASED ON TIMING OF COMPACTION AND FULL BLASTOCYST FORMATION BY TIME-LAPSE MONITORING.</td>
<td>Y. Harada</td>
</tr>
<tr>
<td>P-70</td>
<td>INFLUENCE OF TWO COMMERCIAL EMBRYO CULTURE MEDIA ON IN VITRO FERTILIZATION OUTCOMES.</td>
<td>G. Merdassi</td>
</tr>
<tr>
<td>P-71</td>
<td>QUALITY OF INNER CELL MASS OF EXPANDED BLASTOCYSTS EFFECTS ART OUTCOME MORE THAN TROPHECTODERM QUALITY.</td>
<td>S. Evans</td>
</tr>
<tr>
<td>P-72</td>
<td>THE UTILITY OF TEST-THAW ANALYSIS FOR PATIENTS WITH AZOOSPERMIA UNDERGOING SURGICAL SPERM RETRIEVAL.</td>
<td>M. Valovska</td>
</tr>
<tr>
<td>P-73</td>
<td>BLASTOCYST EUPLOIDY RATES ARE NOT AFFECTED BY INTRACYTOPLASMIC SPERM INJECTION (ICSI) VERSUS CONVENTIONAL INSEMINATION.</td>
<td>C. Wang</td>
</tr>
<tr>
<td>P-74</td>
<td>SPERM DNA FRAGMENTATION (SDF) LEVELS DOES NOT AFFECT OBSTETRICAL AND PERINATAL OUTCOMES IN OOCYTES DONATES CYCLES.</td>
<td>I. Hervas</td>
</tr>
<tr>
<td>P-75</td>
<td>A NOVEL APPROACH TO NATURAL FROZEN EMBRYO TRANSFERS (FET).</td>
<td>L. Ursilio</td>
</tr>
<tr>
<td>P-76</td>
<td>NEONATAL FOLLOW-UP OF BABY BORN DERIVED FROM A TWO PRONUCLEI PLUS ONE MICRO PN OOCYTE FOLLOWING INTRACYTOPLASMIC SPERM INJECTION.</td>
<td>T. Yoshimura</td>
</tr>
<tr>
<td>P-77</td>
<td>CORRELATION BETWEEN PROPORTION OF OOCYTE MATURATION IN AN IVF CYCLE AND SUBSEQUENT BLASTOCYST EUPLOIDY.</td>
<td>H. Silz</td>
</tr>
<tr>
<td>P-78</td>
<td>PLACENTA PREVIA IN IVF AND UNASSISTED PREGNANCIES – PERINATAL OUTCOMES AND PLACENTAL HISTOLOGY.</td>
<td>E. Barber</td>
</tr>
<tr>
<td>P-79</td>
<td>IN VITRO MATURATION, BLASTOCYST DEVELOPMENT AND CLINICAL OUTCOME OF HUMAN METAPHASE-I OOCYTES RETRIEVED FROM STIMULATED ICSI CYCLES.</td>
<td>M. W. Lao</td>
</tr>
<tr>
<td>P-80</td>
<td>THE SECRETOME OF THE EUPLOID EMBRYO IMPLANTATION.</td>
<td>E. G. Lo Turco</td>
</tr>
<tr>
<td>P-81</td>
<td>TRANSCRIPTIIONAL PROFILE OF STRESSED HUMAN EMBRYOS: STUDY OF EARLY-STAGE ARRESTED EMBRYOS.</td>
<td>M. Pérez-Sánchez</td>
</tr>
<tr>
<td>P-82</td>
<td>EVALUATION OF CLINICAL AND LABORATORY OUTCOMES BETWEEN TWO EMBRYO INCUBATOR SYSTEMS: CONVENTIONAL TRI-GAS VERSUS TIME-LAPSE.</td>
<td>B. Cunegatto</td>
</tr>
<tr>
<td>P-83</td>
<td>LASER-ASSISTED HATCHING ON DAY 1 OF EMBRYO CULTURE DEMONSTRATES EQUIVALENT ONGOING CLINICAL PREGNANCY RATES COMPARED TO EMBRYOS WITH STANDARD DAY 3 ASSISTED HATCHING.</td>
<td>E. A. Dilday</td>
</tr>
</tbody>
</table>
P-84 FIRST ONGOING THIRD TRIMESTER PREGNANCY FROM METAPHASE I (M1) OOCYTE CRYOPRESERVATION (CRYO) - M1 OOCYTE CRYO CAN RESULT IN USEABLE EMBRYOS AND PREGNANCY, BUT LESS FREQUENTLY THAN METAPHASE II (M2) OOCYTE CRYO. S. D. Cascante

P-85 SINGLE STEP OR SEQUENTIAL MEDIA IN EMBRYO CULTURE: OUTCOME IN DONOR OOCYTE CYCLES. K. D. Nayar

P-86 EFFECT OF MORPHOLOGICAL ABNORMALITIES OF PROTRUDING AND STRATIFIED ZONA PELLUCIDA ON FERTILIZATION RATE. R. Hirao

P-87 EFFECT OF X-CHROMOSOME COPY NUMBER ON BLASTULATION TIME IN EMBRYOS WITH SEX CHROMOSOME ANEUPLOIDIES. A. Korkidakis

P-88 A CASE REPORT SUGGESTS THAT NOVEL HETEROZYGOUS MUTATION OF ITGB3 GENE IS RESPONSIBLE TO PARTIAL OOCYTE MATURATION ARREST SYNDROME. E. Molinari

P-89 ARE THE NUMBER OF BLASTOMERES AT THE CLEAVAGE-STAGE ASSOCIATED WITH ONGOING PREGNANCY FOLLOWING SINGLE BLASTOCYST FROZEN EMBRYO TRANSFERS? A. Domney

P-90 SPERM MOTILITY CHANGE 18 HOURS POST-INSEMINATION IS NOT A USEFUL MEASURE FOR IN VITRO FERTILIZATION OUTCOME. N. Esfandiari

P-91 DOES THE MORPHOLOGICAL EVALUATION OF NUCLEAR AND CYTOPLASMIC MATURATION OF MII OOCYTES CORRELATE WITH ICSI OUTCOMES? M. Shioya

PST-05 POSTER SESSION: ART LAB: TECHNOLOGY

P-92 THE MECHANISM OF 1PN FORMATION AFTER IVF INCLUDING FEMALE AND MALE GENOMES. X. Wei

P-93 IMPROVING ERICA’S (EMBRYO RANKING INTELLIGENT CLASSIFICATION ASSISTANT) PERFORMANCE. SHOULD WE TRAIN AN AI TO REMAIN STATIC OR DYNAMIC, ADAPTING TO SPECIFIC CONDITIONS? A. Chavez-Badiola

P-94 A GENERALIZABLE MODEL FOR RANKING BLASTOCYST STAGE EMBRYOS USING DEEP LEARNING. K. E. Loewke

P-95 AN EXPEDITED AND SAFE OOCYTE DENUDATION SYSTEM BASED ON SOUNDWAVES IN A MICROFLUIDIC CHIP. P. Xie

P-96 CAN COMPUTER VISION ALGORITHMS NONINVASIVELY RECOGNIZE ANEUPLOIDY IN BLASTOCYSTS?: “PUMPING” APPEARS TO BE A STRONG PREDICTIVE FEATURE M. Meseguer

P-97 QUANTIFICATION OF AN AUTOMATIC ALGORITHM FOR BLASTOCYST SELECTION (KIDScore™ DS V3) ON REPRODUCTIVE OUTCOME IN DIFFERENT IN VITRO FERTILIZATION (IVF) TREATMENTS: A STRATIFIED ANALYSIS. L. Bori

P-98 NOVEL IN-LINE GAS FILTER DEMONSTRATES IMPROVED BLASTOCYST DEVELOPMENT AND EXTENDED SERVICE LIFE - A MULTI-CENTER STUDY. C. A. Alouf

P-99 IMPROVEMENT OF AN AUTOMATIC PRONUCLEAR NUMBER DETECTION SYSTEM BY INTRODUCTION OF NEW ANALYTICAL METHODS. H. Watanabe

P-100 ARTIFICIAL INTELLIGENCE IS MOVING CLOSER TO REPRODUCTIVE MEDICINE: PREDICTION OF BLASTULATION AND EMBRYO IMPLANTATION. L. Bori

P-101 EXPLORING AUTOMATION OF THE EMBRYO EVALUATION PROCESS BY USING NOVEL DEEP LEARNING-BASED METHODS. E. Paya

P-102 MACHINE LEARNING ALGORITHMS CAN PREDICT FUTURE BLASTOCYST DEVELOPMENT AND BLASTOCYST QUALITY BASED EMBRYOS CHARACTERISTICS ON DAY 1, 2 AND 3 WITH ACCURACY RESPECTFULLY OF 77% AND 69% BASED ON MORPHOLOGIC ASSESSMENT. C. Jacques

P-103 THE USE OF VOTING ENSEMBLES AND PATIENT CHARACTERISTICS TO IMPROVE THE ACCURACY OF DEEP NEURAL NETWORKS AS A NON-INVASIVE METHOD TO CLASSIFY EMBRYO PLOIDY STATUS. V. S. Jiang

P-104 NON-APOPTOTIC SPERM SELECTION BY MAGNETIC-ACTIVATED CELL SORTING (MACS) PROVEN SAFE FROM OBSTETRIC AND PERINATAL HEALTH STANDPOINT IN ICSI CYCLES WITH DONATED OOCYTES. M. Gil Julia

P-105 CULTURE MEDIA: ITS IMPACT ON EMBRYO DEVELOPMENT, ART OUTCOMES, AND THE IMPLEMENTATION OF MACHINE LEARNING (ML) MODELS FOR EMBRYO SELECTION. N. Zaninovic

P-106 PICTURE PERFECT?: DETERMINING THE CLINICAL UTILIZATION OF ARTIFICIAL INTELLIGENCE IN OOCYTE CRYOPRESERVATION. C. Peschansky

P-107 INVESTIGATION OF THE RELIABILITY OF AUTOMATIC ANNOTATION BY THE GERI TIME LAPSE INCUBATOR. J. Vandame

P-108 AN ARTIFICIAL INTELLIGENCE PROGRAM REVEALS THAT EUPLOID BLASTOCYSTS EXPAND FASTER THAN MOSAIC ANEUPLOID SUBGROUPS AND MOSAIC Duplications/Deletions USING A STANDARD ASSAY 10 HOURS AFTER BLASTOCYST FORMATION. R. Ghatnekar
P-109 DEVELOPMENT OF AN ARTIFICIAL INTELLIGENCE-BASED ASSESSMENT MODEL FOR PREDICTION OF PREGNANCY AND LIVE-BIRTH USING STATIC IMAGES CAPTURED BY OPTICAL LIGHT MICROSCOPY DURING IVF. T. Kohn

P-110 IDENTIFYING POTENTIAL SOURCES OF BIAS IN DEEP LEARNING MODELS FOR EMBRYO ASSESSMENT. K. E. Loewke

P-111 EUPOIDY RATE ACCORDING TO KIDSCORE SOFTWARE (EMBRYOSCOPE PLUS®) EVALUATION TOOL. B. Cunegatto

P-112 A NEW SIMPLIFIED METHOD FOR SPERM PREPARATION (E.SEP) WITHOUT CENTRIFUGATION: ICSI OUTCOME USING IN VITRO MATURED BOVINE AND HUMAN OOCYTES. P. Patrizio

P-113 COMPARISON OF ZYMOT™ MICROFLUIDIC SPERM SELECTION DEVICE (SSD) TO SIMPLE SWIM-UP (SSU) ON SPERM MOTILITY PARAMETERS AND MORPHOLOGY. S. T. Alexa

P-114 AN ARTIFICIAL NEURAL NETWORK IS CAPABLE OF ACCURATELY IDENTIFYING BLASTOCYSTS WITHIN THE CULTURE WELL. D. Gilboa

P-115 ADVANCED MORPHODYNAMICAL ANALYSIS OF EMBRYOS VERSUS AUTOMATIC MORPHOKINETIC ANNOTATIONS FOR OUTCOME PREDICTION; AN ARTIFICIAL NEURAL NETWORK ANALYSIS. E. Paya

P-116 CYTOPLASMIC MORPHOLOGICAL CHARACTERISTICS AFFECT 2PN DETECTION IN AN AUTOMATIC PRONUCLEAR NUMBER DETECTION SYSTEM USING DEEP LEARNING TECHNOLOGY. F. Kondo

P-117 MATURITY OF OOCYTE COHORT IMPACTS BLASTOCYST DEVELOPMENT AS CLASSIFIED BY ARTIFICIAL INTELLIGENCE (AI). C. R. Sacha

P-118 ANALYSIS OF MORPHOKINETICS PARAMETERS TO CORRELATE WITH EUPOIDY AND CLINICAL PREGNANCY ACCORDING TO MATERNAL AGE SUBGROUPS. C. Jacobs

P-119 ARTIFICIAL INTELLIGENCE ASSISTANCE FOR THE QUALITY ASSESSMENT OF EMBRYO VITRIFICATION, WARMING AND TRANSFERS IN THE IVF LABORATORY. I. Dimitriadis

P-120 A STUDY ON THE NECESSITY OF TIME LAPSE MONITORING FOR IN VITRO MATURATION IN COMBINED PROCEDURE AT THE TIMING OF OVARIAN TISSUE CRYOPRESERVATION. H. Shirasawa

P-121 RELATIONSHIP BETWEEN LENGTH OF GONADOTROPIN STIMULATION FOR IN VITRO FERTILIZATION AND EMBRYONIC EUPOIDY OF MATERNAL ORIGIN. R. K. Power

P-122 EMBRYO CELL-FREE DNA HIGHLY REPRESENTS THE CHROMOSOMAL CONSTITUTION OF BOTH THE INNER CELL MASS AND THE TROPHECTODERM OF HUMAN BLASTOCYSTS. L. Navarro-Sánchez

P-123 OBSTETRIC AND PERINATAL OUTCOMES IN SINGLETON PREGNANCIES RESULTING FROM MEDICATED VERSUS NATURAL CYCLE FROZEN EMBRYO TRANSFER: A SYSTEMATIC REVIEW AND META-ANALYSIS. F. Baird

P-124 OBSTETRIC AND PERINATAL OUTCOMES OF NATURAL CYCLE VS. ARTIFICIAL CYCLE FROZEN EMBRYO TRANSFERS A. T. Gruber

P-125 THE IMPACT OF EGG RETRIEVAL ASPIRATION PUMP PRESSURE ON IVF OUTCOMES. R. G. Sprague

P-126 NATURAL PROLIFERATIVE PHASE FROZEN EMBRYO TRANSFERS (NPP-FET) – A NEW APPROACH THAT FACILITATES SCHEDULING WITHOUT HINDERING PREGNANCY OUTCOMES. C. Godinho

P-127 VALIDATION OF A NEW, ULTRA-FAST BLASTOCYST WARMING TECHNIQUE REDUCES WARMING TIMES TO 1 MIN AND YIELDS SIMILAR SURVIVAL AND RE-EXPANSION COMPARED TO BLASTOCYSTS WARMED USING A STANDARD METHOD. J. N. Manns

P-128 DOES EXCESS SPERM CAUSE CONTAMINATION IN PGT-A AFTER CONVENTIONAL INSEMINATION? N. D. Yoder

P-129 PRONUCLEAR NUMERATION SHOULD NOT BE THE ONLY METHOD TO DETERMINE ABNORMAL FERTILIZATION IN ORDER TO ACCOUNT FOR ALL EUPOID EMBRYOS. L. Henry

P-130 DOES UTERINE POSITION AT TIME OF EMBRYO TRANSFER IMPACT PREGNANCY OUTCOMES? H. Pearson

P-131 MITOCHONDRIAL DNA CONTENT BEFORE VITRIFICATION (Mitoscore®) IS NOT A RELIABLE MARKER OF MITOCHONDRIAL MASS AND ACTIVITY IN THE HUMAN BLASTOCYST: A CONFOCAL AND ELECTRON MICROSCOPY APPROACH. M. Pérez-Sánchez

P-132 A TECHNIQUE TO ENHANCE THE NUMBER OF EMBRYOS FOR THE DESIRED GENDER. S. Cheung
**P-133** IMPACT OF OIL VISCOSITY ON TEMPERATURE, pH, OSMOLALITY, AND EMBRYO CULTURE. E. Mestres

**P-134** ADDITION OF RAPAMYCN AND YOUNG GRANULOSA CELLS TO IMPROVE IN VITRO OOCYTE MATURATION AND EUPLOIDY RATES IN OLDER REPRODUCTIVE AGE WOMEN: A PROSPECTIVE RANDOMIZED STUDY. M. Esbert

**P-135** MICROFLUIDIC SPERM SEPARATION DEVICE (MSSD) AND DENSITY GRADIENT CENTRIFUGATION (DGC): COMPARISON OF IMPROVEMENTS OF OUTCOMES USING PAIRED COMPARISONS. H. Lee

**P-136** IMPACT OF SUPEROVULATION AND IN VITRO FERTILIZATION ON LINE 1 COPY NUMBER AND TELOMERE LENGTH IN C57BL/6J MICE BLASTOCYSTS. T. S. Berteli

**P-137** A MACHINE LEARNING ALGORITHM CAN OPTIMIZE THE DAY OF TRIGGER TO IMPROVE IN VITRO FERTILIZATION OUTCOMES. E. Hariton

**P-138** IMPACT OF EMBRYO MANIPULATION TECHNIQUES ON THE INCIDENCE OF MONOZYGOTIC TWINNING IN EGG DONATION CYCLES. L. A. Van Os-Galdos

**P-139** REDUCING IVF CYCLE MONITORING TO MAINTAIN SOCIAL DISTANCING PRACTICES DURING THE COVID-19 PANDEMIC. S. Kanji

**P-140** PROLONGED EXPOSURE OF HUMAN BLASTOCYSTS TO HYALURONAN-ENRICHED TRANSFER MEDIA HAS NO EFFECT ON PERI-IMPLANTATION STAGE EMBRYO DEVELOPMENT DURING IN VITRO CULTURE. D. Logsdon

**P-141** THE ADDITION OF ANTIOXIDANTS EVERY 12 HOUR TO THE CULTURE MEDIUM SIGNIFICANTLY INCREASES THE RATE OF TOTAL USABLE AND EXPANDED BLASTOCYSTS IN PATIENTS WITH ADVANCED MATERNAL AGE: A PROSPECTIVE STUDY OF 1520 SIBLING HUMAN OOCYTES. I. Maldonado Rosas

**P-142** THE ADJUSTMENT OF OXIDATION REDUCTION POTENTIAL (ORP) LEVELS IN CULTURE MEDIA TO THE OVERALL LEVELS OF FOLLICULAR FLUID PRODUCES SIGNIFICANTLY HIGHER EMBRYO PLOIDY RATES IN PATIENTS: A PROSPECTIVE RANDOMIZED STUDY OF SIBLING OOCYTES. I. Maldonado Rosas

**P-143** INTER-CYCLE CONSISTENCY OF THE WINDOW OF IMPLANTATION (WOI) IN A SUB-FERTILE PATIENT POPULATION. C. Weier

**P-144** MATERNAL BODY MASS INDEX DOES NOT IMPACT THE DURATION OF ESTRADIOL (E2) EXPOSURE DURING PREPARATION FOR FROZEN BLASTOCYST TRANSFER. E. P. New

**P-145** VALIDATION OF A NON-INVASIVE METABOLOMICS METHOD TO PREDICT EMBRYO IMPLANTATION. S. Cabello-Pinedo

**P-146** ASSESSMENT OF GENETIC PLOIDY OF TRIPRONUCLEAR EMBRYOS IDENTIFIES FEW DIPLOID BLASTOCYSTS. N. D. Yoder

**P-147** INCREASED MITOCHONDRIAL DNA CONTENT IS ASSOCIATED WITH DELAYED EMBRYO DEVELOPMENT AND ANEUPLOIDY. C. Hur

**P-148** EFFECT OF EXOGENOUS LUTEINIZING HORMONE (LH) SUPPLEMENTATION IN LONG-ACTING GONADOTROPIN-RELEASING HORMONE AGONIST (GNRHA) ASSISTED REPRODUCTIVE TECHNOLOGY (ART) CYCLES: A RETROSPECTIVE COHORT STUDY. C. Huang

**P-149** MACHINE LEARNING-BASED ASSESSMENT MODEL AS A PREDICTIVE TOOL FOR BLASTOCYST GRADING UTILIZING MORPHOKINETIC PARAMETERS PRIOR TO THE THIRD CLEAVAGE DIVISION. S. Davies

**P-150** AN INTERPRETABLE MACHINE LEARNING MODEL FOR INDIVIDUALIZED PROTOCOL SELECTION AND GONADOTROPIN DOSE SELECTION DURING OVARIAN STIMULATION. K. E. Loewke

**P-151** EMBRYOLOGISTS ARE MORE LIKELY TO CHOOSE EUPLOID EMBRYOS FOR TRANSFER: A PROSPECTIVE BLINDED NON-SELECTION TRIAL. A. M. Klimczak

**P-152** CHARACTERIZATION OF THE US INFERTILITY PATIENT JOURNEY: EVALUATION OF REAL-WORLD DATA FROM US ASSISTED REPRODUCTIVE TECHNOLOGY (ART) CENTERS. P. W. Heiser

**P-153** PLATELET-RICH PLASMA INCREASES HIF1α AND HIF2α IN ENDOMETRIUM AFFECTING LIVE BIRTH RATES IN MURINE ASHERMAN’S SYNDROME MODEL. M. Kim

**P-154** EFFECTS OF EMBRYO RETENTION DURING EMBRYO TRANSFER ON IVF OUTCOMES. E. kadour-Peero

**P-155** PREDICTING WHICH BLASTOCYSTS WILL DEVELOP INTO FETUSES: TIME INTERVAL FROM MORULAE TO BLASTOCYSTS IS A NOVEL AND USEFUL INDICATOR FOR SUCCESSFUL PREGNANCY. N. Morishita

**P-156** SALIVARY HORMONE AS A POTENTIAL MONITORING TOOL TO OVARIAN RESPONSE IN IVF CYCLES. D. M. Chong

**P-157** THE MORPHOLOGY OF MOSAICISM: CHARACTERIZING LOW- AND HIGH-LEVEL MOSAIC EMBRYOS COMPARED TO EUPLOID EMBRYOS. D. Aharon
P-158  MOUSE EMBRYO ASSAY (MEA): ITS NOT WHAT YOU DO, ITS THE WAY THAT YOU DO IT!  P. Vang

P-159  DYDROGESTERONE AS AN ALTERNATIVE TO SUPPRESS LH SURGE IN ART CYCLES.  M. M. Souza

P-160  ASSISTED HATCHING MAY IMPAIR THE OUTCOMES OF SINGLE FROZEN BLASTOCYST TRANSFER IN GOOD PROGNOSIS PATIENTS.  C. T. Bach

P-161  WHAT IS THE DEVELOPMENTAL POTENTIAL OF MATURE OOCYTES DERIVED FROM RESCUE IN-VITRO MATURATION (RIVM)?  A. Kuperman Shani

P-162  HIGH CONCORDANCE BETWEEN EMBRYO CELL-FREE DNA AND TROPHECTODERM BIOPSIES AFTER 8 OR 24 HOURS OF CULTURE OF VITRIFIED-THAWED BLASTOCYSTS.  G. Ardestani

P-163  ORAL DIAZEPAM AS A UTERINE RELAXANT: DOES IT IMPROVE TRANSFER OUTCOMES?  S. Kalluru

P-164  DOES PGT-A SHORTEN TIME TO LIVE BIRTH? THE USE OF PROPENSITY SCORE MATCHING TO COMPARE PGT-A VERSUS NON-PGT-A PATIENTS Y. Eliner

P-165  PRECOMPACTION MOUSE EMBRYOS SHOW METABOLIC PLASTICITY BY UPREGULATING GLUT1 EXPRESSION UNDER ANOXIC CONDITIONS.  N. Kuscu

P-166  BLASTOCYST “PUMPING” IS A DETRIMENTAL FEATURE PREDICTING IMPLANTATION FAILURE: HIGHLY ACCURATE ASSESSMENT BY COMPUTER VISION ANALYSIS OF TIME-LAPSE VIDEOS.  D. Gilboa

P-167  IS IN VIVO BETTER THAN IN VITRO? A COMPARISON OF SIBLING EMBRYO DEVELOPMENT AND PREGNANCY RATES THROUGH INVOCELL AND CONVENTIONAL IVF T. Kim

P-168  DIFFERENTIAL EFFECT OF A NOVEL SINGLE-STEP CULTURE MEDIUM ON EMBRYO DEVELOPMENT IN WOMEN OF DIFFERING AGES.  R. Holmes

P-169  OBESITY IS ASSOCIATED WITH REDUCED PEAK SERUM ESTRADIOL CONCENTRATION IN PROGRAMMED HORMONE REPLACEMENT FROZEN EMBRYO TRANSFER CYCLES.  E. P. New

P-170  WHAT IS THE RELATIONSHIP BETWEEN THE NUMBER OF OOCYTES AND LIVE BIRTH RATES FOLLOWING IN VITRO FERTILIZATION? A SYSTEMATIC REVIEW WITH META-ANALYSIS N. Semonade

P-171  THE RELATIONSHIP BETWEEN SERUM ESTROGEN (E2) LEVELS AND OUTCOMES OF HORMONE REPLACEMENT THERAPY-FROZEN EMBRYO TRANSFER (HRT-FET).  C. Huang

P-172  REMOVAL OF EXCESSIVE TROPHECTODERM CELLS FOR PGT-A ADVERSELY IMPACTS FET OUTCOMES.  M. G. Katz-Jaffe

P-173  THE ASSOCIATION BETWEEN OVULAR TIME TYPE AND PREGNANCY OUTCOME AMONG PATIENTS UNDERGOING INTRARUTINE INSEMINATION.  N. Vyas

P-174  COMPARISON OF ORAL DYDROGESTERONE WITH A MICRONIZED VAGINAL PROGESTERONE IN FRESH EMBRYO TRANSFER IN IVF ± ICSI.  M. Cessot

P-175  COMPARISON OF FROZEN EMBRYO TRANSFERS (FET) FOR INTRAVAGINAL CULTURE (IVC) AND TRADITIONAL IN VITRO FERTILIZATION (IVF).  A. R. Anderson

P-176  AUTOMATIC EMBRYO CLASSIFICATION ALGORITHM APPLIED ON CLEAVAGE STAGE FOR BLASTULATION, ANEUPLOIDY AND IMPLANTATION PREDICTION.  M. Meseguer

P-177  MITOCHONDRIAL CONTENT IN EUPOID BLASTOCYST IS ASSOCIATED WITH BLASTOCYST’S DAY OF DEVELOPMENT.  M. C. Delpiccolo

P-178  THE MORPHOLOGICAL DYNAMICS OF BLASTOCYSTS VITRIFICATION IN EQUILIBRIUM SOLUTION: CLINICAL OUTCOMES AND INFLUENCING FACTORS.  X. Tong

P-179  EFFECT OF ASPIRATION WITH POLICRESULEN COAGULATION OF ISTHMOCELE ON IVF OUTCOME IN INFERTILE PATIENTS UNDERGOING IVF TREATMENT.  C. Kim

P-180  DUO INTRAVAGINAL CULTURE (IVC) PROVIDES A POTENTIALLY ADVANTAGEOUS SECOND SOURCE OF EMBRYOS FOR SAME-SEX FEMALE COUPLES.  P. Uzelac

P-181  TO TEST OR NOT TO TEST: ASSESSING PGT-A OUTCOMES WITH INCREASING MATERNAL AGE.  D. Keating

P-182  DOES PROLONGED ESTRACE ADMINISTRATION EFFECT ON PREGNANCY OUTCOME IN PROGRAMMED FROZEN EMBRYO TRANSFER CYCLE?  T. Kim

P-183  PERINATAL OUTCOMES IN CHILDREN BORN AFTER PREIMPLANTATION GENETIC TESTING-FOR ANEUPLOIDY (PGT-A): DOES THE TECHNIQUE HAVE AN EFFECT?  P. Muñoz Espert

P-184  ASSOCIATION BETWEEN MITOCHONDRIAL DNA (mtDNA) CONTENT AND LIVE BIRTH RATE (LBR).  I. O. Morales

P-185  IDENTIFICATION OF THE OPTIMAL PUNCTURE POSITION BY A REAL-TIME IMAGE ANALYSIS CAN REDUCE OOCYTE DEGENERATION IN PIEZO-ICSI.  T. Morimoto
P-186 Association between progesterone level on human chronic gonadotropin (HCG) trigger day and clinical outcomes of cleavage-stage embryos or blastocysts transfer in assisted reproduction technology (ART) cycles. C. Huang

P-187 Comparison of microfluidic sperm sorting (MFSS) versus physiological intracytoplasmic sperm injection (ICSI) versus density gradient in high DNA fragmentation index sperm samples. K. D. Nayar

P-188 Impact of state IVF insurance mandates on embryo transfer practices in the United States. B. J. Peipert

P-189 Enhancing the accuracy of semen analysis with artificial intelligence-based technology. A. Parrella

P-190 Comparison of two vaginal progesterone formulations, tablet (Lutinos 100mg) and gel (Crinone 8%), for luteal phase support in modified natural cycle frozen-thawed single blastocyst transfers. I. N. Balin Duzguner

P-191 Interrupted or uninterrupted embryo culture: a new habit of embryo assessment. H. J. Sheth

P-192 RCT comparing oral dydrogesterone with micronised vaginal progesterone for luteal phase support in fresh IVF-ICSI cycles. A. Jindal

P-193 Mitochondrial DNA replication after blastocyst vitrification: a heroic act of survival or an alert for the future? M. Pérez-Sánchez

P-194 Consistency evaluation regarding tubal patency diagnosis among delayed films at 4h, 6h and 24h after hysterosalpingography with ethiodized poppy-seed oil. W. Xu

P-195 Differences in ICSI utilization rates among state insurance mandates compared with non-mandated states for third party coverage of ART. P. Zagadailov

P-196 Fresh, frozen embryo transfers and ovulation induction cycles: the importance of birth percentile and immediate neonatal outcomes attention. M. B. de Barth

P-197 Experience of a fertility center in the initial application of an embryo ranking intelligent classification algorithm assistant (ERICA). M. Pérez-Vargas

P-198 Use of InvoCell intravaginal embryo culture system for five days of incubation: a prospective study of safety and tolerability. K. R. Hammond

P-199 Hospital oocyte retrieval- a safe option for the medically complex patient. M. Humphreys

P-200 High insemination concentration versus ICSI in sibling oocytes for non male factor couples undergoing first IVF cycle. C. Chatterjee

P-201 RCT to study the effect of vaginal sildenafil in improving ART outcome in women with recurrent implantation failure undergoing IVF-ICSI cycles. M. J. Singh

P-202 Gonadotropin-releasing hormone agonist (GnRH-A) trigger: will it work with a levonorgestrel (LNG) intrauterine device (IUD) in situ? J. Shaw

P-203 Comparison of laser and non laser blastocyst biopsy methods. A. R. Anderson

P-204 The correlation between obesity and the pregnancy outcomes in fresh embryo transfer cycle. R. Huang

P-205 Investigation of pathogenic variants of BUB1 and BUBR1 genes in the aborted aneuploid fetuses. R. Gorji

P-206 Novel approach to developing technician benchmarks in the contemporary embryology laboratory. T. L. Adams

P-207 Should we use ejaculated sperm or testicular sperm on cryptozoospermia patients. T. A. Vu

P-208 Frozen transfer of single blastocyst embryos and the “crumbling snowball” fragmentation effect. A. S. Tillery

P-209 A prospective cohort study to develop a treatment algorithm for controlled ovarian stimulation to select a starting dose of recombinant follicle stimulating hormone based on patient characteristics and ovarian response (FAME study). C. Choo

P-210 Pain relief with transvaginal oocyte retrieval (TVOR) without general or regional anesthesia: a systematic review. M. Jain

P-211 Characteristics and outcomes of patients undergoing endometrial receptivity analysis (ERA) in a private NYC fertility clinic. Y. Qu
P-212 FINE-TUNING SPEED AND TIME OF CENTRIFUGATION FOR SPERM WASH PROCESS IN MALE FACTOR. S. Chaparro

P-213 IMPROVED BLASTOCYST FORMATION WITH REDUCED EMBRYO-EVALUATION TIME ON POOR-PROGNOSIS PATIENTS. T. A. Vu

P-214 ESTRADIOL VALUES DURING EMBRYO TRANSFER AND CLINICAL OUTCOMES OF LETROZOLE CYCLES. Y. Takahashi

P-215 INFLUENCE OF SPERM PARAMETERS ON INCIDENCE OF PREGNANCY BY INTRAUTERINE INSEMINATION. C. Chatterjee

P-216 FIRST LIVE BIRTHS AFTER APPLICATION OF A READY-TO-USE IONOMYCIN IN CASES OF FAILED ARTIFICIAL OOCYTE ACTIVATION (AOA) USING CALCMYCIN. T. Ebner

P-217 LOW COST DELIVERANCE OF IVF - A BETTER APPROACH IN THE MANAGEMENT OF HIGH RESPONSE IN STIMULATED IUI CYCLES. C. Chatterjee

PST-07 POSTER SESSION: CRYOPRESERVATION

P-218 OOCYTE SURVIVAL AFTER VITRIFICATION USING SUPER-COOLED SLUSH NITROGEN IS SIMILAR TO SURVIVAL AFTER VITRIFICATION WITH CONVENTIONAL LIQUID NITROGEN: A RANDOMIZED CONTROLLED TRIAL. B. M. Hanson

P-219 EGG DONATION: IS IT INDISTINCT TO USE FRESH OR THAWED OOCYTES? R. S. Iaizzo

P-220 VALIDATION OF AN OOCYTE VITRIFICATION USING DAVITRI, A NOVEL AUTOMATED MICROFLUIDICS DEVICE. T. Martin-Villalba

PST-08 POSTER SESSION: ENDOMETRIOSIS

P-221 GSDMD-MEDIATED PYROPTOSIS IN MACROPHAGES IS INVOLVED IN THE PATHOGENESIS OF ENDOMETRIOSIS. Y. Xiang

P-222 REAL-WORLD EFFECTIVENESS OF ELAGOLIX IN IMPROVING ENDOMETRIOSIS QUALITY OF LIFE: 3-MONTH AND 6-MONTH INTERIM RESULTS FROM THE ELAGOLIX LONGITUDINAL OUTCOMES (LOTUS) PROSPECTIVE COHORT STUDY. S. J. Estes

P-223 THE ROLE OF CXCR2 AND ITS LIGANDS IN ATTACHMENT, MIGRATION, AND INVASION OF MOUSE ENDOMETRIOSIS CELLS. K. R. Peterson

P-224 HYALURONIC ACID PATHWAY EXPRESSION IN PAIRED EUTOPIC ENDOMETRIAL AND ENDOMETRIOMA CELLS. K. M. Goldrick

P-225 REAL-WORLD EVIDENCE OF STAGE ASSOCIATED ENDOMETRIOSIS-INDUCED OVARIAN FAILURE. K. Hunter Cohn

P-226 RECURRENCE, RE-OPERATION, AND PREGNANCY RATES AFTER SURGICALLY TREATED OVARIAN ENDOMETRIOMA IN A SINGLE INSTITUTION: LONG-TERM FOLLOW UP OF 756 WOMEN. S. Lee

P-227 SINGLE CELL ANALYSIS REVEALS HETEROGENEITY IN THE DISEASE RELEVANT CELL TYPES OF ADENOMYOSIS. S. Yildiz

P-228 EFFECT OF ENDOMETRIOSIS STAGE ON EMBRYO CHROMOSOMAL STATUS. P. Hernández-Vargas

P-229 MEASUREMENT OF INTRAUTERINE pH IS QUITE USEFUL AS AN AUXILIARY DIAGNOSIS AND FOLLOW-UP METHOD FOR CHRONIC ENDOMETRITIS. T. Endo

P-230 A DISCRETE CHOICE EXPERIMENT STUDY OF PHYSICIANS’ PREFERENCES FOR TREATMENTS FOR ENDOMETRIOSIS-ASSOCIATED PAIN. S. J. Estes

P-231 ENDOMETRIOSIS ASSOCIATED WITH A LOWERED CUMULATIVE LIVE BIRTH RATE IN IVF BY COMPROMISING THE QUANTITY AND QUALITY OF EMBRYOS. L. Zhou

P-232 EXPLORING NON-SURGICAL PREDICTORS OF ENDOMETRIOSIS DISEASE AND SEVERITY. E. N. Sadecki

P-233 INCREASED SUMOYLATION OF TCF21 IMPROVES ITS STABILITY AND FUNCTION IN HUMAN ENDOMETRIOTIC STROMAL CELLS. Q. Xue

P-234 IMPACT OF SURGERY ON OVARIAN RESERVE IN PATIENTS WITH ENDOMETRIOMA AMONG INFERTILE WOMEN. F. Rahman

P-235 IS THE USE OF A NON INVASIVE MOBILE APPLICATION AN EFFECTIVE WAY TO SCREEN WOMEN FOR ENDOMETRIOSIS DURING THE COVID-19 PANDEMIC? J. M. Jackman

P-236 AVERAGE TIME TO CONCEIVE FOLLOWING LAPAROSCOPIC TREATMENT OF ENDOMETRIOSIS IN PATIENTS UNDERGOING IVF. S. Agarwal

P-237 IDENTIFYING ANATOMICAL REGIONS ASSOCIATED WITH ENDOMETRIOSIS PAIN USING NEIGHBOR-JOINING CLUSTERING. A. C. Kiser

P-238 HYALURONIC ACID PATHWAY EXPRESSION IN ESTROGEN-PROGESTERONE TREATMENT AND PROGESTERONE ONLY TREATMENT OF ENDOMETRIOSIS. K. M. Goldrick

P-239 ADENOMYOSIS BUT NOT ENDOMETRIOSIS IMPACTS ADVERSELY ON CUMULATIVE LIVE BIRTH BY ART. M. Chen
POSTER PRESENTATIONS AND ABSTRACTS

P-240 THE ROLE OF LAPAROSCOPIC SURGERY VS MEDICATION IN IMPROVING FERTILITY IN PATIENTS WITH SUSPECTED ENDOMETRIOSIS. J. M. Jackman

P-241 ASSESSMENT OF TESTICULAR SPERM EXTRACTION (TESE) AND INTRACYTOPLASMIC SPERM INJECTION (ICSI) IN COUPLES WITH POST CHEMOTHERAPY NON-OBSTURATIVE AZOOSPERMIA (NOA). T. Morimoto

P-242 HOW MANY EGGS DO I NEED? A COUNSELING TOOL FOR OOCYTE CRYOPRESERVATION (OC) BASED ON REAL-WORLD DATA C. M. Parra

P-243 FERTILITY PRESERVATION BY SPERM BANKING BEFORE GONADOTOXIC TREATMENT: 26 YEARS OF EXPERIENCE. P. Ventruba

P-244 EGG FREEZING UNSCRAMBLED: AUTOLOGOUS OOCYTE (AO) THAW OUTCOMES FROM OVER 500 PATIENTS (PTS) AT A LARGE ACADEMIC FERTILITY CENTER (FC). S. D. Cascante

P-245 FREEZE NOW, SAVE LATER: A SART DATA COST-EFFECTIVENESS ANALYSIS OF PLANNED OOCYTE CRYOPRESERVATION CONSIDERING IDEAL FAMILY SIZE. J. B. Bakkensen

P-246 FERTILITY INTENTION, COUNSELING AND TREATMENT IN FEMALE CANCER SURVIVORS. M. Alzamora

P-247 THE IMPACT OF SULPHASALAZINE-BASED TREATMENT ON SEMEN QUALITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. R. Finelli

P-248 COMPLETE PURGING OF EWING SARCOMA FROM HUMAN OVARIAN CORTEX TISSUE FRAGMENTS BY INHIBITING THE mTOR PATHWAY WITH EVEROLIMUS. L. L. Eijkenboom

P-249 FERTILITY PRESERVATION COUNSELING AND FAMILY PLANNING PRIOR TO AND DURING THE COVID-19 PANDEMIC. J. Chae-Kim

P-250 NEONATAL OVARIAN RESERVE FOLLOWING CHEMOTHERAPY EXPOSURE, EX VIVO MURINE MODEL. M. C. Ozcan

P-251 FERTILITY PRESERVATION (FP) IN THE MEDICALLY COMPLEX: A PROOF-OF-CONCEPT MODEL FOR OOCYTE RETRIEVAL REMOTE FROM THE EMBRYOLOGY LABORATORY. E. Trawick

P-252 THE UNINTENDED CONSEQUENCE OF MEDICAL TRAINING: DELAYED CHILDBEARING. A SURVEY OF REPRODUCTIVE GOALS AND FERTILITY KNOWLEDGE IN MEDICAL RESIDENTS M. L. Bonus

P-253 CHARACTERISTICS OF FOLLICULAR FLUID IN THE TALES RANDOMIZED CONTROLLED TRIAL. A. Wang

P-254 SEMEN PARAMETERS IN TESTICULAR CANCER PATIENTS BEFORE ORCHIECTOMY. R. R. Badia

P-255 DEVELOPMENT, USER-CENTERED DESIGN, AND IMPLEMENTATION MAPPING OF CRISP, AN ONLINE CANCER-RELATED INFERTILITY RISK TOOL FOR FEMALE CANCER SURVIVORS. L. Nerb

P-256 ONCOLOGIC FERTILITY PRESERVATION: PREDICTORS OF PATIENT TREATMENT CHOICE. D. W. Spielman

P-257 DOES OOCYTE VITRIFICATION-WARMING IMPACT BLASTOCYST ANEUPLOIDY RATES? M. Oliva

P-258 AUTOLOGOUS CRYOPRESERVED OVARIAN TISSUE TRANSPLANTATION (ACOTT): AN UPDATE FROM OUR PREVIOUS META-ANALYTICAL DATASET AS OF MARCH 2021. F. Pacheco

P-259 NOVEL CASE OF TRANSVAGINAL OOCYTE RETRIEVAL FOLLOWING OVARIAN TRANSPosition AND REVERSAL IN A PATIENT WITH RECURRENT RECTAL CANCER. T. Luu

P-260 BARRIERS TO FERTILITY PRESERVATION IN REPRODUCTIVE AGE BREAST CANCER PATIENTS. M. Sauerbrun

P-261 LOCKDOWN UPTICK: DID THE SARS-COV-2 PANDEMIC GENERATE AN INCREASE IN PLANNED OOCYTE CRYOPRESERVATION (POC)? E. M. Weidenbaum

P-262 PLANNED OOCYTE CRYOPRESERVATION (POC) AND THE BLACK OBSTETRICAL GYNECOLOGIST (BOG): UTILIZATION AND PERSPECTIVES. A. M. Wiltshire

P-263 WHO IS FREEZING EGGS, Y’ALL? DESCRIPTIVE CHARACTERISTICS OF WOMEN UNDERGOING OOCYTE CRYOPRESERVATION AT TWO URBAN FERTILITY CLINICS IN THE SOUTH, WITH A FOCUS ON RACE/ETHNICITY Q. S. Katler

P-264 TRENDS IN ELECTIVE EGG FREEZING BEFORE AND AFTER THE COVID-19 PANDEMIC. A. E. Martini

P-265 SPERM CRYOPRESERVATION IN MALE CANCER PATIENTS: UTILIZATION AND SPECIMEN QUALITY. J. Garcia de Paredes

P-266 CRYOPRESERVED SEMINAL SAMPLES FROM PATIENTS WITH ACUTE COVID-19 HAVE THE WORST POST-THAW QUALITY WHEN COMPARED TO OTHER ANDROLOGICAL DISEASES. J. R. Paritz

P-267 MEDICAL MANAGEMENT OF UTERINE ARTERIOVENOUS MALFORMATIONS. R. M. Habte

P-268 YOUNG WOMEN DIAGNOSED WITH DISTAL CANCER SHOW TELOMERE ALTERATIONS IN THE OVARY. L. Chico-Sordo

P-269 THE SUCCESSFUL IMPLEMENTATION OF DOUBLE STIMULATION PROTOCOL IN FRAGILE X PREMUTATION: A CASE REPORT. A. S. Garneau
P-270 DETERMINATION OF MELATONIN CONCENTRATION IN SPERM CRYOPRESERVATION BY SLOW FREEZING METHOD. L. N. Chiba

P-271 INTERVENTION TO INCREASE FERTILITY PRESERVATION AWARENESS. K. Schmiech

PST-10 POSTER SESSION: GENETIC COUNSELING

P-272 INFERTILITY ETIOLOGY IMPACTS SUCCESS WITH EUPLOID BLASTOCYST TRANSFER. R. Swihart

P-273 ASSESSMENT OF PROVIDERS’ EXPERIENCES TO FACILITATE INFORMED DECISION-MAKING ABOUT PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) AMONG PATIENTS PURSING IN VITRO FERTILIZATION (IVF). N. Mathew

PST-11 POSTER SESSION: GENETICS

P-274 ACCURATE GENOMIC PREDICTION OF MOSAICISM THROUGH CELL DIVISION ORIGIN OF ANEUPLOIDY ANALYSIS IN THE PREIMPLANTATION EMBRYO. D. Marin

P-275 NON-INVASIVE PREIMPLANTATION GENETIC TESTING (NIPGT) FOR ANEUPLOIDY AND STRUCTURAL REARRANGEMENTS USING NEXT GENERATION SEQUENCING (NGS) ON SPENT CULTURE MEDIA (SCM). D. Christopikou

P-277 EFFECT OF 5-METHYLTETRAHYDROFOLATE IN INFERTILE PATIENTS WITH METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) 677TT MUTATION UNDERGOING IVF. C. Kim

P-278 HIGH MITOCHONDRIAL DNA REPLICATION IN EMBRYOS DERIVED FROM MYOTONIC DYSTROPHY 1 FEMALE. A. Ijuin

PST-12 POSTER SESSION: INFERTILITY TREATMENT OUTCOMES

P-279 TRENDS IN ASSISTED REPRODUCTIVE TECHNOLOGY RELATED MULTI-FETAL GESTATION RATES FROM 2014-2019. H. Kim

P-280 SERUM HCG LEVEL MEASURED 5 DAYS AFTER VITRIFIED-WARMED BLASTOCYST TRANSFER IS PREDICTIVE OF OUTCOME REGARDLESS OF THE USE OF PRE-IMPLANTATION GENETIC TESTING. B. S. Shapiro

P-281 LOW PLASMA DYDROGESTERONE (DYD) LEVEL ON DAY OF ET IS ASSOCIATED WITH REDUCED ONGOING PREGNANCY RATE IN HRT PROGRAMMED FET CYCLES: A PROSPECTIVE OBSERVATIONAL STUDY. G. Griesinger

P-282 PROLONGED DURATION OF ORAL CONTRACEPTIVE USE IMMEDIATELY PRIOR TO IVF STIMULATION DECREASES BLASTULATION RATE IN GnRH ANTAGONIST CYCLES. D. Aharon

P-283 EMBRYOS MORPHOKINETICS: DOES THE SOURCE OF GONADOTROPHIN PREPARATIONS MATTER? D. P. Braga

P-284 ODDS OF LIVE BIRTH FOLLOWING FIRST FRESH VERSUS FROZEN EMBRYO TRANSFER IN WOMEN’S FIRST ART CYCLE USING 154,000 SARTCORS CYCLES 2014-2018. A. Kotlyar

P-285 EARLY PREGNANCY OUTCOMES AFTER IVF AND SLEEP DISORDERED BREATHING. J. R. Walter

P-286 IMPACT OF VITAMIN D DEFICIENCY ON ANEUPLOIDY IN PATIENTS UNDERGOING PREIMPLANTATION GENETIC TESTING. M. O. Solomon

P-287 A MACHINE LEARNING BASED MORPHOLOGY VERSUS AUTOMATIC MORPHOKINETIC ALGORITHMS FOR IMPLANTATION PREDICTION. A. Ben-Meir

P-288 ASSISTED REPRODUCTIVE TECHNOLOGY AND INCREASED ABNORMAL PLACENTATION: A POPULATION-BASED ANALYSIS. N. L. Vestal

P-289 OPTIMAL DURATION OF ESTROGEN PRIMING DURING FROZEN EMBRYO TRANSFER (FET) CYCLES: DOES IT REALLY MATTER? J. Eid

P-290 THE EFFECT OF ADDITIONAL PROGESTERONE INJECTIONS ON CLINICAL OUTCOMES AFTER A LOW SERUM PROGESTERONE ON THE DAY OF EMBRYO TRANSFER. J. Garratt

P-291 BLASTULATION AND EUPLOIDY RATES IN NORMAL AND LOW RESPONDERS AFTER GONADOTROPIN-RELEASEING HORMONE AGONIST (GnRHA) TRIGGER. S. M. Hallisey

P-292 A PREDICTION MODEL FOR LIVE BIRTH FOLLOWING ASSISTED REPRODUCTIVE TECHNOLOGY USING UNITED STATES NATIONAL SURVEILLANCE DATA FROM 2016-2018. A. J. Gaskins

P-293 THE HYPOTHESIS OF PREFERENCIAL LOSS OF FEMALE EMBRYOS: EMBRYONIC SEX IS NOT ASSOCIATED WITH INCREASED ODDS OF EARLY PREGNANCY LOSS. C. Hernandez-Nieto

P-294 GnRH ANTAGONIST ON THE EVENING OF GnRH AGONIST TRIGGER DOES NOT IMPACT OVULATORY RESPONSE. A. Korkidakis

P-295 ANTI-MULLERIAN HORMONE AND BASAL ANTRAL FOLLCLE COUNT AS PREDICTORS FOR OVARIAN RESERVE AND OVARIAN RESPONSE IN WOMEN WITH HYPOGONADOTROPIC HYPOGONADISM. O. S. Abdalmageed

P-296 FIRST TRIMESTER OUTCOMES OF PATIENTS SEEKING INFERTILITY CARE AFTER COVID-19 INFECTION. K. N. Le
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-297</td>
<td>Intrauterine insemination cycle characteristics associated with multiple gestation.</td>
<td>M. Lee</td>
</tr>
<tr>
<td>P-298</td>
<td>Intra-patient inter-cycle variation analysis - does the outcome of a prior IVF cycle predict the outcome of subsequent cycle(s)?</td>
<td>L. Marom Haham</td>
</tr>
<tr>
<td>P-300</td>
<td>Estimation of follicular growth widely used, Seldom studied.</td>
<td>I. Feferkorn</td>
</tr>
<tr>
<td>P-301</td>
<td>Can a high AMH overcome advancing reproductive age? The association between AMH and cumulative live birth among women over age 40.</td>
<td>B. S. Harris</td>
</tr>
<tr>
<td>P-302</td>
<td>High oocyte immaturity rates impact embryo morphokinetics: lessons of time-lapse imaging system.</td>
<td>A. S. Setti</td>
</tr>
<tr>
<td>P-303</td>
<td>Non-invasive assessment of viability in grouped cultured-embryo cohorts through the measurement of the oxidative status of the spent culture media.</td>
<td>M. Valera</td>
</tr>
<tr>
<td>P-304</td>
<td>The optimal follicle size at ovulatory trigger in ovarian stimulation cycles with letrozole co-administration.</td>
<td>A. Aluko</td>
</tr>
<tr>
<td>P-305</td>
<td>Pre-ICSI systematically graded assessment of sperm motility predicts clinical outcomes in severe oligospermic and azoospermic males.</td>
<td>A. T. Mason</td>
</tr>
<tr>
<td>P-306</td>
<td>Serum 24,25-dihydroxyvitamin D₃ is an accurate indicator of follicular vitamin D status and oocyte aging in IVF patients.</td>
<td>E. E. Lara-Molina</td>
</tr>
<tr>
<td>P-307</td>
<td>More may not always be better: the effect of high-dose gonadotropins on cumulative live birth in over 300,000 fresh and freeze-all cycles.</td>
<td>J. L. Eaton</td>
</tr>
<tr>
<td>P-308</td>
<td>The impact of delayed progesterone start on premature luteinization and pregnancy outcomes in medicated frozen embryo transfer cycles.</td>
<td>A. Cantor</td>
</tr>
<tr>
<td>P-309</td>
<td>How does IVF conception affect pregnancy complications in an older cohort of women?</td>
<td>A. Badeghiesh</td>
</tr>
<tr>
<td>P-310</td>
<td>Measurement of the oxidative profile of spent culture media as a non-invasive biomarker of life birth potential.</td>
<td>M. Valera</td>
</tr>
<tr>
<td>P-311</td>
<td>Maternal physiology and blastocyst morphological grade correlate with an inherent difference in human peri-implantation developmental potential.</td>
<td>D. Logsdon</td>
</tr>
<tr>
<td>P-312</td>
<td>High estradiol per retrieved oocyte level predicts poor IVF outcome in patients with less than 15 oocytes.</td>
<td>S. Li</td>
</tr>
<tr>
<td>P-313</td>
<td>Single embryo transfer versus double embryo transfer and the subsequent risk of monozygotic twinning.</td>
<td>S. U. Park</td>
</tr>
<tr>
<td>P-314</td>
<td>Low-dose HCG supplementation in IVF antagonist protocols is associated with delays in embryo development and reduced fertilization rates.</td>
<td>C. Hur</td>
</tr>
<tr>
<td>P-316</td>
<td>Letrozole co-treatment in ovarian stimulation with r-FSH delays embryo morphokinetics and worsen clinical outcomes.</td>
<td>D. P. Braga</td>
</tr>
<tr>
<td>P-317</td>
<td>Length of estrogen supplementation and type of estrogen delivery has no impact on reproductive success.</td>
<td>A. Chaturvedi</td>
</tr>
<tr>
<td>P-318</td>
<td>A pilot study of oocyte production and endocrine response after intraovarian treatment with platelet-rich plasma (PRP) in infertile women of very advanced age.</td>
<td>D. H. Barad</td>
</tr>
<tr>
<td>P-319</td>
<td>Predictors of Preeclampsia in IVF pregnancies: peri-implantation beta-human chorionic gonadotropin and endometriosis.</td>
<td>V. G. Wesevich</td>
</tr>
<tr>
<td>P-320</td>
<td>Dual trigger impact on reproductive outcomes of GNRH antagonist cycles for IVF: a systematic review and meta-analysis.</td>
<td>S. Gayete-Lafuente</td>
</tr>
<tr>
<td>P-321</td>
<td>Premature progesterone elevation during early and mid follicular phases in fresh in vitro fertilization (IVF) cycles is associated with lower implantation and clinical pregnancy rates.</td>
<td>J. S. George</td>
</tr>
<tr>
<td>P-322</td>
<td>Serum anti-Müllerian hormone concentrations impacts not only the quantity, but also the quality of the ovarian reserve: the importance of time-lapse imaging system.</td>
<td>D. P. Braga</td>
</tr>
<tr>
<td>P-323</td>
<td>Comparison of ICSI with fresh and frozen ejaculated sperm in donor oocyte recipient cycles utilizing sibling oocytes.</td>
<td>J. D. Bardos</td>
</tr>
<tr>
<td>P-324</td>
<td>Association between pre-treatment maternal body mass index and reproductive outcomes: an analysis of &gt; 45,000 fresh, autologous IVF treatment cycles from SARTCORS database.</td>
<td>M. Raff</td>
</tr>
<tr>
<td>P-325</td>
<td>Predictability of ovarian sensitivity index for antagonist-protocol ICSI cycle outcomes.</td>
<td>A. M. Abdelmagied</td>
</tr>
<tr>
<td>P-326</td>
<td>Cryo-synthetic frozen embryo transfer cycle outcomes with adjustment of progesterone in oil dosing the day prior to embryo transfer.</td>
<td>C. K. Margolis</td>
</tr>
<tr>
<td>P-327</td>
<td>Body mass index does not affect natural cycle frozen embryo transfers.</td>
<td>I. Beshar</td>
</tr>
</tbody>
</table>
P-328 SHOULDN'T PATIENTS WITH ONLY TWO EMBRYOS ELIGIBLE FOR BIOPSY AFTER A SINGLE CONTROLLED OVARIAN HYPERSTIMULATION CYCLE UTILIZE PGT-A PRIOR TO TRANSFER SELECTION? C. M. Canon

P-329 FAILED THAW CYCLES (FTHC) AS A KEY PERFORMANCE INDICATOR (KPI): EVALUATING THE PROGRESS OF FROZEN EMBRYO TRANSFERS (FET) IN USA. K. A. Wirka

P-330 TROPHOCYTES GRADE AND THE DAY OF TE BIOPSY SIGNIFICANTLY CORRELATE WITH PREGNANCY RATE IN EUPLOID BLASTOCYST TRANSFER. T. Horikawa

P-331 MALE FACTOR INFERTILITY IS ASSOCIATED WITH DECREASED PROGRESSION TO CLINICAL PREGNANCY IN EUPLOID EMBRYO TRANSFERS. D. Aharon

P-332 FERTILITY TREATMENT CHOICES AND PREGNANCY OUTCOMES AMONG SINGLE AND LESBIAN WOMEN. D. Diego

P-333 OVARIAN RESPONSE AND ITS IMPACT ON THE CUMULATIVE LIVE BIRTH RATES. L. Domenech

P-334 PREDICTION OF INTRACYTOPLASMIC SPERM INJECTION CYCLE OUTCOMES USING A MULTIVARIATE SCORING MODEL. A. Yosef

P-335 THE EFFECT OF OOCYTE MATURITY INDEX ON BLASTOCYST RATE AND PREGNANCY OUTCOMES. R. K. Chung

P-336 ORAL SUPPLEMENTATION WITH A COMBINATION ANTIOXIDANT FORMULATION IMPROVES CLINICAL PREGNANCY RATE. B. Rizk

P-337 PREDICTABILITY OF SONOGRAPHIC PARAMETERS FOR ICSI CYCLE OUTCOMES. A. Yosef

P-338 GONADOTROPIN BOOST AT THE TIME OF OVULATION TRIGGER DOES NOT AFFECT OOCYTE PRODUCTION OR MATURATION. B. Y. Zaghi

P-339 YOUNG EGGS IN AN OLD BASKET—IS THERE A MATERNAL AGE LIMIT FOR EMBRYO TRANSFER? J. K. Cheung

P-340 ECTOPIC PREGNANCY RISK FACTORS IN INFERTILE PATIENTS: A 10-YEAR SINGLE CENTER EXPERIENCE. F. Cirilo

P-341 THE ASSOCIATION BETWEEN IMPLANTATION RATE AND AUTOMATED MEASUREMENTS OF EMBRYO ANNOTATION AND BLASTOCYST GEOMETRY. I. Har-Vardi

P-342 WHY DO EMBRYOS FOLLOWING EUPLOID EMBRYO TRANSFER MISCARRY? A. M. Wiltshire

P-343 THE FULL ANALYSIS OF SART REGISTRY LIVE BIRTH RATES: LIVE BIRTH RATES PER FRESH OR FROZEN EMBRYO STRATIFIED BY EMBRYO AND PATIENT AGE. M. S. Awadalla

P-344 IMPACT OF REVISED START CRITERIA FOR GONADOTROPIN-RELEASING HORMONE ANTAGONIST ON IN VITRO FERTILIZATION OUTCOMES. C. N. Fortin

P-345 FROZEN-THAWED EMBRYO TRANSFER CYCLE OUTCOMES OF PATIENTS WITH DYSMORPHIC UTERUS FOLLOWING HYSTEROSCOPIC METROPLASTY: CASE-CONTROLLED STUDY IN A SINGLE IVF CENTER. H. Uyanikoglu

P-346 TRANSDERMAL OESTRADIOL GEL VS ORAL OESTROGEN FOR SUCCESSFUL CLINICAL OUTCOME IN HORMONE REPLACEMENT FROZEN EMBRYO TRANSFER (HR-FET) CYCLES: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. K. D. Nayar

P-347 DOES DUAL TRIGGER WITH COMBINATION OF GONADOTROPIN-RELEASING HORMONE AGONIST AND LOW DOSE HUMAN CHORIONIC GONADOTROPIN IMPROVES CLINICAL OUTCOMES IN NORMAL RESPONDERS IN GnRH ANTAGONIST IVF-ICSI CYCLES. K. D. Nayar

P-348 A MULTICENTER, RANDOMIZED, OPEN AND POSITIVE PARALLEL CONTROLLED CLINICAL STUDY OF CLOTIMAZOLE VAGINAL EXPANSION SUPPOSITORY AND VAGINAL TABLET IN THE TREATMENT OF MILD AND MODERATE VULVOVAGINAL CANDIDIASIS. Q. Zhang

P-349 SERUM PROGESTERONE LEVEL AND PROGESTERONE/ESTRADIOL RATIO MAY BE USEFUL PREDICTORS FOR REPLACING CLEAVAGE STAGE WITH BLASTOCYST STAGE EMBRYO TRANSFER IN FRESH IVF/ICSI CYCLES WITHOUT PREMATURE PROGESTERONE ELEVATION. V. Tokgoz

P-350 PREDICTED LIVE BIRTH RATES (LBRS) FOR SINGLE THAWED EUPLOID EMBRYO TRANSFERS (STEETS) DO NOT DIFFER FOR FRESH ONCOLOGOUS, CRYOPRESERVED (CP), AND DONOR OOCYTES. H. S. Friedlander

P-351 COMPARING TRENDS IN ASSISTED REPRODUCTIVE THERAPY RELATED MULTI-FETAL GESTATION RATES FROM 2014-2019 BETWEEN AUTOLOGOUS AND DONOR EGG CYCLES. H. Kim

P-352 IS THERE A DIFFERENCE IN PROCEDURE TIME BETWEEN WEEKDAY VERSUS WEEKEND OOCYTE RETRIEVALS? M. Tarrash

P-353 FACTORS AFFECTING THE RATES OF OOCYTE MATURATION AND CRYOPRESERVABLE BLASTOCYSTS IN GnRH ANALOG TRIGGER CASES. Y. Sahin

P-354 A RETROSPECTIVE COMPARISON OF IVF-ET OUTCOMES IN THOSE USING FOLLITROPIN-Δ AND FOLLITROPIN-A IN ROUTINE CLINICAL PRACTICE. P. Kovacs

P-355 DOES IN-VITRO FERTILIZATION AFFECT INTER-DELIVERY INTERVAL IN PATIENTS WITH RECURRENT PREGNANCY LOSS? A POPULATION STUDY K. Cho
P-356 DOES THE DURATION OF CRYOSTORAGE OF VITRIFIED-WARMED OOCYTES IMPACT IVF AND PERINATAL OUTCOMES? M. Oliva

P-357 PREDICTIVE VALUE OF THE NUMBER OF FROZEN BLASTOCYSTS IN LIVE BIRTH RATES OF THE TRANSFERRED FRESH EMBRYOS. J. Song

P-358 LIVE BIRTH DIFFERENCES IN WOMEN WITH SIGNIFICANTLY ABOVE AVERAGE AMH LEVEL UNDERGOING IVF. A. Messelt

P-359 DOES A HIGH DOSE PROGESTERONE (P) PROTOCOL IMPROVE PREGNANCY OUTCOMES COMPARED TO A STANDARD DOSE P PROTOCOL IN POOR PROGNOSIS PATIENTS UNDERGOING PROGRAMMED FROZEN-THAWED EMBRYO TRANSFER (FET) CYCLES? A. Marinelli

P-360 A CRITICAL MEDICO-LEGAL ANALYSIS OF CONVERSION THERAPY IN INDIA. B. Singh

P-361 POSTHUMOUS SPERM RETRIEVAL: A MEDICOLEGAL REVIEW OF POSTMORTEM FERTILITY PRESERVATION. D. O. Omil-Lima

P-362 IS ANONYMITY GONE? DIRECT-TO-CONSUMER ANCESTRY TESTING REVEALS OLD SECRETS IN FERTILITY CARE: LEGAL CASE REVIEW M. A. Rasouli

P-363 COMPARING OOCYTE DISPOSITION DECISIONS IN THE ELECTIVE VERSUS MEDICALLY INDICATED FERTILITY PRESERVATION PATIENT POPULATION. R. Kopparam

P-364 DOES OVARIAN RESERVE INFLUENCE EUPLOIDY RATES? M. Irani

P-365 ASSOCIATION OF CLINICAL TRAITS AND OVARIAN RESERVE DECREASES WITH SUBFERTILITY IN PATIENTS WITH AUTOIMMUNE ARTHRITIS. E. A. Santana

P-366 TWO IS NOT ALWAYS GREATER THAN ONE: PATIENTS (PTS) WITH ONE OVARY (1O) HAVE SIMILAR ASSISTED REPRODUCTIVE TECHNOLOGY (ART) OUTCOMES COMPARED TO PTS WITH TWO OVARIES (2O). E. E. Auran

P-367 LONGITUDINAL EXAMINATION OF THE ASSOCIATION BETWEEN HORMONAL CONTRACEPTIVE USE AND ANTI-MÜLLERIAN HORMONE (AMH) LEVELS IN REPRODUCTIVE-AGED AFRICAN-AMERICAN WOMEN. C. N. Fortin

P-368 DIMINISHED OVARIAN RESERVE AND HIGHER BLOOD GLUCOSE LEVELS AMONG SUBFERTILE WOMEN. L. Mínguez-Alarcón

P-369 CLINICAL APPLICATION OF LETROZOLE COMBINED WITH PROGESTIN-PRIMED OVARIAN STIMULATION PROTOCOL IN POOR OVARIAN RESPONDERS AT ADVANCED AGE. X. Li

P-370 DIMINISHED OVARIAN RESERVE IN WOMEN WITH SICKLE CELL ANEMIA. L. H. Pecker

P-371 ANTI-MÜLLERIAN HORMONE AND FOLLICLE STIMULATING HORMONE ARE POOR INDEPENDENT PREDICTORS OF LIVE BIRTH AFTER ASSISTED REPRODUCTIVE TECHNOLOGY. D. R. Siegel

P-372 SERUM TRIGLYCERIDES AND TOTAL CHOLESTEROL ARE ASSOCIATED WITH ANTIMULLERIAN HORMONE LEVELS. E. C. Mauban

P-373 GROUP BASED TRAJECTORY MODELING (GBTM) OF ANTI-MULLERIAN HORMONE (AMH) IN A COHORT OF REPRODUCTIVE AGE AFRICAN AMERICAN WOMEN (AAW). T. C. Plowden

P-374 FACTORS ASSOCIATED WITH LOW OR HIGH ANEUPLOIDY RATES AT THE EXTREMES OF AGE. D. Aharon

P-375 A COMPARISON OF PREGNANCY RATES FOLLOWING IN VITRO FERTILIZATION-EMBRYO TRANSFER IN WOMEN 43 VS. 44 ACCORDING TO DIMINISHED VS. NORMAL EGG RESERVE. J. H. Check

P-376 COST COMPARISON OF HIGHLY PURIFIED HUMAN MENOPAUSAL GONADOTROPIN (HP-HMG) VERSUS RECOMBINANT FOLLICLE-STIMULATING HORMONE (rFSH) FOR CONTROLLED OVARIAN STIMULATION IN US HIGH-RESPONDER PATIENTS BASED ON THE MEGASET-HR TRIAL. M. Markert

P-377 NOBODY SPEAKS ABOUT THIS: FERTILITY TREATMENTS AND ITS IMPACT ON COUPLES SEXUALITY. B. Garcia Ojeda

P-378 RATE OF PATIENTS ELECTING FOR POLYGENIC RISK SCORES IN PREIMPLANTATION GENETIC TESTING. J. Eccles

P-379 REAL-WORLD PERSPECTIVE ON WEARABLE SENSOR TECHNOLOGY AS A COMPLEMENT TO TRADITIONAL FERTILITY SERVICES AND AN EMPLOYER-COVERED BENEFIT. B. M. Goodale
P-381 ONLINE MARKETING PATTERNS OF VASECTOMY REVERSAL PRACTICES. M. Jimbo

P-382 A NATIONAL SURVEY ON EARLY PREGNANCY LOSS: EVALUATING DISPARITIES IN WOMEN’S KNOWLEDGE-BASE AND WORKUP HISTORY. S. I. Seckin

P-383 ESTABLISHMENT OF A COMPREHENSIVE CARE PROGRAM (CCP) AS A COMPLEMENT TO FERTILITY EVALUATION/TREATMENT TO IDENTIFY CO-MORBIDITIES, MAXIMIZE AWARENESS AND IMPROVE OVERALL HEALTH, FERTILITY AND OBSTETRICAL OUTCOMES. S. R. Brownridge

P-384 CHASING INFERTILITY – THE CHAT BOT-WAY TO INCREASE FERTILITY AWARENESS. M. Schenk

P-385 VALIDATION OF PROGNOSIS-BASED IVF GRANT SELECTION CRITERIA. J. B. Bakkensen

P-386 #MOSAIC EMBRYO: AN ANALYSIS OF THE SOCIAL MEDIA CONTENT SURROUNDING EMBRYONIC MOSAICISM. J. Reich

P-387 SUPPORTING TRANSGENDER MALE PATIENTS THROUGH FERTILITY TREATMENT: AIDING CREATION OF THE MODERN FAMILY THROUGH ASSISTED REPRODUCTIVE TECHNOLOGY. A. Ghofranian

P-389 REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) FELLOWS ARE LIKELY TO GRADUATE FROM OBGYN RESIDENCY PROGRAMS WITH REI FELLOWSHIPS. W. Chertman

P-390 CAN A SIMPLE ALGORITHM HELP OUR RESIDENTS BECOME MORE CONFIDENT WITH BASIC INFERTILITY MANAGEMENT? J. K. Cheung

P-391 5 YEARS OF THE SART CORS IVF DATA REGISTRY: QUANTIFYING THE IMPACT. C. L. Curchoe Burton

P-392 UTILIZATION AND PERCEIVED UTILITY OF HOME FERTILITY TESTING AMONG INFERTILITY PATIENTS AT A SINGLE ACADEMIC FERTILITY CENTER. B. J. Peipert

P-393 DEVELOPMENT AND PILOT TEST OF A SURVEY ASSESSING FERTILITY AND FAMILY BUILDING CONCERNS AMONG WOMEN IN MEDICINE. J. B. Bakkensen

P-394 HISTORY OF RECURRENT PREGNANCY LOSS IS ASSOCIATED WITH INCREASED PERINATAL COMPLICATIONS, BUT NOT NECESSARILY LONGER TIME TO DELIVERY: A POPULATION STUDY SPANNING 18 YEARS. K. Cho

P-395 PREGNANCY RESULTS FOLLOWING EUPLOID EMBRYO TRANSFERS IN PATIENTS WITH UNEXPLAINED RECURRENT PREGNANCY LOSS. B. Yuksel

P-396 TEMPORAL TRENDS IN THYROID-STIMULATING HORMONE AND THYROID AUTOIMMUNITY IN SUBSEQUENT PREGNANCIES FOLLOWING THE INDEX VISIT IN A RECURRENT PREGNANCY LOSS POPULATION. S. Jansen

P-397 EFFECT OF FEMALE BODY MASS INDEX ON INTRAUTERINE INSEMINATION OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS. V. Subramanian

P-398 IMPACT OF VITAMIN D LEVEL ON EARLY PREGNANCY OUTCOMES IN OBESE PATIENTS FOLLOWING INTRAUTERINE INSEMINATION. W. Urian

P-399 OBESITY-RELATED ALTERATIONS IN PROTEIN EXPRESSION IN HUMAN FOLLICULAR FLUID. S. B. Schon

P-400 PREDICTORS OF SUBSEQUENT PREGNANCY FOLLOWING MEDICAL TREATMENT IN OBESE WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA. B. L. Klooster

P-401 POSTNATAL ANDROGEN EXPOSURE LEADS TO INCREASED BODY MASS WITH GREATER INCREASE IN FAT COMPARED TO LEAN MASS IN OBESE PCOS MOUSE MODEL. A. Gannon

P-402 WHAT IS THE UPPER LIMIT OF BMI FOR IVF SUCCESS BEFORE DECLINE? V. T. Pham
**POSTER SESSION 2**

### PSW-01 POSTER SESSION: ART LAB: EMBRYOS

- **P-403** Morphologic parameters of euploid blastocysts that predict progression to clinical pregnancy. D. Aharon
- **P-404** Which factors should be used to determine how many embryos to transfer? Analysis of age, fresh or frozen embryo status, and embryo quality. N. Karpaviciute
- **P-405** The competency of single euploid blastocysts from in vitro-matured (IVM) human oocytes with preimplantation genetic testing for aneuploidy (PGT-A) after controlled ovarian hyperstimulation (COH). J. Moon
- **P-406** Let-7 regulates pre-implantation mouse embryo development. W. Liu
- **P-407** Comparison of blastulation rate in group and single embryo culture. S. K. Nguyen
- **P-408** First case report of a healthy live birth following a frozen embryo transfer of a day 8 euploid blastocyst. J. Stanhiser

### PSW-02 POSTER SESSION: ART LAB: SPERM

- **P-409** Strategies for reducing sperm DNA fragmentation by comparing PICSI versus second ejaculate in ICSI patients: A prospective randomized controlled trial. E. M. Hasanen
- **P-410** Improving IVF clinical results with centrifugation-free sperm preparation method. M. T. Do
- **P-411** Does assisted liquefaction instead of incubation affect sperm motility and motile sperm recovery in the sperm wash process? S. Sechler
- **P-412** Clinical outcomes and sperm quality after chemotherapy in patients with testicular cancer. M. Quera
- **P-413** A cross-species comparison of a specimen collection container designed to harvest oxygen radical species. S. D. Prien
- **P-414** The use of testicular sperm in couples with a previous ICSI failure with ejaculated sperm does not decrease aneuploidy rate; a retrospective analysis. I. Hervas
- **P-415** Evaluating the efficiency of physiological ICSI (PICS) in patients with different levels of abnormal sperm DNA fragmentation. E. M. Hasanen
- **P-416** Microfluidic sperm sorting (MFSS) or swim up: Better technique to evaluate sperm DNA integrity. N. J. Brahmbhatt
- **P-417** Success rates of rescue ICSI the day after failed fertilization in conventional insemination: Fresh versus frozen embryo transfers. S. N. Batha
- **P-418** Does ZymöT sperm separation improve embryo development outcomes when applied to all infertility patients compared to density gradient washing or surgically attained sperm? M. C. Schiewe
- **P-419** Sperm DNA fragmentation and functional features of human sperm selected by microfluidic sorting for clinical use. N. Morishita
- **P-420** Utilizing a novel PLCζ assay to guide treatment for couples with complete fertilization failure after ICSI. D. R. Tavares
- **P-421** Straw swim up procedure comparison of commercial sperm media efficacy. S. Levrant
- **P-422** A rapid QC testing platform using frozen semen. S. D. Prien
- **P-423** The efficacy of physiological sperm sorting in addition to morphological sorting. H. Ito
- **P-424** Awareness and reporting of globozoospermia among in-vitro fertilization and andrology laboratories: A national survey. C. C. Gu
- **P-425** Double washing process do not have effect on sperm total RNA concentration in semen assay sample. J. Eum
- **P-426** Significant improvement in the quality of embryos obtained after the use of testicular sperm for ICSI in couples with a previous ICSI failure with ejaculated sperm. I. Hervas
- **P-427** Can microfluidic sperm sorting help separation of sperms with good quality DNA? K. Mantravadi
PSW-03 POSTER SESSION: ART OFFSPRING

P-428 CONCEPTION BY FERTILITY TREATMENT AND CARDIO-METABOLIC BIOMARKERS IN EARLY CHILDHOOD. E. Yeung
P-429 NEONATAL OUTCOMES ARE NOT IMPACTED BY A SECOND TROPHECTODERM BIOPSY. J. G. Kim
P-430 RETROSPECTIVE COMPARISON OF PREGNANCY OUTCOMES OF SINGLE FRESH AND FROZEN-WARMED BLASTOCYST TRANSFER: A 5-YEAR SINGLE CENTER EXPERIENCE. P. Levi Setti
P-431 OFFSPRING CONCEIVED THROUGH ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) HAVE NORMAL THYROID FUNCTION IN ADOLESCENCE. L. A. Wijs
P-432 IN OVULATORY WOMEN, TRANSFER OF FROZEN EMBRYOS IN THE NATURAL CYCLE IS ASSOCIATED WITH LOWER ODDS OF HYPERTENSIVE DISORDERS OF PREGNANCY. P. Bortoletto
P-433 ESTRADIOL LEVEL AT TIME OF OVULATORY TRIGGER IS NOT ASSOCIATED WITH INCREASED ODDS OF HYPERTENSIVE DISORDERS OF PREGNANCY OR SMALL-FOR-GESTATIONAL AGE IN FRESH EMBRYO TRANSFER CYCLES. P. Bortoletto

PSW-04 POSTER SESSION: CONTRACEPTION

P-434 COMPARATIVE COPPER PHARMACOKINETIC PROPERTIES OF A NOVEL LOW-DOSE NIITINOL FRAME COPPER INTRAUTERINE DEVICE (IUD) AND THE COPPER T380A IUD: A RANDOMIZED CONTROLLED TRIAL. J. T. Jensen
P-435 SATISFACTION WITH THE SEGESTERONE ACETATE AND ETHINYL ESTRADIOL CONTRACEPTIVE VAGINAL SYSTEM AMONG PREVIOUS ORAL CONTRACEPTIVE OR CONTRACEPTIVE VAGINAL RING USERS. J. T. Jensen
P-436 TIMING OF ON-STUDY PREGNANCIES WITH A VAGINAL pH MODULATOR IN THE PHASE 3 AMPOWER TRIAL. B. Howard
P-437 IMPACT OF APPLICATION SITE AND BODY MASS INDEX ON ADHESION AND TOLERABILITY OF A LEVONORGESTREL/ETHINYL ESTRADIOL TRANSDERMAL CONTRACEPTIVE DELIVERY SYSTEM. J. A. Chiodo
P-438 EFFECT OF VAGINAL MISOPROSTOL PLUS ISOSORBIDE MONONITRATE ON PAIN PERCEPTION DURING COPPER INTRAUTERINE DEVICE INSERTION IN WOMEN DELIVERED ONLY BY ELECTIVE CESAREAN SECTION. A. M. Abbas
P-439 INTEREST FOR AN AT-HOME TESTING KIT PROVIDING PERSONALIZED CONTRACEPTIVE RECOMMENDATIONS AMONG REPRODUCTIVE-AGE FEMALES. A. Lazorwitz
P-440 ACCURACY OF A WRIST-WORN MEDICAL DEVICE TO IDENTIFY FERTILE WINDOW AND OVULATION DAY. B. M. Goodale
P-441 BARRIERS TO EMERGENCY CONTRACEPTION ACCESS NOT ALLEVIATED WITH BRIEF PHARMACY EDUCATIONAL INTERVENTION. C. A. Stamm
P-442 THE ROLE OF THE GENERAL OBSTETRICIAN-GYNECOLOGISTS IN CONTRACEPTION COUNSELING AND ITS IMPACT ON UNINTENDED PREGNANCIES IN THE UNITED STATES. B. Aroh
P-443 THE INFLUENCE OF SOCIAL MEDIA IN PATIENT’S BEHAVIOR IN THE USE OF CONTRACEPTIVE METHODS. F. Prado
P-444 DYNAMICS OF PREGNANCY INTENTION AND PREGNANCY INCIDENCE AMONG PROFESSIONAL WOMEN. S. Wang

PSW-05 POSTER SESSION: COVID-19

P-445 FET OUTCOMES DURING THE COVID-19 PANDEMIC. I. J. Chamani
P-446 COVID-19 VACCINATION AMONGST INFERTILITY STAFF: HOW CAN WE DO BETTER? K. Bergin
P-447 HOW MUCH LONGER? RATES OF ART DELAY OR CANCELLATION DURING THE COVID-19 CRISIS. S. M. Malloy
P-448 RATES OF COVID-19 INFECTION IN A FERTILITY TREATMENT POPULATION. L. M. Roberts
P-449 VIRTUAL AND IN-PERSON CARE DURING THE COVID-19 PANDEMIC LED TO EQUIVALENT PATIENT SATISFACTION FOR REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) PATIENTS. M. Andrusier
P-450 EFFECT OF COVID-19 INFECTION ON TESTICULAR FUNCTION. K. Khalafalla
P-451 VIRAL FALLOUT: SEMEN PROTEOME REVEALS THAT COVID-19 DYSREGULATES SEVERAL BIOLOGICAL PROCESSES LINKED TO MALE REPRODUCTIVE FUNCTION. S. Parikh
P-452 TELEHEALTH DURING THE COVID-19 PANDEMIC: WHAT YOUR PATIENTS ARE REALLY THINKING. M. A. Mathes
P-453 EFFECT OF COVID-19 mRNA VACCINES ON SPERM QUALITY. D. Gonzalez
P-454 THE EFFECT OF TELEMEDICINE DURING THE COVID-19 PANDEMIC ON IVF TREATMENT. E. kadour-Peero
P-455 READY (OR NOT): CHANGES IN CONCEPTION ATTEMPTS DURING THE COVID-19 PANDEMIC. S. M. Malloy
P-456  OVERALL POSITIVE POSTS AFTER INTRODUCTION OF COVID-19 VACCINE ON FERTILITY-RELATED SOCIAL MEDIA. N. D. Yoder

P-457  FEMALE GAMETE AND HUMAN EMBRYO SUSCEPTIBILITY TO SARS-COV-2. F. Entezami

P-458  PATIENT SATISFACTION OF IMPLEMENTED COVID-19 PROTOCOLS IN A PRIVATE FERTILITY PRACTICE. L. P. Rosenthal

P-459  ASSISTED REPRODUCTIVE TECHNOLOGY PROCEDURES IN THE US PRIOR TO AND DURING THE COVID-19 PANDEMIC. J. Chae-Kim

P-460  THE USE OF ONLINE TOOLS AND APPLICATIONS AS AN ADAPTATION FOR SCIENTIFIC EDUCATION IN ANDROLOGY DURING THE COVID-19 PANDEMIC. R. Finelli

P-461  THE ONGOING IMPACT OF COVID-19 ON STRESSORS DURING FERTILITY TREATMENT. J. Amir

PSW-06 POSTER SESSION: EARLY PREGNANCY

P-462  USING HIGH RESOLUTION PROFILING OF THE HUMAN EMBRYONIC MITOCHONDRIAL GENOME TO DISCOVER BIOMARKER(S) FOR IMPLANTATION AND EMBRYONIC DEVELOPMENT. A. Aggarwal

P-464  WHEN ABNORMAL HCG LEVELS RESULT IN A NORMAL PREGNANCY. K. J. Bollig

P-465  DO EARLY HCG DYNAMICS AFTER EMBRYO TRANSFER DIFFER BASED ON DAY OF EMBRYO BIOPSY? C. M. Canon

P-466  GRAVID UTERINE ARTERY DOPPLER FLOW INDICES IN UTERUS TRANSPLANT RECIPIENTS. E. A. Eagle

P-467  CAUSES OF EARLY PREGNANCY LOSS IN FROZEN-THAWED EMBRYO TRANSFER CYCLES. G. Özer

P-468  ENDOMETRIAL AND MYOMETRIAL VASCULARITY ASSESSED BY 3 DIMENSION (D) VAGINAL POWER DOPPLER AT 3 WEEKS OF GESTATION AS PREDICTORS OF OBSTETRICAL OUTCOMES IN TWIN PREGNANCIES CONCEIVED BY ASSISTED REPRODUCTIVE TECHNOLOGY. C. I. Fakih

P-469  RISK FACTORS THAT CAUSE FIRST-TRIMESTER PREGNANCY LOSS IN FROZEN-THAWED EMBRYO TRANSFER CYCLES. G. Özer

P-470  THE EARLIER THE BETTER: INITIAL SERUM HCG LEVELS PREDICT LIVE BIRTH AFTER SINGLE EMBRYO TRANSFER. L. Hughes

P-471  INCREASED VITAMIN D LEVELS DECREASE ODDS OF EARLY PREGNANCY LOSS FOLLOWING INTRAUTERINE INSEMINATION. E. S. Rubin

P-472  CAN THE PERCENT CHANGE IN BETA-HCG PREDICT PREGNANCY OUTCOMES FOLLOWING SINGLE EMBRYO TRANSFERS? A. Domney

P-473  ASSESSING THE ACCURACY AND QUALITY OF YOUTUBE VIDEOS ON EARLY PREGNANCY LOSS. L. A. McNamee

P-474  IS HORMONE REPLACEMENT FOR ENDOMETRIAL PREPARATION ASSOCIATED WITH PREGNANCY LOSSES IN FROZEN-THAWED SINGLE-BLASTOCYST TRANSFER CYCLES. H. Cai

PSW-07 POSTER SESSION: ENDOMETRIUM

P-475  THE ROLE OF ENDOPLASMIC RETICULUM STRESS RESPONSE IN THE REGULATION OF ENDOMETRIAL INTERFERON BETA PRODUCTION IN DECIDUALIZED VERSUS NON-DECIDUALIZED ENDOMETRIAL CELLS. R. Sethuram

P-476  PGF2 REGULATES THE PLASMINOGEN ACTIVATOR PATHWAY IN HUMAN ENDOMETRIAL ENDOTHelial CELLS: DIFFERENCES BETWEEN NORMAL AND HEAVY MENSTRUAL BLEEDERS. S. Sadek

P-477  CELLULAR COMPOSITION OF THE HUMAN ENDOMETRIUM FOLLOWING UTERUS TRANSPLANTATION. K. O'Neill

P-478  ANALYZE OF THE GENE EXPRESSION PROFILES OF SARS-COV-2-ASSOCIATED RECEPTORS AND PROTEASES IN HUMAN ENDOMETRIUM DURING ART PRACTICE. D. Haouzi

P-479  THE ROLE OF THE ENDOMETRIAL RECEPTIVITY ANALYSIS (ERA) IN PATIENTS WITH NON-RECURRENT IMPLANTATION FAILURE IN THE CHINESE POPULATION. Y. Li

P-480  DEVELOPMENT OF ENDOMETRIAL ORGANOIDS FROM AN ENDOMETRIAL BIOPSY. S. R. Brownridge

P-481  NATURAL KILLER CELL, CYTOTOXIC T-LYMPHOCYTE, AND GRANULYSIN CONTENT IS ELEVATED IN ENDOMETRIUM OF WOMEN WITH ABNORMAL UTERINE BLEEDING (AUB): MECHANISTIC INSIGHTS INTO AUB PATHOPHYSIOLOGY. C. Iweha

P-482  PREGNANCY OUTCOMES FOLLOWING A CONVERSION FROM ORAL TO VAGINAL ESTRADIOL DUE TO ENDOMETRIAL HYPOPROLIFERATION: AN ANALYSIS OF FROZEN, EUPLOID SINGLE EMBRYO TRANSFERS. B. M. Hanson

P-483  MILD OVARIAN STIMULATION WITH LOW DOSE R-FSH MAY BE AN EFFECTIVE STRATEGY FOR ENDOMETRIAL PREPARATION IN WOMEN WITH...
THIN ENDOMETRIUM UNDERGOING FROZEN-THAW BLASTOCYST TRANSFER IN OOCYTE DONATION PROGRAMS. N. M. Chimote

P-484 ADDITION OF SUPPLEMENTAL ESTRADIOL (E) AND/OR INCREASING PROGESTERONE (P) DOSE ON THE DAY OF EMBRYO TRANSFER (ET) DOES NOT IMPROVE PREGNANCY OUTCOMES IN NATURAL FROZEN-THAWED EMBRYO TRANSFER (FET) IN VITRO FERTILIZATION (IVF) CYCLES. P. N. Godiwala

P-485 CAN THE ENDOMETRIUM BE TOO THICK? AN ANALYSIS OF SINGLE EUPLOID EMBRYO TRANSFER (SEET) CYCLE PREGNANCY OUTCOMES C. M. Canon

P-486 SUPRAPHYSIOLOGIC SERUM ESTRADIOL NEGATIVELY IMPACTS EUPLOID EMBRYO IMPLANTATION. K. L. Palmerola

P-487 DEVELOPMENT OF SECRETOR AND GESTATIONAL PATIENT-DERIVED ORGANOIDS FROM ADENOMYOSIS DISEASE AS AN IN VITRO MODEL TO STUDY ADENOMYOSIS-RELATED INFERTILITY AND PERSONALIZED DRUG SCREENING. E. Juárez-Barber

P-488 CLINICAL VALUE OF HISTOLOGIC ENDOMETRIAL DATING IN WOMEN WITH INADEQUATE ENDOMETRIUM DURING FROZEN-THAWED BLASTOCYST-STAGE EMBRYO TRANSFER: A RETROSPECTIVE PILOT STUDY. J. Jayakumaran

P-489 ENDOMETRIAL THICKNESS AND OBSTETRICAL OUTCOME IN ASSISTED REPRODUCTIVE TECHNOLOGY. C. Becquart

P-490 ULTRASOUND BASED ENDOMETRIAL RECEPTIVITY SCORING ACCURATELY IDENTIFIES IVF CYCLES WITH LOW PROBABILITY OF PREGNANCY. H. E. Pierson

P-491 SUBTLE ENDOMETRIAL ABNORMALITIES DO NOT AFFECT THE PREGNANCY RATE IN FRESH ICSI CYCLES. A. M. Abbas

P-492 EFFECT OF ANTIBIOTIC TREATMENT FOR CHRONIC ENDOMETRITIS ON ART OUTCOME. H. Agrawal

P-493 OVARIAN INFLAMMATION: BCL-6 EXPRESSION WITHIN THE ENDOMETRIUM IN COMPARISON WITH ESTABLISHED OVARIAN INFLAMMATION MARKERS. M. A. Mayfield

P-494 ENDOMETRIAL ENDOPLASMIC RETICULUM STRESS IN OBESE PCOS PATIENTS. X. Yang

P-495 ENDOMETRIAL COMPACTION DOES NOT PREDICT CLINICAL PREGNANCY IN SINGLE EUPLOID FROZEN EMBRYO TRANSFERS: A PROSPECTIVE OBSERVATIONAL STUDY. J. S. Shah

P-496 PARTICULATE MATTER INDUCES ABNORMAL PROLIFERATION AND INFLAMMATION OF ENDOMETRIUM OF UTERUS. H. Kim

P-497 THE ENDOMETRIAL RECEPTIVITY ASSAY IMPROVES PREGNANCY RATES IN PATIENTS UNDERGOING FROZEN EMBRYO TRANSFERS. J. Z. Guner

P-498 CLINICAL UTILITY OF THE NEW ENDOMETRIAL RECEPTIVITY TEST IN ADVANCED MATERNAL AGE PATIENTS WITH RECURRENT IMPLANTATION FAILURE. Y. Ohara

P-499 PLATELET-RICH PLASMA INTRAUTERINE PERFUSION COMBINED WITH Hysteroscopic ENDOMETRIAL MECHANICAL STIMULATION: A NEW CHOICE FOR TREATMENT OF THIN ENDOMETRIUM. C. Liu

PSW-08 POSTER SESSION: FEMALE REPRODUCTIVE ENDOCRINOLOGY

P-500 ASSOCIATION BETWEEN CHRONIC INFLAMMATION AND MENSTRUAL CYCLE LENGTH. B. S. Harris

P-501 METABOLIC, REPRODUCTIVE OUTCOMES AND SIDE EFFECTS AFTER THE ADMINISTRATION OF 100 MG DEHYDROEPIANDROSTERONE (DHEA) IN WOMEN WITH AN ADEQUATE OVARIAN RESERVE. M. Rangel

P-502 A PROTON PUMP INHIBITOR ALTERS THE pH OF THE HUMAN UTERINE CAVITY. U. Ikeda

PSW-09 POSTER SESSION: FIBROIDS

P-503 ADMINISTRATION OF HORMONAL ADD-BACK THERAPY (ABT) COUNTERACTS THE UTERINE VOLUME REDUCING EFFECTS OF ORAL GnRH ANTAGONIST THERAPY. J. Donnez

P-504 EVALUATING THE INHIBITORY EFFECT OF ELAGOLIX & RELUGOLIX ON LEIOMYOMA GROWTH IN 2D CELL CULTURE. D. Wright

P-505 DOWNREGULATION OF SIRT3 CONTRIBUTES TO UTERINE FIBROID PHENOTYPE, WHICH IS INHIBITED BY NATURAL SIRT3 ACTIVATOR HONOKIOL. M. Ali

P-506 SULFORAPHANE, AN ORGANIC ISOThIOCYANATE FOUND IN CRUCIFEROUS VEGETABLES, REGULATES EXPRESSION OF GENES INVOLVED IN HIPPO SIGNALING AND FIBROTIC PHENOTYPE IN UTERINE FIBROID CELLS. M. Islam

P-507 EPIGALLOcatechin GALLate (EGCG) FOR TREATMENT OF UNEXPLAINED INFERTILITY ASSOCIATED WITH UTERINE FIBROIDS (PRE-FRIEND TRIAL): EARLY SAFETY ASSESSMENT. H. Siblini
<table>
<thead>
<tr>
<th><strong>PSW-10 POSTER SESSION: GENETIC SCREENING</strong></th>
<th><strong>PSW-12 POSTER SESSION: HYSTEROSCOPY</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P-508</strong> GENOMIC PROFILING OF SURGICALLY RETRIEVED SPERMATOZOA TO EVALUATE THE REPRODUCTIVE POTENTIAL OF AZOOSPERMIC MEN. S. Cheung</td>
<td><strong>P-522</strong> HYSTEROSCOPIC MORCELLATION FOR MISSED ABORTION. K. Sasaki</td>
</tr>
<tr>
<td><strong>P-509</strong> EVALUATING THE MALE GAMETE GENOME TO IMPROVE ART OUTCOME. S. Cheung</td>
<td><strong>P-523</strong> HYSTEROSCOPIC CORRECTION OF INTRACAVITARY LESIONS DOES NOT AFFECT THE ENDOMETRIAL VOLUME AND SUBENDOMETRIAL VASCULARITY BEFORE ICSI. A. M. Abbas</td>
</tr>
<tr>
<td><strong>P-510</strong> CLINICAL IMPLICATIONS OF AN EXPANDED PAN-ETHNIC CARRIER SCREENING PANEL. N. D. Sharma</td>
<td><strong>P-524</strong> OSSEOUS METAPLASIA OF THE CERVIX AS A CAUSE OF SECONDARY INFERTILITY: A CASE REPORT. L. Isa</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>PSW-11 POSTER SESSION: HEALTH DISPARITIES</strong></th>
<th><strong>PSW-13 POSTER SESSION: IMAGING</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P-511</strong> PREGNANCY OUTCOMES AFTER PGT-A BY RACE: MISCARRIAGE, LOW BIRTHWEIGHT, AND PRETERM BIRTH. B. S. Bedrick</td>
<td><strong>P-525</strong> ENDOMETRIAL VOLUME AND SUBENDOMETRIAL VASCULARITY BY THREE-DIMENSIONAL POWER DOPPLER AND ITS CORRELATION WITH PREGNANCY OUTCOME IN FRESH EMBRYO TRANSFER ICSI CYCLES. A. M. Abbas</td>
</tr>
<tr>
<td><strong>P-512</strong> LIMITED DIFFERENCES IN THE INCIDENCE OF ENDOMETRIOSIS AND ADENOMYOSIS IN BLACK VERSUS WHITE WOMEN WITH PELVIC PAIN. A. ADELEYE</td>
<td><strong>P-526</strong> EVALUATING THE RELATIONSHIP BETWEEN CESAREAN SCAR NICHES AND POSTMENSTRUAL SPOTTING BASED ON MRI FINDINGS. A. M. Abbas</td>
</tr>
<tr>
<td><strong>P-513</strong> GEOGRAPHIC DISPARITIES IN ACCESS TO FERTILITY SERVICES IN THE UNITED STATES. U. L. Franca</td>
<td><strong>P-527</strong> EFFICACY AND SAFETY OF LINZAGOLIX FOR THE TREATMENT OF SEVERE ADENOMYOSIS: FINAL RESULTS FROM A PILOT STUDY. J. Donnez</td>
</tr>
<tr>
<td><strong>P-514</strong> REPRODUCTIVE HEALTH MEASURES IN A LARGE POPULATION OF U.S. WOMEN MILITARY VETERANS A. K. Kosturakis</td>
<td><strong>P-528</strong> TRANS-VAGINAL SONOGRAPHY POST OFFICE HYSTEROSCOPY AS A SCREENING TOOL FOR TUBAL PATENCY: A RELIABLE AND FEASIBLE TECHNIQUE IN AN OUTPATIENT SETTING. K. Rotshenker Olshinka</td>
</tr>
<tr>
<td><strong>P-515</strong> LIVE BIRTH AFTER PGT-A BY RACE IN THE UNITED STATES. B. S. Bedrick</td>
<td><strong>P-529</strong> PREDICTORS OF POSTMENSTRUAL SPOTTING IN WOMEN WITH CESAREAN SCAR NICHES USING MRI. A. M. Abbas</td>
</tr>
<tr>
<td><strong>P-516</strong> RACIAL/ETHNIC DIFFERENCES IN SELF-REPORTED SATISFACTION WITH FERTILITY CLINICS AND DOCTORS. A. Wang</td>
<td><strong>P-530</strong> 3D NON-INVASIVE ELECTROPHYSIOLOGY IMAGING OF HUMAN UTERINE PERISTALSIS. K. L. Anderson</td>
</tr>
<tr>
<td><strong>P-517</strong> CHARACTERIZATION OF NORMATIVE ANTI-MULLERIAN HORMONE (AMH) VALUES AND CORRELATES OF AMH CONCENTRATIONS IN A LARGE COHORT OF REPRODUCTIVE AGE LATINX WOMEN: FINDINGS FROM THE ENVIRONMENT, LEIOMYOMAS, LATINAS AND ADIPOSITY STUDY. A. R. Schwartz</td>
<td><strong>P-531</strong> HYSTEROSALPINGOGRAPHY CONTRIBUES TO REPRODUCTIVE OUTCOME BY INCREASING ENDOMETRIAL LIF mRNA EXPRESSION. N. Dokuzeylulu Gungor</td>
</tr>
<tr>
<td><strong>P-518</strong> WHERE ARE WE NOW? UNDERSTANDING TRENDS IN REPRODUCTIVE HEALTH DISPARITIES RESEARCH OVER THE LAST 20 YEARS. G. E. Whiteley</td>
<td><strong>P-532</strong> SPOUSAL ASSOCIATIONS OF SERUM METABOLOMIC PROFILES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. K. Al Rashid</td>
</tr>
<tr>
<td><strong>P-519</strong> THE IMPACT OF ETHNICITY ON OUTCOMES IN AUTOLOGOUS OOCYTE CRYOPRESERVATION/THAW CYCLES. A. E. Martini</td>
<td><strong>P-533</strong> QUANTITATIVE ANALYSIS OF UTERINE PERISTALSIS FOR PREDICTION OF PREGNANCY IN IVF PATIENTS: EXTERNAL VALIDATION OF THE WAVES METHOD. C. O. Rees</td>
</tr>
<tr>
<td><strong>P-520</strong> THE ROLE OF ESTIMATED HOUSEHOLD INCOME AND INSURANCE COVERAGE ON LIVE BIRTH OUTCOMES IN INFERTILE PATIENTS RESIDING IN NEW YORK STATE. A. Chung</td>
<td><strong>P-534</strong> THE IMPACT OF CLINICAL FEATURES AND IMAGING FINDINGS IN THE PAIN SCORE LEVELS OF PATIENTS SUBMITTED TO CT VIRTUAL HYSTEROSALPINGOGRAPHY. M. R. Hentschke</td>
</tr>
<tr>
<td><strong>P-521</strong> INVESTIGATING DEMOGRAPHICS OF UTERINE TRANSPLANT (UTX) DONORS AND RECIPIENTS: SEARCHING FOR DISPARITIES. C. M. Cottrell</td>
<td></td>
</tr>
</tbody>
</table>
P-535 USING LIVE IMAGING AND FUCCI ESC TO PROVIDE DIRENESS AND STIMULATION INDICES THAT REPORT THAT PFOA HAS GREATER ADVERSE EFFECTS THAN THE PHTHALATE DEP. E. E. Puscheck

P-548 AGE-DEPENDENT REPRODUCTIVE AND EXOCRINE FUNCTION AFTER UNILATERAL TESTIS LOSS IN C57BL/6 MICE. D. E. Nassau

P-549 SIXTEEN YEAR LONGITUDINAL STUDY OF U.S. SPERM DONORS CONTINUES TO DEMONSTRATE DECLINING SPERM COUNT AND MOTILITY C. M. Canon

P-550 HOW DO SPERM PARAMETERS OF MALE PHYSICIANS COMPARE AS PATIENTS? N. Parikh

P-551 Mn2 Is REQUIRED In REGULATING SPERMATOGONIAL DIFFERENTIATION AND MEIOSIS. C. Guo

PSW-14 POSTER SESSION: MALE REPRODUCTION

P-536 MALE FACTOR INFERTILITY AND ADVANCED PATERNAL AGE ARE CHARACTERIZED BY UNIQUE SPERM EPigenomes. M. M. Denomme Tignanelli

P-537 THE INCUBATION OF ADULT TESTIS TISSUES BASED ON THE GAS-LIQUID INTERFACE METHOD MAINTAIN GERM CELL WITH TESTICULAR ARCHITECTURE. M. Komeya

P-538 THE EFFECT OF INTRATESTICULAR INJECTION OF AUTOLOGOUS PLATELET RICH PLASMA (PRP) ON SPERM RETRIEVAL RATES AND IVF OUTCOMES IN MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA AND HISTORY OF FAILED TESTICULAR SPERM EXTRACTION. Y. Cakiroglu

P-539 AI TO PREDICT SPERM PARAMETER UPGRADING AFTER MICROSURGICAL VARICOCELE REPAIR: INTERNATIONAL EXTERNAL VALIDATION. M. B. Tradewell

P-540 IMPACT OF TESTOSTERONE THERAPY ON INTRATESTICULAR TESTOSTERONE: EVALUATION OF TWO OPEN-LABEL RANDOMIZED CLINICAL TRIALS OF TESTOSTERONE PELLETS, INJECTIONS, AND INTRANASAL GEL IN HYPOGONADAL MEN. D. Gonzalez

P-541 SEVERE MALE FACTOR DOES NOT AFFECT THE EUPLOID BLASTOCYST RATE. A FUNCTION OF SOURCE OR CONCENTRATION? O. Perez

P-542 A PROSPECTIVE STUDY OF MALE SLEEP AND SEMEN QUALITY. J. J. Yland

P-543 ASSESSMENT OF AGE-ASSOCIATED SPERM DNA METHYLATION ALTERATION INHERITANCE IN 4 CELL MOUSE EMBRYOS. T. G. Jenkins

P-544 SPERM PROTEOME ANALYSIS TO IDENTIFY DNA REPAIR MECHANISMS IN VARICOCELE PATIENTS – AN IN SILICO STUDY. R. Finelli

P-545 ADD-ON EFFECT OF ORAL ANTIOXIDANT THERAPY TO SURGICAL VARICOCECTOMY ON THE OUTCOME OF ASSISTED REPRODUCTIVE TECHNOLOGY: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY. T. Takeshima

P-546 VITAMIN D AND SPERM DNA FRAGMENTATION AND SEMEN QUALITY IN AN INFERTILITY TREATMENT-SEEKING POPULATION. S. L. Mumford

P-547 NOVEL SPERM CAPACITATION SYSTEM BASED ON MICROFLUIDICS, THE PATH TO AUTOMATION. F. Meseguer

P-548 SPERM MOTILITY ON TESTICULAR SPERM EXTRACTION (TESE) SAMPLES DEFINES SPECTRUM OF NORMALCY IN POST-VASeCTOMY PATIENTS. A. A. Khoei

P-555 ASSOCIATION BETWEEN FOLLICLE STIMULATING HORMONE (FSH) AND BASELINE SEMEN PARAMETER ABNORMALITIES IN MEN PRESENTING FOR FERTILITY EVALUATION. J. M. Dubin

P-556 EFFECT OF RE-DO MICROSURGICAL SUBINGUINAL VARICOCECTOMY ON FERTILITY POTENTIAL: CASE SERIES AND META-ANALYSIS. M. Arafa

P-557 CONSULTING “DR. GOOGLE” FOR FINASTERIDE SEXUAL SIDE EFFECTS: A CONTEMPORARY WORLDWIDE TRENDS ANALYSIS. K. Asanad

P-558 CHARACTERIZATION OF EXTRACELLULAR VESICLES FROM HUMAN SEMINAL PLASMA BY HIGH-RESOLUTION FLOW CYTOMETRY: NOVEL BIOMARKERS FOR MALE FERTILITY? L. Sánchez-S-Mellado

P-559 PHARMACOKINETICS AND SAFETY OUTCOMES OF GENERIC VERSUS BRANDED TESTOSTERONE PELLETS IN MEN WITH TESTOSTERONE DEFICIENCY: A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED TRIAL. E. Kresch

P-560 SPERM VERY LONG CHAIN POLYUNSATURATED FATTY ACID (VLC-PuFA) CONCENTRATION: RELATION TO SEMEN PARAMETERS AND LIVE-BIRTH OUTCOME IN A MULTICENTER TRIAL. S. Z. Gavriizi

P-561 MELATONIN ATTENUATES TESTICULAR DYSFUNCTION AND SPERM DAMAGE INDUCED BY CHEMOTHERAPY REGIMEN BASED ON BLEOMYCIN, ETOPOSIDE, AND CISPLATIN (BEP): AN EXPERIMENTAL STUDY. M. Moradi

P-562 THE USE OF FRESH COMPARED TO FROZEN EJACULATED SPERM HAS MINIMAL IMPACT ON FRESH EMBRYO TRANSFER CYCLE REPRODUCTIVE OUTCOMES. N. Punjani
P-563 A DOUBLE-BLIND, PROSPECTIVE TEST DEMONSTRATES AN ASSOCIATION BETWEEN CAPACITATION STATUS AND PREGNANCY. B. Kloos

P-564 ICSI OUTCOMES IN INFERTILITY MALE WITH MULTIPLE MORPHOLOGY ABNORMALITIES OF THE SPERM FLAGELLA CAUSED BY DNAH1 MUTATION. K. Feng

P-565 OXIDATIVE STRESS TESTING AND ANTIOXIDANT TREATMENT OF MALE INFERTILITY – SURVEY OF CURRENT CLINICAL PRACTICES. A. Agarwal

P-566 ALTERATION OF SPERM PROTAMINE 1 SERINE 29 PHOSPHORYLATION IS ASSOCIATED WITH MALE-FACTOR INFERTILITY. S. B. Schon

P-567 INSTANTANEOUS TRACKING OF POST-VARICOCECTOMY RECOVERY DYNAMICS USING THE HOME-BASED SEMEN QUALITY MONITORING DEVICE LensHooke® X1. C. Tsai

P-568 WHAT A TANGLED WEB WE WEAVE: THE INTERNET PRESENCE OF VASECTOMY REVERSAL PROVIDERS IN THE UNITED STATES. S. Lundy

P-569 UNLIKE TRADITIONAL SEMEN ANALYSIS, SPERM CAPACITATION SCORES ARE CONSTANT UNTIL AGE 50: A PROSPECTIVE LONGITUDINAL STUDY. F. I. Sharara

P-570 PRE-VASECTOMY REVERSAL HORMONAL ASSESSMENT: DOES IT MATTER? M. E. Ahmed

P-571 PRESENCE OF BISPHENOL A IN SEMINAL PLASMA IS ASSOCIATED WITH LOWER SEMEN PARAMETERS, ESPECIALLY IN MEN WITH VARICOCELE. M. Ješeta

P-572 CHARACTERIZATION OF PRE-TREATMENT LUTEINIZING AND FOLLICLE STIMULATING HORMONE THRESHOLD VALUES FOR PREDICTING THE EFFICACY OF CLOMIPHENE CITRATE IN HYPOGONADAL AND SUBFERTILE MEN. A. Santamaria

P-573 TESTICULAR CORE BIOPSY PRIOR TO SURGICAL SPERM EXTRACTION: A NOVEL ALGORITHM FOR AZOOSPERMIA. K. Campbell

P-574 ANALYSIS OF EMBRYO DEVELOPMENT AND PREGNANCY OUTCOME IN PATIENTS WITH MICRODELETION OF AZF REGION ON Y CHROMOSOME AFTER ICSI TREATMENT. X. Yang

P-575 PREDICTORS OF SPERM RETRIEVAL IN PATIENTS WITH NON-OBSTRUCTIVE AZOOSPERMIA AND CHROMOSOMAL ABNORMALITIES: A SYSTEMIC REVIEW AND META-ANALYSIS. A. Majzoub

P-576 IMPACT OF TESTOSTERONE THERAPY ON POLYCYTHEMIA: EVALUATION OF DATA FROM TWO ONGOING OPEN-LABEL RANDOMIZED SINGLE-CENTER CLINICAL TRIALS. D. Gonzalez

P-577 BENEFIT OF SHORTER ABSTINENCE PERIOD ON SPERM DNA INTEGRITY IN CASE OF HIGH LEVEL OF OXIDATIVE STRESS. M. Ben Khelifa

P-578 A NOVEL AND RAPID ASSAY FOR EVALUATING DOUBLE-STRAND DNA FRAGMENTATION IN HUMAN SPERMATOZOA. A. Agarwal

P-579 ANABOLIC-ANDROGENIC STEROIDS ARE ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER AND SUICIDE ATTEMPT: ANALYSIS OF A MULTI-NATIONAL DATABASE. M. S. Patel

P-580 THE ASSOCIATION OF MALE FACTOR INFERTILITY WITH ADVERSE MATERNAL AND NEONATAL OUTCOMES. A. Domney

P-581 ASSESSMENT OF SEMEN CHARACTERISTICS IN CONSECUTIVE EJACULATES WITH SHORT ABSTINENCE USING SQA-V SPERM QUALITY ANALYZER. P. Kaingade

P-582 MODULATING EFFECTS OF CASTRATION ON VAS DEFERENS SMOOTH MUSCLE ELECTRICAL ACTIVITIES: INSIGHTS FROM A QUANTITATIVE STUDY. C. Mahapatra

P-583 WHOLE EXOME SEQUENCING IDENTIFIES A RARE NONSENSE MUTATION IN NACAD AS A POSSIBLE CAUSE OF COVID ORCHITIS IN BROTHERS. R. Reddy

P-584 WHICH SUBFERTILE MEN SHOULD BE TREATED WITH ANTIOXIDANT THERAPY? – RESULTS OF A SCIENTOMETRIC STUDY AND PRACTITIONER’S SURVEY A. Agarwal

P-585 TESTICULAR SPERM EXTRACTION (TESE) FOR INTRACYTOPLASMIC SPERM INJECTION (ICSI) IN SUB-SAHARAN AFRICA - A TWO - YEAR MULTI-CENTRE REVIEW IN GHANA. P. E. Sefogah

P-586 DOES THE LOW SPERM CONCENTRATION ON THE DAY OF INTRAUTERINE INSEMINATION (IUI) AFFECT THE REPRODUCTIVE OUTCOME OF IUI CYCLES. S. Nagireddy

P-587 ATP AS INDICATOR OF SPERM NORMALCY AND REPRODUCTIVE FITNESS. R. Jeyendran

P-588 THE IMPACT OF PATERNAL AGE ON REPRODUCTIVE OUTCOME IN ICSI-DONOR CYCLES: A COMPARISON BETWEEN FRESH AND VITRIFIED SPERMATOZOA. A. Parrella

P-589 ANTIOXIDANT THERAPY FOR MALE INFERTILITY – 3 MONTH OR 6 MONTHS: WHICH IS BETTER? S. Kuroda

P-590 COMBINED TESTOSTERONE ENANTHATE AND HUMAN CHORIONIC GONADOTROPIN (HCG) THERAPY FOR HYPERGONADOTROPIC HYPOGONADAL MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA UNDERGOING MICROSCOPIC TESTICULAR SPERM EXTRACTION (MICROTESE). T. Kohn

P-591 CLINICAL OUTCOMES FOLLOWING ICSI CYCLES USING TESTICULAR SPERM IN OBSTRUCTIVE (OA) VS. NON-OBSTRUCTIVE (NOA) AZOOSPERMIA AND THE IMPACT OF MATERNAL AND PATERNAL AGE: A SART DATABASE STUDY S. Sadek
P-592  A PHARMACOVIGILANCE STUDY OF HUMAN CHORIONIC GONADOTROPIN-ASSOCIATED ADVERSE EVENTS IN MALES. K. Y. AlKhatib

P-593  LIABILITY FOR USE OF SPERM OUTSIDE SPERM STORAGE CONTRACT PROVISIONS AND WITHOUT CONSENT. M. A. Rasouli

P-594  PLAYING NICE IN THE SANDBOX: FACTORS ASSOCIATED WITH A COLLABORATIVE REFERRAL RELATIONSHIP BETWEEN MALE INFERTILITY SPECIALISTS AND REPRODUCTIVE ENDOCRINLOGISTS. K. Asanad

P-595  IMPACT OF DIET ON SPERM OXIDATION-REDUCTION POTENTIAL. N. Sayme

P-596  IS THERE A ROLE FOR USE OF SURGICALLY RETRIEVED TESTICULAR SPERMS IN INDIVIDUALS WITH CRYPTOZOOSPERMIA? K. Mantravadi

P-597  ADVANCED PATERNAL AGE AND SPERM DNA FRAGMENTATION: A SYSTEMATIC REVIEW. D. Gonzalez

P-598  LOW PERCENTAGE MOTILITY WHEN SPERM CONCENTRATION IS NORMAL DOES NOT APPEAR TO BE A CAUSE OF UNEXPLAINED FAILURE TO HAVE A LIVE DELIVERY DESPITE IN VITRO FERTILIZATION (IVF). J. H. Check

P-599  INFLUENCE OF INGUINAL HERNIA REPAIR ON SPERM AUTOIMMUNITY: THE LARGEST SINGLE CENTER EXPERIENCE. P. Levi Setti

P-600  TESTICULAR BIOPSY IN OBSTRUCTIVE AZOOSPERMIC MEN: DO THE DONOR OR THE AUTOLOGOUS OOCYTES HAVE AN IMPACT ON THE CLINICAL OUTCOMES? A. Parrella

P-601  TEMPORAL DECLINE IN SEMEN PARAMETERS IN INDIAN MEN WITH MALE FACTOR AND NON-MALE FACTOR INFERTILITY. P. Makwana

P-602  EFFECT OF CONTINUOUS LOW DOSE OF R-FSH FOR IDIOPATIC OAT IN NORMOGONADOTROPIC OAT IN NORMOGONADOTROPIC OAT. S. Diaz Ibarra

P-603  IS AGE MORE THAN JUST A NUMBER? CHARACTERISTICS OF MEN PRESENTING FOR REPRODUCTIVE UROLOGY FERTILITY EVALUATION IN NORTH AMERICA STRATIFIED BY AGE GROUPS. K. Asanad

P-604  SPERM DNA FRAGMENTATION TEST IN ADDITION TO GENERAL SEMEN TEST MAY LEAD TO ELUCIDATION OF POTENTIAL FACTORS FOR PREDICTING IVF OUTCOMES. T. Okubo

P-605  ASSOCIATION BETWEEN TESTOSTERONE THERAPY AND CHANGE IN HEMATOCRIT: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROL TRIALS. S. Nackeeran

PSW-15 POSTER SESSION: MENOPAUSE

P-606  CLINICAL IMPACT OF HORMONE REPLACEMENT THERAPY ON LONE ATRIAL FIBRILLATION IN POSTMENOPAUSAL WOMEN: A NATIONWIDE COHORT STUDY. J. Lee

P-607  OVULATION INDUCTION AND SUCCESSFUL LIVE DELIVERY IN A 46.5-YEAR-OLD WOMAN IN OVERT MENOPAUSE BY RESTORING FOLLICULAR SENSITIVITY TO FOLLICLE STIMULATING HORMONE (FSH). J. H. Check

P-608  ASSOCIATION BETWEEN ANTI-MULLERIAN HORMONE AND MOTHER'S AGE AT MENOPAUSE. J. Selter

PSW-16 POSTER SESSION: MENTAL HEALTH

P-609  ANXIETY AND DEPRESSION IN PATIENTS UNDERGOING OOCYTE CRYOPRESERVATION AND INFERTILITY. A. Wang

P-610  EFFECT OF MUSIC THERAPY ON ANXIETY LEVELS AMONG INFERTILE WOMEN UNDERGOING IVF PROCEDURES: A RANDOMIZED CONTROL TRIAL. H. Vaithianathan

P-611  INFLUENCE OF PATIENT CHARACTERISTICS ON SUPERNUMERARY EMBRYO DISPOSITION DECISIONS. J. S. Hynes

P-612  EFFECTS OF PSYCHOLOGICAL SUPPORT ON COPING STRATEGIES AND QUALITY OF LIFE IN INFERTILE COUPLES: A LONGITUDINAL CASE-CONTROL STUDY. P. Salvatori

P-613  PSYCHOLOGICAL DISTRESS IN WOMEN CONSIDERING OR UNDERGOING FERTILITY TREATMENTS DURING THE COVID-19 PANDEMIC. L. A. Kassi

P-614  EVOLUTION OF ANXIETY AND DEPRESSION AMONG LONG TERM INFERTILE HETEROSEXUAL COUPLES. O. Kaabia

P-615  QUALITATIVE INSIGHTS INTO INFERTILITY PATIENT DISCONTINUATION OF CARE: RESULTS OF A NATIONWIDE SURVEY. B. L. Collura

P-616  PENILE PROSTHESIS IS PROTECTIVE AGAINST MAJOR DEPRESSIVE DISORDER IN MEN WITH ERECTILE DYSFUNCTION: A MULTICENTER RESEARCH NETWORK STUDY. S. Nackeeran

P-617  VACCINE HESITANCY AND MEDICAL MISTRUST IN WOMEN CONSIDERING OR UNDERGOING FERTILITY TREATMENTS. L. A. Kassi

P-618  DIFFERENCES IN ANXIETY CONCERNING THE COVID-19 VIRUS AND COVID-19 VACCINE BETWEEN WOMEN UNDERGOING INFERTILITY TREATMENT AND THOSE NOT PURSUING TREATMENT. A. Kwok
| P-619 | ASSOCIATIONS BETWEEN COVID-19 PANDEMIC CONDITIONS AND MATERNAL MENTAL HEALTH AND MATERNAL-INFANT BONDING. E. L. Kelley | EMBRYOS AFFECT FROZEN EMBRYO TRANSFERS (FET) OUTCOMES? J. Shaw |
| P-620 | THE PSYCHOLOGICAL IMPACT OF THE COVID-19 PANDEMIC ON WOMEN PREGNANT FOLLOWING ART: A LONGITUDINAL STUDY. A. D. Domar | IN VITRO FERTILIZATION OUTCOMES IN PCOS PATIENTS WITH ELEVATED BASAL LUTEINIZING HORMONE DURING A GONADOTROPIN-RELEASING HORMONE ANTAGONIST CYCLE: A RETROSPECTIVE COHORT STUDY. S. Xiao |
| P-621 | ATTITUDES AND PERCEIVED IMPACT OF THE COVID-19 PANDEMIC ON FERTILITY TREATMENT AND CONCEPTION PLANNING AMONG HEALTHCARE WORKERS WITH INFERTILITY. R. K. Chung | DELAYING OVULATION TRIGGERING DOESN'T COMPROMISE CUMULATIVE PREGNANCY RATES IN FROZEN EMBRYO TRANSFER. S. Cambray |
| P-622 | THE RELATIONSHIP BETWEEN DIENOGEST (VISANNE®) AND DEPRESSIVE SYMPTOMS: A PROSPECTIVE COHORT STUDY. S. Choo | DO THE RIGHT AND LEFT OVARIAN RESPONSES LABELED AS EQUALLY DURING CONTROLLED OVARIAN STIMULATION? M. Greenman |
| P-623 | WOMEN IN MEDICINE: CAREER VS FAMILY. CAN WE HAVE BOTH? N. Parikh | IMPACT OF GONADOTROPHIN RECEPTOR POLYMORPHISMS ON THE RELATIONSHIP BETWEEN SERUM AMH AND OVARIAN RESPONSE. E. Bosch |
| P-625 | MARITAL ADJUSTMENT AND SEXUALITY AFTER PARENTHOOD IN HETEROSEXUAL COUPLES WHO UNDERWENT ASSISTED REPRODUCTION TECHNIQUES. O. Kaabia | EFFECT OF ORAL GnRH ANTAGONIST RELUGOLIX ON BLOOD HORMONE AND OOCYTE RETRIEVAL: A STUDY OF THE METHOD OF RELUGOLIX ADMINISTRATION -. C. Yamashita |
| P-626 | VIRGINITY TESTING IN THE UNITED STATES: PREVALENCE AND EFFECTS. E. Sheinin | INNOVATIVE CONTROLLED OVARIAN STIMULATION (COS) METHOD FOR SEVERE POLYCYSTIC OVARY SYNDROME (PCOS) WITHOUT OVARIAN HYPERSTIMULATION SYNDROME (OHSS) AND HIGHER OOCYTE QUALITY. A. Tanaka |
| P-627 | PSYCHOLOGICAL WELL BEING AND FERTILITY: HABITS THAT INCREASE HAPPINESS IN WOMEN INCREASE THEIR REPRODUCTIVE CAPACITY. R. S. Iaizzo | INNOVATIVE CONTROLLED OVARIAN HYPERSTIMULATION PROTOCOL FOR POLYCYSTIC OVARY SYNDROME PRODUCES HIGHER QUALITY OOCYTES, THE HIGHEST ACCUMULATIVE PREGNANCY RATE AT ONE CYCLE AND NO OVARIAN HYPERSTIMULATION SYNDROME. Y. Yanagihara |
| PSW-17 POSTER SESSION: OVARIAN STIMULATION | | |
| P-628 | A DOSE FINDING STUDY FOR CONTROLLED OVARIAN STIMULATION FOR INSEMINATION WITH FOLLITROPIN DELTA. S. Arab | PROSTAGLANDIN D2 ASSOCIATION WITH POOR OVARIAN RESPONDER IN FEMALE INFERTILITY. J. H. Lee |
| P-629 | HOW TESTOSTERONE THERAPY IS ADVANTAGEOUS IN IMPROVING THE ART OUTCOME IN POOR OVARIAN RESPONDERS UNDERGOING IVF-ICSI CYCLES. P. C. Jindal | THE PREDICTIVE VALUE OF CHANGES IN PROGESTERONE (P) LEVELS AFTER ADMINISTRATION OF A HUMAN CHORIONIC GONADOTROPIN (HCG) TRIGGER IN IN-VITRO FERTILIZATION (IVF) CYCLES. A. Taggar |
| P-630 | LUTEAL PHASE STIMULATION PROVIDES HIGHER MATURE OOCYTE AND BLASTOCYST YIELD IN PATIENTS UNDERGOING A DOUBLE STIMULATION IN THE SAME OVARIAN CYCLE (DUOSTIM) PROTOCOL. J. A. Moreno-Sepulveda | BILATERAL PLEURAL EFFUSIONS WITHOUT SIGNIFICANT ASCITES IN AN OVARIAN HYPERSTIMULATION PATIENT RECOVERED FROM COVID-19: A CASE REPORT. K. L. Anderson |
| P-631 | LUTEAL PHASE STIMULATION AFTER FOLLICULAR PHASE STIMULATION DURING THE SAME MENSTRUAL CYCLE (DUOSTIM) IN A REDUCED OVARIAN RESERVE POPULATION: WHEN IS IT COST-EFFECTIVE? A. S. Cambiaghi | |
POSTER PRESENTATIONS AND ABSTRACTS

PSW-18 POSTER SESSION: PRACTICE MANAGEMENT

P-644 US CONSUMER MARKET REPORT 2020: AN IVF CONSUMER SENTIMENT ANALYSIS. E. H. Chung

P-645 COST-EFFECTIVENESS OF IN VITRO FERTILIZATION WITH PREIMPLANTATION GENETIC TESTING TO PREVENT TRANSMISSION OF SPINAL MUSCULAR ATROPHY. A. Khorshid

P-646 HIGH LEVEL OF ACCEPTANCE OF GESTATIONAL SURROGACY DESPITE THE ABSENCE OF LEGISLATION IN ARGENTINA. P. Nicotra Perassi

P-647 SURVEY OF NORTH AMERICAN IVF LAB PROFESSIONALS: GOALS AND CHALLENGES. S. K. Jindal

P-648 AVERAGE COST OF IN VITRO FERTILIZATION WITH PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS AND ANEUPLOIDY PER UNAFFECTED LIVE BIRTH FOR CARRIER COUPLES. A. Khorshid

P-649 EXCESSIVE FLUSHING MAY REDUCE IVF CYCLE CANCELLATIONS BY ENABLING EGG RETRIEVAL AND MAY PROVIDE POSITIVE OUTCOMES IN ONLY SINGLE FOLLICLE-DEVELOPED POOR RESPONDERS. M. Aygun

P-650 PATIENT PERSPECTIVES OF TELEHEALTH FOR FERTILITY CARE: A NATIONAL SURVEY. I. L. Lersten

P-651 BENEFITS AND DRAWBACKS OF WORKING WITHIN AN IVF LAB NETWORK: A SURVEY OF CLINICAL EMBRYOLOGISTS. C. L. Curchoe Burton

P-652 TRENDS IN FROZEN EMBRYO TRANSFERS (FET) AT A SINGLE ACADEMIC INTUITION FROM 2015-2019. D. Miranian

P-653 A COLLABORATIVE ASSESSMENT TO MEASURE VARIANCE IN CRYOSPECIMEN RETRIEVAL METHODS ACROSS MULTIPLE IVF CLINICS. R. Gupta

P-654 IVF CLINIC POLICIES- ARE THEY ACCESSIBLE TO THE PATIENT VIA THE CLINIC’S WEBSITE? A. M. Lewis

PSW-19 POSTER SESSION: PREIMPLANTATION GENETIC TESTING

P-655 THE CONCORDANCE RATES OF AN INITIAL TROPHECTODERM BIOPSY WITH THE REST OF THE EMBRYO USING PGTSEQ, A TARGETED NEXT-GENERATION SEQUENCING PLATFORM. J. G. Kim

P-656 YOUNGER PATIENTS ARE MORE LIKELY TO HAVE MOSAIC-ONLY EMBRYOS DUE TO THEIR LOWER LIKELIHOOD OF AGE-RELATED WHOLE CHROMOSOME ANEUPLOIDY. C. Hernandez-Nieto

P-657 COMPARISON OF EUPLID DONOR EGG BLASTOCYST EXPANSION WITH SUBGROUPS OF SINGLE CHROMOSOME, MULTIPLE CHROMOSOME, AND SEGMENTAL ANEUPLOIDY CALLS USING AN AI PLATFORM. T. T. Huang

P-658 CLINICAL OUTCOMES OF MOSAIC EMBRYO TRANSFER: WHAT KIND OF MOSAICISM HAVE HIGHER POTENTIAL TO GET PREGNANT? J. Huayhua

P-659 VALIDATION OF AN INTEGRATED PGT-A STRATEGY FOR PARALLEL ASSESSMENT OF ANEUPLOIDY, PLOIDY LEVEL, AND PRESENCE OF MAJOR MICRODELETIONS IN A SINGLE TROPHECTODERM BIOPSY. A. Capalbo

P-660 NEWBORNS DERIVED FROM EMBRYOS SHOWING LOW/MODERATE-DEGREE MOSAICISM DO NOT EXHIBIT CHROMOSOMAL ABERRATIONS OR UNIPARENTAL DISOMY PROFILES. A. Capalbo

P-661 DOES THE MOSAIC EMBRYO RATIO OF PGT-A CYCLES IMPACT THE LIVE BIRTH CHANCE EVEN WHEN AN EUPLID EMBRYO IS TRANSFERRED? M. Cetinkaya

P-662 IS DAY OF BIOPSY A PREDICTOR OF OUTCOMES FOLLOWING MOSAIC EMBRYO TRANSFER? A. M. Wiltshire

P-663 INFERTILITY DIAGNOSIS AND MOSAICISM RATE. G. M. Grant

P-664 INTRODUCTION OF EXPANDED CARRIER SCREENING (ECS) HAS INCREASED REFERRALS FOR PREIMPLANTATION GENETIC TESTING FOR MONOGENIC CONDITIONS (PGT-M). R. Mnushkin

P-665 THE EFFECT OF INSEMINATION METHODS ON EMBRYO MOSAICISM IN PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) CYCLES. J. L. Matucha

P-666 AN ANALYSIS OF THE EFFECT OF MATERNAL AGE ON SEGMENTAL CHROMOSOMAL ANEUPLOIDY. J. Reich

P-667 AN ANALYSIS OF THE EFFECT OF MATERNAL AGE ON SEGMENTAL CHROMOSOMAL ANEUPLOIDY. J. Reich

P-668 DO FMR1 MUTATIONS IMPACT ANEUPLOIDY RATES IN EMBRYOS? N. Wemmer

P-669 CHROMOSOMAL CONSTITUTION IN RELATION WITH CHROMOSOMAL LENGTH IN BLASTOCYSTS OF YOUNG WOMEN. P. Villanueva
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-672</td>
<td>Quantification of the Mitochondrial DNA to Assess Embryo Potential and Its Impact on Reproductive Outcomes.</td>
<td>M. Fabbro</td>
</tr>
<tr>
<td>P-673</td>
<td>The Utility of Preimplantation Genetic Testing for Aneuploidy During IVF in Patients with Different Infertility Diagnoses.</td>
<td>P. Sarkar</td>
</tr>
<tr>
<td>P-674</td>
<td>Expanded Carrier Screening and Clinical Decision Making in 2020.</td>
<td>A. Namath</td>
</tr>
<tr>
<td>P-675</td>
<td>Concordance Rates Between Embryonic Cell-Free DNA and Trophoderm Biopsy from Fresh and Frozen-Thawed Blastocysts.</td>
<td>D. Monahan</td>
</tr>
<tr>
<td>P-676</td>
<td>The Impact of Culture Conditions and Genetics Testing Methodologies on Non-Invasive Preimplantation Genetic Testing (NI-PGT) Results.</td>
<td>A. Jones</td>
</tr>
<tr>
<td>P-677</td>
<td>Preimplantation Genetic Testing (PGT) Significantly Increases Implantation and Live Birth Rates in Patients of All Age Groups Undergoing IVF.</td>
<td>L. Y. Ying</td>
</tr>
<tr>
<td>P-678</td>
<td>Results of Prenatal Diagnosis After Mosaic Embryo Transfer Indicate Low Risk of Fetal Chromosome Abnormality.</td>
<td>A. G. Besser</td>
</tr>
<tr>
<td>P-680</td>
<td>Associations Between Preimplantation Genetic Testing and Adverse Obstetric and Neonatal Outcomes.</td>
<td>S. E. Speedy</td>
</tr>
<tr>
<td>P-681</td>
<td>Outcome of Simultaneous Preimplantation Genetic Testing (PGT) for Aneuploidy and Hereditary Breast Cancer (PGT-A/M) for Fertility Preservation or Prevention of Vertical Transmission.</td>
<td>M. Madjunkov</td>
</tr>
<tr>
<td>P-682</td>
<td>Effect of Trophoderm Biopsy for PGT-A on Live Birth Rate Per Embryo in Good Prognosis Patients.</td>
<td>M. S. Awadalla</td>
</tr>
<tr>
<td>P-683</td>
<td>Amplification Rate and Ploidy Concordance of Two Different Protocols for Noninvasive Preimplantation Genetic Testing for Aneuploidy (NIPGT-A).</td>
<td>O. Ocali</td>
</tr>
<tr>
<td>P-684</td>
<td>The Impact of Implementing a Noninvasive Preimplantation Genetic Testing for Aneuploidy (NIPGT-A) Protocol on Outcomes.</td>
<td>O. Ocali</td>
</tr>
<tr>
<td>P-686</td>
<td>Assessment of Bioskryb Whole Genome Amplification Methodology for Genome-Wide Assessment for SNPs and Indels Using Illumina Whole Genome Sequencing.</td>
<td>N. A. Rouse</td>
</tr>
<tr>
<td>P-687</td>
<td>The Incidence of Complex Chromosomal Abnormality (CCA) in Human Embryos Is Age-Dependent and Follows a U-Curve Over Female Reproductive Age.</td>
<td>F. Wang</td>
</tr>
<tr>
<td>P-688</td>
<td>Do All Women Aged 43 and Over Have the Same Chance of Pregnancy Using Autologous Oocytes with ART? Which Patients Have a Higher Chance of Pregnancy?</td>
<td>I. N. Balin Duzguner</td>
</tr>
<tr>
<td>P-689</td>
<td>Does Having a Genetic Counselor Change the Utilization of Preimplantation Genetic Testing?</td>
<td>P. Singh</td>
</tr>
<tr>
<td>P-690</td>
<td>Artificial Intelligence Increases Euploidy Rate and Clinical Pregnancy Rate in Single Thawed Euploid Embryo Transfer and Decreases the Rate of Mosaic Results.</td>
<td>R. N. Salasin</td>
</tr>
<tr>
<td>P-691</td>
<td>The Relationship Between Anti-Mullerian Hormone and Aneuploidy in Patients Undergoing in Vitro Fertilization with Preimplantation Genetic Testing.</td>
<td>E. S. Rubin</td>
</tr>
<tr>
<td>P-694</td>
<td>Preimplantation Genetic Testing for BRCA: 10 Years of Experience at a Large Academic Fertility Center.</td>
<td>F. Barrett</td>
</tr>
<tr>
<td>P-695</td>
<td>Day 7 Embryo Morphology is Not Predictive of Biopsy Results.</td>
<td>J. R. Walter</td>
</tr>
<tr>
<td>P-696</td>
<td>Examination of Inter Centre Variation in PGT-A “No Result Rate” and Efficacy of Rebiopsy - Analysis of 22,833 Samples 2015-2019.</td>
<td>C. A. Lynch</td>
</tr>
<tr>
<td>P-697</td>
<td>Comparison of Four National Reproductive Genetics Lab PGT-A Results from Vitrified Donor Eggs.</td>
<td>J. D. Bardos</td>
</tr>
<tr>
<td>P-698</td>
<td>Does the PGT-A Shorten the Time to Pregnancy in an Egg Donation Program?</td>
<td>M. B. Miguens</td>
</tr>
<tr>
<td>P-699</td>
<td>PGT-M to Prevent 2 or 3 Genetic Disorders, Mostly Dominant.</td>
<td>A. Peyser</td>
</tr>
<tr>
<td>P-700</td>
<td>Factors Affecting Embryo Aneuploidy.</td>
<td>B. S. Shapiro</td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>P-701</td>
<td>RECURRENT IMPLANTATION FAILURE – ROLE OF PGT AND ERA TO OPTIMIZE REPRODUCTIVE OUTCOMES?</td>
<td>D. G. Rao</td>
</tr>
<tr>
<td>P-702</td>
<td>RETROSPECTIVE ANALYSIS OF 479 PGT-SR CYCLES - ANALYSIS OF CHROMOSOME INFORMATION AND AVAILABILITY OF EMBRYOS FOR TRANSFER</td>
<td>C. A. Lynch</td>
</tr>
<tr>
<td>P-703</td>
<td>RETROSPECTIVE ANALYSIS OF RE-BIOPSIED MOSAIC BLASTOCYSTS, AS IT PERTAINS TO GENETIC COUNSELING PRACTICES</td>
<td>A. Harutunian</td>
</tr>
<tr>
<td>P-704</td>
<td>CHROMOSOME ANOMALIES DO NOT INCREASE IN RESCUE-IVM OOCYTES: ANALYSIS OF TROPHECTODERM BIOPSIES BY NEXT-GENERATION SEQUENCING FOR PREIMPLANTATION GENETIC TESTING</td>
<td>R. Matsunaga</td>
</tr>
<tr>
<td>P-705</td>
<td>CLINICAL UTILITY OF HUMAN REVIEW: EXPERIENCE WITH PREVIOUSLY UNKNOWN REARRANGEMENT CARRIERS USING FAST-SEQS, A NEXT-GENERATION SEQUENCING PGT ASSAY</td>
<td>L. Walters-Sen</td>
</tr>
<tr>
<td>P-706</td>
<td>THE USE OF ARTIFICIAL INTELLIGENCE (AI) IN INTERPRETING THE VALIDITY OF MITOSENSE</td>
<td>D. Naik</td>
</tr>
<tr>
<td>P-707</td>
<td>GENETIC SEGREGATION OF MITOCHONDRIAL 3697G&gt;A MUTATION IN PGD CYCLES</td>
<td>D. Ji</td>
</tr>
<tr>
<td>P-708</td>
<td>REPORTING EMBRYO MOSAICISM USING PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A): IMPACT ON EUPLOIDY RATE AND LIKELIHOOD OF EMBRYOS AVAILABLE FOR TRANSFER</td>
<td>A. Armstrong</td>
</tr>
<tr>
<td>P-709</td>
<td>NATIONAL TRENDS AND OUTCOMES FOR PRE-IMPLANTATION GENETIC TESTING IN THE UNITED STATES, 2014-2018</td>
<td>H. S. Hipp</td>
</tr>
<tr>
<td>P-710</td>
<td>GENETIC REFERRALS FOR PRE-PGT-M NEEDS; OPPORTUNITIES FOR COLLABORATION ON SETTING PATIENT EXPECTATIONS</td>
<td>P. Callum</td>
</tr>
<tr>
<td>P-711</td>
<td>DOES TROPHECTODERM BIOPSY IN PREIMPLANTATION GENETIC TESTING AFFECT SERUM BETA HCG LEVELS?</td>
<td>D. G. Rao</td>
</tr>
<tr>
<td>P-712</td>
<td>VALUE OF PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) IN THE CONTEXT OF IN VITRO FERTILIZATION (IVF) USING DONOR OOCYTES</td>
<td>S. Daneshmand</td>
</tr>
<tr>
<td>P-713</td>
<td>PREVALENCE OF SPECIFIC CHROMOSOME-LEVEL ANOMALIES IN MOSAIC AND ANEUPLOID EMBRYOS</td>
<td>D. Aharon</td>
</tr>
<tr>
<td>P-714</td>
<td>INITIAL DEVELOPMENT OF A LIBRARY PREPARATION AND ANALYSIS PROTOCOL FOR PREIMPLANTATION GENETIC TESTING OF CHROMOSOMAL STRUCTURAL REARRANGEMENTS USING OXFORD NANOPORE TECHNOLOGIES (ONT)</td>
<td>M. Wilmarth</td>
</tr>
<tr>
<td>P-715</td>
<td>PGT-M FOR AUTOSOMAL RECESSIVE CARRIERS OF CONDITIONS WITH AN AUTOSOMAL DOMINANT CANCER RISK: A CALL FOR ACTION</td>
<td>A. Peyser</td>
</tr>
<tr>
<td>P-716</td>
<td>PGT-A SINGLE FROZEN BLASTOCYST TRANSFER IMPROVES OUTCOMES AND REDUCES AGE-RELATED DECLINE IN PREGNANCY COMPARED TO UNTESTED SINGLE FROZEN BLASTOCYST TRANSFERS</td>
<td>R. Holmes</td>
</tr>
<tr>
<td>P-717</td>
<td>USABLE EMBRYOS POST PGT-M FOR ATAXIA-TELANGIECTASIA-MUTATED GENE: RECESSIVE VS. DOMINANT</td>
<td>A. Peyser</td>
</tr>
<tr>
<td>P-718</td>
<td>THE ASSOCIATION BETWEEN SELF-REPORTED RACE AND EMBRYONIC MOSAICISM</td>
<td>R. A. Frankel</td>
</tr>
<tr>
<td>PSW-20</td>
<td>POSTER SESSION: PUBLIC HEALTH AND REPRODUCTION</td>
<td></td>
</tr>
<tr>
<td>P-719</td>
<td>HPV VACCINATION RATE AMONGST WOMEN PRESENTING FOR FERTILITY CARE</td>
<td>S. L. Estevez</td>
</tr>
<tr>
<td>P-720</td>
<td>INCORPORATING DIRECT PATIENT HEALTH OUTCOMES INTO CLINICAL TRIALS FOR THE PREVENTION OF UROGENITAL CHLAMYDIA TRACHOMATIS INFECTION: ANALYSIS OF A NOVEL ENDPOINT IN A CLINICAL TRIAL OF EVO100 (EVO-003)</td>
<td>B. Howard</td>
</tr>
<tr>
<td>P-721</td>
<td>A POLYCYSTIC OVARY SYNDROME DIAGNOSIS IS A MARKER OF SOCIOECONOMIC ADVANTAGE</td>
<td>K. V. Actkins</td>
</tr>
<tr>
<td>P-722</td>
<td>CHARACTERISTICS OF WOMEN REPORTING INFERTILITY IN THE WOMEN’S HEALTH INITIATIVE: CROSS-SECTIONAL STUDY</td>
<td>A. Wang</td>
</tr>
<tr>
<td>P-724</td>
<td>PREVALENCE OF OBSTRUCTIVE SLEEP APNEA IN WOMEN SEEKING FERTILITY TREATMENT</td>
<td>B. Leenann</td>
</tr>
<tr>
<td>P-725</td>
<td>REPRODUCTIVE ORIGINS OF ALLERGIES IN CHILDREN</td>
<td>M. Q. Gowett</td>
</tr>
<tr>
<td>P-726</td>
<td>SIDE EFFECTS BY FREQUENCY OF USE WITH EVO100 VAGINAL GEL: RESULTS FROM THE PHASE 2B/3 AMPREVENCE TRIAL</td>
<td>B. Howard</td>
</tr>
<tr>
<td>P-727</td>
<td>INTERNAL VAGINAL DOUCHING INCREASES THE RATE OF VAGINAL INFECTION IN INTRAUTERINE CONTRACEPTIVE DEVICE USERS: A CROSS SECTIONAL STUDY</td>
<td>A. M. Abbas</td>
</tr>
<tr>
<td>P-728</td>
<td>PREDICTION OF PREGNANCY POSSIBILITY USING MACHINE LEARNING BASED ON THE CHARACTERISTICS OF PATIENTS AND EMBRYO GRADE IN IVF-ET CYCLES</td>
<td>S. Lee</td>
</tr>
</tbody>
</table>
P-731 OVARIAN RESPONSE AND BLASTULATION RATES OF FERTILIZED OOCYTES FROM SUPEROVULATED FEMALE MICE TREATED WITH DEPOT LEUPROLIDE ACETATE (LA) AND TESTOSTERONE CYPIONATE (T): IMPLICATIONS FOR THE FERTILITY CARE OF TRANSGENDER MALES. P. N. Godiwala

P-732 QUANTIFICATION OF EMBRYONIC MITOCHONDRIAL DNA CONTENT ONLY REFLECTS BLASTOCYST DEVELOPMENTAL STAGE AND NOT CLINICAL OUTCOMES. C. Wageman

P-733 THE MICROBIOME OF THE REPRODUCTIVE TRACT DOES NOT IMPACT REPRODUCTIVE OUTCOMES. N. S. Herlihy

P-734 DEVELOPMENT OF A METHOD TO STUDY SEQUENTIAL PROLIFERATION WITHIN HUMAN OVARIAN FOLLICLES UTILIZING THYMIDINE ANALOGUE INCORPORATION. N. Lustgarten Guahmich

P-735 THE DYNAMIC AGEING TRANSCRIPTOME ARCHITECTURE OF THE OVARY, FOLLICLE, AND OOCYTE. M. E. Haywood

P-736 THE INTERPLAY BETWEEN NUCLEAR MEIOTIC ERRORS AND MITOCHONDRIAL DNA CONTENT DRIVE OOCYTE ANEUPLOIDY. J. C. Parks

P-737 FERTILIZATION OF OOCYTES GENERATED FROM SOMATIC CELL HAPLOIDIZATION. A. Trout

P-738 IDENTIFICATION OF ASSOCIATED GENES AND PATHWAYS IN CYCLOPHOSPHAMIDE-INDUCED PRIMORDIAL FOLLICLE DEPLETION USING A MOUSE MODEL. X. Hao

P-739 MITOCHONDRIAL DYSFUNCTION CAUSED BY TARGETED DELETION OF CLPP RESULTS IN TELOMERE SHORTENING IN OOCYTES AND SOMATIC CELLS. M. Cozzolino

P-740 CHARACTERIZATION OF TELOMERES IN HUMAN ANEUPLOID BLASTOCYSTS. F. Wang

P-741 TRANSCRIPTOMIC ANALYSIS REVEALS ALTERED GENE EXPRESSION IN MICE OOCYTES DURING THE PUBERAL TRANSITION. E. Babayev

P-742 EXPRESSION OF RELAXIN AND RELAXIN FAMILY PEPTIDE RECEPTOR ARE ALTERED FOLLOWING SUPEROVULATION WITH HUMAN CHORIONIC GONADOTROPHIN AND GONADOTROPIN RELEASING HORMONE AGONIST TRIGGERS IN EARLY AND MID-GESTATION IN A MOUSE ART MODEL. C. Burks

P-743 CALORIC RESTRICTION INCREASES OVARIAN FOXO3A EXPRESSION IN A MOUSE MODEL OF DELAYED AGING: IMPLICATIONS FOR REPRODUCTIVE LONGEVITY. N. C. Llarena

P-744 CANNABIS SIGNIFICANTLY ALTERS DNA METHYLATION OF THE HUMAN OVARIAN FOLLICLE IN A DOSE-DEPENDENT MANNER. N. Fuchs Weizman

P-745 URINARY AND RECOMBINANT FOLLICLE-STIMULATING HORMONE IN SUPPORTING PRIMATE FOLLICULAR DEVELOPMENT IN VITRO. F. Xu

P-746 TGF-B SIGNALING REGULATES WNT/B-Catenin PATHWAY IN UTERINE LEIOMYOMA CELLS. M. El Sabeh

P-747 TOTAL RNA CONCENTRATION IN BLASTOCOEFLUID-CONDITIONED BIOPSY MEDIA VARIES WITH EMBRYO PLOIDY STATUS. M. A. Riehs

P-748 SINGLE CELL RNA-SEQ ANALYSIS OF THE HUMAN FALLOPIAN TUBE PROVIDES INSIGHTS INTO THE PATHOPHYSIOLOGY OF THE HYDROSALPINX DISEASE STATE. N. D. Ulrich

P-749 LIVER AND ADIPOSE TISSUES OF MICE CONCEIVED BY IN VITRO FERTILIZATION (IVF) SHOW INCREASED OXIDATIVE DAMAGE. A. Portugal

P-750 EXTENDED EXPOSURE TIME TO EMBRYOGLUE™ RESULTS IN IMPROVED MOUSE FETAL DEVELOPMENT. H. Joris

P-751 CYTOLOGICAL ANALYSIS OF SPERM PENETRATION AND ARREST OF FERTILIZATION IN MATURE OOCYTES THAT DID NOT FORM PRONUCLEI FOLLOWING CONVENTIONAL IVF. D. Kuzuhara

P-752 USING AUTOMATED CAPILLARY GEL ELECTROPHORESIS TO DETECT MULTIPLE PROTEINS FROM SINGLE OOCYTE AND BLASTOCYST. S. A. Khan

P-753 PROTEIN EXPRESSION OF UBIQUITIN C-TERMINAL HYDROLASE L1 (UCHL1) RISES AS OOCYTES SUCCESSFULLY TRANSITION TO LONG TERM QUIESCENCE. M. C. Ozcan

P-754 GLYCOSYLATION FEATURES OF FOLLITROPIN DELTA (REKOVELLE®) MORE RESEMBLE THOSE OF NATURAL HUMAN FSH COMPARED TO FOLLITROPIN ALFA (GONAL F®). S. Jespersen

P-755 INCREASED AGE AND BODY MASS INDEX RELATES TO INCREASED TIME-LAPSE VARIABILITY AMONG EMBRYOS FROM THE SAME CYCLE. D. Parvanov

P-756 SIMVASTATIN SUPPRESSES PROLIFERATION, EXTRACELLULAR MATRIX ACCUMULATION AND Wnt4/B-Catenin PATHWAYS IN HUMAN LEIOMYOMA STEM CELLS. S. Afrin

P-757 CHARACTERIZATION OF UMBILICAL CORD TISSUE MESENCHYMAL STEM CELLS BASED ON DONOR SEX FOR PREMATUREROVARIAN INSUFFICIENCY. K. S. Brown
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-758</td>
<td>Polymeric and Collagen Biomaterials Enhance Implantation of Mouse Blastocysts in Three-Dimensional Culture Models.</td>
<td>Y. Ergun</td>
</tr>
<tr>
<td>P-759</td>
<td>Local Activation of Glucocorticoid Signaling in Uterine Fibroid Cells Drives Growth.</td>
<td>T. L. Glenn</td>
</tr>
<tr>
<td>P-760</td>
<td>Effect of HCG on Human Peripheral Blood Mononuclear Cells (PBMC) Secretion of Pro- and Anti-Inflammatory Cytokines.</td>
<td>D. Parvanov</td>
</tr>
<tr>
<td>P-761</td>
<td>Study of the Premature Fertility Decay in Senescence Accelerated Mouse Prone 8 (SAMP8) and Its Relationship with Systemic Age.</td>
<td>A. M. Polonio</td>
</tr>
<tr>
<td>P-762</td>
<td>Weakness of Karyoplast Deteriorate the Quality of Aged Human MII Oocyte.</td>
<td>H. Liu</td>
</tr>
<tr>
<td>P-763</td>
<td>Hypoxia-Hindered Methylation of Ptgs in Endometrial Stromal Cells Accelerates Endometriosis Progression by Inducing CD16+ NK Cells Differentiation.</td>
<td>H. Peng</td>
</tr>
<tr>
<td>P-764</td>
<td>Autophagy Induction Rescues DNA Damage Response in Mouse Oocytes.</td>
<td>F. Sun</td>
</tr>
<tr>
<td>P-765</td>
<td>Microbial Flora Changes in Caesarean Section Uterus and Its Possible Correlation.</td>
<td>X. Yang</td>
</tr>
<tr>
<td>P-766</td>
<td>Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model.</td>
<td>M. Ulin</td>
</tr>
<tr>
<td>P-767</td>
<td>Oral Administration of Sodium Tungstate in Healthy Women of Childbearing Age is Safe and Well-Tolerated. Results of Two Phase I Studies of a Drug in Development to Treat Female Infertility.</td>
<td>A. Agnes</td>
</tr>
<tr>
<td>P-768</td>
<td>Knockdown of Dnm11 and Dnm13a Enzymes Disrupts Preimplantation Embryo Development by Affecting Global DNA Methylation.</td>
<td>F. Uysal</td>
</tr>
<tr>
<td>P-769</td>
<td>Using Live Imaging and Fucci ESC to Distinguish G1 Cell Cycle Delays for General Stressors like BPA or G2 Cell Cycle Delay for Mutagenic Stressors like Benzo(A)Pyrene.</td>
<td>E. E. Puscheck</td>
</tr>
<tr>
<td>P-770</td>
<td>Maternal and Paternal Age Contributions to Fertility Outcomes in the Mouse.</td>
<td>J. L. Balough</td>
</tr>
<tr>
<td>P-771</td>
<td>Indomethacin Can Protect Placental Inflammation and Delay Preterm Birth in the LPS-Induced Preterm Delivery Model.</td>
<td>S. Avci</td>
</tr>
<tr>
<td>P-772</td>
<td>Formononetin Inhibits Proliferation of Endometriosis via Down-Regulation of p27-Perk-pStat3-Twist1 Pathway.</td>
<td>Y. Park</td>
</tr>
<tr>
<td>P-773</td>
<td>Sodium Tungstate Increases Embryo Implantation and Reproductive Efficiency in Sprague-Dawley Rats.</td>
<td>I. Canals</td>
</tr>
<tr>
<td>P-774</td>
<td>Pro- and Anti-Inflammatory Cytokines (TNF-a, IL-6, IL-4, IL-10) Secretion from PBMC.</td>
<td>R. Ganeva</td>
</tr>
<tr>
<td>PSW-22</td>
<td>Poster Session: Reproductive Surgery</td>
<td></td>
</tr>
<tr>
<td>P-775</td>
<td>Follicular Activation in Poor Ovarian Responders (FAPPOR): A Randomized Controlled Trial.</td>
<td>C. Diaz-Garcia</td>
</tr>
<tr>
<td>P-776</td>
<td>Severity of Intrauterine Adhesions at Time of Surgery and Not the Endometrial Thickness Prior to Subsequent Cycle Determines Clinical Pregnancy Rate.</td>
<td>S. Elder</td>
</tr>
<tr>
<td>P-777</td>
<td>A Novel Use of a Tissue Oxygenation Monitor at Time of Uterine Transplantation and Hysterectomy – A Feasibility Study.</td>
<td>J. Applebaum</td>
</tr>
<tr>
<td>P-778</td>
<td>Clinical Analysis of Pregnancy Outcome of Intrauterine Adhesions.</td>
<td>Y. Chang</td>
</tr>
<tr>
<td>P-779</td>
<td>The Effect of Laparoscopic Surgery Under General Anesthesia on Pregnancy Outcomes in Patients with Heterotopic Pregnancy Following IVF-ET.</td>
<td>J. Chen</td>
</tr>
<tr>
<td>P-780</td>
<td>Hidden in Plain Sight- Cesarean Section Scar and Secondary Infertility. Clinical Pregnancy Following Laparoscopic-Hysteroscopic Repair of Niche: A Retrospective Cohort Study.</td>
<td>J. M. Jackman</td>
</tr>
<tr>
<td>P-781</td>
<td>Obstructed Hemivagina and Ipsilateral Renal Anomaly Syndrome: A Nonclassical Presentation with an Intercervical Communication.</td>
<td>M. N. Wilhoite</td>
</tr>
<tr>
<td>P-782</td>
<td>A Comparative Study of Hysteroscopic Repair and Transvaginal Repair in the Management of Patients with Post Cesarean Scar Defect.</td>
<td>Y. Chang</td>
</tr>
<tr>
<td>P-783</td>
<td>Primary Omental Ectopic Pregnancy After Frozen-Thawed Single Embryo Transfer: A Case Report and Review of the Literature.</td>
<td>P. N. Godiwala</td>
</tr>
<tr>
<td>P-784</td>
<td>Effectiveness of Hyaluronan Gel, Intrauterine Device and Their Combination for Prevention Adhesions in Patients after Intrauterine Surgery: Systematic Review and Meta-Analysis.</td>
<td>L. Pivazyan</td>
</tr>
<tr>
<td>P-785</td>
<td>Uterine Torsion and Preserved Reproductive Function: The Rarest Case in Clinical Practice of Pediatric Gynecologist.</td>
<td>L. Pivazyan</td>
</tr>
</tbody>
</table>
PSW-23 POSTER SESSION: THIRD PARTY REPRODUCTION

P-787 PERINATAL OUTCOMES AMONG 831 CHILDREN BORN AFTER OOCYTE DONATION - AN ANALYSIS OF SINGLETONS, TWINS, AND TRIPLETs. R. Rahav Koren

P-788 CLINICAL EXPERIENCE WITH SPERM DONOR QUALIFICATION BASED ON EXPANDED CARRIER SCREENING RESULTS. J. Luque

P-789 STATE INSURANCE MANDATES AND MULTIPLE BIRTH RATES AMONG WOMEN UNDERGOING DONOR FROZEN EMBRYO TRANSFER. B. S. Harris

P-790 SINGLE IUI IN PATIENTS USING DONOR SPERM RESULTS IN EQUIVALENT PREGNANCY OUTCOMES COMPARED TO DOUBLE IUI. D. Aharon

P-791 ATTITUDES AMONG OOCYTE DONORS TOWARD A DONOR REGISTRY. D. Tober

P-792 THE AGE AND BY WHOM A DONOR-CONCEIVED PERSON RECEIVES INFORMATION SIGNIFICANTLY EFFECTS THEIR EXPERIENCE. D. R. Siegel

P-793 DOES THE USE OF DONOR OOCYTES INCREASE THE LIKELIHOOD OF ADVERSE MATERNAL OR NEONATAL OUTCOMES IN SINGLETON GESTATIONS CONCEIVED USING IN VITRO FERTILIZATION (IVF)? R. A. Frankel

P-794 LIVE BIRTH (LB) AND RACIAL DISPARITIES IN DONOR OOCYTE RECIPIENT CYCLES: A SART CORS ANALYSIS. R. M. Whynott

P-795 HOW EXPERIENCE FRAMES DONOR-CONCEIVED PEOPLES’ FEELINGS ABOUT UTILIZING DONOR-ASSISTED REPRODUCTION THEMSELVES: INSIGHTS FROM INDIVIDUALS CONCEIVED VIA DONOR-ASSISTED REPRODUCTION. D. R. Siegel

P-796 OUTCOMES FOR GESTATIONAL CARRIERS VERSUS KNOWN CARRIERS, INCLUDING SAME-SEX COUPLES. A. Namath

P-797 FACTORS AFFECTING LIVE BIRTH RATES IN DONOR OOCYTES FROM COMMERCIAL EGG BANKS VS. PROGRAM EGG DONORS: AN ANALYSIS OF 40,485 CYCLES FROM THE SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY (SART) REGISTRY IN 2016-2018. R. S. Williams

P-798 OOCYTE DONORS’ EXPERIENCES AND SATISFACTION WITH POST-DONATION RELATIONSHIPS WITH RELATIVES, FRIENDS, AND PREVIOUSLY UNKNOWN OOCYTE RECIPIENTS. D. Tober

P-799 A SURVEY TO ASSESS THE INFORMED CONSENT PRACTICES OF PHYSICIANS CARING FOR OOCYTE DONORS. C. Shields

P-800 GENETIC TESTING DECISIONS IN GESTATIONAL CARRIER PREGNANCIES. M. A. Rasouli

P-801 PREFERENCES AMONG OOCYTE DONORS FOR ANONYMOUS VERSUS NON-ANONYMOUS DONATION. D. Tober

P-802 WHERE ARE THE DONORS: DO DONOR CONCEIVED PEOPLE BECOME DONORS THEMSELVES? J. Rushing

P-803 EXAMINING TWIN RATES IN DONOR EGG CYCLES FROM 2014-2019 AS SEEN THROUGH NATIONAL REPORTED DATA. H. Kim
### ABSTRACT TOPIC INDEX

#### TOPIC INDEX: ORAL AND POSTER SESSIONS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Access Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access to Care</td>
<td>O-31, O-32, O-33, O-46, O-105, O-106, O-107, O-124, O-179, P-2, P-3, P-4, P-6, P-362, P-461, P-513, P-521, P-721</td>
</tr>
<tr>
<td>Access to Care (ART Lab)</td>
<td>P-175, P-447</td>
</tr>
<tr>
<td>Access to Care (ART Techniques)</td>
<td>P-122, P-152, P-162, P-188, P-199, P-210</td>
</tr>
<tr>
<td>Access to Care (Contraception/ Family Planning)</td>
<td>O-114, P-441, P-442, P-443</td>
</tr>
<tr>
<td>Access to Care (Female Infertility Diagnosis and Treatment)</td>
<td>P-1, P-194</td>
</tr>
<tr>
<td>Access to Care (Fertility Preservation)</td>
<td>O-103, O-104, O-145, P-247, P-249, P-251, P-252, P-254, P-262, P-263, P-265, P-270, P-271, P-519</td>
</tr>
<tr>
<td>Access to Care (Male Reproduction)</td>
<td>O-152, P-568, P-593, P-594</td>
</tr>
<tr>
<td>Access to Care (Patient Support)</td>
<td>O-69, O-108, P-379, P-381, P-382, P-383, P-385, P-455, P-727</td>
</tr>
<tr>
<td>Access to Care (Practice Management)</td>
<td>O-35, O-67, O-77, O-78, P-387, P-452, P-454, P-646, P-651, P-655</td>
</tr>
<tr>
<td>Access to Care (Third Party Reproduction)</td>
<td>P-800</td>
</tr>
<tr>
<td>Adenomyosis</td>
<td>O-119, O-134, P-227, P-527</td>
</tr>
<tr>
<td>Advanced Reproductive Technology</td>
<td>V-1, V-5, V-7</td>
</tr>
<tr>
<td>Age as a Factor (Female Infertility Diagnosis and Treatment)</td>
<td>P-26, P-375, P-376, P-623</td>
</tr>
<tr>
<td>Age as a Factor (Fertility Preservation)</td>
<td>O-19, P-20, O-102, O-218, P-242, P-260</td>
</tr>
<tr>
<td>Age as a Factor (Male Reproduction)</td>
<td>O-155, O-232, P-552, P-562, P-569, P-588, P-597, P-603</td>
</tr>
<tr>
<td>Age as a Factor (Preimplantation Genetic Testing)</td>
<td>O-83, O-239, P-659, P-685, P-687, P-688, P-692, P-700, P-702, P-712, P-716</td>
</tr>
<tr>
<td>Androgen Excess</td>
<td>O-193, O-194, O-262, P-7, P-12, P-13, P-23</td>
</tr>
<tr>
<td>Animal and Experimental Studies</td>
<td>O-57, O-125, O-185, O-248, O-249, O-251, O-253, O-254, O-255, O-256, O-257, O-258, P-36, P-221, P-348, P-401, P-535, P-731, P-734, P-737, P-738, P-739, P-741, P-742, P-743, P-745, P-749, P-750, P-758, P-761, P-766, P-768, P-769, P-770, P-771, P-773</td>
</tr>
<tr>
<td>ART Hormone Treatment</td>
<td>P-121, P-124, P-159, P-171, P-202, P-209</td>
</tr>
<tr>
<td>ART Lab</td>
<td>P-74, P-647, P-654</td>
</tr>
<tr>
<td>ART Long-term Pregnancy Risks</td>
<td>O-209, P-288, P-309, P-430, P-432, P-433</td>
</tr>
<tr>
<td>ART Offspring</td>
<td>O-40, O-41, O-144, P-428, P-429, P-430, P-431, P-432, P-433</td>
</tr>
<tr>
<td>ART Outcomes (Practice Management)</td>
<td>P-239, P-454, P-649, P-653</td>
</tr>
<tr>
<td>ART Procedures and Techniques</td>
<td>O-74</td>
</tr>
<tr>
<td>Artificial Intelligence</td>
<td>P-728</td>
</tr>
<tr>
<td>Topic</td>
<td>Pages</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Artificial Intelligence (ART Techniques)</td>
<td>O-242, O-243, P-137, P-150, P-166, P-189</td>
</tr>
<tr>
<td>Artificial Intelligence (Pre-Clinical and Basic Research)</td>
<td>O-253</td>
</tr>
<tr>
<td>Basic Reproductive Research- Other</td>
<td>O-2, O-3, O-156, O-252, O-253, O-257, O-278, P-733, P-737, P-738, P-740, P-744, P-752, P-754, P-756, P-761</td>
</tr>
<tr>
<td>Cancer Treatment and Reproduction</td>
<td>O-22, O-23, O-24, O-103, O-218, O-220, P-241, P-246, P-250, P-254, P-255, P-258, P-259, P-260</td>
</tr>
<tr>
<td>Coding</td>
<td>P-653</td>
</tr>
<tr>
<td>Complementary and Integrative Medicine</td>
<td>P-370</td>
</tr>
<tr>
<td>Complimentary and Integrative Medicine</td>
<td>O-98, P-546</td>
</tr>
<tr>
<td>Complimentary and Integrative Medicine (Male Reproduction)</td>
<td>P-380, P-383</td>
</tr>
<tr>
<td>Complimentary and Integrative Medicine (Patient Support)</td>
<td>P-384, P-391, P-460</td>
</tr>
<tr>
<td>Continuing Medical Education</td>
<td>P-438, P-439, P-442, P-443</td>
</tr>
<tr>
<td>Cost and Economics</td>
<td>O-75, P-644, P-645, P-646, P-650</td>
</tr>
<tr>
<td>Cost and Insurance Coverage (Patient Support)</td>
<td>O-69, P-377, P-380</td>
</tr>
<tr>
<td>Cost and Insurance Coverage (Practice Management)</td>
<td>P-650</td>
</tr>
<tr>
<td>Cryopreservation</td>
<td>O-205, O-206, O-208, O-210, P-46, P-48, P-60, P-84, P-106, P-178, P-193, P-219, P-220</td>
</tr>
<tr>
<td>Diabetes</td>
<td>P-16, P-21</td>
</tr>
<tr>
<td>Donor Embryos</td>
<td>P-789, P-793, P-802, P-803</td>
</tr>
<tr>
<td>Donor Gametes-Oocytes</td>
<td>O-85, O-89, O-90, P-218, P-787, P-791, P-792, P-795, P-797, P-799, P-801, P-802, P-803</td>
</tr>
<tr>
<td>Donor Gametes-Sperm</td>
<td>O-87, P-788, P-790, P-792, P-795, P-802</td>
</tr>
<tr>
<td>Early Pregnancy</td>
<td>P-620</td>
</tr>
<tr>
<td>Early Pregnancy - Genetic Testing</td>
<td>O-13, P-462, P-470</td>
</tr>
<tr>
<td>Early Pregnancy - Other</td>
<td>O-13, O-16, O-17, O-137, O-138, P-462, P-464, P-466, P-471, P-472</td>
</tr>
<tr>
<td>Early Pregnancy Loss</td>
<td>O-13, O-15, O-17, O-135, P-394, P-462, P-464, P-467, P-469, P-471, P-473, P-474</td>
</tr>
<tr>
<td>Embryo Biology</td>
<td>O-3, O-257, P-51, P-274, P-278, P-336, P-457, P-729, P-737, P-740, P-747, P-752, P-755, P-762, P-768</td>
</tr>
<tr>
<td>Embryo Biopsy</td>
<td>O-243, P-128, P-162, P-172, P-181, P-183, P-184, P-203</td>
</tr>
<tr>
<td>Category</td>
<td>References</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Embryo Transfer</td>
<td>O-241, O-244, O-246, O-248, O-250, P-122, P-123, P-124, P-126, P-130, P-133, P-140, P-144, P-154, P-163, P-169, P-171, P-181, P-184, P-188, P-196, P-204, P-208, P-209, P-211, P-214</td>
</tr>
<tr>
<td>Embryos</td>
<td>O-8, O-9, O-200, O-201, O-202, O-203, O-206, P-30, P-32, P-37, P-40, P-54, P-59, P-60, P-81, P-83, P-86, P-87, P-89, P-107, P-109, P-114, P-131, P-147, P-151, P-157, P-161, P-165, P-177, P-343, P-402, P-403, P-404, P-405, P-406, P-407, P-408, P-426</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>O-100, O-193, O-259, O-262, P-496, P-500, P-501, P-606</td>
</tr>
<tr>
<td>Endometrial Biology</td>
<td>O-92, O-182, O-247, P-475, P-476, P-477, P-480, P-767, P-773</td>
</tr>
<tr>
<td>Endometriosis-Basic (Female Reproductive Surgery and Gynecology)</td>
<td>O-117, P-225, P-228, P-230, P-234, P-235</td>
</tr>
<tr>
<td>Endometriosis-Basic (Pre-Clinical and Basic Research)</td>
<td>O-115, O-258, P-223, P-763, P-772</td>
</tr>
<tr>
<td>Endometrium</td>
<td>O-92, O-182, O-184, O-247, O-248, O-258, P-475, P-476, P-478, P-479, P-480</td>
</tr>
<tr>
<td>Environment and Reproduction</td>
<td>O-33, O-94, O-101, O-105, O-165, O-175, O-212, O-216, P-723, P-725</td>
</tr>
<tr>
<td>Environment and Toxicology</td>
<td>P-36, P-535, P-744, P-769, P-770</td>
</tr>
<tr>
<td>Environmental Causes and Factors (Female Infertility Diagnosis and Treatment)</td>
<td>O-213, O-214, P-722, P-724</td>
</tr>
<tr>
<td>Environmental Causes and Factors (Male Reproduction)</td>
<td>O-211, O-215, P-451, P-546, P-549, P-550, P-552, P-583</td>
</tr>
<tr>
<td>Ethics</td>
<td>O-44, O-46, O-48, P-362</td>
</tr>
<tr>
<td>Ethics (Fertility Preservation)</td>
<td>P-361, P-363</td>
</tr>
<tr>
<td>Ethics (Genetics)</td>
<td>O-129</td>
</tr>
<tr>
<td>Ethics (Patient Support)</td>
<td>O-47, P-379, P-626</td>
</tr>
<tr>
<td>Ethics (Practice Management)</td>
<td>O-74, P-655</td>
</tr>
<tr>
<td>Ethics (Third Party Reproduction)</td>
<td>O-86</td>
</tr>
<tr>
<td>Fallopian Tubes</td>
<td>P-748</td>
</tr>
<tr>
<td>Family Planning</td>
<td>O-114, P-436, P-439, P-440, P-442, P-444</td>
</tr>
<tr>
<td>Fellow Education</td>
<td>O-169, O-170, O-174, P-389</td>
</tr>
<tr>
<td>Female Reproductive Hormones</td>
<td>P-225, P-227, P-507</td>
</tr>
<tr>
<td>Female Reproductive Surgery</td>
<td>O-271, P-240, P-775, P-776, P-778, P-780, P-781, P-782</td>
</tr>
<tr>
<td>Category</td>
<td>Pages</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Female Reproductive Tract</td>
<td>P-229, P-481, P-502, P-530</td>
</tr>
<tr>
<td>Fertility Preservation &amp; Embryo Disposition</td>
<td>P-611, P-624</td>
</tr>
<tr>
<td>Fertility Preservation - LGBTQ</td>
<td>O-104, O-145, O-146</td>
</tr>
<tr>
<td>Reproductive Issues</td>
<td></td>
</tr>
<tr>
<td>Fertility Preservation - Non-cancer</td>
<td>O-19, O-20, O-22, P-247, P-252, P-258, P-264, P-266, P-267, P-269, P-270</td>
</tr>
<tr>
<td>Fertility Preservation - Planned Oocyte</td>
<td>O-21, O-146, O-222, P-244, P-252, P-257, P-261, P-262, P-263, P-264, P-363, P-519</td>
</tr>
<tr>
<td>Cryopreservation</td>
<td></td>
</tr>
<tr>
<td>Fertilization</td>
<td>P-751</td>
</tr>
<tr>
<td>Fibroid Treatment</td>
<td>O-26, P-507</td>
</tr>
<tr>
<td>Fibroid Treatment- Nonsurgical</td>
<td>O-5, O-25, O-30, O-116, P-503, P-504, P-507</td>
</tr>
<tr>
<td>Fibroids-Basic</td>
<td>O-27, O-28, O-29</td>
</tr>
<tr>
<td>Follicle Monitoring</td>
<td>P-139, P-156</td>
</tr>
<tr>
<td>Genetic Counseling (Genetics)</td>
<td>O-52, O-54, O-96, O-127, O-128, O-129, O-130, O-131, O-132, P-272, P-273, P-508, P-509, P-656, P-664, P-710</td>
</tr>
<tr>
<td>Genetic Counseling (Patient Support)</td>
<td>P-379</td>
</tr>
<tr>
<td>Genetic Counseling (Preimplantation Genetic Testing)</td>
<td>O-235, O-236, P-657, P-673, P-674, P-678, P-689, P-694, P-715, P-717</td>
</tr>
<tr>
<td>Genetic Counseling (Third Party Reproduction)</td>
<td>P-788, P-800</td>
</tr>
<tr>
<td>Gestational Carriers</td>
<td>O-86, P-796, P-800</td>
</tr>
<tr>
<td>Gynecology</td>
<td>O-120, O-180, P-222, P-226, P-227, P-527, P-776, P-778, P-782, P-784</td>
</tr>
<tr>
<td>Health Disparities</td>
<td>O-4, O-31, O-32, O-33, O-46, O-106, O-179, O-216, P-3, P-4, P-6, P-512, P-513, P-514, P-516, P-517, P-520, P-521, P-719, P-721, P-723</td>
</tr>
<tr>
<td>Health Disparities (ART Lab)</td>
<td>O-7, P-447</td>
</tr>
<tr>
<td>Health Disparities (ART Techniques)</td>
<td>P-138, P-183, P-195</td>
</tr>
<tr>
<td>Health Disparities (Contraception/ Family Planning)</td>
<td>O-114</td>
</tr>
<tr>
<td>Health Disparities (Female Infertility Diagnosis and Treatment)</td>
<td>O-34, O-213, P-371, P-487, P-623</td>
</tr>
<tr>
<td>Health Disparities (Fertility Preservation)</td>
<td>O-145, O-146, P-249, P-251, P-262, P-263, P-519</td>
</tr>
<tr>
<td>Health Disparities (Male Reproduction)</td>
<td>O-152, O-215, P-549, P-550</td>
</tr>
<tr>
<td>Health Disparities (Patient Support)</td>
<td>P-382, P-518</td>
</tr>
<tr>
<td>Health Disparities (Practice Management)</td>
<td>O-35, O-78, P-387, P-454</td>
</tr>
<tr>
<td>Health Disparities (Third Party Reproduction)</td>
<td>P-794, P-796</td>
</tr>
<tr>
<td>Health Policy and Advocacy</td>
<td>O-148, P-626</td>
</tr>
<tr>
<td>Health Policy and Advocacy (Public Health and Reproduction)</td>
<td>O-48, O-105, O-106, O-176, O-177, P-2, P-6, P-446, P-448, P-521, P-719</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Human Studies</td>
<td>O-181, O-182, O-183, O-184, O-185, O-186, P-278, P-399, P-494, P-744, P-762, P-765, P-767</td>
</tr>
<tr>
<td>Hysteroscopy</td>
<td>O-271, O-275, P-522, P-523, P-524, P-776, P-778, P-780, P-782, P-785</td>
</tr>
<tr>
<td>ICSI</td>
<td>O-208, P-38, P-53, P-55, P-58, P-59, P-63, P-66, P-72, P-73, P-79, P-86, P-91, P-132, P-185, P-200, P-414, P-417, P-420, P-423, P-426</td>
</tr>
<tr>
<td>Imaging (Early Pregnancy)</td>
<td>O-135, O-137, O-138, P-468</td>
</tr>
<tr>
<td>Imaging (Female Infertility Diagnosis and Treatment)</td>
<td>O-133, O-136, P-528, P-529, P-531, P-533, P-534</td>
</tr>
<tr>
<td>Imaging (Female Reproductive Surgery and Gynecology)</td>
<td>O-134, P-525, P-526, P-527, P-781</td>
</tr>
<tr>
<td>Implantation</td>
<td>O-181, O-184, P-336, P-480, P-733, P-750, P-758, P-773</td>
</tr>
<tr>
<td>In Vitro Maturation of Oocytes</td>
<td>O-208, P-57, P-79, P-88, P-134, P-161, P-405, P-764</td>
</tr>
<tr>
<td>Infertility Diagnosis, Treatment &amp; Associated Psychosocial Aspects</td>
<td>O-164, O-167, P-613, P-614, P-615, P-617, P-618, P-625</td>
</tr>
<tr>
<td>Insulin Resistance</td>
<td>P-11, P-13</td>
</tr>
<tr>
<td>Intrauterine Insemination (ART Techniques)</td>
<td>P-173, P-215</td>
</tr>
<tr>
<td>Intrauterine Insemination (Female Infertility Diagnosis and Treatment)</td>
<td>P-300, P-397, P-628</td>
</tr>
<tr>
<td>Intrauterine Insemination (Infertility Treatment Outcomes)</td>
<td>O-139, O-142, P-297, P-332, P-340</td>
</tr>
<tr>
<td>IVF</td>
<td>O-91, O-246, P-121, P-125, P-128, P-130, P-135, P-139, P-148, P-154, P-156, P-170, P-171, P-186, P-196, P-199, P-202, P-204, P-208, P-209, P-217</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Access to Care</td>
<td>O-36, P-5, P-459</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Age</td>
<td>O-140, O-142, P-292, P-306, P-311, P-318, P-334, P-339</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Cryopreservation</td>
<td>O-40, O-207, O-209, P-284, P-329, P-350, P-356</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Embryo Biology</td>
<td>P-293, P-303</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Embryo Culture</td>
<td>P-302, P-303, P-310, P-311, P-316, P-322, P-357</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Embryo Selection</td>
<td>P-287, P-310, P-330, P-341, P-350</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Embryos</td>
<td>P-298, P-342, P-357</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Endometrium</td>
<td>O-144, P-28, P-289, P-337, P-342, P-346, P-430, P-482, P-483, P-484, P-485, P-486, P-488, P-489, P-490, P-491, P-492, P-493, P-495, P-497, P-498</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Gestational Carriers</td>
<td>P-339</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Health Disparities</td>
<td>O-36, P-292, P-324, P-511, P-515</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Hormone Levels</td>
<td>O-64, O-144, P-281, P-286, P-312, P-319, P-321, P-334, P-344, P-349, P-353, P-358, P-433, P-484, P-486</td>
</tr>
<tr>
<td>IVF Outcome Predictors- ICSI</td>
<td>O-37, P-305, P-325, P-337</td>
</tr>
<tr>
<td>IVF Outcome Predictors- LH Surge Prevention</td>
<td>P-344</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Luteal Phase Support</td>
<td>O-38, P-290, P-326, P-359, P-484</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Oocytes</td>
<td>P-302, P-304, P-325, P-335, P-338, P-350, P-352, P-356, P-493</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Ovarian Reserve</td>
<td>O-140, P-295, P-301, P-318, P-322, P-333, P-334</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Ovarian Reserve Testing</td>
<td>O-95, P-295, P-311, P-358</td>
</tr>
<tr>
<td>IVF Outcome Predictors- PGT</td>
<td>O-36, O-39, O-141, P-280, P-286, P-291, P-293, P-298, P-328, P-342</td>
</tr>
<tr>
<td>IVF Outcome Predictors- POI</td>
<td>O-140</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Procedures and Techniques</td>
<td>P-303, P-310, P-320, P-345, P-352, P-495</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Progesterone levels</td>
<td>P-290, P-308, P-321, P-326, P-486</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Sperm</td>
<td>O-142, P-305, P-323, P-331</td>
</tr>
<tr>
<td>IVF Outcome Predictors- Trigger</td>
<td>O-64, P-291, P-294, P-304, P-320, P-347, P-353</td>
</tr>
<tr>
<td>Laparoscopy</td>
<td>O-276, P-235, P-240, P-779, P-780, P-784</td>
</tr>
<tr>
<td>Legal Reproductive Issues</td>
<td>O-43, P-360, P-362</td>
</tr>
<tr>
<td>Legal Reproductive Issues (Patient Support)</td>
<td>P-626</td>
</tr>
<tr>
<td>Legal Reproductive Issues (Third Party Reproduction)</td>
<td>O-45</td>
</tr>
<tr>
<td>Leiomyoma- Basic</td>
<td>P-505, P-506, P-746, P-759</td>
</tr>
<tr>
<td>LGBTQ Reproductive Issues</td>
<td>O-150</td>
</tr>
<tr>
<td>LGBTQ Reproductive Issues (Female Infertility Diagnosis and Treatment)</td>
<td>O-88</td>
</tr>
<tr>
<td>LGBTQ Reproductive Issues (Male Reproduction)</td>
<td>O-147</td>
</tr>
<tr>
<td>LGBTQ Reproductive Issues (Patient Support)</td>
<td>O-69, O-148</td>
</tr>
<tr>
<td>LH Surge Prevention</td>
<td>P-159</td>
</tr>
<tr>
<td>Lifestyle and Reproduction</td>
<td>O-31, O-101, O-124, O-165, O-175, O-177, O-212, P-514, P-720, P-726</td>
</tr>
<tr>
<td>Luteal Phase Support (ART Techniques)</td>
<td>O-91, P-124, P-190, P-192</td>
</tr>
<tr>
<td>Luteal Phase Support (Early Pregnancy)</td>
<td>O-16, O-18</td>
</tr>
<tr>
<td>Male Factor ART</td>
<td>O-151, O-153, O-155, O-541, P-547, P-553, P-562, P-563, P-564, P-573, P-580, P-581, P-585, P-591, P-593, P-596, P-598, P-604</td>
</tr>
<tr>
<td>Topic</td>
<td>Code</td>
</tr>
<tr>
<td>---------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Male Reproduction and Urology - SMRU Traveling Scholars (Male Reproduction)</td>
<td>O-55, O-56, O-58, O-59, O-60, P-544, P-580, P-582, P-589, P-593, P-599</td>
</tr>
<tr>
<td>Male Reproduction- Basic (Pre-Clinical and Basic Research)</td>
<td>O-126, O-156, P-595</td>
</tr>
<tr>
<td>Male Reproductive Endocrinology</td>
<td>O-60, O-224, O-225, P-540, P-546, P-559, P-576, P-579, P-592, P-605</td>
</tr>
<tr>
<td>Male Reproductive Hormones</td>
<td>O-59, O-225, P-450, P-548, P-554, P-557, P-559, P-570, P-572, P-579, P-592, P-605</td>
</tr>
<tr>
<td>Male Reproductive Surgery</td>
<td>O-55, O-226, O-232, O-274, P-539, P-554, P-556, P-567, P-568, P-570, P-573, P-575, P-585, P-590, P-594, P-599, P-603, P-616</td>
</tr>
<tr>
<td>Male Sexuality</td>
<td>O-228, P-557, P-616</td>
</tr>
<tr>
<td>Menopause</td>
<td>O-162, P-606, P-607, P-608</td>
</tr>
<tr>
<td>Menstral Disorders</td>
<td>O-233, P-500</td>
</tr>
<tr>
<td>Mental Health</td>
<td>O-17, O-165, P-461</td>
</tr>
<tr>
<td>Mental Health (Female Infertility Diagnosis and Treatment)</td>
<td>P-623</td>
</tr>
<tr>
<td>Mental Health (Fertility Preservation)</td>
<td>O-222, P-609</td>
</tr>
<tr>
<td>Mental Health (Male Reproduction)</td>
<td>O-223, P-579, P-616</td>
</tr>
<tr>
<td>Mental Health (Patient Support)</td>
<td>O-68, O-70, P-610</td>
</tr>
<tr>
<td>Mental Health (Third Party Reproduction)</td>
<td>O-45, O-87, P-792, P-795, P-798</td>
</tr>
<tr>
<td>Metabolic Syndrome</td>
<td>O-195, P-14, P-16, P-17, P-18, P-22, P-373, P-400, P-532</td>
</tr>
<tr>
<td>Minimally Invasive Surgery</td>
<td>O-275, O-276, P-226, P-236, P-785</td>
</tr>
<tr>
<td>Mosaicism</td>
<td>O-79, O-84, P-659, P-661, P-663, P-665, P-666, P-668, P-678, P-679, P-685, P-718</td>
</tr>
<tr>
<td>Nursing</td>
<td>O-72</td>
</tr>
<tr>
<td>Nursing (ART Techniques)</td>
<td>P-198</td>
</tr>
<tr>
<td>Nursing (Female Infertility Diagnosis and Treatment)</td>
<td>P-194</td>
</tr>
<tr>
<td>Nursing (Practice Management)</td>
<td>O-67, P-387</td>
</tr>
<tr>
<td>Nutrition (Endocrinology)</td>
<td>P-373, P-398</td>
</tr>
<tr>
<td>Nutrition (Pre-Clinical and Basic Research)</td>
<td>P-399, P-401, P-595</td>
</tr>
<tr>
<td>Obesity and Metabolism</td>
<td>O-123, O-179</td>
</tr>
<tr>
<td>Office Procedures</td>
<td>O-67, P-458</td>
</tr>
<tr>
<td>Oocyte Biology</td>
<td>O-2, O-185, O-251, P-457, P-730, P-735, P-736, P-741, P-751, P-752, P-753, P-762</td>
</tr>
<tr>
<td>Other (ART Lab)</td>
<td>P-43, P-45, P-49, P-77, P-84, P-95, P-119, P-133, P-136, P-158, P-177, P-417, P-424</td>
</tr>
<tr>
<td>ABSTRACT TOPIC INDEX</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>Other (Female Reproductive Endocrinology) O-160, O-261, O-264, P-23, P-501, P-777</td>
<td></td>
</tr>
<tr>
<td>Outcomes O-7, O-10, O-12, O-200, O-205, O-206, P-29, P-41, P-45, P-46, P-47, P-49, P-50, P-52, P-53, P-54, P-55, P-56, P-57, P-58, P-59, P-61, P-62, P-64, P-65, P-66, P-69, P-71, P-72, P-73, P-74, P-75, P-76, P-78, P-79, P-80, P-81, P-82, P-83, P-84, P-86, P-90, P-91, P-97, P-100, P-102, P-104, P-116, P-403, P-414</td>
<td></td>
</tr>
<tr>
<td>Ovarian Function O-259, O-260, P-11, P-20, P-25, P-27, P-369, P-607</td>
<td></td>
</tr>
<tr>
<td>Ovarian Hyperstimulation Syndrome P-637, P-643</td>
<td></td>
</tr>
<tr>
<td>Ovarian Reserve (Endocrinology) O-122, P-19, P-366, P-368, P-373, P-374</td>
<td></td>
</tr>
<tr>
<td>Ovarian Reserve (Female Infertility Diagnosis and Treatment) P-26, P-364, P-367, P-370, P-371, P-372, P-375, P-376</td>
<td></td>
</tr>
<tr>
<td>Ovarian Reserve Testing P-635, P-636</td>
<td></td>
</tr>
<tr>
<td>Ovarian Stimulation O-65, P-630, P-632, P-635, P-636, P-637, P-638, P-641, P-642</td>
<td></td>
</tr>
<tr>
<td>Ovarian Stimulation- High Responders O-61, P-633, P-637, P-639, P-640</td>
<td></td>
</tr>
<tr>
<td>Ovarian Stimulation- Poor Responders O-66, P-629, P-631, P-641, P-642</td>
<td></td>
</tr>
<tr>
<td>Ovaries O-125, O-254, O-399, P-734, P-735, P-738, P-743, P-745, P-757</td>
<td></td>
</tr>
<tr>
<td>Ovulation Induction O-65, P-634</td>
<td></td>
</tr>
<tr>
<td>Oxidative Stress O-93, P-336, P-595, P-749</td>
<td></td>
</tr>
<tr>
<td>Patient Counseling &amp; Support O-164, O-167, P-612, P-614, P-615, P-619, P-622, P-624, P-625</td>
<td></td>
</tr>
<tr>
<td>Patient Education O-71, P-392</td>
<td></td>
</tr>
<tr>
<td>Patient Retention/Satisfaction O-78, P-449, P-452, P-458, P-644, P-651</td>
<td></td>
</tr>
<tr>
<td>Pediatric and Adolescent Gynecology (Female Reproductive Endocrinology) O-233</td>
<td></td>
</tr>
<tr>
<td>Pediatric and Adolescent Gynecology (Female Reproductive Surgery and Gynecology) P-786</td>
<td></td>
</tr>
<tr>
<td>PGT - other P-662, P-672, P-677, P-679, P-680, P-693, P-702, P-705, P-709, P-711</td>
<td></td>
</tr>
<tr>
<td>Polycystic Ovary Syndrome (Endocrinology) O-195, O-197, P-14, P-15, P-16, P-17, P-19, P-21, P-22</td>
<td></td>
</tr>
<tr>
<td>Polycystic Ovary Syndrome (Female Reproductive Endocrinology) O-160, O-194, O-196, O-198, O-264, P-7, P-9, P-10, P-11, P-12, P-13, P-20, P-23, P-24, P-25, P-27</td>
<td></td>
</tr>
<tr>
<td>Practice Management O-68, O-148, P-381, P-383</td>
<td></td>
</tr>
<tr>
<td>Practice Management - Other O-35, O-73, O-76, O-77, P-449, P-458, P-644, P-647, P-650, P-653</td>
<td></td>
</tr>
<tr>
<td>Pregnancy Loss and Termination O-14</td>
<td></td>
</tr>
<tr>
<td>Preimplantation Genetic Testing (Genetics) O-50, O-129, O-130, P-273, P-656, P-664, P-669, P-671, P-695, P-697, P-698, P-703, P-704, P-706, P-707, P-710, P-713</td>
<td></td>
</tr>
<tr>
<td>Topic</td>
<td>Index</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Primary Ovarian Insufficiency (Endocrinology)</td>
<td>O-99, O-158</td>
</tr>
<tr>
<td>Primary Ovarian Insufficiency (Female Reproductive Endocrinology)</td>
<td>O-157, O-160, O-161</td>
</tr>
<tr>
<td>Primary Ovarian Insufficiency (Female Reproductive Surgery and Gynecology)</td>
<td>O-159, P-775</td>
</tr>
<tr>
<td>Procedures and Techniques (Female Infertility Diagnosis and Treatment)</td>
<td>O-136, P-143, P-174, P-179, P-194, P-370</td>
</tr>
<tr>
<td>Procedures and Techniques (Preimplantation Genetic Testing)</td>
<td>O-81, O-237, P-662, P-672, P-676, P-681, P-683, P-684, P-686, P-690, P-693, P-696, P-701, P-705, P-711, P-714</td>
</tr>
<tr>
<td>Professional Development</td>
<td>O-171, O-172, O-230, P-388, P-391, P-393, P-460</td>
</tr>
<tr>
<td>Psychosocial Aspects of Reproduction</td>
<td>O-163, O-164, O-166, O-167, O-168, P-611, P-613, P-614, P-617, P-618, P-619, P-621, P-624, P-625, P-627</td>
</tr>
<tr>
<td>Psychosocial Issues Concerning LGBTQ+ Populations</td>
<td>O-149</td>
</tr>
<tr>
<td>Puberty</td>
<td>O-233</td>
</tr>
<tr>
<td>Public Health and Reproduction</td>
<td>P-613, P-617</td>
</tr>
<tr>
<td>Recurrent Pregnancy Loss (Early Pregnancy)</td>
<td>O-135, P-394, P-395</td>
</tr>
<tr>
<td>Recurrent Pregnancy Loss (Preimplantation Genetic Testing)</td>
<td>O-240, P-705</td>
</tr>
<tr>
<td>Reproductive Anomalies</td>
<td>O-272, O-273, O-275, P-228, P-781</td>
</tr>
<tr>
<td>Reproductive Biology</td>
<td>O-2, O-183, O-249, O-254, O-255, P-274, P-475, P-535, P-730, P-731, P-732, P-734, P-740, P-741, P-743, P-745, P-747, P-761, P-768, P-769, P-770</td>
</tr>
<tr>
<td>Reproductive Education - Other</td>
<td>O-173, O-230, P-384, P-391, P-460</td>
</tr>
<tr>
<td>Reproductive Endocrinology</td>
<td>O-57, O-92, O-252, P-221, P-476, P-731</td>
</tr>
<tr>
<td>Reproductive Genetics</td>
<td>O-3, O-183, O-256, P-274, P-730, P-735, P-758</td>
</tr>
<tr>
<td>Reproductive Hormones</td>
<td>O-100, O-193, O-261, O-262, O-263, P-12, P-20, P-25, P-501, P-606</td>
</tr>
<tr>
<td>Reproductive Immunology</td>
<td>O-265, O-267, O-268, O-269, O-270, O-271, P-774</td>
</tr>
<tr>
<td>Reproductive Immunology (Pre-Clinical and Basic Research)</td>
<td>O-181, P-221, P-760</td>
</tr>
<tr>
<td>Reproductive Surgery (Gyn)</td>
<td>V-2, V-3, V-4, V-6, V-8, V-10, V-11, V-12</td>
</tr>
<tr>
<td>Topic</td>
<td>References</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Resident Education</td>
<td>O-169, O-170, O-174, P-389, P-390</td>
</tr>
<tr>
<td>Robotic Surgery</td>
<td>P-236, P-783</td>
</tr>
<tr>
<td>Sexuality</td>
<td>P-378</td>
</tr>
<tr>
<td>Sperm</td>
<td>O-11, P-53, P-58, P-65, P-72, P-74, P-104, P-112, P-113, P-132, P-409, P-410, P-412, P-413, P-414, P-415, P-416, P-418, P-419, P-420, P-421, P-422, P-423, P-424, P-425, P-426, P-427</td>
</tr>
<tr>
<td>Sperm Biology</td>
<td>O-57, O-156</td>
</tr>
<tr>
<td>Staff Retention/Satisfaction</td>
<td>P-647, P-652</td>
</tr>
<tr>
<td>Technology</td>
<td>P-42, P-65, P-82, P-95, P-98, P-103, P-106, P-107, P-108, P-112, P-119, P-165, P-416, P-427</td>
</tr>
<tr>
<td>Testes (Male Reproduction)</td>
<td>P-450, P-548, P-551, P-561, P-596</td>
</tr>
<tr>
<td>Testes (Pre-Clinical and Basic Research)</td>
<td>O-125</td>
</tr>
<tr>
<td>The Web (Education)</td>
<td>O-174, O-230, P-384, P-456</td>
</tr>
<tr>
<td>The Web (Patient Support)</td>
<td>P-381, P-386</td>
</tr>
<tr>
<td>The Web (Practice Management)</td>
<td>P-449, P-452</td>
</tr>
<tr>
<td>Thin Endometrium Treatment</td>
<td>O-245, P-153, P-182, P-201, P-499</td>
</tr>
<tr>
<td>Third Party Screening</td>
<td>O-86, P-788, P-796</td>
</tr>
<tr>
<td>Thyroid Disease</td>
<td>P-396</td>
</tr>
<tr>
<td>Timelapse</td>
<td>O-8, O-10, O-12, O-204, P-32, P-42, P-44, P-62, P-64, P-68, P-69, P-82, P-92, P-97, P-99, P-101, P-107, P-108, P-111, P-114, P-115, P-118, P-120, P-147, P-149, P-155</td>
</tr>
<tr>
<td>Toxicology and Reproduction</td>
<td>O-175, O-216, P-723</td>
</tr>
<tr>
<td>Unexplained Infertility (Female Infertility Diagnosis and Treatment)</td>
<td>P-277</td>
</tr>
<tr>
<td>Unexplained Infertility (Male Reproduction)</td>
<td>P-558, P-563, P-570, P-587</td>
</tr>
<tr>
<td>Urology</td>
<td>V-9</td>
</tr>
<tr>
<td>Uterus</td>
<td>P-733, P-766</td>
</tr>
<tr>
<td>Vaginal Incubator</td>
<td>P-167, P-180, P-198</td>
</tr>
<tr>
<td>Varicocele</td>
<td>P-539, P-544, P-545, P-556, P-567</td>
</tr>
<tr>
<td>Weight as a Factor</td>
<td>O-121, O-122, P-17, P-19, P-21, P-3</td>
</tr>
</tbody>
</table>
All oral and poster presenters at the ASRM 2021 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships an immediate family member or institution disclosed.

<table>
<thead>
<tr>
<th>Author Name</th>
<th>Institution/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aban, I.</td>
<td>Myasthenia Gravis Foundation of America (MGFA); RA Pharm through MGFA; Verona</td>
</tr>
<tr>
<td>Abou Ghayda, R.</td>
<td>Legacy</td>
</tr>
<tr>
<td>Adeleye, A.</td>
<td>Carrot</td>
</tr>
<tr>
<td>Agarwal, S. K.</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Agnes, A.</td>
<td>Oxolife, SL</td>
</tr>
<tr>
<td>Al-Hendy, A.</td>
<td>Evofem Biosciences, Inc.</td>
</tr>
<tr>
<td>Allyn, V.</td>
<td>Vitrolife</td>
</tr>
<tr>
<td>Alouf, C.</td>
<td>Invitae</td>
</tr>
<tr>
<td>Alouf, C. A.</td>
<td>Invitae</td>
</tr>
<tr>
<td>Alvero, R. J.</td>
<td>Orchid Bioscience (Scientific Advisor)</td>
</tr>
<tr>
<td>Anderson, A. R.</td>
<td>Invo Biosciences</td>
</tr>
<tr>
<td>Anderson-Bialis, D.</td>
<td>FertilityIQ</td>
</tr>
<tr>
<td>Andrade, G. M.</td>
<td>Nilo Frantz Reproductive Medicine</td>
</tr>
<tr>
<td>Angle, M.</td>
<td>DxNow</td>
</tr>
<tr>
<td>Antaki, R.</td>
<td>AbbVie; Byosent; EMD Serono</td>
</tr>
<tr>
<td>Antonelli, C.</td>
<td>GLS</td>
</tr>
<tr>
<td>Antunes, R. A.</td>
<td>Ferring</td>
</tr>
<tr>
<td>Arab, J.</td>
<td>Vitrolife</td>
</tr>
<tr>
<td>Aradhya, S.</td>
<td>Invitae</td>
</tr>
<tr>
<td>Arav, A.</td>
<td>FertileSafe</td>
</tr>
<tr>
<td>Arbiser, J. L.</td>
<td>Emory (I hold IP on derivatives of honokiol)</td>
</tr>
<tr>
<td>Archer, D. F.</td>
<td>Abbvie; Agile Therapeutics; Agile Therapeutics (Stock Options); Exelixis; InnovaGyn, Inc; Mithra; Mithra (Grant Recipient); ObsEva; ObsEva (Grant); Myovant; TherapeuticsMD</td>
</tr>
<tr>
<td>Arjona Ferreira, J.</td>
<td>Myovant Sciences Inc</td>
</tr>
<tr>
<td>As-Sanie, S.</td>
<td>Myovant; Bayer; Eximis; Abbvie</td>
</tr>
<tr>
<td>Awwad, J.</td>
<td>Rovi pharmaceuticals</td>
</tr>
<tr>
<td>Baldwin, M. K.</td>
<td>Bayer Pharmaceuticals</td>
</tr>
<tr>
<td>Baldwin, K.</td>
<td>Generate Life Sciences</td>
</tr>
<tr>
<td>Barad, D. H.</td>
<td>Fertility Neutraceuticals (Patent Royalties)</td>
</tr>
</tbody>
</table>
ABSTRACTS AUTHORS DISCLOSURES

Barrett, C. B. Fujifilm Irvine ³a (Advisory Board)
Barsøe, C. Ferring ³a
Bau, D. Igenomix ³a
Behfar, A. Rion LLC ¹a
Beltsos, A. EMD Serono ⁷a; Ferring ⁷a; Future Fertility ²a; Future Fertility ⁸a (Offered stock- not sure of start date); Merck ⁷a; MRSI ⁵a; TMRW ²a
Ben-Meir, A. Fertility LTD ¹a
Benchaib, M. MerckSerono ⁶a
Berkeley, A. S. Prelude Holdings ²a
Bernick, B. TherapeuticsMD ¹a
Berntsen, J. Vitrolife A/S ²a
Bestel, E. Obseva ²a
Blaivas, M. Anavasi Inc ⁶a; Ava AG ¹a; EchoNous Inc ¹a; Sonosim Inc ⁶a
Blazek, J. CooperSurgical, Inc ³a
Blesa Jarque, D. IGENOMIX ³a
Bosch, E. Ferring ⁶a; Gedeon-Richter ⁶a; Merck ⁶a
Braverman, A. M. California Cryobank ⁴c
Brethous, M. ObsEva SA ³a
Briggs, S. Modern Fertility ²a
Brogaard, K. Inherent Biosciences ¹a
Bromer, J. Sema4 ⁴b (Advisory Board)
Brown, K. S. Amag Pharmaceuticals, Inc. ²a; Genentech ³b; Generate Life Sciences ³a
Brown, H. L. Generate Life Sciences ³a
Budde, R. Heartflow ³c (Research agreement); Siemens ³c (Research agreement)
Burks, H. R. Ferring Pharmaceuticals ⁸a (Site Investigator)
Buyuk, E. EMD SERONO ⁶a
Buyuk, E. EMD SERONO ⁶a
Callum, P. Generate Life Sciences ³a; Tandem Genetics ¹a
Canals, I. Oxolife SL ¹a
Cancio-Villalonga, D. Overture Life ³a
Capalbo, A. Igenomix ³a
Caroselli, S. Igenomix Italia srl ³a
Carriere, M. Vitrolife ³a
Cataldo, N. A. INVO Bioscience ⁶b; INVO Bioscience ⁶a; AbbVie ⁷b
Catherino, W. American Board of Obstetrics and Gynecology ⁸a (Board Member for REI Division); EMD Serono ³a; American Society for Reproductive Medicine ⁸a
Catherino, A. B. EMD Serono ³a
Cedars, M. I. Ferring pharmaceutical ⁴a
Chambost, J. Apricity ³a
<table>
<thead>
<tr>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chang, L.</td>
<td>Bonraybio Inc.</td>
</tr>
<tr>
<td>Chappell, B.</td>
<td>Evofem Biosciences, Inc. (Research); Evofem Biosciences, Inc.</td>
</tr>
<tr>
<td>Chavez-Badiola, A.</td>
<td>IVF 2.0 LTD</td>
</tr>
<tr>
<td>Chen, S. H.</td>
<td>Genomic Prediction (Medical Advisory Board); FertilityAnswers; Cooper Genomics</td>
</tr>
<tr>
<td>Chiodo, J. A.</td>
<td>Agile Therapeutics, Inc.</td>
</tr>
<tr>
<td>Cho, J.</td>
<td>Alife Health</td>
</tr>
<tr>
<td>Chopra, R.</td>
<td>IGENOMIX FZ LLC</td>
</tr>
<tr>
<td>Choy, K. R.</td>
<td>Suzhou Basecare Medical Corp Ltd</td>
</tr>
<tr>
<td>Christman, G. M.</td>
<td>DOT LABORATORIES (Clinical Trial Site Principal Investigator); Myovant Sciences</td>
</tr>
<tr>
<td>Chung, E. H.</td>
<td>Turtle Health (Clinical Trial Lead)</td>
</tr>
<tr>
<td>Ciray, H. N.</td>
<td>FUJIFILM Irvine Scientific</td>
</tr>
<tr>
<td>Cohen, J.</td>
<td>Althea Science; KindBody; TMRW; IVF 2.0</td>
</tr>
<tr>
<td>Collares, F.</td>
<td>EMD Serono Inc</td>
</tr>
<tr>
<td>Copperman, A. B.</td>
<td>Sema4 (CMO); Sema4 (Medical Director); Progyny</td>
</tr>
<tr>
<td>Cordero, T.</td>
<td>IGENOMIX S. L.</td>
</tr>
<tr>
<td>Costa-Borges, N.</td>
<td>Embrotools SL</td>
</tr>
<tr>
<td>Cowan, P.</td>
<td>Vitrolife</td>
</tr>
<tr>
<td>Creinin, M. D.</td>
<td>Estetra; Evofem; HRA Pharma; Mayne Pharma; Merck; Searchlight; Sebela</td>
</tr>
<tr>
<td>Cronin, M.</td>
<td>Ava AG; Vifor Pharma</td>
</tr>
<tr>
<td>Culwell, K. R.</td>
<td>Evofem Biosciences</td>
</tr>
<tr>
<td>Cummings, S. R.</td>
<td>Myovant</td>
</tr>
<tr>
<td>Cunchillos, E.</td>
<td>Oxolife SL</td>
</tr>
<tr>
<td>Daftary, G. S.</td>
<td>Ferring Pharmaceuticals</td>
</tr>
<tr>
<td>Daines, B.</td>
<td>Inherent Biosciences, Inc.</td>
</tr>
<tr>
<td>de Carvalho, P. S.</td>
<td>NOVAGEN</td>
</tr>
<tr>
<td>Diamond, M. P.</td>
<td>AbbVie; Advanced Reproductive Care; Advanced Reproductive Care (Board of Directors); Bayer</td>
</tr>
<tr>
<td>Domar, A. D.</td>
<td>Best Shot; EMD Serono; Ferring; Ferring (paid to create stress management materials); FertiCalm LLC; Merck; Nestle</td>
</tr>
<tr>
<td>Dominguez, C. E.</td>
<td>Abbvie</td>
</tr>
<tr>
<td>Doody, K. J.</td>
<td>INVO Bioscience</td>
</tr>
<tr>
<td>Doody, K. M.</td>
<td>Ferring Pharmaceutical; INVO Bioscience</td>
</tr>
<tr>
<td>Drakeley, A. J.</td>
<td>IVF 2.0</td>
</tr>
<tr>
<td>Drevet, J.</td>
<td>Cellaxess LLC (scientific advisor)</td>
</tr>
<tr>
<td>Duffy, L.</td>
<td>Genomic Prediction Inc.</td>
</tr>
<tr>
<td>Dumesic, D. A.</td>
<td>Spruce Biosciences, Inc</td>
</tr>
<tr>
<td>Dupree, J. M.</td>
<td>Lipocine</td>
</tr>
<tr>
<td>Dyr, B.</td>
<td>LabCorp</td>
</tr>
<tr>
<td>Abstracts Authors Disclosures</td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td>Eaton, J. L.</td>
<td>Hologic, Inc.$^a$</td>
</tr>
<tr>
<td>Ebner, T.</td>
<td>Esco$^a$; Gynemed$^a$; Hamilton Thorne$^a$(Scientific Board)</td>
</tr>
<tr>
<td>Eccles, J.</td>
<td>Genomic Prediction$^3a$</td>
</tr>
<tr>
<td>Echave, P.</td>
<td>PerkinElmer$^3a$</td>
</tr>
<tr>
<td>Eckart, E.</td>
<td>Amgen Inc.$^2a$; Johnson &amp; Johnson$^2a$</td>
</tr>
<tr>
<td>Einarsson, J. I.</td>
<td>Arthrex$^6a$; Hologic$^6a$; Olympus$^6a$</td>
</tr>
<tr>
<td>Eisenberg, M. L.</td>
<td>Hannah$^2a$; Ro$^2a$; Sandstone$^4a$; Underdog$^7a$</td>
</tr>
<tr>
<td>Elci, O. U.</td>
<td>Ferring Pharmaceuticals $^3a$</td>
</tr>
<tr>
<td>Elopre, L. E.</td>
<td>Merck$^8a$(site-PI); MedIQ$^6a$; Merck$^6a$; Verywell$^6a$</td>
</tr>
<tr>
<td>Eskew, A.</td>
<td>OvulifeMD$^8a$(Co-founder); Flo Inc$^5a$</td>
</tr>
<tr>
<td>Estes, S. J.</td>
<td>Abbvie$^6a$; Abbvie$^8a$(Research funding (Institution)); Ferring$^6c$(Research funding); Obseva$^6c$(Research funding)</td>
</tr>
<tr>
<td>Esteves, S. C.</td>
<td>Merck$^5a$</td>
</tr>
<tr>
<td>Fabbro, M.</td>
<td>NOVAGEN$^3a$</td>
</tr>
<tr>
<td>Falk, O.</td>
<td>Fellow Health, Inc$^3a$</td>
</tr>
<tr>
<td>Fanelli, K. A.</td>
<td>Laboratory Corporation of America$^3a$</td>
</tr>
<tr>
<td>Farland, L. V.</td>
<td>Smith and Nephew$^2b$</td>
</tr>
<tr>
<td>Farmer, A.</td>
<td>Takara Bio, Inc.$^3a$</td>
</tr>
<tr>
<td>Faulkner, N.</td>
<td>InVitae$^3a$</td>
</tr>
<tr>
<td>Faunce, A.</td>
<td>Genomic Prediction$^3a$</td>
</tr>
<tr>
<td>Feinberg, E. C.</td>
<td>Ferring $^5a$; Ferring $^8a$(one time consultant role for Ferring (above)); Fertility and Sterility$^8a$(Associate Editor)</td>
</tr>
<tr>
<td>Fernandez, G.</td>
<td>Overture Life$^3a$</td>
</tr>
<tr>
<td>Flack, P.</td>
<td>CooperSurgical$^5a$</td>
</tr>
<tr>
<td>Flores, V. A.</td>
<td>Abbvie$^7a$</td>
</tr>
<tr>
<td>Flores-Saiffe Farias, A.</td>
<td>IVF 2.0 Limited$^3a$</td>
</tr>
<tr>
<td>Foster, E. D.</td>
<td>Ferring Pharmaceuticals$^3a$</td>
</tr>
<tr>
<td>Fought, A.</td>
<td>Coeus Health$^6a$; iRhythm$^8a$(Was a paid consultant in the past, but now unpaid work...finishing a paper as the biostatistician)</td>
</tr>
<tr>
<td>Frantz, N.</td>
<td>NILO FRANTZ REPRODUCTIVE MEDICINE$^3a$</td>
</tr>
<tr>
<td>Fritz, R.</td>
<td>Cradle Genomics$^8a$(Medical Advisory Board)</td>
</tr>
<tr>
<td>Gada, R.</td>
<td>ReUnite Rx$^1a$</td>
</tr>
<tr>
<td>Gairani, A. M.</td>
<td>Embryo Options $^3a$</td>
</tr>
<tr>
<td>Galain, M.</td>
<td>Novagen$^3c$</td>
</tr>
<tr>
<td>Garcia-Pascual, C. M.</td>
<td>Igenomix$^3a$</td>
</tr>
<tr>
<td>Garcia-Velasco, J. A.</td>
<td>Ferring$^6c$; Gedeon Richter$^6c$; Merck$^6c$</td>
</tr>
<tr>
<td>Garner, E.</td>
<td>ObsEva$^2a$</td>
</tr>
<tr>
<td>Gamsev, H.</td>
<td>Genomic Prediction Inc.$^3a$; Foundation for Embryonic Competence$^3a$</td>
</tr>
<tr>
<td>Garrido-Gómez*, T.</td>
<td>Igenomix S.L.$^8a$(Partial-Time Company Employee)</td>
</tr>
<tr>
<td>Authors</td>
<td>Affiliations</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
</tr>
<tr>
<td>Gibson, C. B.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gilboa, D.</td>
<td>AIVF&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Giralt, G.</td>
<td>Overture Life&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Girardi, L.</td>
<td>IGENOMIX ITALY&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Giudice, L. C.</td>
<td>ForEndo&lt;sup&gt;6a&lt;/sup&gt;; MERCK&lt;sup&gt;2a&lt;/sup&gt;; Myovant&lt;sup&gt;6a&lt;/sup&gt;; PFIZER&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Glazner, C.</td>
<td>Celmatix Inc.&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gleicher, N.</td>
<td>Fertility Nutraceuticals&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Goodale, B. M.</td>
<td>Ava AG&lt;sup&gt;6a&lt;/sup&gt;; Delfina Care&lt;sup&gt;2a&lt;/sup&gt;; Delfina Care&lt;sup&gt;2b&lt;/sup&gt;; LifeCircle&lt;sup&gt;6b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Goodall, N.</td>
<td>CooperGenomics&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Goodman, L. R.</td>
<td>LiNA Medical&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gordon, K.</td>
<td>AbbVie&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Graham, S.</td>
<td>TherapeuticsMD&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Grambow, S. C.</td>
<td>Gilead Sciences&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Griesinger, G.</td>
<td>Abbott&lt;sup&gt;4c&lt;/sup&gt;; Ferring&lt;sup&gt;6c&lt;/sup&gt;; Ferring&lt;sup&gt;6c&lt;/sup&gt;; Gedeon-Richter&lt;sup&gt;5c&lt;/sup&gt;; Gedeon-Richter&lt;sup&gt;6c&lt;/sup&gt;; Merck&lt;sup&gt;6a&lt;/sup&gt;; MSD&lt;sup&gt;6a&lt;/sup&gt;; ObsEva&lt;sup&gt;5c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Griffith, J.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Grifo, J. A.</td>
<td>Inception Fertility&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gross Dutra, C.</td>
<td>Nilo Frantz Reproductive Medicine&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Grover, S. A.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gu, R.</td>
<td>San Diego Fertility Center&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gupta, R.</td>
<td>TMRW Life Sciences and Spectrum Solutions&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gurtcheff, S. E.</td>
<td>AbbVie Pharmaceuticals&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hall, A. R.</td>
<td>Foenestra Corporation&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hammond, K. R.</td>
<td>INVO bioscience&lt;sup&gt;6a&lt;/sup&gt;(Scientific Advisory Board); INVO bioscience&lt;sup&gt;6a&lt;/sup&gt;; AbbVie&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Han, C. S.</td>
<td>Jubel&lt;sup&gt;6a&lt;/sup&gt;(Advisory board)</td>
</tr>
<tr>
<td>Hansen, K. R.</td>
<td>Ablacare&lt;sup&gt;6a&lt;/sup&gt;(consultant); Ferring&lt;sup&gt;4c&lt;/sup&gt;; NICHD&lt;sup&gt;4a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hansen, C. S.</td>
<td>Vitrolife A/S&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hariton, E.</td>
<td>ALife Health&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hart, R. J.</td>
<td>Ferring pharmaceuticals&lt;sup&gt;6a&lt;/sup&gt;; Merck&lt;sup&gt;5a&lt;/sup&gt;; Western IVF&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Harton, G. L.</td>
<td>Cryos International&lt;sup&gt;6a&lt;/sup&gt;(Medical/Scientific Advisory Board); PerkinElmer&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hayward, B.</td>
<td>EMD Serono, Inc.&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>He, C.</td>
<td>Accent Therapeutics&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Heiser, P. W.</td>
<td>Ferring Pharmaceuticals, Inc.&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Herati, A. S.</td>
<td>Teleflex&lt;sup&gt;6a&lt;/sup&gt;; Dadi&lt;sup&gt;6a&lt;/sup&gt;(Advisor)</td>
</tr>
<tr>
<td>Hickman, C.</td>
<td>Tmrw&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hill, S. V.</td>
<td>Med-IQ&lt;sup&gt;5a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hill, M. J.</td>
<td>Thread Robotics&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Holt, M. D.</td>
<td>Gedeon Richter&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Holzer, H. E.</td>
<td>MERCK&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Author</td>
<td>Institution</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Homaifar, N.</td>
<td>June Motherhood, Natalist</td>
</tr>
<tr>
<td>Hong, C. X.</td>
<td>Cosm Medical</td>
</tr>
<tr>
<td>Hotaling, J.</td>
<td>advanced conceptions, andro360, Boston Scientific, streamdx, turtle health</td>
</tr>
<tr>
<td>Howard, B.</td>
<td>Evofem Biosciences</td>
</tr>
<tr>
<td>Howard, K. L.</td>
<td>natera, inc.</td>
</tr>
<tr>
<td>Hsu, G. C.</td>
<td>Bonraybio Co. Ltd.</td>
</tr>
<tr>
<td>Huddleston, H. G.</td>
<td>Abbvie, Exactech</td>
</tr>
<tr>
<td>Humberstone, A.</td>
<td>ObsEva</td>
</tr>
<tr>
<td>Hunsche, E.</td>
<td>Myovant Sciences GmbH</td>
</tr>
<tr>
<td>Hurley, E. G.</td>
<td>Innoviva Inc, Theravance Biopharma Inc</td>
</tr>
<tr>
<td>Hyniman, K.</td>
<td>GeneScreen Counseling</td>
</tr>
<tr>
<td>Imm, S.</td>
<td>Myovant Sciences</td>
</tr>
<tr>
<td>Invik, J.</td>
<td>Synergyne Incorporated</td>
</tr>
<tr>
<td>Isley, L.</td>
<td>Generate Life Sciences</td>
</tr>
<tr>
<td>Jackman, J. M.</td>
<td>Abbvie (I am in training to promote endometriosis awareness with the company. I have not yet started doing any forums and have not received any payments. I have done NO research or abstracts with the company or that contain their products in this ASRM conference)</td>
</tr>
<tr>
<td>Jacques, C.</td>
<td>Apricity</td>
</tr>
<tr>
<td>Jarvi, K.</td>
<td>FlowLabs</td>
</tr>
<tr>
<td>Jensen, J. T.</td>
<td>Abbvie, Bayer, Dare, Evofem, Mayne, Medicines360, Merck, Sebela, TherapeuticsMD</td>
</tr>
<tr>
<td>Jimenez-Almazán, J.</td>
<td>Igenomix</td>
</tr>
<tr>
<td>Johnson, N.</td>
<td>Guerbet, Myovant Sciences, Roche Diagnostics</td>
</tr>
<tr>
<td>Johnson, J. J.</td>
<td>Wholesome Nutritional</td>
</tr>
<tr>
<td>Jones, C.</td>
<td>Ferring Canada and EMD Serono Canada (The GREI Fellowship Fund at the University of Toronto receives grants from these institutions for which I am the Fellowship Program Director)</td>
</tr>
<tr>
<td>Joris, H.</td>
<td>Vitrolife</td>
</tr>
<tr>
<td>Junkins, S.</td>
<td>Roche (Advisory board)</td>
</tr>
<tr>
<td>Kaiser, B. N.</td>
<td>Ionis Pharmaceuticals</td>
</tr>
<tr>
<td>Kaneshiro, B.</td>
<td>Sebela Pharmaceuticals</td>
</tr>
<tr>
<td>Kantor, B.</td>
<td>Faihtility Ltd.</td>
</tr>
<tr>
<td>Kashanian, J. A.</td>
<td>Roman Health</td>
</tr>
<tr>
<td>Kaunitz, A. M.</td>
<td>Merck, Medicines360, Mithra</td>
</tr>
<tr>
<td>Kavoussi, P. K.</td>
<td>Acerus Pharmaceuticals, Antares Pharmaceuticals, Clarus Therapeutics</td>
</tr>
<tr>
<td>Kedar, L.</td>
<td>AIVF (advisor)</td>
</tr>
<tr>
<td>Keefe, D. L.</td>
<td>cradle genomics, Illumina</td>
</tr>
</tbody>
</table>
Keelan, J. A.  SpeeDx Pty Ltd\textsuperscript{a}(Patent licensed to this Company)
Kenfield, S.  Fellow Health Inc.\textsuperscript{a}; Fellow Health Inc.\textsuperscript{a}(Nonstatutory Stock Option Holder)
Khair, A. F.  Ferring Pharmaceuticals\textsuperscript{a}
Kim, J.  Takara Bio USA\textsuperscript{a}
Kohler, T.  Coloplast\textsuperscript{a}
Korner, P.  Agile Therapeutics, Inc\textsuperscript{a}
Kottel, I.  AIVF\textsuperscript{a}
Kragh, M. F.  Vitrolife\textsuperscript{a}
Krantz, D.  Eurofins NTD, LLC\textsuperscript{a}
Krisher, R. L.  FujiFilm Irvine Scientific\textsuperscript{a}
Kroll, R.  Abbvie\textsuperscript{a}; Agile\textsuperscript{a}; Allergan\textsuperscript{a}; Bayer\textsuperscript{a}; Biohaven\textsuperscript{a}; Chemo\textsuperscript{a}; Merck\textsuperscript{a}; Sebela\textsuperscript{a}; Therapeutics MD\textsuperscript{a}
Kuball, A.  Vitrolife GmbH\textsuperscript{a}
Kunselman, A. R.  Merck\textsuperscript{a}; Novavax\textsuperscript{a}
Kutteh, W. H.  Abbvie\textsuperscript{a}; Ferring\textsuperscript{c}; Natera\textsuperscript{a}(Research Consultant)
Lamb, D. J.  American Board of Bioanalysts\textsuperscript{a}(Secretary Treasurer of the Board); Fellow\textsuperscript{a}(Stock Options not executed)
Lanes, A.  BORN Ontario\textsuperscript{a}
Lanzkron, S.  Bluebird bio\textsuperscript{a}; Imara\textsuperscript{c}; GBT\textsuperscript{c}; Novartis\textsuperscript{c}; Novartis\textsuperscript{a}; Pfizer\textsuperscript{a}; Takeda\textsuperscript{c}
Large, M.  CooperSurgical\textsuperscript{a}
Larman, M. G.  Vitrolife\textsuperscript{a}
Lassen, J. T.  Vitrolife\textsuperscript{a}
Laven, J.  Ansh Labs\textsuperscript{a}; Ferring\textsuperscript{a}; Titus Healthcare\textsuperscript{a}
Lazorwitz, A.  Dama Health\textsuperscript{a}; Merck & Co\textsuperscript{a}
Lee, H.  Vitrolife\textsuperscript{a}
Lee, H.  Bonraybio.Co.,LTD.\textsuperscript{a}
Legro, R. S.  Guerbet\textsuperscript{a}
Lello, L.  Genomic Prediction\textsuperscript{a}
Letourneau, J. M.  Alnylam Pharmaceuticals\textsuperscript{a}; EMD Serono\textsuperscript{a}
Levitsky, L. L.  Eli Lilly\textsuperscript{a}; ON*X Valve Company\textsuperscript{b}
Levy, B.  Igenomix\textsuperscript{a}; Natera\textsuperscript{a}
Libermann, T. A.  Google Ventures\textsuperscript{a}(Part time Employee); Nimbus Therapeutics\textsuperscript{b}; Rome Therapeutics\textsuperscript{b}; Schroedinger\textsuperscript{b}
Lin, S.  FujiFilm Irvine Scientific\textsuperscript{a}
Lipshultz, L. I.  Abbvie\textsuperscript{a}; American Medical Systems\textsuperscript{a}(Speaker); Augmenta LLC\textsuperscript{a}; Aytu BioScience\textsuperscript{a}; Clarus Therapeutics\textsuperscript{a}; Endo Pharmaceuticals\textsuperscript{a}; Inherent Biosciences\textsuperscript{b}(Advisor); Lipocine\textsuperscript{a}; Vault Health, Inc.\textsuperscript{a}(Advisor)
Llorens, M.  OXOLIFE\textsuperscript{a}
Loewke, K. E.  Alife Health, Inc.\textsuperscript{a}
<table>
<thead>
<tr>
<th>Authors</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lukes, A. S.</td>
<td>AbbVie(^{6c}); Astellas(^{4c}); Bayer(^{4c}); Ferring(^{4c}); Forendo(^{6a}); Gynesonics(^{6c}); Merck(^{4c}); Myovant(^{4c}); ObsEva(^{4c}); Sebela(^{4c})</td>
</tr>
<tr>
<td>Lundy, S.</td>
<td>Wolters Kluwer(^{6a})</td>
</tr>
<tr>
<td>Luque, J.</td>
<td>California Cryobank/Generate Life Sciences(^{3a}); Progenity (^{3a})</td>
</tr>
<tr>
<td>Mackion, N.</td>
<td>Abbott(^{6a}); Anecova(^{5a}); ArtPRED(^{6a}); Ferring(^{6a}); Merck(^{5a}); Vivoplex(^{2a})</td>
</tr>
<tr>
<td>Maeder-York, P.</td>
<td>Alife Health(^{1a})</td>
</tr>
<tr>
<td>Mahony, M. C.</td>
<td>DxNow, Inc.(^{6a}); EMD Serono US Medical Affairs(^{6a}); MedTech for Solutions(^{6a}); TMRW(^{6a})</td>
</tr>
<tr>
<td>Maisenbacher, M. K.</td>
<td>Natera(^{2a})</td>
</tr>
<tr>
<td>Malloy, S. M.</td>
<td>Ovia Health(^{3a})</td>
</tr>
<tr>
<td>Maor, R.</td>
<td>AiVF(^{3a})</td>
</tr>
<tr>
<td>Marin, D.</td>
<td>Genomic Prediction(^{3a})</td>
</tr>
<tr>
<td>Markert, M.</td>
<td>Ferring Pharmaceuticals A/S(^{3a})</td>
</tr>
<tr>
<td>Marsh, E. E.</td>
<td>Myovant Sciences(^{6a})</td>
</tr>
<tr>
<td>Mathur, V.</td>
<td>Esclent(^{6a}); Equilibrium(^{6a}); Galderma(^{6a}); myovant(^{6a}); Trevi(^{6a}); Trevi(^{8a})(DSMB); Tricida(^{6a}); Tricida(^{6a})(stock options, patents)</td>
</tr>
<tr>
<td>Matthews, W. J.</td>
<td>Fellow Health Inc.(^{2a})</td>
</tr>
<tr>
<td>McClung, M. R.</td>
<td>Alexion(^{7a}); Amgen(^{6a}); Myovant(^{6a})</td>
</tr>
<tr>
<td>McCullogh, D. H.</td>
<td>Buffalo IVF(^{6a}); Ferring Pharmaceuticals(^{5a}); GranataBio(^{6a}); ReproART; Georgian American Center for Reproductive Medicine(^{1a}); Sperm &amp; Embryo Bank of New York(^{1a})</td>
</tr>
<tr>
<td>McLaughlin, J.</td>
<td>Merck(^{8a})(Co-author Merck manual)</td>
</tr>
<tr>
<td>mendizabal-Ruiz, G.</td>
<td>IVF2.0 Limited(^{6a})</td>
</tr>
<tr>
<td>Merrion, K.</td>
<td>Natera, Inc.(^{3a})</td>
</tr>
<tr>
<td>Meseguer, M.</td>
<td>Merck(^{8a})(Speaker Fee); Theramex(^{8a})(Speaker fee); Vitrolife(^{6a})(speaker fee)</td>
</tr>
<tr>
<td>Mex-Puc, A.</td>
<td>Vitrolife(^{3a})</td>
</tr>
<tr>
<td>Meyers, J.</td>
<td>Takara Bio USA(^{1a})</td>
</tr>
<tr>
<td>Milad, M. P.</td>
<td>baxter(^{6a})(advisory board); doximity(^{6a})(advisory board); myovant(^{6a})(advisory board); storz(^{6a})</td>
</tr>
<tr>
<td>Miller, K. A.</td>
<td>Genomic Prediction Inc.(^{8a})(Scientific Advisory Board); Igenomix(^{6a}); aLIFE Health, Inc.(^{6a})(Scientific Advisory Board); Genomic Prediction Inc.(^{7a})</td>
</tr>
<tr>
<td>Miller, C. E.</td>
<td>Allergen(^{6a})(Research Study); AbbVie(^{7a}); AbbVie(^{6a})(Research Study); Blue Seas Med Spa(^{8a})(Investor); Boston Scientific(^{6a}); Espiner Medical(^{6a}); Espiner Medical(^{6a})(Research Study); Eximis Surgical, Inc.(^{6a}); Gynesonics(^{6a}); Halt Medical(^{6a}); Hologic(^{6a}); Karl Storz(^{6a}); Medtronic(^{6a}); Seikagaku Corporation (^{6c}); Temple Therapeutics B.V.(^{2c}); Temple Therapeutics B.V.(^{8a})(Advisory Board Member)</td>
</tr>
<tr>
<td>Miller, J. O.</td>
<td>CooperSurgical(^{3a})</td>
</tr>
<tr>
<td>Miller, P. B.</td>
<td>Abbvie Pharmaceuticals(^{7a})</td>
</tr>
<tr>
<td>Miller, R.</td>
<td>Inherent Biosciences(^{3a})</td>
</tr>
<tr>
<td>Mills, J.</td>
<td>Endo(^{4c}); Boston Scientific(^{4c})</td>
</tr>
</tbody>
</table>
Mollan, S. G.  Evofem Biosciences, Inc. (Employee of ICON plc which received funding to conduct the study.)

Mollinedo, L.  Overture Life

Mor, A.  AGM Medical LLC

Moral-Blanch, M.  Oxilife SL

Moravek, M. B.  NUVO (Investor)

Morlock, R.  Evofem, Heron, Johnsson and Johnson Vision Care, Taiho

Munne, S.  Overture Life

Nackeeren, S.  Boston Scientific

Nag, P. L.  Praxis Genomics LLC

Narayanan, N. P.  Fellow Health

Navarro-Sánchez, L.  Igenomix

Neff, L. M.  Novo Nordisk (Research Investigator); Aegerion

Neitzel, D.  Invitae

Nelson, A. L.  Agile Pharmaceutical; Bayer Healthcare; Merck; Mylan; Myovant; Sagami Rubber Industries; Sebela Pharmaceutical; TherapeuticsMD

Nelson, S. M.  Access Fertility; Delivery I; Ferring; Merck; Modern Fertility; Roche

Nguyen, B. T.  Aqua Therapeutics; Lupin Pharmaceuticals, Inc

Niederberger, C.  American Board of Urology (Examiner); American Society for Reproductive Medicine (Journal editor); American Urological Association (Journal section editor); COMMIT (Advisor); Ferring (Scientific study); Letters and Sciences LLC; Posterity Health; Posternity Health (Advisory board)

Nitibhon, V.  Labcorp

Noblia, F.  CEGYR

Noorhasan, D.  Medtronics

Nusblat, D.  CooperSurgical

Nutting, V. I.  Alife Health (Full-Time Company Intern)

Oken, E.  Novartis, Inc; Takeda

Ortiz Maffei, N. V.  Cegyr (Physician); Cegyr

Ostermeier, G. C.  Androvia LifeSciences

Padmanabhan, K.  Takara Bio USA

Paidas, M.  BioIncept, LLC; BioIncept, LLC (Scientific advisor, stock option)

Park, J. K.  Ferring Pharmaceuticals

Patrick, J. L.  Revolution Genetics

Patrizio, P.  FertileSafe Ltd (Co-Founder)

Peek, R.  Merck B.V. (The Netherlands), an affiliate of Merck KGaA, Darmstadt, Germany

Penrose, L. L.  RSI Technologies Group

Pépin, D.  Bluebird bio
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation and Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peterson, T.</td>
<td>Rion LLC&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Peterson, C.</td>
<td>Clinical Innovations&lt;sup&gt;8a&lt;/sup&gt;(Royalties); TheraTarget&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Petrozza, J. C.</td>
<td>Hologic&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pfeifer, S. M.</td>
<td>RESOLVE&lt;sup&gt;8a&lt;/sup&gt;(Medical Advisory Board); RESOLVE&lt;sup&gt;8b&lt;/sup&gt;(Medical Advisory Board); Roman Health&lt;sup&gt;6b&lt;/sup&gt; Theralogix&lt;sup&gt;8b&lt;/sup&gt;;</td>
</tr>
<tr>
<td>Pierson, H. E.</td>
<td>Synergyne Imaging Technologies, Inc.&lt;sup&gt;1b&lt;/sup&gt;; Synergyne Imaging Technologies, Inc.&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pierson, R. A.</td>
<td>Synergyne Imaging Technology, Inc.&lt;sup&gt;1a&lt;/sup&gt;; Temple Therapeutics BV&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Polak, A.</td>
<td>Igenomix&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Poli, M.</td>
<td>Igenomix&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Poll, S.</td>
<td>Invitae&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Polotsky, A. J.</td>
<td>PrimaTemp&lt;sup&gt;5a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pope, R.</td>
<td>Johnson and Johnson Global Health&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Powers, J. H.</td>
<td>Arrevus&lt;sup&gt;6a&lt;/sup&gt;; Bavarian Nordic&lt;sup&gt;6a&lt;/sup&gt;; Celularity&lt;sup&gt;6a&lt;/sup&gt;; DaVolterra&lt;sup&gt;6a&lt;/sup&gt;; Eicos&lt;sup&gt;6a&lt;/sup&gt;; Evofem&lt;sup&gt;6a&lt;/sup&gt;; Eyecheck&lt;sup&gt;6a&lt;/sup&gt;; Fujifilm&lt;sup&gt;6a&lt;/sup&gt;; Gilead&lt;sup&gt;6a&lt;/sup&gt;; Johnson &amp; Johnson&lt;sup&gt;6a&lt;/sup&gt;; Microbion&lt;sup&gt;6a&lt;/sup&gt;; OPKO&lt;sup&gt;6a&lt;/sup&gt;; Otsuka&lt;sup&gt;6a&lt;/sup&gt;; Romark&lt;sup&gt;6a&lt;/sup&gt;; Shinogi&lt;sup&gt;6a&lt;/sup&gt;; Vir&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Previtera, M.</td>
<td>Agile Therapeutics Inc&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Prien, S. D.</td>
<td>RSI Technologies Group&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Puscheck, E. E.</td>
<td>AbbVie&lt;sup&gt;4c&lt;/sup&gt;; Allergan&lt;sup&gt;4c&lt;/sup&gt;; Bayer Pharmaceutical&lt;sup&gt;4c&lt;/sup&gt;; ObsEva&lt;sup&gt;4c&lt;/sup&gt;; Pfizer&lt;sup&gt;4c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Quaas, A. M.</td>
<td>Ferring Pharmaceuticals&lt;sup&gt;6a&lt;/sup&gt;; Natera&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rafalko, J.</td>
<td>Labcorp&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ramos Membrive, J.</td>
<td>Overture Life&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ratts, V.</td>
<td>Aesculap Implant Systems&lt;sup&gt;6b&lt;/sup&gt;; Kaliber&lt;sup&gt;2b&lt;/sup&gt;; Medtronic&lt;sup&gt;6b&lt;/sup&gt;; Medtronic&lt;sup&gt;8b&lt;/sup&gt;(Royalties); Midwest Imaging&lt;sup&gt;2b&lt;/sup&gt;; MRI Partners of Chesterfield&lt;sup&gt;2b&lt;/sup&gt;; Nocimed&lt;sup&gt;8b&lt;/sup&gt;; OuroBoros&lt;sup&gt;8b&lt;/sup&gt;; Pain and Rehabilitation Specialists, LLC&lt;sup&gt;2b&lt;/sup&gt;; Paradigm Spine&lt;sup&gt;2b&lt;/sup&gt;; St. Louis Spine and Orthopedic Surgery Center&lt;sup&gt;2b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rechitsky, S.</td>
<td>RG&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Richter, K. S.</td>
<td>TMRW&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rienzi, L. F.</td>
<td>Cooper Surgical, Cook, Nterizer, Ferring, Fujifilm-Irvine Scientific, Genera Health Care srl, Global Investment Clinics s.à.r.l., Ibsa, Medea, Merck KGaA, MSD, Nterizer, has been of Flam srl&lt;sup&gt;2c&lt;/sup&gt;; Universal clinics&lt;sup&gt;5c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rimestad, J.</td>
<td>Vitrolife&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rios, J. S.</td>
<td>Abbvie&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rizk, B.</td>
<td>fairhaven health&lt;sup&gt;7a&lt;/sup&gt;; Hologic</td>
</tr>
<tr>
<td>Rosen, M. P.</td>
<td>DxNow&lt;sup&gt;8a&lt;/sup&gt;(scientific advisory board); future fertility&lt;sup&gt;8a&lt;/sup&gt;(scientific advisory board); vivoplex&lt;sup&gt;8c&lt;/sup&gt;(scientific advisory board)</td>
</tr>
<tr>
<td>Rothenbüehler, M.</td>
<td>Ava AG&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Rouse, N. A.</td>
<td>Praxis Genomics&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sakkas, D.</td>
<td>Legacy&lt;sup&gt;9a&lt;/sup&gt;(Consultant); Igenomix&lt;sup&gt;8c&lt;/sup&gt;(Scientific Advisory Board); EMD Serono&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sammel, M.</td>
<td>Astarte Medical&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Samplaski, M. K.</td>
<td>Fellow Health(^8a)</td>
</tr>
<tr>
<td>Samplaski, M. K.</td>
<td>Fellow Health(^8a)</td>
</tr>
<tr>
<td>Samuelsen, C. H.</td>
<td>Ferring Pharmaceuticals(^6a); Outcomes Analytica AS(^8a)</td>
</tr>
<tr>
<td>Sanami, S.</td>
<td>Dai Nippon Printing Co., Ltd.(^3a)</td>
</tr>
<tr>
<td>Santora, A. C.</td>
<td>Merck &amp; Co. Inc(^2a); Merck &amp; Co. Inc(^8a); (Retired Former Full time employee); Myovant(^6a); Myovant(^8a); (Consultant on interpretation and presentation of clinical study results at scientific meetings)</td>
</tr>
<tr>
<td>Santoro, N. F.</td>
<td>Ansh Labs, Inc(^6a); Astellas(^6a); Menogenix, Inc(^4a)</td>
</tr>
<tr>
<td>Santos-Ribeiro, S.</td>
<td>MSD(^7a)</td>
</tr>
<tr>
<td>Sasaki, K.</td>
<td>Abbvie(^7a)</td>
</tr>
<tr>
<td>Schadt, E.</td>
<td>Sema(^4a)</td>
</tr>
<tr>
<td>Schickedanz, A.</td>
<td>Wi Inc.(^3c)</td>
</tr>
<tr>
<td>Schickel, E. F.</td>
<td>American Journal of Epidemiology(^8a); (Editor-In-Chief )</td>
</tr>
<tr>
<td>Schlegel, P. N.</td>
<td>Ferring Pharmaceuticals(^6a); Paid for talk 8/2020; Posterity Health(^2a); Roman Health(^2a); Theralogix(^8a)</td>
</tr>
<tr>
<td>Schnorr, J.</td>
<td>Coastal Fertility Specialists(^2a)</td>
</tr>
<tr>
<td>Schreifels, M.</td>
<td>Sebela Pharmaceuticals, Inc.(^3a)</td>
</tr>
<tr>
<td>Sebra, R. P.</td>
<td>Sema4, a Mount Sinai venture(^2a); Sema4, a Mount Sinai venture(^8a); (Part-time employee)</td>
</tr>
<tr>
<td>Segars, J. H.</td>
<td>Abbvie(^8a); (Research PI); ABOG(^1a); Bayer(^8a); (Research study PI); Obseva(^8a); (Research PI)</td>
</tr>
<tr>
<td>Seidman, D. S.</td>
<td>AIF Ltd.(^2a)</td>
</tr>
<tr>
<td>Seifer, D. B.</td>
<td>Rutgers Medical School/MB(^8a); (Royalties from license with Beckman Coulter for patent of AMH determining ovarian reserve)</td>
</tr>
<tr>
<td>Seli, E.</td>
<td>Foundation for Embryonic Competence(^6a)</td>
</tr>
<tr>
<td>Shafiee, H.</td>
<td>Fertility Inc(^2a); Fertility Inc(^8a); (Co-founder); Verity LLC(^2a); Verity LLC(^8a); (Co-founder); XX(^8a); (IP licensing)</td>
</tr>
<tr>
<td>Shamonki, J. M.</td>
<td>California Cryobank, LLC(^2a)</td>
</tr>
<tr>
<td>Sharara, F. I.</td>
<td>Ferring Pharmaceuticals(^7a)</td>
</tr>
<tr>
<td>Sharma, P. A.</td>
<td>Zergo(^8a); Lilia(^2a)</td>
</tr>
<tr>
<td>Shirazi, T.</td>
<td>Modern Fertility(^8a); (Consultant)</td>
</tr>
<tr>
<td>Simón, C.</td>
<td>Igenomix SL(^5a)</td>
</tr>
<tr>
<td>Skiles, M. L.</td>
<td>Athersys Inc(^2a); Bausch Health(^2a); Bristol Myers Squibb(^2a); Fate Therapeutics(^2a); Generate Life Sciences(^3b); Grifols(^2a); Johnson and Johnson(^2a); Mesoblast Ltd(^2a); Sangamo Therapeutics(^2a)</td>
</tr>
<tr>
<td>SMITH, J.</td>
<td>Fellow Health(^8a); (Stock Options); Posterity Health(^2a)</td>
</tr>
<tr>
<td>Smith, Y. R.</td>
<td>UpToDate(^8a); (Receive Royalties)</td>
</tr>
<tr>
<td>Smith, J.</td>
<td>Fellow Health(^8a); (Stock Options); Posterity Health(^2a)</td>
</tr>
<tr>
<td>Smith, P.</td>
<td>Praxis Genomics(^3a)</td>
</tr>
<tr>
<td>Smits, J. E.</td>
<td>Lavima Fertility Inc(^2a)</td>
</tr>
<tr>
<td>Snider, A.</td>
<td>Igenomix(^3a)</td>
</tr>
<tr>
<td>Soares, S. R.</td>
<td>Ferring, Gedeon Richter, Merck (pharmaceuticals)(^4a); Roche</td>
</tr>
<tr>
<td>Authors</td>
<td>Affiliations</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Sommer, G.</td>
<td>Sandstone Diagnostics, Inc.</td>
</tr>
<tr>
<td>Sonoda, M.</td>
<td>Sonoda Momoyo ART clinic</td>
</tr>
<tr>
<td>Sparks, A. E.</td>
<td>Ferring Pharmaceuticals</td>
</tr>
<tr>
<td>Stamm, C. A.</td>
<td>Merck nexplanon trainer but accept no honorarium</td>
</tr>
<tr>
<td>Steiner, A. Z.</td>
<td>Seikagaku corporation; Prima-Temp</td>
</tr>
<tr>
<td>Steyn, F. M.</td>
<td>EngagedMD</td>
</tr>
<tr>
<td>Strait, E.</td>
<td>Vitrolife, Inc.</td>
</tr>
<tr>
<td>Surrey, E. S.</td>
<td>AbbVie; DOT Laboratories</td>
</tr>
<tr>
<td>Swain, J. E.</td>
<td>Fujifilm (Key Opinion Leader- lecturer)</td>
</tr>
<tr>
<td>Swan, R.</td>
<td>Generate Life Sciences</td>
</tr>
<tr>
<td>Takeda, S.</td>
<td>Dai Nippon Printing Co., Ltd.</td>
</tr>
<tr>
<td>Tal, R.</td>
<td>Celmatix</td>
</tr>
<tr>
<td>Taske, H. D.</td>
<td>Ferring Pharmaceutical</td>
</tr>
<tr>
<td>Teal, S. B.</td>
<td>Merck &amp; Co (DSMB member)</td>
</tr>
<tr>
<td>Tellier, L. C.</td>
<td>Genomic Prediction</td>
</tr>
<tr>
<td>Thakore, S.</td>
<td>Swiss Precision Diagnostics</td>
</tr>
<tr>
<td>Thomas, M. A.</td>
<td>Levocept; Agile</td>
</tr>
<tr>
<td>Thornton, K. L.</td>
<td>ALife Health (Board of advisors)</td>
</tr>
<tr>
<td>Tillman, S.</td>
<td>Feminist Midwife, LLC</td>
</tr>
<tr>
<td>Torres, R.</td>
<td>OXOLIFE S.L</td>
</tr>
<tr>
<td>Treff, N. R.</td>
<td>Genomic Prediction</td>
</tr>
<tr>
<td>Trinh, Q.</td>
<td>Astellas</td>
</tr>
<tr>
<td>Trolice, M. P.</td>
<td>Alto Pharmacy; Cryos International</td>
</tr>
<tr>
<td>Tsai, S.</td>
<td>VGAC</td>
</tr>
<tr>
<td>Tsai, H.</td>
<td>Bonraybio</td>
</tr>
<tr>
<td>Tseng, H.</td>
<td>California Cryobank</td>
</tr>
<tr>
<td>Tsuzuki, Y.</td>
<td>Dai Nippon Printing Co., Ltd.</td>
</tr>
<tr>
<td>Turok, D. K.</td>
<td>Sebela Pharmaceuticals</td>
</tr>
<tr>
<td>Ubaldì, F. M.</td>
<td>Cook, Cooper Surgical, Ferring, Fujifilm-Irvine Scientific, Genera Health Care srl, Nterilizer, has been of Flam sàrl Global Investment Clinics s.à.r.l., Ibsa, Medea, Merck KGaA, MSD, Nterilizer, Universal clinics</td>
</tr>
<tr>
<td>Vadaparampil, S. T.</td>
<td>GSK; BMS</td>
</tr>
<tr>
<td>Valencia, R.</td>
<td>IVF 2.0 LTD</td>
</tr>
<tr>
<td>Vang, P.</td>
<td>Vitrolife</td>
</tr>
<tr>
<td>Vaughan, D. A.</td>
<td>Granata Bio</td>
</tr>
<tr>
<td>Venier, B.</td>
<td>NextGen Genetics; TMRW</td>
</tr>
<tr>
<td>Walter, J. R.</td>
<td>Sibel Health</td>
</tr>
<tr>
<td>Walters-Sen, L.</td>
<td>Invitae</td>
</tr>
<tr>
<td>Authors</td>
<td>Affiliations</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Wang, S.</td>
<td>Cooper Genomics&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wantman, E.</td>
<td>Redshift Technologies&lt;sup&gt;1a&lt;/sup&gt;; SART&lt;sup&gt;8a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Warsi, Q.</td>
<td>Myovant Sciences&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Weckstein, L. N.</td>
<td>Alife&lt;sup&gt;8a&lt;/sup&gt;(Medical Advisory Board); Progyny&lt;sup&gt;8a&lt;/sup&gt;(Medical Advisory Board); US Fertility&lt;sup&gt;8a&lt;/sup&gt;(Board of Directors)</td>
</tr>
<tr>
<td>Weier, C.</td>
<td>CooperSurgical&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wemmer, N.</td>
<td>Natera&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Westphal, L.</td>
<td>Kindbody&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>White, E. M.</td>
<td>Fujifilm Irvine Scientific&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wilkinson, J.</td>
<td>Invitae&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Will, M.</td>
<td>Fertility Pharmacy of America&lt;sup&gt;2a&lt;/sup&gt;; Ovation Fertility&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Williams, A.</td>
<td>Shady Grove Fertility&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wilmarth, M.</td>
<td>Ovation Fertility&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wise, L. A.</td>
<td>AbbVie, Inc.&lt;sup&gt;5a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Worthington, A. K.</td>
<td>Modern Fertility&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Wroblecki, K. K.</td>
<td>AbbVie&lt;sup&gt;5a&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;2b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Xu, Y.</td>
<td>AbbVie, Inc.&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Xu, J.</td>
<td>Genomic Prediction, Inc.&lt;sup&gt;1a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Xu, S.</td>
<td>Sibel Health&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Yamashita, C.</td>
<td>Sonoda Momoyo ART clinic&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Yandell, M.</td>
<td>BackDrop Health Inc.&lt;sup&gt;1a&lt;/sup&gt;; Backdrop Health Inc.&lt;sup&gt;2a&lt;/sup&gt;; BackDrop Health Inc.&lt;sup&gt;8a&lt;/sup&gt;(CSO)</td>
</tr>
<tr>
<td>Yavari, M.</td>
<td>Natera&lt;sup&gt;2a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Young, S. L.</td>
<td>CiceroDx&lt;sup&gt;8a&lt;/sup&gt;(patent license)</td>
</tr>
<tr>
<td>Zaninovic, N.</td>
<td>ALIFE&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zhai, D.</td>
<td>Myovant Sciences, Inc.&lt;sup&gt;6a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zhan, Y.</td>
<td>Foundation for Embryonic Competence&lt;sup&gt;3a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Zimmerman, S.</td>
<td>Ferring Pharmaceutical&lt;sup&gt;7a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
AUTHOR AND FAMILY DISCLOSURES INDEX: ORAL AND POSTER SESSIONS

All oral and poster presenters at the ASRM 2021 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships an immediate family member or institution disclosed.

<table>
<thead>
<tr>
<th>Author</th>
<th>Company Officer</th>
<th>Direct Stockholder</th>
<th>Full-Time Company Employee</th>
<th>Grant Recipient</th>
<th>Honoraria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Einarsson, J. I.</td>
<td>Arthrex(^a); Hologic(^a); Olympus(^a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meseguer, M.</td>
<td>Theramex (^a)(Speaker fee); Merck (^a)(Speaker Fee); Vitrolife (^a)(speaker fee)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Petrozza, J. C.</td>
<td>Hologic(^a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfeifer, S. M.</td>
<td>RESOLVE(^ab)(Medical Advisory Board; Roman Health(^ab); Theralogix(^ab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Company Officer  \(^b\)Direct Stockholder  \(^c\)Full-Time Company Employee  \(^d\)Grant Recipient  \(^e\)Honoraria
ASRM Is Paperless!

The Final Program for the ASRM 2021 Scientific Congress & Expo in Baltimore will be posted online and available for download prior to, during, and after the Scientific Congress & Expo. The downloadable online PDF program will include complete, detailed program information, including the Daily Schedule and CME/CE materials (needs assessments/descriptions, learning objectives) for all CME activities (Postgraduate courses, plenary lectures, symposia, interactive sessions).

***

THERE WILL NOT BE A PRINTED FINAL PROGRAM BOOK

At the Congress, you will receive a printed copy of:

- Pocket calendar with room numbers
- Pocket listing of oral abstracts with room numbers
- Pocket listing of poster abstracts
- Listing of exhibits

ASRM’s free mobile app will list all of the activities, including oral and poster abstracts, with their room numbers for both the Postgraduate program and the Scientific Congress. The complete abstracts will be available on the:

- Mobile app
- Fertility and Sterility website
- Fertility and Sterility mobile app
- ASRMCongress.org website

For your convenience, there will be free wireless mobile hotspots in the Convention Center.
Getting pregnant isn’t always easy.

But IVF financing should be.

Help your patients make something beautiful.
PASSPORT GAME

PLAY ON THE CONGRESS APP!

Must attend in-person Congress to participate.

- Play the Game
- Download the ASRM2021 Mobile App Passport Game. Play is free.
- Create a user profile
- Collect codes around the Baltimore Convention Center.
- Drawings Wednesday October 20 @ noon
- Win Big!

Prizes include

- One Apple Watch
- Two Fitbits
- Three $100 Amazon Gift Cards

Limit one prize per person.
Exhibitors

- Exhibitors Booth Index 176-177
- Baltimore Convention Center 178
  Expo Floor Plan
- Exhibitor Listings 179-199
- Industry Sponsored Sessions 200-201
- Expo Theater Schedule 202
- Future ASRM Scientific Congress & Expo Dates 203
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agile Therapeutics</td>
<td>2237</td>
</tr>
<tr>
<td>Alto Pharmacy</td>
<td>910</td>
</tr>
<tr>
<td>American Society for Reproductive Medicine</td>
<td>1209</td>
</tr>
<tr>
<td>ARC Fertility</td>
<td>1915</td>
</tr>
<tr>
<td>Artisan Medical Solutions</td>
<td>2503</td>
</tr>
<tr>
<td>Asian Egg Bank</td>
<td>812</td>
</tr>
<tr>
<td>ASRM Meetings</td>
<td>2810</td>
</tr>
<tr>
<td>ASTEC Co. Ltd</td>
<td>2631</td>
</tr>
<tr>
<td>BabySentry</td>
<td>1620</td>
</tr>
<tr>
<td>Brown &amp; Brown Lone Star Insurance Service Inc.</td>
<td>1422</td>
</tr>
<tr>
<td>Business Recovery Center Inc.</td>
<td>1207</td>
</tr>
<tr>
<td>California Cryobank by Generate Life Sciences</td>
<td>2026</td>
</tr>
<tr>
<td>Carrot Fertility</td>
<td>922</td>
</tr>
<tr>
<td>Catalyst Healthcare Marketing</td>
<td>2820</td>
</tr>
<tr>
<td>CellOxess, LLC</td>
<td>1507</td>
</tr>
<tr>
<td>CellOxess, LLC</td>
<td>1503</td>
</tr>
<tr>
<td>Center for Surrogate Parenting, Inc.</td>
<td>1010</td>
</tr>
<tr>
<td>Cicero Diagnostics, Inc.</td>
<td>1327</td>
</tr>
<tr>
<td>Coast Science</td>
<td>1822</td>
</tr>
<tr>
<td>ColdStash</td>
<td>1124</td>
</tr>
<tr>
<td>Cook Medical Incorporated</td>
<td>1220</td>
</tr>
<tr>
<td>CooperSurgical</td>
<td>MR-6, MR-7, 2407</td>
</tr>
<tr>
<td>Core Cryolab</td>
<td>1126</td>
</tr>
<tr>
<td>Cryopoint</td>
<td>1920</td>
</tr>
<tr>
<td>Cryoport Systems</td>
<td>2804</td>
</tr>
<tr>
<td>Cryos International - USA</td>
<td>2031</td>
</tr>
<tr>
<td>Cryotherm, Inc</td>
<td>1326</td>
</tr>
<tr>
<td>Digital Instruments, Inc.</td>
<td>1731</td>
</tr>
<tr>
<td>Donor Egg Bank USA</td>
<td>2026</td>
</tr>
<tr>
<td>Eastern Virginia Medical School</td>
<td>1127</td>
</tr>
<tr>
<td>eIVF</td>
<td>1803</td>
</tr>
<tr>
<td>Embryo Options, A Cooper Brand</td>
<td>1003</td>
</tr>
<tr>
<td>Embryodirector.com</td>
<td>2136</td>
</tr>
<tr>
<td>Embryotech Laboratories, Inc.</td>
<td>1520</td>
</tr>
<tr>
<td>EMD Serono</td>
<td>MR-1, MR-2, 2013</td>
</tr>
<tr>
<td>ENCI Eggbank</td>
<td>1937</td>
</tr>
<tr>
<td>Endometriosis Association</td>
<td>1125</td>
</tr>
<tr>
<td>EngagedMD</td>
<td>2803</td>
</tr>
<tr>
<td>Esco Technologies Inc.</td>
<td>1825</td>
</tr>
<tr>
<td>EVERSANA</td>
<td>721</td>
</tr>
<tr>
<td>eXEm Foam</td>
<td>2234</td>
</tr>
<tr>
<td>Fairfax Cryobank and Fairfax EggBank</td>
<td>1020</td>
</tr>
<tr>
<td>Fairhaven Health</td>
<td>2003</td>
</tr>
<tr>
<td>Fellow</td>
<td>2338</td>
</tr>
<tr>
<td>Femasys Inc.</td>
<td>1634</td>
</tr>
<tr>
<td>Ferring Pharmaceuticals Inc.</td>
<td>MR-10, 1907, 2007</td>
</tr>
<tr>
<td>Fertility Pharmacy of America</td>
<td>712</td>
</tr>
<tr>
<td>Fertility Pro</td>
<td>1622</td>
</tr>
<tr>
<td>Fertility Storage Solutions</td>
<td>1010</td>
</tr>
<tr>
<td>Fertility Technology Resources, Inc.</td>
<td>1707</td>
</tr>
<tr>
<td>Form Health</td>
<td>715</td>
</tr>
<tr>
<td>Freedom Fertility Pharmacy</td>
<td>2610</td>
</tr>
<tr>
<td>FUJIFILM Irvine Scientific</td>
<td>2410</td>
</tr>
<tr>
<td>Galen US, Inc.</td>
<td>1324</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>2403</td>
</tr>
<tr>
<td>Gene2Genome</td>
<td>1423</td>
</tr>
<tr>
<td>Generate Life Sciences</td>
<td>2026</td>
</tr>
<tr>
<td>Genomic Prediction, Inc.</td>
<td>1424</td>
</tr>
<tr>
<td>GlyneX</td>
<td>2823</td>
</tr>
<tr>
<td>Hamilton Thorne, Inc.</td>
<td>2231</td>
</tr>
<tr>
<td>IC Biomedical</td>
<td>2135</td>
</tr>
<tr>
<td>IFFS</td>
<td>1325</td>
</tr>
<tr>
<td>igenomix</td>
<td>2813</td>
</tr>
<tr>
<td>In Vitro Sciences</td>
<td>803</td>
</tr>
<tr>
<td>Indian Egg Donors</td>
<td>1303</td>
</tr>
<tr>
<td>Innovative Health Diagnostics</td>
<td>1836</td>
</tr>
<tr>
<td>Invitae Corporation</td>
<td>2807</td>
</tr>
<tr>
<td>Invitrocare, Inc</td>
<td>2134</td>
</tr>
<tr>
<td>INVO Bioscience</td>
<td>2339</td>
</tr>
<tr>
<td>IVF Store</td>
<td>1014</td>
</tr>
<tr>
<td>IVFCRYO</td>
<td>703</td>
</tr>
<tr>
<td>Karl Storz Endoscopy-America</td>
<td>1603</td>
</tr>
<tr>
<td>Kindbody</td>
<td>920</td>
</tr>
<tr>
<td>Kitazato</td>
<td>2023</td>
</tr>
<tr>
<td>LabCorp</td>
<td>1703</td>
</tr>
<tr>
<td>LendingClub Patient Solutions</td>
<td>1908</td>
</tr>
<tr>
<td>LifeAire Systems LLC</td>
<td>2624</td>
</tr>
<tr>
<td>LINA Medical</td>
<td>912</td>
</tr>
<tr>
<td>LOUNGE</td>
<td>2414</td>
</tr>
<tr>
<td>Male Fertility Diagnostics</td>
<td>1912</td>
</tr>
<tr>
<td>Medical Electronic Systems, LLC 1</td>
<td>522</td>
</tr>
<tr>
<td>Meditab Software Inc.</td>
<td>1831</td>
</tr>
<tr>
<td>Mellowood Medical-Ideas</td>
<td>2603</td>
</tr>
<tr>
<td>Men Having Babies, Inc.</td>
<td>1936</td>
</tr>
<tr>
<td>MFB Fertility</td>
<td>2036</td>
</tr>
<tr>
<td>Mindray North America</td>
<td>2821</td>
</tr>
<tr>
<td>Minerva Surgical</td>
<td>1524</td>
</tr>
<tr>
<td>MVE Biological Solutions</td>
<td>711</td>
</tr>
<tr>
<td>Myovant Sciences, Inc.</td>
<td>MR-4, MR-8, 2620</td>
</tr>
<tr>
<td>Myriad Genetics, Inc.</td>
<td>2103</td>
</tr>
<tr>
<td>Nableivf</td>
<td>1403</td>
</tr>
<tr>
<td>Narishige International USA, Inc.</td>
<td>1420</td>
</tr>
<tr>
<td>Natera, Inc.</td>
<td>807</td>
</tr>
<tr>
<td>National Embryo Donation Center</td>
<td>822</td>
</tr>
<tr>
<td>NextGen LifeLabs</td>
<td>2626</td>
</tr>
<tr>
<td>NextGen LifeLabs</td>
<td>2724</td>
</tr>
<tr>
<td>Nikon Instruments Inc.</td>
<td>1815</td>
</tr>
<tr>
<td>EXHIBITOR COMPANY LISTING</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td></td>
</tr>
<tr>
<td>NxGen MDx ..................</td>
<td>REVA Global Medical, LLC</td>
</tr>
<tr>
<td>Olympus America Inc. ......</td>
<td>Samsung ..................</td>
</tr>
<tr>
<td>Optum Specialty and Infusion Pharmacy</td>
<td>SCSA Diagnostics ......</td>
</tr>
<tr>
<td>Organon LLC .................</td>
<td>Seattle Sperm Bank ........</td>
</tr>
<tr>
<td>Ovation Fertility ...........</td>
<td>Sema4 ...................</td>
</tr>
<tr>
<td>Overture, Inc. ..............</td>
<td>Siemens Healthineers ......</td>
</tr>
<tr>
<td>Ovobank ......................</td>
<td>SMP Fertility Pharmacy ...</td>
</tr>
<tr>
<td>Oxford Nanopore Technologies</td>
<td>Society for the Study of Reproduction</td>
</tr>
<tr>
<td>Pacific Coast Reproductive Society</td>
<td>Spectrum Technologies- Your Pure Sperm Source</td>
</tr>
<tr>
<td>pcos-diet.com ...............</td>
<td>Springer Nature ........</td>
</tr>
<tr>
<td>PerkinElmer Inc. ..........</td>
<td>The Fibroid Foundation ....</td>
</tr>
<tr>
<td>PharmaWatch ..................</td>
<td>The VFP Pharmacy Group ..</td>
</tr>
<tr>
<td>Pixel ........................</td>
<td>The World Egg Bank .......</td>
</tr>
<tr>
<td>Progenesis ..................</td>
<td>Theralogix ...............</td>
</tr>
<tr>
<td>Progyny ......................</td>
<td>TMRW ....................</td>
</tr>
<tr>
<td>Redia FIV S.L. ..............</td>
<td>Tosoh Bioscience .........</td>
</tr>
<tr>
<td>Rees Scientific Corp .......</td>
<td>Unilab ...................</td>
</tr>
<tr>
<td>Reprobiogen Inc. ............</td>
<td>Univfy Inc. ..............</td>
</tr>
<tr>
<td>Reproductive Genetic Innovations</td>
<td>Vanguard Communications</td>
</tr>
<tr>
<td>Reproductive Possibilities LLC</td>
<td>VirtaMed Inc. ........</td>
</tr>
<tr>
<td>Reproductive Solutions ......</td>
<td>VitroLife, Inc. ..........</td>
</tr>
<tr>
<td>ReproSource Fertility Diagnostics</td>
<td>Walgreens ...........</td>
</tr>
<tr>
<td>ReproTech, LLC ..............</td>
<td>WInFertility .............</td>
</tr>
<tr>
<td>Rescripted ...................</td>
<td>XiltriX North America ......</td>
</tr>
<tr>
<td>Resolve: The National Infertility Association</td>
<td>Xytex Corporation ....</td>
</tr>
<tr>
<td>Reunite RX ..................</td>
<td>720</td>
</tr>
<tr>
<td>Progenesis ..................</td>
<td>1625</td>
</tr>
<tr>
<td>Progyny ......................</td>
<td>1903</td>
</tr>
<tr>
<td>Redia FIV S.L. ..............</td>
<td>2035</td>
</tr>
<tr>
<td>Rees Scientific Corp .......</td>
<td>1225</td>
</tr>
<tr>
<td>Reprobiogen Inc. ............</td>
<td>2238</td>
</tr>
<tr>
<td>Reproductive Genetic Innovations</td>
<td>707</td>
</tr>
<tr>
<td>Reproductive Possibilities LLC</td>
<td>1531</td>
</tr>
<tr>
<td>Reproductive Solutions ......</td>
<td>2337</td>
</tr>
<tr>
<td>ReproSource Fertility Diagnostics</td>
<td>1813</td>
</tr>
<tr>
<td>ReproTech, LLC ..............</td>
<td>815</td>
</tr>
<tr>
<td>Rescripted ...................</td>
<td>923</td>
</tr>
<tr>
<td>Resolve: The National Infertility Association</td>
<td>1935</td>
</tr>
<tr>
<td>Reunite RX ..................</td>
<td>708</td>
</tr>
</tbody>
</table>
Agile Therapeutics Booth: 2237
101 Poor Farm Road
Princeton, NJ 08540
www.agiletherapeutics.com
Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.

Alto Pharmacy Booth: 910
1400 Tennessee Street, Unit 2
San Francisco, CA 94107
www.alto.com/fertility
Alto Pharmacy has supported more than 50,000 fertility journeys with personalized support and affordable access to fertility medications. Alto delivers a fundamentally better fertility pharmacy experience, with a best-in-class mobile app; free same-day delivery, 7 days a week; pharmacist-led injection training; insurance benefits coordination; and financing support. With locations in CA, WA, NV, CO, TX and NY, learn more about how Alto’s delivers more for your patients at alto.com/fertility.

American Association of Bioanalysts Booth: 715
906 Olive Street, Ste. 1200
Saint Louis, MO 63101-1448
www.aab.org
AAB’s College of Reproductive Biology (CRB) represents embryologists and andrologists. The American Board of Bioanalysis (ABB) is the only CLIA-approved board that certifies embryologists and andrologists. AAB Proficiency Testing (PT), a CLIA-approved PT service, surveys Antisperm Antibodies, Sperm Count/ Motility/Morphology/Viability, Embryology, Fertility Endocrinology, and PGS. The AAB Board of Registry (ABOR) certifies embryology and andrology laboratory scientists.

American Society for Reproductive Medicine (ASRM)
Booth: 1209
1209 Montgomery Highway
Birmingham, AL 35216-2809
www.asrm.org

ARC Fertility Booth: 1915
20195 Stevens Crk. Blvd. Ste 100
Cupertino, CA 95014-2380
www.arcfertility.com
ARC® Fertility is a nationwide network of top fertility clinics offering discounted treatment packages and financing for patients, as well as tools and technology to help manage your practice. Founded by physicians in 1997, ARC is the established leader in providing resources and services to patients; the ARC Success Program, ARC Pharmacy Plan and the ARC Employer Program, and also offers ARCIS a powerful PM and EHR system built for fertility clinics.

Artisan Medical Solutions Booth: 2503
35 Casa Street, Suite 260
San Luis Obispo, CA 93405-1890
www.artisanfertility.com
The Artisan EMR is the complete cloud-based electronic medical records, laboratory management and practice management system, specialized for the fertility practice.

Asian Egg Bank Booth: 812
4910 Directors Place, Suite 320
San Diego, CA 92121
www.asianeggbank.com
Asian Egg Bank is dedicated to recruiting egg donors of Asian ancestry. Our donor database is comprised of hundreds of donor profiles, and we constantly recruit and cycle egg donors with exceptional qualities. In our quest to build the largest frozen egg bank inventory of Asian egg donors, we have the greatest selection of donors with East Asian heritage: Chinese, Japanese, Korean, Vietnamese, Filipino, etc. Our donors are also available for an exclusive, matched fresh cycle.

ASTEC Co. Ltd Booth: 2631
4-6-15 Minamizato
Kasuya, Fukuoka 811-2207
www.astec-bio.com/global/
Established in 1978, Astec designs, manufactures and sells incubators and state-of-the-art medical laboratory equipment for the ART Industry worldwide. All equipment is engineered with stringent quality control and customer-oriented features and manufactured in our ISO 13485 certified facility in Japan, providing IVF laboratories the safest environment for embryo development and backed by a global network of highly-trained professionals. Astec has subsidiaries in Korea, China and USA.
BabySentry
1121 S. Meyler Street
San Pedro, CA 90731-3534
www.babysentry.com

BabySentry | Medical Genetics Software Corp. 1121 S. Meyler, San Pedro, CA 90731, USA T: +1-310-832-2223 | E: info@babysentry.com | W: www.babysentry.com

BabySentry is the leading Management System designed for the Assisted Reproduction Technology workplace. The software in its 12th version, is composed of a central database Electronic Medical Record (EMR) with multiple interfaces and connections to HIS systems (Epic, Cerner), analyzers, third-party software, web patient portal, smart phone app (iMineIVF), referral labs and national registries (SART-CORS, NASS, CARTR+, ANZARD, HFEA-PRISM, ABM-GAIA). Modules are structured to cover all functionalities of ART and affiliated practices.

Brown & Brown Lone Star Insurance Service Inc.
Booth: 1422
1717 N. Sam Houston Pkwy. #115
Houston, TX 77038
www.bbtexas.com

Brown & Brown, unlike most other large insurance brokers, specializes in serving those involved with the reproductive medical and infertility treatment process. Our company’s Fertility Insurance Program® is the leading provider of such insurance to physicians, clinics, and agencies participating in the human egg donation, gestational carrier (surrogate mother), and in-vitro fertilization process.

Business Recovery Center Inc.
Booth: 1207
181 New Road, Suite 304
Parsippany, NJ 07054
www.brc-cloud.com

BRC has been proudly hosting IVF clinic clients in our secure private cloud environment for over 20 years. We remotely monitor systems, components and networks for performance and security. Utilizing enterprise toolsets, BRC proactively manages applications, systems, networks and the entire security technology infrastructure of your business. Our customer attrition is among the lowest in the industry, attributable to the level of service and commitment we bring as a trusted business partner.

California Cryobank by Generate Life Sciences
Booth: 2026
11915 La Grange Avenue
Los Angeles, CA 90025
www.cryobank.com

California Cryobank, the industry leader in donor sperm; we have the largest and most rigorously screened selection of donors with 43 years of scientific expertise. We have helped create and grow 75,000+ families through our sperm and fertility preservation services making us the #1 choice of physicians and patients worldwide. We have a team of reproductive genetic specialists and client services representatives to help provide outstanding service every step of the way to becoming a parent.

Carrot Fertility
Booth: 922
101 Jefferson Avenue, 1st Floor
Menlo Park, CA 94205
www.get-carrot.com

Carrot Fertility is the leading global fertility benefits provider for employers and health plans, built to support employees through their entire fertility healthcare journey. Companies use Carrot to customize a fertility benefit that provides employees financial, medical, and emotional support as they pursue parenthood, reducing healthcare costs and resulting in better clinical outcomes. Carrot’s clinically-managed program includes fertility preservation like egg and sperm freezing, IVF, donor and gestational carrier services, adoption, and pregnancy support; Carrot Rx®, a premium pharmacy experience, at significant savings; and the Carrot Card®, a flexible fertility benefits debit card employees can use to pay for their care. Learn more at www.carrotfertility.com.

Catalyst Healthcare Marketing
Booth: 2820
4203 Jubilee Drive
Flower Mound, TX 75028-3033
www.catalysthcm.com

Need a marketing strategy that sparks growth? Let us be the catalyst that boosts your visibility and increases your patient load. At Catalyst Healthcare Marketing, we help practices achieve their business goals. Our cohesive marketing services set you apart from your competitors, build brand recognition and keep your business moving forward. Our experienced team can serve as your virtual marketing department or seamlessly integrate with your existing marketing team.
Celloxess, LLC Booth: 1503 and 1507
830 Bear Tavern Road
Ewing, NJ 08628

In the crowded space of nutritional and antioxidant therapies, Celloxess has revolutionized the field with the development of our signature, science-driven, personalized nutraceutical formulations to optimize male and female fertility potential before, during, and after pregnancy. Resolution of oxidative stress in the reproductive tract towards optimum gametogenesis is a critical first step for achieving a healthy pregnancy and child. The company’s flagship line of fertility products, Fertilix®, restores, rather than overwhelms, the redox balance of the reproductive tract. Using our simple online algorithm, personalized Fertilix® male and female formulations are recommended according to age and fertility potential. Other products that offer “one size fits all” solutions carry the very serious risk of over-supplementing individuals, which in turn can also impair fertility. Fertilix® is now recognized as the choice suite of fertility products among fertility experts worldwide.

Center for Surrogate Parenting, Inc. Booth: 1010
15821 Ventura Boulevard. Suite 625
Encino, CA 91436
www.creatingfamilies.com

A world-renowned surrogacy agency, the Center for Surrogate Parenting has been Creating Families® for more than four decades, welcoming more than 3,000 babies. CSP’s inclusive program serves intended parents worldwide, regardless of nationality, gender, sexual orientation or marital status. CSP creates positive and seamless surrogacy journeys, providing an intensive surrogate pre-screening process along with counseling support and medical and legal resources for both parents and surrogates, from consultation until after delivery. Learn more at CreatingFamilies.com.

Cicero Diagnostics, Inc. Booth: 1327
5075 Warner Avenue, Suite 202
Huntington Beach, CA 92649-4059
www.receptivadx.com

CiceroDx, Inc. is the exclusive provider of ReceptivaDx (BCL6) testing for failed IVF, unexplained infertility, and recurrent pregnancy loss. Working with over 300 fertility centers in the US and around the world, Our BCL6 marker provides answers for your most challenging cases, even in situations where PGS tested embryos and optimized transfer windows have failed to yield a pregnancy. Stop by to review the latest published clinical data and ongoing research via our NIH commercial grant.

Coast Science Booth: 1822
4653 Carmel Mountain Road, Suite 308-123
San Diego, CA 92130-6650
www.coastscience.com

Coast Science® is a leader in the science & manufacturing of top-quality, nutraceuticals. We are the proud maker of premium Fertility Supplements since 2001. Our all in one Preconception Formulas: MFSg5 – The Male Prenatal™, Fertile One® PC 600 & Fertile One® PCOS 600 provide advanced nutrition based on science to optimize sperm or egg quality. Coast Science® is committed to optimizing fertility health & success for all fertility patients. Now introducing she-ology™ for Women. Three new daily vitamin, antioxidant & herbal blends to relieve symptoms of Menopause, Peri-Menopause & PMS. Our newest line she-ology™ allows women to have the most advanced dietary supplements for natural health & hormonal balance throughout their cycles. Trusted & recommended by over 1500 Physicians worldwide in over 50 countries, for their couples who are trying to conceive. All Coast Science® products are scientifically based & made in the USA, with the highest quality manufacturing & ingredients.

ColdStash Booth: 1124
879 Hopkins Hill Road
West Greenwich, RI 02817
www.coldstash.com

ColdStash is a global business providing market-leading LN2/Cryogenic storage solutions. We help our clients to operate safely and efficiently, saving space and costs with products such as the VitroStash and VitroStash MAX dewar systems, as well as traditional storage options. The MAX is a dewar and canister combination that increases storage capacity by 500% with only a 25% footprint increase, significantly reducing space required for storing vitrified specimens and cost per patient. In addition to products already available, ColdStash is excited to unveil new offerings for ASRM 2021. These products include our liquid level and “vacuum breach” alarm systems, “StrawStash,” a one piece embryo straw aluminum storage cassette, and “SecureStash” solid bottom canisters which offer the ultimate in safe, secure handling and storage of critical specimens. ColdStash, the safest, most secure, and cost effective solution for all your cryogenic storage needs.
Cook Medical Incorporated Booth: 1220
750 Daniels Way
Bloomington, IN 47402
www.CookMedical.com/rh

Cook Medical has been collaborating with physicians and researchers for over 50 years to create minimally invasive medical devices. And for over 30 years, Cook’s Reproductive Health division has brought that collaboration and experience to reproductive medicine. Cook Reproductive Health offers products for diagnostic imaging, assisted reproduction, maternal-fetal medicine, obstetrics, and gynecology. In addition to creating medical devices, Cook Reproductive Health is committed to advancing education, research, and collaboration with physicians in order to enhance patient care for women and men throughout their reproductive lives—from diagnosis to delivery and beyond. Visit www.cookmedical.com/web/reproductive-health to learn more about Cook Reproductive Health.

CooperSurgical Booth: 2407
95 Corporate Drive
Trumbull, CT 06611-1350
www.coopersurgical.com

At CooperSurgical, we are continuing to push the boundaries of what is possible to build a better journey for all, to change fertility care for generations to come. This means changing fertility standards, the fertility journey, and providing better access globally to fertility treatments. We will do this by continuing to deliver solutions for different patients’ needs, and by collaborating closely with clinics worldwide to standardize, optimize and automate clinical workflows. We will help clinics reach a higher level of efficiency and insight throughout the entire fertility journey, by bringing scientifically based best practices into day-to-day care, utilizing digital platforms and artificial intelligence. This is how CooperSurgical, together with you, will help change fertility care. Not just today, but for generations to come. Visit our websites to find out more at fertility.coopersurgical.com or contact us at Telephone 1-800-648-1151.

Core Cryolab Booth: 1126
585 University Avenue
Toronto, ON M5G 2N2 CANADA
corecryolab.com

Core Cryolab specializes in cryogenic services: Cryo-Shipping, Cryo-Storage, and Cryo-Equipment Sales. Over the last 15 years, Core has safely transferred thousands of IVF samples both domestically and internationally. The company’s best-in-class equipment and comprehensive shipping solutions offer peace of mind for patients and clinics. Core’s success has been built on an extreme dedication to quality management and customer care.

Cryopoint Booth: 1920
1533 E. Northfield Drive, Suite 300
Brownsburg, IN 46112
cryopointllc.com

Cryopoint is dedicated to the safe transportation and long-term cryostorage of reproductive tissues for currently cycling IVF patients as well as abandoned specimens. Our experienced and compassionate team is focused on providing tailored service to your patients that allows complete peace of mind. Our state-of-the-art facility is monitored under 24-hour video surveillance with motion sensor detection and real-time storage tank temperature monitoring.

Cryos International - USA Booth: 2031
2200 N. Alafaya Trl., Suite 550
Orlando, FL 32826-3995
www.cryosinternational.com

Cryos International is the world’s largest sperm and egg bank. We are here to help people make the dream of having a child come true. For over 30 years, Cryos has provided specialized reproductive products, excellent customer care, and personal consultation to customers. Sperm donors and egg donors come from all backgrounds and can be used for both home insemination and fertility treatments at IVF clinics. We ship to over 100 countries with a wide selection of frozen donor sperm and donor eggs.
Cryotherm, Inc  Booth: 1326  
5126 South Royal Atlanta Drive  
Tucker, GA 30084

Digital Instruments, Inc.  Booth: 1731  
580 Ensminger Road  
Buffalo, NY 14150  
www.digitalinstruments.com/ivf

Since 1977, Digital Instruments, Inc. has developed custom solutions for a variety of commercial, industrial and medical clients, including the IVF Lab marketplace. LabCapture is our monitoring system, which can be implemented to monitor and alarm on a variety of IVF Lab equipment. This system offers a multi-functional wireless solution for the entire Lab. Additionally we offer Custom designed workstations, integrated with Heated stages and Scope mounts. We manufacture legacy products such as the CryoSave Monitor and support remote monitoring systems such as SmartSense/TempAlert, other products include a 270 ML LN2 Ladle, Custom Incubator Alarm Cables and sensors, Fill n’ Go Cryo Tanks with pre-installed Sensors, Integrated Tank Cork LN2 Level Sensors, IEC 60601 Compliant Dewar Rollers and more. Leading our efforts to support IVF Lab clients is Leo McNamara and industry veteran with 35+ years of experience in medical/IVF Sales and Service.

Donor Egg Bank USA  
Booth: 2026  
1355 Piccard Drive, Suite 330  
Rockville, MD 20850  
DonorEggBankUSA.com

Donor Egg Bank USA, a Generate Life Sciences company, is the number one choice for patients and physicians since 2012. With more than 300 high screened donors, we guarantee a blastocyst with every egg lot shipped. Our diverse egg donors receive extensive genetic, psychological, family history, biological and infectious disease screening. Knowing that fertility care is expensive and can sometimes be unpredictable, Donor Egg Bank USA offers a 100% money back guarantee with our Assured Refund Plan. This plan offers up to 6 egg lots and unlimited frozen embryo transfers for one price, and if you do not bring home a baby, we provide a full plan fee refund. Visit DonorEggBankUSA.com or call us at (855) 344-2265 to speak with a client services specialist who will answer your questions and support you in choosing the donor that’s right for you. Donor Egg Bank USA is part of Generate Life Sciences, a global company that has helped build and protect nearly 1 million families.

DotLab  Booth: 2703  
655 Montgomery Street, Floor 7  
San Francisco, CA 94111  
dotlab.com

Endometriosis is a complex, heterogeneous disease that may present inconsistently across patients. By measuring disease-specific biomarkers and applying machine learning, DotEndo provides the information you need to attribute her symptoms.

Eastern Virginia Medical School  
Booth: 1127  
651 Colley Avenue  
Norfolk, VA 23507-1627

eIVF  Booth: 1803  
1212 Corporate Drive, Suite 200  
Irving, TX 75038  
www.eivf.org

PracticeHwy is a leader in healthcare software which serves fertility practices and clinics worldwide. In 2002, eIVF was launched, one of the first EMR platforms focused on Reproductive Endocrinology and Infertility practices. Since then, eIVF has been utilized on over a million cycles. Known for its pursuit of excellence in the fertility industry, PracticeHwy has seen trajectory growth by continuously developing software solutions which support all aspects of a fertility clinic’s operations.

Embryo Options, A Cooper Brand  
Booth: 1003  
211 W. Jefferson Avenue  
Naperville, IL 60540  
www.embryooptions.com

Embryo Options is a web based application that automates cryo-billing, and streamlines the disposition process for embryos, eggs, and sperm. Embryo Options is designed to increase cryo-billing collections rates, reduce specimen abandonment, and provide patients easier access to donate embryos back to the practice to help other couples achieve a pregnancy.
**Embryodirector.com** Booth: 2136
21708 Hardy Oak Boulevard, # 104
San Antonio, TX 78258
www.embryodirector.com

Making embryologists, andrologists, and nursing great with the worlds only One on One Hands On Training alongside a working IVF laboratory. Now offering online training with technique demonstrations. Each in person and online module is complete with certifications. Now partnering with ART Compass, an essential tool for; evaluating the technique, competency and process in the IVF Lab through a mobile app at your fingertips. https://www.linkedin.com/company/art-compass/about/

**Encompass Fertility** Booth: 1203
2700 Northeast Expressway NE, Suite B800
Atlanta, GA 30345
encompassrx.com

Encompass Fertility specializes in navigating fertility benefits to offer a comprehensive solution to manage specialty drug costs that maximize the medical and prescription benefit, lowering the overall cost of treatment for the patient. We strive to supply every provider and patient with the confidence, ability, knowledge, and a dedicated team they need to feel empowered and comfortable throughout their fertility journey.

**Embryotech Laboratories, Inc.**
Booth: 1520
140 Hale Street
Haverhill, MA 01830-3985

An ISO-17025 Accredited contract test laboratory catering to the human reproductive industry, Embryotech™ continues to provide the latest quality control assays including Mouse Embryo Assay, Endotoxin (Gel-Clot & Kinetic), an array of Human Sperm Assays. Embryotech™ is also the leader in providing all stages of fresh and cryopreserved mouse embryos, hamster ova to clinics and universities around the world aiding in technician training and proficiency testing.

**Endometriosis Association** Booth: 1125
8585 N. 76th Place
Milwaukee, WI 53223-2633
EndometriosisAssn.org

The Endometriosis Association (EA) is an international nonprofit, founded in 1980, that supports and educates patients, the public, and professionals, and conducts seminal research which has changed understanding of the disease. Research has included collaboration with NIH and a long-term partnership with Vanderbilt. EA President Mary Lou Ballweg and the Association have authored numerous publications including four books, scientific articles, brochures in 31 languages. EndometriosisAssn.org

**EMD Serono** Booth: 2013
One Technology Place
Rockland, MA 02370
www.emdseronofertility.com

EMD Serono is committed to connecting important details within the fertility cycle. Thanks to our long-standing expertise, support programs, and partnerships, we provide you and your patients with solutions that can help impact OI and ART treatment success.

**EngagedMD** Booth: 2803
1639 4th Street Northwest
Washington, DC 20001
www.engaged-md.com

EngagedMD is a B2B software company that offers the leading patient journey management solution for the fast-growing fertility sector. Our mission is to make life easier for doctors, nurses, administrators, staff, and patients. Nearly half of fertility patients in the US use EngagedMD for education and informed consent. Clinics use our software to reduce manual tasks and streamline the patient journey, which reduces staff burnout and increases capacity to make care accessible to more patients.
Esco Technologies Inc.  Booth: 1825
903 Sheehy Drive, Suite F
Horsham, PA 19044
www.escomedicalgroup.com

Esco Medical is a leading manufacturer and innovator of high-quality equipment such as benchtop incubators, ART workstations, and time-lapse incubators. We are continuously developing advanced technologies to meet the increasing demand of the IVF industry. Products are designed using the Silent Embryo Hypothesis as a guiding principle: the less disturbed an embryo can remain, the better its developmental potential will be. Most products are designed in Denmark and made in the EU.

EVERSANA  Booth: 721
190 N. Milwaukee Street
Milwaukee, WI 53202
www.eversana.com

EVERSANA™ is the leading provider of global commercial services to the life sciences industry. Our integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. We serve more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world.

ExEm Foam  Booth: 2234
424 Church St., Suite 2000
Nashville, TN 37219
www.exemfoam.com

ExEm® Foam, a first-line investigation to diagnose Tubal Patency using Ultrasound. Experience the performance and accuracy as compared to HSG and Saline. Worldwide 500,000+ procedures have will be available, enabling you to experience the latest innovation in Tubal patency. You are invited to visit us at booth 2234.

Fairhaven Health  Booth: 2003
1410 11th St
Bellingham, WA 98225-7309
www.fairhavenhealth.com

Fairhaven Health is a leading provider of products for trying to conceive couples, including fertility supplements and BabyDance Fertility Lubricant, the first ever sperm-friendly lubricant made without parabens. We are proud to showcase FH PRO for Men and Women – our comprehensive, antioxidant-based, and clinically-studied fertility supplements. Recently, FH PRO for Men was shown in a clinical study to improve motility by 102%, count by 38% and reduce DNA fragmentation by 17%.

Fellow  Booth: 2338
1509 Long Lake Boulevard
Orono, MN 55356
www.meetfellow.com

Femasys Inc.  Booth: 1634
3950 Johns Creek Court, Suite 100
Suwanee, GA 30024
www.femasys.com

Femasys is a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies. Its reproductive health portfolio includes FemVue®, a commercially available product for fallopian tube assessment by ultrasound and FemaSeed™, a first and only approach that delivers sperm directly to the fallopian tube that is currently being studied in a pivotal trial.
Ferring Pharmaceuticals Inc.
Booth: 1907 and 2007
100 Interpace Parkway
Parsippany, NJ 07054
www.ferringfertility.com

RUBY Level Supporter - Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. With global headquarters in Saint-Prex, Switzerland and its US Operations Center in Parsippany, NJ, Ferring is a leader in Reproductive Medicine and Maternal Health, and in specialty areas within Gastroenterology and Orthopaedics. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Fertility Pharmacy of America
Booth: 712
1911 Church Street
Nashville, TN 37203

Fertility Pharmacy of America is a boutique fertility pharmacy created to provide patients with better service and value while giving Reproductive Endocrinologists more control over how the pharmacy operates.

Fertility Pro
Booth: 1622
482 S. Arroyo Parkway, Suite 404
Pasadena, CA 91105
www.fertilitypro.com

Fertility Pro is a software company that works collaboratively with clinics, labs, and scientific companies worldwide to design applications for managing and promoting growth in the fertility industry. With modules designed specifically for every aspect of fertility management, Fertility Pro enables users to capture essential data and meet legal obligations, regulatory requirements such as SART & CDC, and create their own standards of excellence.

Fertility Storage Solutions
Booth: 1010
2769 Sunridge Heights Parkway
Henderson, NV 89052
www.fertilitystoragesolutions.com

Fertility Storage Solutions provides the most advanced, secure storage available for eggs, sperm, embryos and ovarian tissue, backed by outstanding customer service.

Our purpose-built storage facility uses failsafe liquid nitrogen cryopreservation equipment, with 24/7/365 dual digital temperature monitoring, redundant alarm systems, and daily tank checks. All specimens are shipped insured by GPS-tracked courier, providing peace of mind for patients. Learn more at FertilityStorageSolutions.com.

Fertility Technology Resources, Inc.
Booth: 1707
1539 Jackson Avenue, Suite 410
New Orleans, LA 70130

Form Health
Booth: 2239
179 Lincoln Street 4th Floor
Boston, MA 02111
www.formhealth.co

A modern medical weight loss program delivered entirely through the convenience of telehealth.

Freedom Fertility Pharmacy
Booth: 2610
12 Kent Way
Byfield, MA 01922-1221
www.freedomfertility.com

Our mission is to help people through a very complex process during one of their most vulnerable and emotional times in life. Our patients count on us to give compassion, empathy, and peace of mind along with an expertise in providing what they need to be successful in their fertility journey.

FUJIFILM Irvine Scientific
Booth: 2410
1830 E. Warner Avenue
Santa Ana, CA 92705-5533
www.irvinesci.com

As a cell culture media pioneer, we leverage decades of industry insight to deliver advanced cell culture media solutions for use in reproductive medicine, medical and translational research, biopharmaceuticals, regenerative medicine, and clinical diagnostics. Our innovative products and services enable scientists to fulfill the potential of emerging therapies and help clinicians achieve successful outcomes for their patients. FUJIFILM Irvine Scientific was acquired by Fujifilm in 2018. As one of the Fujifilm Healthcare companies, we utilize their expertise in engineering and manufacturing to accelerate the innovation of media and technologies for assisted reproduction and deliver inventive products and workflows aimed to meet the evolving needs of the reproductive medicine community and help patients successfully achieve their dreams of a family.
EXHIBITOR COMPANY LISTING

Galen US, Inc. Booth: 1324
25 Fretz Road
Souderton, PA 18964
www.galen.co.uk

Galen is a recognized Specialty Pharmaceutical Company marketing products throughout the UK, Ireland, Europe and the US in therapy areas such as gastroenterology, psychiatry, female health and pain management. By combining innovation in product development with competitive pricing, Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value, a major factor in the company’s success to date.

GE Healthcare Booth: 2403
9900 W Innovation Drive
Wauwatosa, WI 53226

GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.

Gene2Genome Booth: 1423
8659 Baypine Road
Jacksonville, FL 32256
www.gene2genome.com

Gene2Genome (G2G) is an independent reference laboratory providing Preimplantation Genetic Testing (PGT) services to physicians, medical groups and healthcare facilities. G2G’s test services primarily focuses on reproductive genetic tests including PGT-A, PGT-SR and PGT-M, and Chromosome analysis.

Generate Life Sciences Booth: 2026
11915 La Grange Avenue
Los Angeles, CA 90025
generate.com

Generate Life Sciences™ is a global life sciences company helping couples and individuals grow and protect their family’s future, through guidance anchored in scientific advancements and services ranging from preconception into adulthood. Our longstanding brands — which include California Cryobank™, Donor Egg Bank USA™, CBR® (Cord Blood Registry®), Insception Lifebank, Cells for Life, Cell Care, , NW Cryobank™, ReadyGen™, Kitazato USA™, and Donor Application™ — are pioneering leaders that have helped nearly one million families through reproductive, newborn stem cell, genetic screening, medical device, and healthcare technology services. Headquartered in Los Angeles, Generate operates facilities spanning from the United States and Canada to Australia, alongside frozen donor gamete distribution to more than 40 countries.

Genomic Prediction, Inc. Booth: 1424
675 Us Highway 1 Ste 126
North Brunswick, NJ 08902-3378
www.genomicprediction.com

Genomic Prediction is the first laboratory in the country to offer PGT for polygenic conditions (PGT-P) such as cancer, heart disease and diabetes. Our methods allow for simultaneous detection of aneuploidy, single gene disorders and chromosome rearrangements, with the capacity to differentiate between balanced and normal karyotypes. We have also developed an innovative testing platform for PGT-A, SEQ. A one step library prep makes testing safer, faster and more affordable.

Gynex Booth: 2823
14603 NE 87th Street
Redmond, WA 98052-6552
www.gynexcorporation.com

Gynex is a provider of quality medical devices of obstetrics and gynecology for over 20 years.

Hamilton Thorne, Inc.
Booth: 2231
100 Cummings Ctr., Suite 465E
Beverly, MA 01915-6143

Hamilton Thorne is showcasing our LYKOS® clinical laser with Dynamic Targeting System (DTS), IVOS™ and CEROSTM CASA systems, ZANDAIR® air purification units, Gynemed micropipettes and media, and Planer incubators and monitoring system. We also distribute the Geri® embryo monitoring system, Gidget® electronic witnessing system, Lenshooke X1 Pro Semen Quality Analyzer and PCHBI stackable, multigas incubator. In addition, we offer complete IVF lab build-out solutions.
**IFFS** Booth: 1325  
19 Mantua Road  
Mount Royal, NJ 08061-1006  
www.iffs-reproduction.org

IFFS - International Federation of Fertility Societies creates global programs & initiatives to advance fertility care and education so that all women & men have access to quality fertility and reproductive health care. Events: IFFS/FERSOG Workshop: Management of Infertility and Assisted Conception, 18 - 20 September 2019, Accra, Ghana; IFFS Course at Argentine Congress SAMer 2020, 2 September 2020, Rosario, Argentina; IFFS World Congress, 2 - 6 April 2022, Athens, Greece  
www.iffs-reproduction.org

**Igenomix** Booth: 2813  
7955 NW 12th Street, Suite 415  
Miami, FL 33126-1823  
www.igenomix.com

IGENOMIX is a biotechnology company that provides advanced services in Reproductive Genetics. Our experience and advanced research capabilities have made this company one of the world leaders in its field, enabling it to provide effective solutions tailored to different infertility problems. IGENOMIX has lab operations in Miami, Los Angeles and New York, and 21 other laboratory affiliates around the world.

**In Vitro Sciences** Booth: 803  
22 Waterville Road  
Avon, CT 06001  
www.invitrosciences.com

**Indian Egg Donors** Booth: 1303  
Surrogacy4All  
1148 5th Avenue, Suite 1B  
New York, NY 10128  
www.IndianEggDonors.com

Www.IndianEggDonors.com is the premier resource in New York City and across the United States for those who are looking for egg donors and surrogates. We have over 1,000 egg donors and surrogates in our database and work with top fertility clinics and clients world-wide. Through our affiliated site, www.Surrogacy4All.com we provide low cost overseas surrogate mothers for $39,000 at an FDA standard IVF Center. We also provide US Surrogates for $105,000 per surrogate mother.

**Innovative Health Diagnostics** Booth: 1836  
1565 McGaw Avenue, Suite B  
Irvine, CA 92614  
www.ihdlab.com

Our mission is to empower every person with access to accurate and actionable clinical testing when and where it matters most.

**Invitae Corporation** Booth: 2807  
1400 16th Street  
San Francisco, CA 94103  
invit.ae/asrm21

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices.

**Invitrocare, Inc.** Booth: 2134  
8415 Progress Drive, Unit F  
Frederick, MD 21701-4762

InVitroCare Inc provides a full range of ART products, including products for both gamete and embryo preparation and freezing. Our IVC Media Series is designed to support embryo growth at each stage of development. Additional products include double-washed Mineral Oil, ICSI reagents and a complete line of IUI products and equipment specifically designed for the doctor’s office. Our products are manufactured in FDA registered facilities in full compliance with cGMP and ISO 9001 standards.

**INVO Bioscience** Booth: 2339  
5582 Broadcast Court  
Sarasota, FL 34240  
invobioscience.com

The INVO Bioscience® mission is to increase access to care and expand fertility treatment and patient care across the globe. For many couples struggling with infertility, access to treatment is often not possible. Financial challenges, limited availability of specialized medical care, religious, social or cultural roadblocks can prevent these hopeful parents from realizing their dream to have a baby. INVOcell® is the first Intravaginal Culture (IVC) system granted FDA clearance in the United States, providing millions of infertile couples across the country access to this revolutionary infertility treatment.
treatment. This novel device utilizes the women’s vagina as an incubator to support a more natural fertilization and embryonic development environment. The INVOCell device and INVO® Procedure will provide couples the opportunity to have an additional option other than the thirty-year-old traditional treatments, Intrauterine Insemination (IUI) and In Vitro Fertilization (IVF).

**IVF Store** Booth: 2831
5975 Shiloh Road, Suite 101
ALPHARETTA, GA 30005

IVF STORE, is a full service, online store representing the finest IVF products supported with traditional and exceptional customer service. For maximum convenience to customers, our easy to use and functional website is fully responsive, allowing IVF orders to be taken with a computer or mobile device. Our one-stop-shop for "Everything IVF" makes ordering easier than traditional channels through multiple vendors and allows us to serve you with focus and efficiency.

**IVFCRYO** Booth: 703
12223 Lindley Drive
Noblesville, IN 46060
www.ivfcryo.com

IVFCRYO is a premium cryogenic service business specifically created and tailored to help the fertility industry mitigate the risk of specimen loss. Initially acting as a cryogenic consulting company to help advise clients on best practices, IVFCRYO has grown and expanded its product line to provide full service “EVERYTHING-CRYO” for the IVF industry. These services now include Specimen Shipping, Tissue Storage, Cryogenic Facility Design, Consulting, and Cryogenic Services such as Cryo-Equipment Sales/Distribution, Repairs, and Maintenance.

**Karl Storz Endoscopy-America**
Booth: 1603
2151 E. Grand Avenue
El Segundo, CA 90245
www.karlstorznetwork1.com/gynecology

KARL STORZ is a global provider of advanced endoscopic instruments and related technologies. With longstanding expertise in gynecology and reproductive medicine, KARL STORZ offers a comprehensive suite of minimally invasive devices, including various types of hysteroscopes and resection systems. KARL STORZ is dedicated to providing quality instruments that enhance the treatment of women in diverse clinical settings without losing sight of the need to control costs.

**Kindbody** Booth: 920
1140 Broadway, 11th Floor
New York, NY 10001
www.kindbody.com

In boutique, modern, tech-enabled clinics, we provide fertility services, gynecologic care, and wellness support - offering the first one-stop-shop for all women’s health and fertility needs. Our best-in-class clinical team serves the modern day women in retail and mobile locations across the country, delivering a new generation of care - elevated, seamless, and accessible. By women, for all of us.

**Kitazato** Booth: 2023
100-10 Yanagishima
Fuji, Shizuoka 416-0932 Japan
www.kitazato-ivf.com

Kitazato Corporation is a global company based in Japan, dedicated to extensive research, develop, manufacture and market medical devices and media to support a wide range of fertility treatments, from IUI to PGT. We aim to contribute to the happiness and health of society by providing high quality products and services that help couples fulfill the dream of having a baby. This goal encourages us to develop new technologies and deliver the best quality products for the entire IVF Lifecycle.

**Labcorp** Booth: 1703
531 S. Spring Street
Burlington, NC 27215
www.labcorp.com

We believe in harnessing science for human good. And so we work day and night, around the world, to deliver answers for all your health questions—whether you’re a provider, drug developer, hospital, medical researcher or patient. That means everything from advancing diagnostic testing, to helping launch new drugs, to offering new perspectives through data, all drawing from a deep well of scientific expertise. So when you need trusted information to make clear, confident health decisions, consider us your source. The groups we serve include managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings is listed on the New York Stock Exchange (NYSE) under the ticker symbol LH. Labcorp headquarters are located in Burlington, North Carolina.
**Labotect GmbH** Booth: 2824
Kampweg 12
37124 Rosdorf, Germany
labotect.com

Expertise from the beginning in the field of Assisted Reproduction! Located in Germany Labotect produces a wide range of products; among our products you’ll find e.g. CO2 incubators, embryo transfer catheters, devices and disposables for aspiration. The company is represented by a strong network of reliable and well-trained distributors in over 60 countries. Whatever it is you are looking for in an IVF laboratory, Labotect is the right and ISO 13485 certified partner. Quality – Made in Germany!

**LendingClub Patient Solutions** Booth: 1908
1700 West Park Drive, Suite 310
Westborough, MA 01581

Don’t let cost be a barrier to your patient’s dreams of parenthood. Discover a more affordable way them to pay for their fertility treatment and related care with payment plans offered through LendingClub Patient Solutions.

**LifeAire Systems LLC** Booth: 2624
1275 Glenlivet Drive
Allentown, PA 17520
www.lifeaire.com

Formulated by 26 patents, the LifeAire technology specifically targets the cytotoxic levels of volatile organic compounds (VOCs), viable and nonviable particulates in air to bring levels within optimal ranges to protect the human embryo. Cells cultured in LifeAire-purified air have demonstrated statistically significant increases cellular metrics and clinical outcomes beyond any other technology in the market.

**LiNA Medical** Booth: 912
1856 Corporate Drive, Suite 135
Norcross, GA 30093
linamed.com

LiNA Medical® develops innovative, simple to use devices for minimally invasive gynecology that are designed to improve patient care. LiNA’s latest innovation, the LiNA OperåScope™, is the first and only fully disposable, operative hysteroscopy system. Designed specifically for the office, the convenient single-use design is ready for use out of the box without the cost and complexity of traditional hysteroscopy.

**Male Fertility Diagnostics** Booth: 1912
2145 Davie Boulevard
Ft. Lauderdale, FL 33312
infertilitylab.com

Male Fertility Diagnostics, LLC is a diagnostics lab providing sperm analysis through our partner lab Unilab. Our goal is to test DNA integrity and functional compacity to complete the post-fertilization process and result in an embryo/blastocyst with the highest likely hood for developing to term.

**Medical Electronic Systems, LLC** Booth: 1522
5757 West Century Boulevard, Suite 805
Los Angeles, CA 90045
www.mes-global.com

Remember, it All Started with a Sperm! Medical Electronic Systems is a Los Angeles-based technology company specializing in rapid, automated semen analysis for the laboratory, veterinary, and at-home markets. The MES line of CE and FDA-approved Sperm Quality Analyzers, YO Home Sperm Test Kits, and complimentary testing supplies are sold through an extensive network of international distributors. MES is ISO certified as a medical manufacturer and has distribution offices in America, Europe, Asia, and Israel. From The Laboratory to the Living Room Medical Electronic Systems provides Automated Semen Analysis solutions to check the swimmers. Please swing by our booth to learn more and pick up a souvenir. And Remember, it ALL Started with a Sperm!

**Meditab Software Inc.** Booth: 1831
1420 River Park Drive, Suite 120
Sacramento, CA 95815
www.fertilityehr.com

Introducing FertilityEHR — the top all-in-one EHR, practice management, and billing platform specially designed for reproductive endocrinologists, obstetrician-gynecologists, andrologists, embryologists, reproductive immunologists, fertility lab technicians, and reproductive surgeons. Our innovative system provides everything from centralized dashboards for quickly managing patient cycles to an integrated ultrasound interface that automatically records ultrasound measurements.
Mellowood Medical-Ideas
Booth: 2603
45 Mellowood Drive, Suite 1B
Toronto, ON M2L 2E4 CANADA
www.mellowoodmedical.com

‘State of the ART’ fertility clinic management software at leading academic (including Nobel Prize-winning) and private centres – 20 + Years of IVF Sector Experience with the largest cohort of reproductive clinics in the English-speaking world; multi-language versions available. IDEAS caters for all elements of patient care – appointments, billing, treatment, monitoring, IVF laboratory, cryogenic storage, prescriptions and statistics. HL7 and Web Services interfaces to major blood analyzers, ultrasounds, CASA, witnessing, time-lapse, consenting and genetic/pathology services. Web-based patient/physician portal too! Registry support, including: SART (USA) BELRAP (Belgium), BORN (Canada), NPSU (Australia), HFEE (UK). QC/QA modules ensure compliance for CAP/EU/ESHRE/SEC directives. IDEAS includes ‘One-World View®’ of treatment progress, SMARTS® for pregnancy rates, and KPI’s and follow embryo development to individual eggs/oocytes, among other many more features.

Men Having Babies, Inc. Booth: 1936
6151 TYNDALL Avenue
Riverdale, NY 10471
www.menhavingbabies.org

The nonprofit Men Having Babies (MHB) provides educational and financial support for prospective gay surrogacy parents worldwide. MHB runs annual conferences in NY, Chicago, Brussels, San Francisco, Texas, Florida, Taipei and Tel Aviv. Our Gay Parenting Assistance Program (GPAP) provides cash grants, discounts, and free services from leading surrogacy providers. www.menhavingbabies.org

MFB Fertility Booth: 2036
1630a, 30th Street Pmb 143
Boulder, CO 80301
proovtest.com

Proov offers the first and only non-invasive, FDA cleared, and clinically validated diagnostic test to assess implantation potential after ovulation. Proov is used by clinicians worldwide to decrease early pregnancy loss and increase live birth rates. For more information, visit www.proovtest.com

Mindray North America Booth: 2821
800 MacArthur Boulevard
Mahwah, NJ 07430
www.mindraynorthamerica.com

Mindray provides a broad range of ultrasound solutions based on Living Technology architectures. Using next generation technologies, advanced signal processing and newly designed algorithms offer end users highly-featured systems with premium image quality. The powerful system performances deliver deeper penetration and higher resolution, which can assist with bringing clinical certainty within reach. Systems, DC-70 and DC-40, offer clinicians many options for a wide variety of imaging needs.

Minerva Surgical Booth: 1524
4255 Burton Drive
Santa Clara, CA 95054

Minerva Surgical is dedicated to technological innovations for the modern treatment of Abnormal Uterine Bleeding (AUB). In 2020 Minerva affirmed this commitment with the acquisition of the Symphion System for Operative Hysteroscopy, the Genesys HTA Endometrial Ablation System, and Resectr for office-based tissue removal. Minerva revolutionized the treatment of AUB in 2015 with the introduction of its endometrial ablation system, Minerva ES.

MVE Biological Solutions Booth: 711
3055 Torrington Drive
Ball Ground, GA 30107-4686
www.mvebio.com

MVE is the preferred brand for cryogenic equipment IVF Centers, hospitals, and clinics. The MVE 816P-2T-190 High Efficiency Freezer is designed with the fertility market in mind. This unique inventory system incorporates a two-tier storage tray that utilizes an access portal to allow removal of product stored on the lower level. Also ask about MVE’s complete Straw-Visotube Inventory System and special SUC Racks.
Myovant Sciences, Inc.
Booth: 2620
2000 Sierra Point Parkway, 9th Floor
Brisbane, CA 94005
www.myovant.com

Myovant Sciences is focused on women’s health because when she moves forward, we all move forward. Relugolix combination therapy, an oral, once-daily GnRH receptor antagonist plus low-dose estradiol and norethindrone acetate, is in clinical development for uterine fibroids with recent completion of two replicate Phase 3 studies (LIBERTY 1 and LIBERTY 2). Relugolix combination therapy is also in clinical development for endometriosis-associated pain with two ongoing Phase 3 studies (SPIRIT 1 and SPIRIT 2). MVT-602, an oligopeptide kisspeptin-1 receptor agonist, is in clinical development for female infertility with recent completion of a Phase 2a study.

Myriad Genetics, Inc.
Booth: 2103
320 Wakara Way
Salt Lake City, UT 84108
www.myriad.com

Myriad Genetics is a personalized medicine company dedicated to being a trusted advisor and transforming patient lives worldwide with molecular diagnostics. Myriad discovers and commercializes diagnostic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more info, please visit: www.myriad.com.

NableIVF
Booth: 1403
12 Greenway Plaza, Suite 1110
Houston, TX 77046
www.nAbleIVF.com

Nth Technologies was launched in 1999 as an Ob/Gyn-focused EMR/PM company with the goal of creating a technology platform, that was simple, reliable and accessible from anywhere, anytime. So, we pioneered and designed from the ground up the web-based EMR (nAbleMD) at a time when the word cloud-based had not yet been coined. We added other primary care and sub-specialties during the first fifteen years. Building on our experience with Ob/Gyn, we re-imagined our focus in 2015 to develop a seamlessly integrated, comprehensive IVF system (nAbleIVF) that is cloud-based, scalable to practices of all sizes, and customized to individual clinic needs. Since its launch in 2018, nAbleIVF has become the most desired IVF EMR with support and value second to none.

Narishige International USA, Inc.
Booth: 1420
415 Bayview Avenue
Amityville, NY 11701-2838

With over 60 years’ experience in micromanipulation technology, NARISHIGE offers the most reliable and latest technology in a wide range of products including both in vivo and in vitro experiments such as isolation stages, motorized and manual manipulators, pullers, microforges, patch clamp systems, perfusion systems, and stereotaxic instruments. Any requests and opinion are welcome. Narishige also specializes in customized products to help accommodate the researcher’s needs, allowing us to be the “CRAFTSMAN FOR YOUR SOLUTIONS”.

Natera, Inc.
Booth: 807
201 Industrial Road, Suite 410
San Carlos, CA 94070-2396
www.natera.com

Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide by harnessing the power of DNA from a single blood sample to improve the management of reproductive health, oncology, and organ transplantation. Natera® is driven by a passion for improving the path to parenthood with a suite of high-quality reproductive health genetic tests that support families in their journey from preconception, to pregnancy, and birth.

National Embryo Donation Center
Booth: 822
11126 Kingston Pike
Knoxville, TN 37934-2806
www.embryodonation.org

Since 2003, the National Embryo Donation Center (NEDC) has been the country’s leading comprehensive non-profit embryo donation program. Our mission is to protect the lives and dignity of human embryos. We do that by promoting, facilitating and educating about embryo donation. We’re also the only clinic-based organization that works with families of all races, faiths and ethnic backgrounds. Our office is in Knoxville, TN.
NextGen LifeLabs
Booth: 2626 and 2724
384 Nina Way
Warminster, PA 18974
www.nextgenlifelabs.com

Established in 2012, NextGen LifeLabs is your premier supplier of complete solutions for the modern IVF (A.R.T.) laboratory. Our team is dedicated to providing your IVF program with the most cutting-edge laboratory equipment, consumables, and industry leading service and support. We offer an extensive catalog of services including skilled installation of a wide range of equipment, laboratory design, planning, and implementation, as well as laboratory expansion and relocation consultation.

Nikon Instruments Inc.  Booth: 1815
1300 Walt Whitman Road
Melville, NY 11747
www.microscope.healthcare.nikon.com/

Nikon Instruments provides a broad range of imaging systems to suit a variety of microscopy needs, from tissue culture to fully automated high-content screening and super-resolution. Nikon’s systems feature industry leading optics and flexible configurations that evolve with your facility’s needs. All of Nikon’s systems are unified under one software platform, NIS-Elements, for streamlined training and optimal user-experience.

NxGen MDx  Booth: 1407
801 Broadway Avenue NW, Suite 203
Grand Rapids, MI 49504
nxgenmdx.com

NxGen MDx is a women’s health care company that provides precise genetic screening combined with best-in-class science, unrivaled accuracy, and personal genetic counselors to help you make informed decisions when planning to get pregnant or expecting a baby. For more information, visit www.nxgenmdx.com.

Olympus America Inc.  Booth: 716
3500 Corporate Parkway
Center Valley, PA 18034
medical.olympusamerica.com

Olympus Gynecology’s mission is to be your partner of choice to advance women’s health across the continuum of care. From Office to OR, our goal is to be a full-service organization to meet your need for cost-effective, and innovative solutions to ensure that your surgical experience is satisfying, and the quality of your patients’ care better.

Optum Specialty and Infusion Pharmacy  Booth: 2137
15529 College Blvd
Lenexa, KS 66219
specialty.optumrx.com

Organon LLC  Booth: 2020
30 Hudson Street, 33rd Floor
Jersey City, NJ 07302
www.organon.com

Organon is a global healthcare company focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. For more information, visit www.organon.com and connect with us LinkedIn and Instagram.

Ovation Fertility  Booth: 1010
15821 Ventura Boulevard, Suite 550
Encino, CA 91436-4793
www.ovationfertility.com

Ovation’s state-of-the-art, evidence-based fertility services raise the bar for IVF. Physicians partner with Ovation to offer patients advanced embryology and andrology services, preimplantation genetic testing, frozen donor eggs, surrogacy, and secure storage for frozen reproductive material. Ovation also helps IVF labs across America improve quality and performance with expert off-site lab direction and consultation services. Learn more at www.OvationFertility.com.

Overture, Inc.  Booth: 1024
Avenida de Europa 4; Alcobendas
Madrid, 28224 Spain

Ovobank  Booth: 924
Avenida Severo Ochoa No. 7
Marbella, Malaga 29603 Spain
ovobank.com

Oxford Nanopore Technologies  Booth: 2039
Gosling Building Edmund Halley Road
Oxford Science Park
Oxford, OX4 4DQ UK
www.nanoporetech.com
Pacific Coast Reproductive Society  Booth: 1631
2150 N 107th Street, Suite 205
Seattle, WA 98133
www.pcrsonline.org

The Pacific Coast Reproductive Society’s global commitment to exceptional patient care is embodied in the continuing medical education of physicians, their teams, and allied professionals. Promoting the highest standards of clinical practice, patient safety, and improved patient outcomes, related to the treatment of infertility, is consistent with the principles and goals of PCRS.

pcos-diet.com  Booth: 1734
808 Joliet Suite 230
Lubbock, TX 79415
pcos-diet.com

PerkinElmer Inc.  Booth: 1007
940 Winter Street
Waltham, MA 02451
www.perkinelmer.com

PerkinElmer, Inc. offers automated solutions which improve the efficiency of genomic and proteomics workflows. With our nucleic acid isolation technology, liquid handlers, library preparation kits, automated nucleic acid and protein analysis systems, and solutions for single cell genetic analysis, PerkinElmer is eliminating the challenges associated with genomic and proteomic analysis.

PharmaWatch  Booth: 2037
222 N, 13th St, Suite 200
Boise, ID 83702
www.pharmawatch.com/pharmawatch

PharmaWatch™ is a software solution designed to deliver the best environmental monitoring and compliance reporting for the life sciences industry. Our solution helps biorepositories successfully manage their cold storage through continuous data collection, remote alerting, and fully compliant audit reports. PharmaWatch monitors your specimens and critical environments in real-time, continuously reporting data to the portal every 5 minutes. Completely customizable, remote alerts are sent to you via SMS, voice mail, or email when your specimens begin to trend out of range. Our web-based dashboard allows you to check on the status of your critical environments anytime, anywhere, from any internet-connected device.

Pixel  Booth: 720
3 Wing Drive, Suite 102
Cedar Knolls, NJ 07927
www.get-pixel.com

Progenesis  Booth: 1625
4150 Regents Park Row, Suite 245
La Jolla, CA 92037-1414
progenesis.com

Driven by science and innovation, Progenesis has become the new leader of preimplantation genetic testing to help build healthy families. Our portal design and function is the product of the best minds in the IVF industry, helping to optimize clinics’ genetic testing workflow. Our success lies in our passionate team, dedicated to providing the best quality testing and customer care. Phone: (858) 257-2122
Email: info@progenesis.com

Progeny  Booth: 1903
1359 Broadway, Floor 2
New York, NY 10018
progeny.com

Progeny is a leading fertility benefits management company in the US. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive fertility solution can simultaneously benefit employers, patients, and physicians.

Redia FIV S.L.  Booth: 2035
Jerusalen 8, Floor 2
Alicante, 03001 Spain
ivftravel.com

Redia is the leading provider of Refund Guarantee Fertility Programs in Europe and it is now expanding its operations globally. We partner with fertility clinics in more than 12 countries who outsource all risk for refund guarantee IVF programs to us. Our programs include 3 full stimulation IVF or Egg Donation cycles with a 100% refund guarantee for live birth. We currently looking for clinic partners in the USA.
Rees Scientific Corp  Booth: 1225
1007 Whitehead Road Ext
Ewing, NJ 08638-2405
www.reesscientific.com

Rees Scientific provides continuous automated monitoring systems for the In Vitro Fertilization industry. Our FDA compliant monitoring system helps monitor critical assets, equipment and environments. We set the standard for monitoring cold storage (refrigerators, freezers, cryogenics, incubators), ambient conditions (temperature, humidity, LN2, O2, CO2), and room conditions (temperature, humidity, differential pressure, air changes and quality). Our system can monitor a diverse facility with multiple locations while providing immediate data access from your desktop, tablet or phone. It can be stand alone, network or web based. It can also be hard wired, wireless, WiFi or cloud based. As an ISO 9001 & 17025 accredited Company, Rees Scientific is constantly upgrading policies, procedures, and protocols to comply with today’s highly regulated environments. Meet compliance for FDA, WHO, AABB, GxP, and other regulatory requirements. We offer a full array of validation & calibration.

Reprobiogen Inc.  Booth: 2238
790 Bay Street Suite 1100
Toronto, Ontario M5G 1N8 CANADA
www.reprobiogen.com

Reproductive Genetic Innovations  Booth: 707
2910 Macarthur Boulevard
Northbrook, IL 60062-2005
www.RGIscience.com

RGI - Reproductive Genetic Innovations is a recognized global pioneer in the field of preimplantation genetic testing. We have performed PGT testing for thousands of families worldwide.

Reproductive Possibilities LLC  Booth: 1531
1 Paragon Drive, Suite 160
Montvale, NJ 07645
www.reproductivepossibilities.com

We are a Surrogate Agency with the experience and dedicated staff necessary to guide intended parents down the pathway to parenthood. We match intended parents with a gestational carrier and take you step by step on this amazing journey. Our company practices are designed to help you manage your expenses throughout a process which is very expensive. We have successfully helped our clients have over 2000 babies & we would love to add your child/ren to that list. Let us make your dreams come true.

Reproductive Solutions  Booth: 2337
5400 LBJ FreewaySuite 1250
Dallas, TX 60564
www.reproductive.solutions

Reproductive Solutions (RSI) is a leading medical technology company in the fertility space, focused on transforming semen sample collection methods, backed by scientific insights. RSI was founded in 2009 by a team of renowned Texas Tech University reproductive experts and health scientists, who — for the first time in the fertility industry — researched the adequacy and impact of traditional semen sample collection methods. With research insights at hand, they developed a patented solution to completely transform and improve the category. RSI is revolutionizing semen sample collection methods, starting with the first-ever FDA-listed technology scientifically engineered for improved semen care and protection, branded as ProteX.

ReproSource Fertility Diagnostics  Booth: 1813
200 Forest Street, 2nd Floor, Ste B
Marlborough, MA 01952
reprosource.com

ReproSource is a CLIA certified and CAP accredited reference laboratory focused solely on fertility and reproductive health testing. ReproSource diagnostic solutions include the Ovarian Assessment Report (OAR), sperm DNA fragmentation testing, comprehensive RPL panels, and the new @Home Semen Collection system that allows for a comprehensive and accurate semen analysis the day after specimen collection.

ReproTech, LLC  Booth: 815
33 Fifth Avenue NW, Suite 900
St. Paul, MN 55112
www.reprotech.com

ReproTech specializes in long-term cryostorage and transportation of reproductive tissues. Our 4 facilities provide safe and secure storage managed by experienced staff. ReproTech’s proven protocols, 24/7 tank monitoring with data analysis, and disaster safe rooms offer peace of mind to patients. ReproTech’s Auto Transfer Management Program enables IVF centers to automatically transfer specimens to a storage center by pre-consenting all patients, thus eliminating abandoned specimens.
Rescripted Booth: 923
4040 E. 5th Avenue
Denver, CO 80220
fertility.rescripted.com

We are stronger together than we are alone. Rescripted is committed to improving the fertility patient experience with a tech-enabled holistic care platform, including a vibrant community, trusted content, medication management, and medication fulfillment services, small group therapy, and a product marketplace. Rescripted is taking back the narrative around fertility and burning the word "normal" when it comes to what a family is and how one comes to be. We are rescripting fertility, together.

Resolve: The National Infertility Association Booth: 1935
7918 Jones Branch Drive Suite 300
McLean, VA 22102-4306
www.resolve.org

RESOLVE: The National Infertility Association, established in 1974, is dedicated to ensuring that all people challenged in their family building journey reach resolution through being empowered by knowledge, supported by community, united by advocacy, and inspired to act. RESOLVE exists to provide: ◊ Access to Care ◊ Advocacy for Coverage ◊ Access to Support & Community ◊ Access to Education ◊ Awareness of All Family Building Options

Reunite RX Booth: 708
2290 Springlake Road, Suite 100
Farmers Branch, TX 75234

Samsung Booth: 1607
14 Electronics Avenue
Danvers, MA 01923
www.neurologica.com

Hera, Samsung’s premium women’s health platform, is committed to delivering exceptional image clarity and color sensitivity to help clinicians see the tiny details in every image without the need for excessive manipulation. With re-imagined ergonomics, advanced technologies that reveal additional anatomical detail and elevated patient interactions, Hera is transforming ultrasound in ways never seen before.

SCSA Diagnostics Booth: 1307
425 8th Street South
Brookings, SD 57006-1160
www.scasatest.co

The SCSA remains the most robust test and is the only test of sperm DNA/chromatin for which validated clinical interpretation criteria exist, and these are based on many thousands of tests and hundreds of clinical treatment cycles. Basic Laboratory Andrology. Cambridge Press; 2001. Bjorndahl L, Mortimer D, Barratt C, et.

Seattle Sperm Bank Booth: 1426
4915 25th Avenue NE, Suite 204
Seattle, WA 98105
www.seattlespermbank.com

Seattle Sperm Bank is an industry-leading sperm bank, offering the most comprehensive genetic testing and screening practices with a focus on high quality, Open ID vials with exceptional customer service. Our focus is about combining a personal, compassionate approach with uncompromising medical expertise and the very best in donor selection.

Sema4 Booth: 1735
333 Ludlow Street, South Building, 3rd Floor
Stamford, CT 06902
www.sema4.com

Sema4 is a patient-centered predictive health company founded on the idea that more information, deeper analysis, & increased engagement will improve the diagnosis, treatment, & prevention of disease. Sema4 is dedicated to transforming healthcare by building more dynamic models of human health & defining optimal, individualized health trajectories, starting with reproductive health & oncology. Sema4 believes patients should be treated as partners, & data should be shared for the benefit of all.

Siemens Healthineers Booth: 1834
40 Liberty Boulevard, Mailcode 40-3E
Malvern, PA 19355
www.siemens-healthineers.com/en-us/ultrasound

Enhance your diagnosis with improved imaging performance and adaptive technologies with ultrasound machines, solutions and services from Siemens Healthineers. Our portfolio of ultrasound machines, sonography equipment and advanced technologies address your clinical requirements offering the versatility and functionality you need for confident diagnosis in your IVF clinic.
SMP Fertility Pharmacy  Booth: 1526
7500 NW 26th Street
MIAMI, FL 33122
SMPpharmacy.com

SMP Pharmacy is an award-winning fertility and specialty pharmacy that prides itself in exceptional customer service and competitive pricing. All of our patients are connected with a Fertility Care Coordinator that will assist them with their fertility medications, savings programs, and health insurance plans. Our state-of-the-art pharmacy offers services throughout the United States and Internationally. Come visit us at our booth #1526 to see how SMP can assist you and your patients.

Society for the Study of Reproduction  Booth: 1226
11130 Sunrise Valley Drive, Suite 350
Reston, VA 20191
www.ssr.org

The Society for the Study of Reproduction (SSR) was founded in 1967 to promote the study of reproduction by fostering interdisciplinary communication among scientists, holding conferences, and publishing meritorious studies. Today, our members come from 50 countries around the world. Our annual conference showcases the cutting-edge research in the reproductive sciences and serves as an excellent opportunity for networking and career development.

Spectrum Technologies- Your Pure Sperm Source  Booth: 1934
1532 Chablis Road, Suite 101
Healdsburg, CA 95448
www.yourpurespermsource.com

Springer Nature  Booth: 1431
233 Spring Street
New York, NY 10013
www.springernature.com

Springer Nature is one of the world’s leading global research, educational and professional publishers, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher and numbers almost 13,000 staff in over 50 countries. www.springernature.com

Sunlight Medical Inc.  Booth: 2034
5570 Florida Mining Blvd S., Suite 603
Jacksonville, FL 32257-3248
www.sunlightmedical.net

Sunlight Medical Inc is specialized in manufacture and supply of high quality micropipettes for human IVF procedures such as ICSI, embryo biopsy, assisted hatching and denudation. We offer consistent high quality products and competitive pricing.

The Fibroid Foundation  Booth: 1026
10319 Westlake Drive, Suite 102
Bethesda, MD 20817
www.fibroidfoundation.org

The VFP Pharmacy Group  Booth: 1913
335 Bear Hill Rd
Waltham, MA 02451
www.villagepharmacy.com

For over thirty years, VFP Pharmacy Group has built a reputation by providing fast, compassionate and dependable service to fertility professionals and their patients. Our focus is on exceptional service and competitive pricing. You will find our staff thoroughly knowledgeable about the medications we provide and the issues you face.

The World Egg Bank  Booth: 1809
7227 N 16th Street, Suite 160
Phoenix, AZ 85020
www.TheWorldEggBank.com

The World Egg Bank is the only egg bank worldwide built solely for egg donation. Our unique centralized business model ensures we conduct all egg vitrification with optimized protocols and the same experienced laboratory systems and staff. Our only operational focus is providing quality donor eggs from our state of the art facility designed solely for egg freezing. We manage all recruiting, screening, stimulation, retrievals, vitrification, and shipping from our egg banking facility.
Theralogix Booth: 1722
401 E Jefferson Street, Suite 108
Rockville, MD 20850-2617
theralogix.com

Guided by recognized ART experts and an eminent Medical Advisory Board, Theralogix offers the only full line of independently-certified fertility supplements. Setting the standard with an evidence-based approach, all products are also third-party tested for content, dose accuracy, and freedom from contaminants. Theralogix supplements are recommended by providers worldwide and used by hundreds of U.S. ART practices. For more information, visit www.theralogix.com

Unilab Booth: 1910
2145 Davie Boulevard, Suite 106
Fort Lauderdale, FL 33312-3155

Unilab offers an extensive testing menu: diagnostics (including male infertility), in-cycle monitoring and FDA donor testing. Since being founded in 1988 by Dr Julio Cortes Unilab has served physicians and patients by providing the fastest turnaround time while upholding the highest standards of accuracy and precision. The lab is FDA-registered and provides testing to clients worldwide.

TMRW Booth: 823
250 Hudson Street, 701
New York, NY 10013
TMRW.ORG

TMRW Life Sciences has created the first automated solution for how frozen eggs and embryos are stored, tracked, and monitored. Before TMRW, irreplaceable eggs and embryos were managed using manual and analog methods borrowed from livestock breeding. TMRW’s technology brings the IVF lab into the 21st century and ushers in a new standard of care for eggs and embryos just as fertility care has reached an inflection point: It’s estimated that 15% of couples worldwide now struggle with infertility. The outdated systems clinics have put in place are simply incapable of meeting this rising demand for IVF and egg freezing. With the TMRW platform, eggs and embryos are traceable using RFID technology and safely maintained at cryogenic temperatures using robotics, 24/7 remote monitoring, and fully integrated software. The TMRW platform is transforming the possibilities for fertility by safeguarding the most precious cells for life.

Univfy Inc. Booth: 1820
1 1st Street, Suite 16
Los Altos, CA 94022-2756
www.univfy.com

The Univfy AI Platform for IVF defines a new era, combining machine learning, AI and fintech to dramatically improve the experience of fertility patients, increase success rates and make highly effective treatment affordable to more women and couples.

Vanguard Communications Booth: 1811
2400 N Broadway, Suite 3
Denver, CO 80205-2087
vanguardcommunications.net

Want more patients? Vanguard Communications guarantees a 15%-30% increase in new patients in just 13 months or we work for free. (In 27 years, we’ve never had to work for free.) We guide academic and private fertility clinics to grow with our proven patient education and digital medical marketing program called MedMarketLink. It integrates all the components needed to attract new patients and grow revenue, including content marketing, online reputation management, search engine optimization, secure web forms, e-newsletters, PR and more. In fact, we guarantee it. We also resolve common practice pain points, such as phone bottlenecks, billing, patient retention, appointment no-shows and more. That’s because our research shows 96% of damaging online patient complaints about physicians have nothing to do with the medical care but everything to do with customer service. Patient experience matters. If you’re serious about growth, visit us at booth #1811 at the Expo.
VirtaMed Inc. Booth: 1533
16144 Churchview Drive, Unit 101
LITHIA, FL 33547
www.virtamed.com

VirtaMed is the world leader in medical training using hybrid simulators for minimally invasive diagnostic and therapeutic interventions in obstetrics and gynecology, including ultrasound, hysteroscopy, laparoscopy, IUD placement and embryo transfer. VirtaMed simulators provide the most realistic training environment, combining photorealistic graphics with original instruments and anatomically correct rubber models.

Vitrolife, Inc. Booth: 2420
3601 S Inca Street
Englewood, CO 80110-3430
www.vitrolife.com

Maximize success every step of the way. The key to success in IVF is care. Careful handling of gametes and embryos outside the human body is an enormous challenge. Our unbroken chain of innovative high quality products ensure optimal care at every step of the way. Working together with Vitrolife means having a partner that understands the overall challenges involved in running an IVF clinic. We provide what you need to secure improved results throughout the IVF journey. Visit our page and www.vitrolife.com to learn more about the latest product news and educational content to help you maximize success.

Walgreens Booth: 1720
304 Wilmot Road, MS #3B55
Deerfield, IL 60015
www.walgreenshealth.com

Walgreens and AllianceRx Walgreens Prime provide specialized fertility pharmacy services through an experienced care team available 24/7 devoted to helping patients achieve successful outcomes. We understand the importance of timing and the need for personalized treatment and are committed to compassionate care and support throughout a patient’s journey to having a family.

WINFertility Booth: 2826
1 American Lane, Terrace Level
Greenwich, CT 06831
www.winfertility.com

WINFertility is the largest fertility benefit management company in the U.S., delivering family-building benefit solutions to employers, payers and individual patients. With more than 20 years of experience, WIN helps providers grow their practice, improve patient experience and simplify administration. Connect with WIN to join its network and gain access to employer group contracts, health plan contracts and consumer direct programs by visiting www.winfertility.com/providers.

Wolters Kluwer Booth: 1227
Two Commerce Sq
2001 Market Street
Philadelphia, PA 19103
shop.lww.com/ASRM_WK_2021

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers, and the next generation of healthcare providers. With a focus on clinical effectiveness, research and learning, safety and surveillance, and interoperability and data intelligence, our proven solutions drive effective decision-making and consistent outcomes across the continuum of care.

XiltriX North America Booth: 1835
9255 Towne Centre Dr, Suite 925
San Diego, CA 92121
xiltrixusa.com

XiltriX North America provides Lab Monitoring-as-a-Service. As lab monitoring service providers for 30+ years, we can address all your hardware, software, and reporting needs (with a service custom to your IVF clinic). Our team will address all of your equipment, environmental, and facility monitoring needs with 24/7 support to help ensure the security of your work.

Xytex Corporation Booth: 1807
1100 Emmett St
Augusta, GA 30904-5826
www.xytex.com

For 45 years, Xytex has helped thousands of families, with personalized donor selection for the LGBTQ+, SMBG, and infertility communities. Diverse donor profiles include family medical histories and testing for 283 carrier conditions, plus the largest adult photo selection. With thousands of success stories and an international presence, we’re the longest-running sperm bank in the US. When it’s a life-changing decision, your sperm bank choice is crucial. We make miracles happen.
Exploring Access, Education, and Advocacy: An Honest Conversation

Monday October 18, 2021
12:20 pm – 1:20 pm • Baltimore Convention Center - Room 310

• Hear from the perspective of patient advocates on the challenges, opportunities, and perceptions of fertility care and find out how your clinic can be responsive to the needs of all patients.
• Walk away with a greater understanding of your patients’ perspective and identify opportunities for connecting and servicing their individual needs.

Moderators
Cindy M. Duke, M.D., Ph.D., F.A.C.O.G., University of Nevada, Las Vegas and Nevada Fertility Institute,
Inger Britt Carlsson, Ph.D., INVO Bioscience

Speakers
Andrea Syrtash, N.Y., Founder & Editor-in-Chief, pregnantish, Inc.,
Barbara Lynn Collura, M.A., RESOLVE: The National Infertility Association, and

Thank you to our ASRM Corporate Members
AbbVie; Cook Medical; Cooper Surgical; EMD Serono; Elsevier; Ferring Pharmaceuticals, Inc.; GE Healthcare; Growing Generations; INVO Bioscience, Inc.

Non-ticketed event. Includes complimentary boxed lunch for first 150 attendees. This is a Non-CME activity.
Carrier screening is increasingly used by couples planning to start a family, helping to identify those at high risk of having children affected by serious inherited conditions (autosomal recessive and X-linked). This form of genetic screening has become particularly common in assisted reproductive treatment cycles using donor gametes, with many clinics and donor banks routinely performing screening to reduce the likelihood of patient-donor combinations associated with an increased risk of affected children. Strategies for the application of carrier screening, and the technologies that underpin them, have evolved greatly in recent years. This session will involve a lecture which describes the evolution of carrier screening and considers its current and future application in the context of IVF treatment.

Speaker
Dagan Wells, Ph.D.
Director of Juno Genomics,
University of Oxford
Expo Theater

Monday, October 18, 2021
10:05 AM – 10:45 AM

ASRM Modified Classification for Mullerian Anomalies: MAC2021

Speaker: Samantha M. Pfeifer, M.D.,
Weill Medical College of Cornell University,
New York, NY
Sarah D. Ramaiah, M.S.Ed.,
American Society for Reproductive Medicine,
Birmingham, AL

Monday, October 18, 2021
3:45 PM – 4:30 PM

Ferring Pharmaceuticals, Inc. presents:
COVID-19 – A Journey of Hope, Learning and Accomplishment

Speaker: Brian Levine, M.D.
CCRM New York

Tuesday, October 19, 2021
10:05 AM – 10:45 AM

Oxford Nanopore Technologies presents:
Rapid Aneuploidy Detection using Nanopore Sequencing
Anaheim, California
October 22-26, 2022

New Orleans, Louisiana
October 14-18, 2023

Denver, Colorado
October 19-23, 2024